"companyid","keydevid","transcriptid","headline","mostimportantdateutc","keydeveventtypename","companyname","speakertypename","componenttextpreview","word_count","componenttext"
1002291,321212057,922303,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Operator","Good day, ladies and gentlemen, and welcome to the Mead Johnson Nutrition Fourth Quarter 2015 Earnings Conference Call. My name is Liz, and I'll be your coordinator for today. [Operator Instructions] As a reminder, this conference is being recorded for re",62,"Good day, ladies and gentlemen, and welcome to the Mead Johnson Nutrition Fourth Quarter 2015 Earnings Conference Call. My name is Liz, and I'll be your coordinator for today. [Operator Instructions] As a reminder, this conference is being recorded for replay purposes. I would now like to turn the conference call over to Kathy MacDonald, Vice President, Investor Relations. Please proceed, Kathy."
1002291,321212057,922303,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Thank you, Liz. Good morning, and thank you for joining Mead Johnson Fourth Quarter and Full Year 2015 Conference Call. With me today are Kasper Jakobsen, our Chief Executive Officer; and Michelle Cooper, our Chief Financial Officer. Earlier today, we iss",309,"Thank you, Liz. Good morning, and thank you for joining Mead Johnson Fourth Quarter and Full Year 2015 Conference Call. With me today are Kasper Jakobsen, our Chief Executive Officer; and Michelle Cooper, our Chief Financial Officer. Earlier today, we issued our earnings release and financial reference slides which are available on our website. As we start, let me remind everyone that our comments will include forward-looking statements about our future results, including statements about our financial prospects and projections, commodity costs, currency fluctuations, pricing, taxes, capital spending, depreciation and amortization, new product launches, product quality, other growth initiatives and market conditions that constitute forward-looking statements for purposes of the Safe Harbor provisions under the Private Securities Litigation Reform Act of 1995. A more detailed explanation of our forward-looking statements will appear in the materials posted on our website in connection with today's conference call. Keep in mind that our actual results may differ materially from expectations as of today due to various factors, including those listed in our Annual Report on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K, in each case, as filed with or furnished to, the Securities and Exchange Commission, and our earnings release issued this morning, all of which are available upon request or on our website at meadjohnson.com. Today's comments will include discussion of non-GAAP financial measures. A reconciliation of these measures to comparable GAAP measures, appears in the morning's earnings release posted on our website. In addition, any forward-looking statements represent our estimates only as of today and should not be relied upon as representing our estimates as any subsequent date. While we may elect to update forward-looking statements at some point in the future, we specifically disclaim any obligation to do so even if our estimates change. I will now turn the call over to Kasper."
1002291,321212057,922303,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Thank you, Kathy, and thank you to all of you for listening to our fourth quarter and full year earnings call this morning. Over the next 35 minutes or so, Michelle and myself will summarize our fourth quarter and full year 2015 financial results. We'll a",3384,"Thank you, Kathy, and thank you to all of you for listening to our fourth quarter and full year earnings call this morning. Over the next 35 minutes or so, Michelle and myself will summarize our fourth quarter and full year 2015 financial results. We'll also outline our expectations for 2016. 
I'll begin by providing an overview focusing on revenue performance, our key strategic initiatives and business drivers and underlying business momentum. How then how would hand over to Michelle who give a further analysis of our financial metrics and provide an outlook for key cost drivers. After Mitchelle completes his segment, I will return with a few summary remarks before I give you an opportunity to ask questions. Except where noted otherwise, I'll be referring to non-GAAP results. A full reconciliation to our GAAP results is available in our 10-Q that was filed alongside our earnings release earlier this morning. Both documents are available on our website. 
Let me start with a high-level overview of our fourth quarter 2015 results the global business before I move on to discuss full year results and then performance of each of our regions. As we exited the year and I refer now to fourth quarter results specifically, I'm pleased to say we saw a sequential improvement versus the third quarter in our underlying sales performance. Net of withheld shipments to Venezuela, a topic I'll return to later, we saw sequential growth in constant dollars sales of 1%. This represented a modest reversal of the trend we've seen over the previous 3 quarters, despite sales performance being adversely affected by select of retailer inventory adjustments in Thailand and Malaysia. 
Structural changes made to our investment profile in China and the recent launch of our fully imported line of Enfa products helped us deliver on the promise we made in July. At that time, we said we expected to see sequential improvement in China sales as we exited the year. And in the fourth quarter, our China/Hong Kong business grew 2% sequentially over the third quarter. 
Our North America/Europe segment also grew sequentially by nearly 5% on a constant-dollar basis. 
Let me now address our full year results. 2015 was a challenging year for us. We were challenged by a strengthening dollar and the general weakness in many economies throughout Asia and Latin America. GDP growth across Asia and Latin America was lower than prior year and this affected both consumer and retailer confidence. Additionally, in China, we saw increased price-based competition and channel shifts that adversely impact sales growth and required us to boost investment to protect our competitiveness. 
In Southeast Asia, in particular, we saw a slowing economic growth in Thailand and Malaysia. Combined with some company-specific executional issues, this resulted in lower volumes through the year. 
In the Philippines, where GDP growth remain more robust, we saw relatively better performance and there, we are satisfied with the progress we made through the year. We continue to benefit from lower dairy costs and an improved gross margin as a consequence. This helped partially offset the EBIT and EPS impact of foreign exchange and lower sales. For full year 2015, constant dollar net sales were 2% below prior year, largely due to our challenges in China and Hong Kong. Gross sales, however, were in line with 2014. This shows continued solid demand for our branch though a challenging trading environment so as report sales below prior year level. 
The impact of a strengthening dollar was significant throughout the year reducing reported sales by about 6%, and earnings per share by $0.26. Where possible, we took price to mitigate the impact of foreign exchange. However, competitor strategies and abnormally low dairy costs made price increases more difficult than we've seen in recent years. Price consequently contributed 1% -- percentage point of growth for the full year. As we progress through the year, the carryover benefit of price increases taken in 2014 gradually disappeared and price promotional activity became more evident. Against the same quarter of prior year, this increased dynamic adversely affected fourth quarter gross by 1 percentage point. This was largely driven by increased trade promotional activity in China. 
Global volume was 3% lower than prior year, growth in North America and Europe didn't fully offset weaker performance in Asia and Latin America and the impact of our decision to slow shipments into Venezuela was also significant. Infant formula and product sales for 2015 were in line with prior year on a constant-dollar basis. It follows that we were relatively more challenged within our children's category outside of North America. The children's category is more price-sensitive and prior to reshaping our competitive starts in the third quarter, we suffer share losses due to competitors price commotion of activity. However, having addressed the price disadvantage as the cohort of infants age the consumer brand, this should help sales of our children's franchise going forward. We understand recovery of momentum in China and select other emerging markets could take time, and we need to probably fund key growth initiatives. As a consequence, the company invests -- as the company's advancement in advertising and promotion remain strong in the fourth quarter at 15.6% of sales. This was 190 basis points above prior year's fourth quarter level. 
To help fund these investments and offset the impact of foreign exchange, we accelerated the implementation of some of our operating expense reductions. We refer to this initiative as fuel for growth. As a direct result of this focus, our operating expenses came in approximately $20 million favorable versus the forecast that underpinned guidance issued in October. This favorability allowed us to offset the impact of unanticipated dollar strength in the final quarter of the year and still deliver earnings-per-share slightly above the high end of our guidance range. We delivered $0.78 in non-GAAP earnings per share for the final quarter of 2015. As mentioned, this was slightly better-than-expected and allowed us to finish 2015 with $3.44 in non-GAAP earnings per share. Even as we grapple with our adverse dynamics in many of our markets in 2015, I'm pleased that we avoided any temptation to fuel bank and investment. We know that continues innovation is critical to our long-term growth prospects. Here's some examples of new products we introduced around the world. In the United States, we introduced new and more convenient plastic packaging for our 32-ounce ready-to-feed liquid infant formula, building on the success of our 8-ounce launch a couple of years ago. We also responded quickly to competitive activity by introducing a new formulation of infant formula free from genetically-modified raw materials. Across North America, we became the first company to meet newly developed guidance for premature infant formula. And in China, we introduced a fully imported range of Enfa-branded products to complement our manufactured range. These fully imported products now account for 35% of our sales within the mainland. 
In Southeast Asia, we upgraded our formulations and added increased levels of DHA to our children's products. We also introduced plastics packaging in several countries, and we had a ready-to-drink versions to our lineup of Enfa products. In Latin America, we introduced liquid versions of our key infant formula products and in Mexico, I Enfagrow Toddler product. For our powdered products, we began the introduction of upgraded plastics packaging. 
Further, over more than 70 years, we worked diligently to develop clinical evidence in support of our specialty portfolio, predominantly on our new and allergy brand. Educating health care professionals about and its benefits allowed us to grow constant-dollar sales double digits in 2015. As I complete my comments on overall company performance and before I moved to discussing our reporting segments in more detail, I want to maintain that as promised, we executed and accelerated share repurchase program in the most recent quarter. This reflects our commitment to the creation of long-term shareholder value. Michele will be quivered to this topic later. Let me now briefly comment on the performance within each of our recording segment and I begin with Asia. 
Sequentially, Asia's sales were in line with third quarter with improvements in China, offset by lower sales in Thailand and Malaysia. For fourth quarter, constant dollar sales were 10% below the prior year quarter and full year sales compared unfavorably to 2014 by 8%. As mentioned, sequentially, we grew sales in China/Hong Kong by 2% from the third quarter of 2015. A more aggressive trading stance allowed as the stabilize sales of our locally manufactured product line. Though we've had to increase our investments we encourage the prices to consumers at appear to have stabilized in the fourth quarter. 
At the same time, demand for our recently introduced fully imported range continued to grow. As mentioned earlier, sales of this product range now accounts to 35% of our sales in Mainland China and a full 22% of our combined China/Hong Kong business. As we expand direct shipments of our fully imported product into Mainland China, we expect to see continued cannibalization of our Hong Kong business. Such channel ships may obscure underlying business process in the near term, but ultimately, should be favorable to the company overall as we build a stronger, more sustainable portfolio with greater reach inside Mainland China. 
As mentioned at our Investor Day in October, we are committed to make investments in support of our recent introductions. We're advancing digital marketing capabilities, expanding our channel coverage and strengthening our retail chain relationships through focused investments. Beyond the early sales success with our imported product range, as a further sign our strategy is working, we are seeing market share gains in baby stores. As you know, we've also focused on strengthening our presence in business to consumer e-commerce. This represents the fastest growing part of the e-commerce market in China. And the segment is growing as approximately 5x the rate of the rest of the e-commerce channel. In a sign of our commitment to strengthening our presence in web and app-based commerce, we recently signed joint business partnership agreements with [indiscernible], owner of leading e-commerce site, JD.com; and $0.10, owner of WeChat, the leading social app in China. Under these agreements, we agreed to cooperate by sharing and technology platforms to the mutual benefits of our separate businesses. These agreements recognize the expertise of each party, including Mead Johnson China, and we are thrilled to partner with such great companies. 
While our China business began to show progress, our businesses in Malaysia and Thailand experienced challenges as mentioned earlier. Both economies are going through a challenging time due to political uncertainty and weak commodity prices. As a result, both consumer and business confidence is reduced. However, despite this backdrop, I want to acknowledge that we have not executed, as well as expected in either country for much of 2015. Though we cannot control economic trends, we can and will, control our execution, and we are taking steps to improve performance going forward. In the meantime, we continue to manage trade inventory bills carefully in the fourth quarter. 
In the third quarter, we enhanced our products in Thailand with increased levels of DHA and introduce new packaging, including a plastic top. Early signs are encouraging with share increasing in the 3 months following our relaunch. However, it took longer than expected to defeat old inventory in the trade and consequently we chose to address this more aggressively in the most recent quarter. Having discussed some areas of relative challenge, let me now point to our relatively stronger performance in the Philippines. The Philippines business has delivered solid growth over the past 2 years. We've managed to offset foreign exchange impacts with improved pricing, and we've successfully expanded our that some children's brand into the infant formula category. This move gives us exposure to a growing economy beyond traditional premium price position. 
Turning now to Latin America. The region delivered constant-dollar sales growth of 3% for the full year cup period to 2014. Regional currencies weakened substantially through 2015, with large adverse impacts on sales growth in Brazil, Argentina, Colombia, Venezuela and Mexico. As a consequence, reported sales was 13% below prior year level. For the fourth quarter, excluding Venezuela to where we post shipments for much of the quarter, sales grew 5% on a our constant dollar basis over the same quarter of prior year. Including Venezuela, the region sales for fourth quarter '15 were 4% lower in constant dollars than the same quarter in 2014. 
As you can tell, our decision to pause shipments to Venezuela was a significant driver of relatively weaker segment performance. As stated in previous calls, we are carefully managing risk associated with our intercompany payables within defined parameters. In the near term, this means matching new shipments to Venezuela to hard currency payments receipt. We are actually working with the Venezuelan government to address this challenge in order that in order that we can once again help provide much needed nutrition to children in that country. 
Looking at the overall economy of Latin America, over the past decade, these commodity-driven economies benefited substantially from stronger prices. Since the collapse in commodity prices, Latin America's GDP growth has slowed dramatically. Countries beyond the obvious example of Brazil that's in the recession are grappling with sharp reductions in their growth rates for the first time since 2009. These macroeconomic conditions, coupled with a strengthening dollar resulted in sharp depreciation of local currencies. I'd like to provide a little more detail in today's discussion. And for that purpose, I'll group the region into 3 sessions. I've excluded Venezuela which I've discussed separately already. 
I'll now discuss Mexico, the Caribbean and Central America as a distinct area from the southern cone area of Brazil and Argentina. And finally, touch briefly on the Andean region, in which we include Peru, Ecuador and Colombia. In Mexico, the Caribbean and Central America, the Enfa family of premium products grew strongly in constant dollars boasts sequentially over the third quarter and in full year 2015, and now represents about 2/3 of sales within the area. Outside of Mexico, much of our business in this area is conducted in U.S. dollars. This helped partially offset the impact from a decline in the Mexican peso. That said, the Mexican business is our third largest business globally and many of you already know our Mexican portfolio augments our global Enfa branded products with 2 very strong local brands amid modifiers, [indiscernible]. These 2 milk modifier brands gave us a leading-edge -- or a leading shared, I'm sorry, of the large Mexican modifier market. A large category that's, however, characterize by strong competition from global and local players. With limited potential to expand consumer penetration, competition is tough and occasionally price-based. These dynamics over the last several years of course our milk modifier brands to grow more slowly than our Enfa-branded infant and children's business. In 2015, milk modifiers net sales declined as we expanded trade discounts to protect our competitive position. This impacted the overall Mexico results adversely. Our performance in the South cone area was adversely impacted by the economic recession and currency weakness in Brazil. In Argentina price schemes more than covered the impact of currency depreciation. And across the area, we continue to grow our infant formula in toddler sales strongly in local currency. However, in Brazil, we also sell the Sustagen brand of milk modifiers. And in this category, we saw consumers moved to cheaper competitive offerings and we lost sales as a consequence. Within the Andean region, we saw Colombia delivered strong double-digit growth for both the latest quarter and the full year. The smaller market of Ecuador also performed well but these encouraging results were offset by challenging retail conditions in Peru. 
To wrap up, the key drivers for the Latin America full year results are volume, which was lower primarily from our intentional constraint of Venezuela shipments and Mexico the modifier sales reductions; price, that was predominantly from the high inflationary markets of Argentina, Colombia and Venezuela; and finally, foreign exchange that negatively impacted the region. 
I'll now turn to our performance in North America and Europe. In the full year 2015, the North America/Europe segment delivered 4% constant dollar revenue growth over 2014. Volume improved 1% with price and product mix contributing 3% to our annual growth rate. In the fourth quarter, this segment sales were in line with the prior year's quarter. Sequentially, as stated earlier, sales increased 5% over the third quarter. With little to no growth in the category in North America, our volume growth was realized through market share gains and our Enfagrow children's business continued double-digit growth. Our premium price specialty and solutions offerings also include double digits. 
And our Canadian business continued to execute extremely well and exited the year with record high-market shares. Europe posted its strongest sales and EBIT performance in the last 5 years, though the sales impact was partially offset by our exit from the Russian market earlier in the year. Overall, 2015 was another strong year for this segment. A year in which we saw profit margins expand to approach historic levels. In many ways, this was proof that our decision to maintain investment levels through the 2009 to 2012 economic downturn was the right one. 
Turning now to our outlook for 2016. Our outlook is broadly similar to that provided at our Investor Day in October. We expect constant-dollar sales to continue to show gradual improvement sequentially through the coming quarters. But due to tough comparisons from the first half of 2015, we do not expect to report positive revenue growth over same quarter of prior year till the second half of 2016. For this reason, we expect full year 2016 constant-dollar sales growth to be modest in the range of 0% to 2%. 
Based on current exchange rates, we expect currency to reduce sales growth by approximately 600 basis points. As a result, reported sales may decrease by 4% to 6% this year. We now have a good fix on dairy costs, as this item will impact our profit and loss statement through the first 7 or 8 months of the year. Based on this year, we are comfortable saying that again in 2016, dairy prices would have a favorable impact on our cost of goods. At our Investor Day event last October, we characterized our 2016 as the year of transition. In the context of headwinds from a strengthening dollar, we committed to reduce non-demand-creating operating expenses by $60 million in order to reinvest in select growth initiatives and particular earnings growth. As headwinds from currencies have grown stronger since our October gathering, this initiative has become even more essential to our strategy, and I'm pleased to report, we're making good progress and remain confident in our ability to deliver on our cost-reduction ambition. 
As mentioned in our press release this morning, I believe it's important for us to give you a better picture of the expected evolution and underlying profitability, without the polluting effect of currency impact. To this end, let me clarify that we expect to deliver 9% to 12% constant-dollar, non-GAAP earnings per share growth. And based on our assumption of power on foreign exchange, we expect therefore non-GAAP earnings per share when expressed in U.S. dollars to be in the range of $3.48 to $3.60. Not included in our estimates of 2016 as in additional benefits that might accrue from a review of efficiency and productivity opportunities within our demand-generating investments. Such overview is currently scheduled for mid-2016. I must point out that we remain highly focused on further strengthening on -- sorry, we remain highly exposed to the further strengthening of the dollar or selected weakening in foreign currencies. Anticipating that we may continue to see some variability in exchange rates through the year, we decided to provide to with a reconciliation to growth in non-GAAP constant dollar earnings per share. I'll now turn the call over to Michel who will provide some more details on our fourth quarter and full year financials. Michel will also elaborate on our guidance for 2016 and upon the completion of his prepared remarks, I'll return with some summary remarks before we open the lines to questions. Michel, over to you."
1002291,321212057,922303,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Thank you, Kasper, and good morning, everyone. Today, I will discuss our fourth quarter and full year 2015 financial results. I will then briefly highlight segment results and conclude with a summary of our 2016 guidance. Unless otherwise noted, my commen",2214,"Thank you, Kasper, and good morning, everyone. Today, I will discuss our fourth quarter and full year 2015 financial results. I will then briefly highlight segment results and conclude with a summary of our 2016 guidance. Unless otherwise noted, my comments will be on the non-GAAP financial results. References a growth impact on the face of currency fluctuations generally refer to the impact on the translation of local currency financial statements into U.S. dollars. 
Let me start with sales. Kasper addressed constant dollar sales growth. I will focus more on the foreign exchange impacts. As you can see, from Slide 3, fourth quarter sales on a reported basis were 12% below the prior year quarter. Adverse foreign exchange rates contributed to a decline of 6%, a similar rate to that seen in the third quarter. For the full year, sales on a reported basis were 8% below last year. The adverse foreign exchange impact on sales was 6%, or $229 million. On Slide 4, we have summarized the impact of foreign exchange or a quarter. The U.S. dollar continue to strengthen in the fourth quarter and its affect on translation of local currency negatively impact all reporting segments. Over 1/3 of the negative currency impact in the fourth quarter were from the Mexican peso and the Chinese renminbi. The balance of the foreign exchange impact was widespread especially from our large market by Canada and Malaysia and Thailand. We expect to see additional adverse foreign exchange impact in 2016 base on the continued strengthening of the across a very broad basket of currencies. I'll address this foreighn exchange impact in the EPS guidance section as well. 
I will now move on to the factors that impacted our gross margin on Slide 5. Gross margin was 63.9% in the fourth quarter, up 200 basis points from the same quarter of 2014. Lower dairy costs fueled majority of the improvement. However, the benefit was cut in half but adverse foreign exchange impacts. Productivity improvements offset other commodity increases and higher manufacturing costs. In the last earnings call, we highlighted 3 factors that would result in a sequential gross margin decrease. That benefit from new price increase trade investment especially, China, and our annual U.S. plant shutdown. These factors came in as expected during the fourth quarter. 
On a full year basis, gross margin was 64.6%, which is due to 70 basis points improvement versus the prior year. Mainly due to lower dairy costs, which benefited all segments. Supply chain productivity delivered approximately 5% of savings in cost of goods sold, which mitigated other costs and as noted previously. 
Moving on to operating expenses on Slide #6. Our advertising and promotion spending was 15.6% of sales in the fourth quarter compared to 13.7% in the prior year quarter. This was an increase of 7% on a constant-dollar basis. A&P investment on the fourth quarter includes support for China's fully imported products media for the U.S. children business and support for new product launches like the 32-ounce liquid and non-GMO product line that Kasper described earlier. SG&A, on a constant dollar basis, was 6% or $14 million lower than the fourth quarter of 2014. 
Savings were result of a lower incentive compensation and a reduction in corporate cost partly driven by our fuel for growth initiatives. SG&A, on a full year basis, were flat compared to 2014 on a constant-dollar basis. As you can see the from Slide 7, our cost-related research and development marketing decreased by 3% in 2015 versus 2014 on a constant-dollar basis. When comparing the second half year 2015 to the first half year 2015, the corporate support function decreased 8% mainly driven by the fuel for growth program. 
In the fourth quarter, we made the first wave of employee reductions. Compared to June, 2015, we reduced approximately 200 FTEs mainly within the corporate support functions where we reduced 18% of our headcount. 
We eliminated some outside services, initiated negotiations for key services. The headcount and outside sales' actions to take to date have allowed us to secure most of our $60 million fuel-for-growth target for 2016. We are very comfortable to deliver this year's savings. 
Turning now to Slide 8. On a constant-dollar basis, the fourth quarter EBIT was 3% below the prior year quarter and the full year EBIT was aligned with 2014. Including currency impact, EBIT was down 13% in the fourth quarter and down 7% for the full year. The EBIT margin as a percent of sales for the fourth quarter was slightly lower than the prior year quarter as continued investments were not fully offset on a higher gross margin. EBIT margins percent of sales for the full year increased by 30 basis points. 
I will now discuss EBIT for each segment. Starting with Asia on Slide 9. In Q4, Asia delivered EBIT of $140 million, a decrease of 24% on a constant-dollar basis. On a reported basis, EBIT was 28% lower mainly due to impacts of the Chinese renminbi. The EBIT margin at 30% was lower than the fourth quarter 2014 and the third quarter '15. As we continued to invest especially in China, these investments included price promotions on the locally manufactured products to protect competitiveness. Along with AMP support for the fully imported product line introduced earlier this year. As custom mentioned Greater China sales imprint sequentially as a result of these investments. For the full year, the ESA EBIT margin at 32% remains the highest of our 3 segments. However, the EBIT margin was lower than in 2014 as lower sales and high-demand generation investments were not fully offset by the the dairy benefit. Latin America on Slide #10 delivered EBIT of $34 million in the fourth quarter, an increase of 15% on a constant-dollar basis. On a reported basis, EBIT declined 26% as the region continued to have a large negative impact from currencies most notably, the Mexican peso. If we exclude the impact of Venezuela, where we contentiously reduced shipments, the segments reported EBITDA dollars for 2015 would have been in line with 2014 for both the fourth quarter and the full year. For the full year, Latin America EBIT margin improved slightly to 23.1%. Lower dairy costs more than offset the impact of the higher investments. 
Let me addressed North America and Europe on Slide 11. For the fourth quarter, EBIT was $97 million, an increase of 14% on a constant dollar basis and 8% on a reported basis. In the midst of a type comparison, the gross margin continued to be strong. The team managed to maintain operating expense in line with the prior year quarter, while increase in AMP by 9% on a constant-currency basis. For the full year, the North America and European EBIT margin was 28%, benefiting primarily from gross margin. I will now address our financial results from EBIT to net results on Slides #12. The fourth quarter interest expense increased to approximately $22 million reflecting the issuance of the new $1.5 billion notes to finance the share repurchase programs. During our October earnings call, we announced a new share repurchase program of our $1.5 billion. Of the company's common stock, with $1 billion in the form an accelerated share repurchase or ASR. The ASR was executed after the close of business on that same date. Under the accelerated share repurchase program, 10.7 million shares of stock were delivered in the quarter. Following this portion of the ASR, the average number of shares in the fourth quarter were 189.8 million. As of December 31, 2015, the outstanding shares were 186.4 million. It is expected that additional shares will be delivered in 2016 under the current ASR program. The ASR program was initially financed by a $1 billion term loan. Shortly thereafter, refinanced by the issuance notes, 7 of $50 million 5-year notes at a rate of 3% and $750 million 10-year notes at a rate of 4.125%. 
Taxes. For 2015, our non-GAAP effective tax rate or EPR was 24.8% compared to 22.5% in 2014. The 2014 rates was unusually low as a result of $0.05 per share nonrecurring tax benefit. Also, the 2015 EPR was also higher as a result of an a favorable change in geographic earnings mix. 
Let me briefly address our EPS on Slide 13. Non-GAAP EPS for the fourth quarter was $0.78, a decline of $0.14 versus the prior year quarter. Sales negatively impacted EPS by $0.16 offset by gross margin benefit. Foreign exchange adversely impacted EPS by $0.10. Full year non-GAAP EPS was $3.44, slightly above the high end of our guidance versus the prior year EPS declined by $0.30. The foreign-exchange alone negatively impacting EPS by $0.26. The sales decline impacted EPS by $0.26 as well. Gross margin benefit was offset by additional AMP investments to support our innovation especially our investments in China. 
Specified items. For 2015, specified items were $45 million or $0 17. The largest charge was $25 million. This occurred in the fourth quarter and was related to a restructuring provision fuel for growth productivity program. This was in line with our expectations we highlighted in our third quarter earnings call. Including the specified items, EPS on a non-GAAP basis was $3.27. 
Let me finish the 2015 discussion as a high-level overview of the cash flow and balance sheet. Despite the challenging operating environment, we generated strong cash flow, which further strengthened our balance sheet. As you can see, from Slide 14, free cash flow defined as operating cash flow less capital expenditures was $726 million due in 2015, up 20% from the prior year. For 2015, capital expenditures were $174 million consistent with our long-term goal of about 4% of sales. The most significant capital investments were to expand capacity at our European plant to support demand for the new China fully imported product line and in the U.S. to support new liquids manufacturing. Depreciation and amortization expenses was $99 million for the full year. For the full year 2015, we increased our dividends by 10% to $1.65 per share resulting in a total dividend payments of $326 million. The total payout ratio was close to 50% of our net results. Our cash balance, as of December 31, was $1.7 billion, an increase of approximately $400 million compared to December 2014. Nearly 90% of our cash is held outside the United States. Our net debt position as of December 31 was less than $1.3 billion. 
I will now wrap up with the summary of our 2016 guidance on a non-GAAP basis on Slide 15. We forecast constant-dollar sales in the range of 0% to 2% this year versus 2015. Assuming exchange rate remain at the current levels, this will translate to 2016 sales 4% to 6% below the prior year or reported basis. Please note that we expect positive sales comparison in the first half of 2016 versus 2015. This is due in part to a more favorable performance scene in China and especially in the first quarter of 2015. Constant-dollar sales in Q1 2016 are expected to be in line or slightly higher above the Q4 2015 performance. The company expects positive trend in the second half of 2016 on a constant-dollar basis. We expect higher investments in AMP in the first half of 2016. As a result, we expect the growth of non-GAAP EPS towards the second half of 2016. Please note that quarter 1 2016 non-GAAP EPS will have a tough comparison. From an EPS guidance perspective, there are several key factors to consider. We expect that our gross margins will be around 64%, similar to the fourth quarter 2015 level. We entered into dairy contracts at attractive prices to secure more than 80% of our expected 2016 dairy needs. Nearly all of the expected $60 million fuel for growth savings will be invested in demand-generating activities to enable long-term market share improvement. The benefits of all share repurchase in 2015, including the ASR program net of interest expense, is expected to be an $0.11 benefit per share. EPS guidance includes an annual estimated adverse impact of currency rates as of generated 2016, which is expected to be approximately $0.40 per share. Another 1% strengthening of the dollar against all currencies where we operate would lead to a further reduction EPS of about $0.04 per share. On a full year basis, just from translation. Taking all of this into account, non-GAAP EPS guidance is expected to be in the range of $3.48 to $3.60, excluding specified items. On a constant dollar basis, non-GAAP EPS guidance expected to grow 9% to 12% this excludes $0.11 from the benefits of the share repurchase program in 2015. The company expects to incur charges of approximately $25 million to $30 million associated with the fuel for growth program in 2016. Specified items, including charges fuel for growth are expected to be approximately $0.12 per share. Therefor GAAP EPS is expected to be in the range of $3.36 to $3.48, excluding future costs related to market-to-market, pension adjustments, which are not reflected in the guidance. This concludes my discussion on our quarter 4 and full year 2015 financial results. Thanks again for your time this morning. And with that, I will now turn the call back to Kasper."
1002291,321212057,922303,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Thank you, Michel. Lets me briefly provide some summary remarks before we open the lines for your questions. I'm proud of many of the operational adjustments we made in the second half of 2015 when we were faced with significant change. Likewise, I feel g",354,"Thank you, Michel. Lets me briefly provide some summary remarks before we open the lines for your questions. I'm proud of many of the operational adjustments we made in the second half of 2015 when we were faced with significant change. Likewise, I feel good that our key strategies are paying off, much investment in the United States was made because we believe the profession of that market. Sales and margins have now rebounded and are helping us overcome challenges Likewise, our decision to reshape our portfolio in China and focus on new growing sales channels is showing signs of paying off. Faced with macroeconomic challenges, we are making adjustments in other markets to. Change is inevitable and in many ways, businesses should be just by how will the hedges and adapt, and I'm confident that we'll look back at the end of this year able to notice that we did this quite well. Through last year, I repeatedly pointed to 4 important factors that critically influence company's performance. To remind you all, I'm referring to currency movements, dairy cost evolution, our ability to evolve our strategy and portfolio in China and our momentum in North America particularly in the United States. All of these 4 variables remain as relevant in 2016 as they were to our performance in 2015, but I should add pricing to the list. Our ability to offset partially foreign-exchange weakness with price increases would be very important. I'd add that I see some encouraging signs at price increases will become easier as we move through the year. I'll close with message that we'll continue to provide the clear visibility on the impact of foreign exchange as we move through 2016. We'll do so by providing updates on both the sales and profit growth, net of foreign-exchange. In addition to our traditional non-GAAP earnings per share numbers, we hope you'll find this informative. Operators, I'd now like to open the lines to questions and because our prepared remarks have taken longer than anticipated, we're prepared to go a few minutes over if the questions doing so. Operator, over to you."
1002291,321212057,922303,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Operator","[Operator Instructions] The first question comes from David Driscoll with Citi Research.",12,"[Operator Instructions] The first question comes from David Driscoll with Citi Research."
1002291,321212057,922303,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","This is Alexis for David. So question on China. Kasper, I appreciate your kind of comment on your prepared remarks. Still, I'd like to ask this bigger picture. Is your China strategy working? What evidence can you point us to and are your China market sha",52,"This is Alexis for David. So question on China. Kasper, I appreciate your kind of comment on your prepared remarks. Still, I'd like to ask this bigger picture. Is your China strategy working? What evidence can you point us to and are your China market share increasing? And I have a follow-up."
1002291,321212057,922303,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Well, I think I tried to provide some metrics that could hopefully support my statement that I believe our strategy is working. I think, we introduced the fully imported line of products into China sort of towards the back half really of the second quarte",263,"Well, I think I tried to provide some metrics that could hopefully support my statement that I believe our strategy is working. I think, we introduced the fully imported line of products into China sort of towards the back half really of the second quarter. And the fact that this product line is already making up 35% of our sales in the mainland and 22% of our sales in the combined China/Hong Kong business, I think, it's fairly impressive progress. I want to remind you also that of the message we gave on our Investor Day that we have confirmed our intention to enter the super-high premium category sometime in 2016. I'm sure you can understand that for competitive reasons, I'm not prepared to tell you what our plan timing is, but it goes without saying that we obviously have one. So I feel quite good about that. We now, if I add the Hong Kong business and our fully imported line together, we've now got more than half of our sales in the China/Hong Kong business coming out of our Netherlands facility. And therefore, meeting consumer desire for imported quality. So I think we're managing that transition quite well. I'm satisfied with the progress we're making in baby stores also. Through March of last year, we discussed the fact that we were under-indexing in baby stores, which is one of the faster growing sales channels. But as of late, we've seen some fairly satisfactory improvements to our market shares in the style. And I'm sure we'll continue to do so going forward."
1002291,321212057,922303,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Great. Alexis, just for the time constraints that we have, I'd like to go on to the next analyst.",19,"Great. Alexis, just for the time constraints that we have, I'd like to go on to the next analyst."
1002291,321212057,922303,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Operator","And the next question comes from Bryan Spillane from Bank of America.",12,"And the next question comes from Bryan Spillane from Bank of America."
1002291,321212057,922303,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","So just one question. I think, in 2015, in certain markets, you were able to price the try to take raise prices in order to try to offset some of the negative effects of foreign-exchange. I guess, in 2016, as you look at some of these markets that you in",112,"So just one question. I think, in 2015, in certain markets, you were able to price the try to take raise prices in order to try to offset some of the negative effects of foreign-exchange. I guess, in 2016, as you look at some of these markets that you in terms of whether it's currency volatility, does the cost savings that you're generating take some of the pressure off or give you more flexibility and not meeting the necessarily needed to try to price for offset the currency? Or are you still going to be looking to sort of prices in some of these markets where the currencies have moved so dramatically?"
1002291,321212057,922303,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Brian, thanks for the question. I think, we will definitely look to price in these markets. I think, as you heard us talk about, we were quite some distance off managing to cover the impact of foreign-exchange weakness through price in 2015. So that will",230,"Brian, thanks for the question. I think, we will definitely look to price in these markets. I think, as you heard us talk about, we were quite some distance off managing to cover the impact of foreign-exchange weakness through price in 2015. So that will a be continued challenge or task for us as we go through 2016. As I was trying to indicate, I think, the pricing environment will become so much more friendly. What we saw in '15 was that there was still particularly, I would say, in Asia, there were still governments in Asia that were very resistant to price increases in our sector as they still focused very much on kind of inflationary pressure -- on perceived inflationary pressure, which we think we all know was really a threat that evaporated sometime in 2014. And they would repeatedly point to the fact that we were seeing significant upside from the dairy costs coming down as we discussed the price increases. I think now that the dairy prices have stabilized, I believe that as both us and our competitors lack the no dairy costs, it will become a little bit more straightforward to raise prices. But we obviously had to do that in a responsible manner. We have to assess that in the context of general price inflation and wage inflation in the markets we operate in."
1002291,321212057,922303,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Operator","Your next question comes from Amit Sharma with BMO Capital Markets.",11,"Your next question comes from Amit Sharma with BMO Capital Markets."
1002291,321212057,922303,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","Kasper, without asking you to speculate on the timing of it or even heard that, that the Chinese government is looking at changing the tariff regulation for cross-border trade online. On a wider context, how do you think about how your positioned in the B",59,"Kasper, without asking you to speculate on the timing of it or even heard that, that the Chinese government is looking at changing the tariff regulation for cross-border trade online. On a wider context, how do you think about how your positioned in the B2B channel and on tax on how will that impact your positioning in that channel?"
1002291,321212057,922303,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Well, I think there are -- as it relates to China, I expect that we're going to see regulatory adjustments coming sometime in 2016. I don't want to speculate on whether those regulatory adjustments will address all of the imbalances that we are seeing cur",199,"Well, I think there are -- as it relates to China, I expect that we're going to see regulatory adjustments coming sometime in 2016. I don't want to speculate on whether those regulatory adjustments will address all of the imbalances that we are seeing currently in China, but I believe that they will begin to address some of them. At the moment, it's clear that inadvertently, the China regulations have created a tilted playing field, but it's very much tilting in favor of imported products sold through e-commerce. I don't believe that, that was the intention of either the regulators or the China government at large and I think, they will find ways to address that. I also think that they remain concerned about the large number of smaller brands that have been created in China have that really led the expertise all the resources to guarantee consumer quality and I think, that will be addressed. So, I think, you're going to a whole slew attempt at least by regulators to get at some of these issues through this year. But since you gave me a free pass on the timing, I'll probably take advantage of that, I met."
1002291,321212057,922303,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Operator, to the next?",4,"Operator, to the next?"
1002291,321212057,922303,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Operator","Your next question comes from Ken Goldman with JPMorgan.",9,"Your next question comes from Ken Goldman with JPMorgan."
1002291,321212057,922303,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","Michel, I think, if I'm not wrong, that Mead Johnson locked in a bit more milk supply than usual this early in the year. I know it sometimes goes back and forth, it's hard to tell but it feels like it's a little more than usual. So first, correct me if I'",114,"Michel, I think, if I'm not wrong, that Mead Johnson locked in a bit more milk supply than usual this early in the year. I know it sometimes goes back and forth, it's hard to tell but it feels like it's a little more than usual. So first, correct me if I'm wrong on that. And second, if that's correct, is that more of a tactical move just based on where milk cost and prices are? Or is it more of a strategic change that you'd like to implement whereby you maybe get a little more visibility there and a little more ability to price in line with where you think you have cost?"
1002291,321212057,922303,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Yes, I think, it is correct. It's a higher level than we used to have. And it also threw that we've taken that position on purpose given the current benefits that we see. I don't like too much volatility into the P&L, so nobody does that, so the more you",66,"Yes, I think, it is correct. It's a higher level than we used to have. And it also threw that we've taken that position on purpose given the current benefits that we see. I don't like too much volatility into the P&L, so nobody does that, so the more you can control the better that is and this was one of the actions we have taken."
1002291,321212057,922303,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","So should I interpret that as I got to figure out more tactical or strategic. I kind of heard both in there.",22,"So should I interpret that as I got to figure out more tactical or strategic. I kind of heard both in there."
1002291,321212057,922303,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Correct.",1,"Correct."
1002291,321212057,922303,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Operator","Your next question comes from the line of John Baumgartner with Wells Fargo.",13,"Your next question comes from the line of John Baumgartner with Wells Fargo."
1002291,321212057,922303,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","Kasper, I wanted to ask about North America. So you measure the margins being close to record levels here. How much of the margin expansion over the past 2 years is a function of the commodity cost benefits are more temporary versus maybe something more s",72,"Kasper, I wanted to ask about North America. So you measure the margins being close to record levels here. How much of the margin expansion over the past 2 years is a function of the commodity cost benefits are more temporary versus maybe something more structural in terms of the cost savings or portfolio mix? Should we think of the this high 20s level kind of a new normal for the business?"
1002291,321212057,922303,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Yes, John, I don't think -- if I said record levels, I misspoke. I think, I said historic levels. So but it may go back to days before we were public company so you may have in perfect visibility. I guess, what I was trying to indicate was that I believe",189,"Yes, John, I don't think -- if I said record levels, I misspoke. I think, I said historic levels. So but it may go back to days before we were public company so you may have in perfect visibility. I guess, what I was trying to indicate was that I believe that these levels of profitability in the North American business are sustainable, to put it sort of candidly. It's not inconsistent with where we have been and what we see in the North American businesses that we get a lot of leverage on both sales and volume growth in that business. So put another way, our marginal costs are very low in that business and hence, we see big swings in profitability as sales move up and down. So I'm quite comfortable, I feel good about where the margins are, and I think we've got other parts of our global portfolio where we are working in difficult trading environments and that, that results some perhaps and margin pressure so it's quite rewarding to see that this part of our portfolio has the opposite dynamic paying in its favor."
1002291,321212057,922303,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Operator","The next question comes from the line of Michael Mabry with sealless a.",13,"The next question comes from the line of Michael Mabry with sealless a."
1002291,321212057,922303,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","Could you talk a little bit more about your prior investments in China and how much of that is trade spending or discounting versus AMP investments. And I also just update your timing you said at the Investor Day you felt you had about the former quarters",56,"Could you talk a little bit more about your prior investments in China and how much of that is trade spending or discounting versus AMP investments. And I also just update your timing you said at the Investor Day you felt you had about the former quarters of discounting pressure there is that still your view?"
1002291,321212057,922303,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","My investments in China primarily I would say in the second half of 2015 were largely focused on changing our trading profile. That means matching both competitors pricing and also matching their general profile with the retail trade. As we go forward, an",82,"My investments in China primarily I would say in the second half of 2015 were largely focused on changing our trading profile. That means matching both competitors pricing and also matching their general profile with the retail trade. As we go forward, and we look at 2016, we will, obviously, invest behind our new growth initiatives so that you expect that, that will lead to some increase in both of those lands, both the trade support and the advertising and promotional expense."
1002291,321212057,922303,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Operator","Your next question comes from the line of Matthew Grainger with Morgan Stanley.",13,"Your next question comes from the line of Matthew Grainger with Morgan Stanley."
1002291,321212057,922303,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","Kasper or Michel, just wanted to clarify a bit further into the EPS guidance and I joined a bit late, so I may have missed an aspect of the explanation. But you've maintained the expectation of mid-single-digit EPS growth despite the FX headwind being sig",74,"Kasper or Michel, just wanted to clarify a bit further into the EPS guidance and I joined a bit late, so I may have missed an aspect of the explanation. But you've maintained the expectation of mid-single-digit EPS growth despite the FX headwind being significantly higher. So just curious what the Delta was over the past few months that's giving you more confidence in the constant-currency outlook or sort of margins flexibility during 2016?"
1002291,321212057,922303,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","I mean you understand the correct, we indicated that investments the mid-single digit and that is in line on what we are confirming now, despite the fact that we will have a higher from currencies. I indicated in the investments day that at that point of",218,"I mean you understand the correct, we indicated that investments the mid-single digit and that is in line on what we are confirming now, despite the fact that we will have a higher from currencies. I indicated in the investments day that at that point of time, foreign-exchange impact would have been around $0.15. Right now, we are looking at base on current spot rates, we're looking at the 14 -- $0.40 impact on from currencies. So it clearly look into how we can mitigate that to still deliver mid-single-digit growth. On one hand side, like Kasper, we clearly look into pricing because that's an area where we think we need to be very cautious to see what can we do in certain markets, that's one. Two, I highlight specifically and refer most of the earlier question on dairy benefits. We secured 80%, which is higher-than-expected also in quarter 3 so that's one of the weather if tactical or strategic initiatives to secure the benefit to avoid volatility. And thirdly, like Kasper also indicated, we are pleased starting further assessments what can we do in terms of the demand investments and that will be leaning more towards mid-of this year. So all of these initiatives, we accelerated actually, and we took actions to mitigate the higher foreign-exchange exposure."
1002291,321212057,922303,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","Okay so it's more the actions you just mentioned as opposed to further acceleration of fuel for growth savings?",20,"Okay so it's more the actions you just mentioned as opposed to further acceleration of fuel for growth savings?"
1002291,321212057,922303,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Well it is. It is a combination, right? As I said, fuel growth savings that's confirmed. Significantly confirm so that wasn't the case yet to the investments they but secondly, like I said, we also going further for the assessment in demand investment.",43,"Well it is. It is a combination, right? As I said, fuel growth savings that's confirmed. Significantly confirm so that wasn't the case yet to the investments they but secondly, like I said, we also going further for the assessment in demand investment."
1002291,321212057,922303,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Operator","Your next question comes from Jason English with Goldman Sachs.",10,"Your next question comes from Jason English with Goldman Sachs."
1002291,321212057,922303,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","Housekeeping question, I think, about I heard you say that in the first quarter, that if the sales are in constant currency would be flat to may be up 2 versus the fourth quarter of '15. Can you confirm that I heard that right and also urges mathematicall",94,"Housekeeping question, I think, about I heard you say that in the first quarter, that if the sales are in constant currency would be flat to may be up 2 versus the fourth quarter of '15. Can you confirm that I heard that right and also urges mathematically as I'm looking at my model, it seems to suggest that sales could be down close to 20% in the fourth quarter. Is that right? And if so, where -- what should we be brace for in terms of pockets outsize weakness in the first quarter?"
1002291,321212057,922303,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Well, I think -- let me try and repeat what we said. I said in my prepared remarks that we expect to see sequential quarterly improvement incessant constant dollar sales. So that would translate into sales in the first quarter as opposed to being or above",51,"Well, I think -- let me try and repeat what we said. I said in my prepared remarks that we expect to see sequential quarterly improvement incessant constant dollar sales. So that would translate into sales in the first quarter as opposed to being or above the level Indo fourth quarter."
1002291,321212057,922303,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","And that's with currency?",5,"And that's with currency?"
1002291,321212057,922303,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","No, that was in constant dollars.",6,"No, that was in constant dollars."
1002291,321212057,922303,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","I'll try to get clarification  I'll pass it on for now.",12,"I'll try to get clarification  I'll pass it on for now."
1002291,321212057,922303,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","For the full year, we've clearly expect to see adverse currency impact. I think, we've said, Jason, that we expect about a 600 basis points adverse impact from foreign exchange, and we also said that we have based that on basically the current exchange ra",70,"For the full year, we've clearly expect to see adverse currency impact. I think, we've said, Jason, that we expect about a 600 basis points adverse impact from foreign exchange, and we also said that we have based that on basically the current exchange rates as of this month. So that would stand to reason that, that's 600 basis an adverse impact would start at the beginning of the year."
1002291,321212057,922303,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Operator","Your next question comes from the line of Robert Moscow with Crdit Suisse.",13,"Your next question comes from the line of Robert Moscow with Crdit Suisse."
1002291,321212057,922303,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","This is kind of a follow-up to Matthew's question. I mean, if you do the math, the foreign exchange headwind is significantly than what you thought in October. And but you're kind of maintaining, I think, the same guidance you had before and that guidance",135,"This is kind of a follow-up to Matthew's question. I mean, if you do the math, the foreign exchange headwind is significantly than what you thought in October. And but you're kind of maintaining, I think, the same guidance you had before and that guidance implies quite a bit of growth in the core business in order to be achievable. You mentioned to pricing and that's probably the tool that you would use, and then locking in dairy, although, I think, if you locked in, I'm not sure how that's a benefit from October. So Michel, maybe you can help we decided a bit more, don't you have to push the pricing lever quarter than you thought in October in order to achieve this guidance or are there other levers on that aware of?"
1002291,321212057,922303,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","It is indeed in combination of the price mix. What we need to look into country mix but yes, I mean it's a component that is higher than we indicated the us that been anticipated in quarter 3.",38,"It is indeed in combination of the price mix. What we need to look into country mix but yes, I mean it's a component that is higher than we indicated the us that been anticipated in quarter 3."
1002291,321212057,922303,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","And how is that -- is it is achievable given the competitive environment or do something has to change in the competitive environment in order for that to happen?",29,"And how is that -- is it is achievable given the competitive environment or do something has to change in the competitive environment in order for that to happen?"
1002291,321212057,922303,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Look, part of that is driven by certain innovation rollouts that we have been scheduled, we're tragic and by that us most as possible to take further than initiative thought.",30,"Look, part of that is driven by certain innovation rollouts that we have been scheduled, we're tragic and by that us most as possible to take further than initiative thought."
1002291,321212057,922303,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Operator","And expression comes from Eric Katzman with Deutsche Bank.",9,"And expression comes from Eric Katzman with Deutsche Bank."
1002291,321212057,922303,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","I guess, let me ask about promotion for a second. Back at our conference in Paris, Kasper, you talked about promotion being kind of the initial signs of being more concerned about it in China, and then, I guess, it broadened out into Latin America and oth",112,"I guess, let me ask about promotion for a second. Back at our conference in Paris, Kasper, you talked about promotion being kind of the initial signs of being more concerned about it in China, and then, I guess, it broadened out into Latin America and other regions. So I guess it's been a long call, but just, so I frame it, did you kind of end 2015 with what, I think, you had dubbed kind of irrational behavior on the part of competition? Was that kind of sequentially flats or did it get worse? And kind of what assumptions are you making around promotion into 2016? And I'll pass it on."
1002291,321212057,922303,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Yes, it's an excellent question and -- but you caught my comment correctly. I indicated that we've seen the environment stabilize so there's still -- I would not say it has improved, but the environment has stabilized. And I think, having now entered the",111,"Yes, it's an excellent question and -- but you caught my comment correctly. I indicated that we've seen the environment stabilize so there's still -- I would not say it has improved, but the environment has stabilized. And I think, having now entered the phase, so to speak in order to protect our competitive position, we saw that payoff in terms of stabilizing and even improving our underlying self performance in the fourth quarter. So yes, I feel the environment, including in China is now a little bit more stable, but it's clearly stable at a much higher level of promotion then say where we were a couple of years ago."
1002291,321212057,922303,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","And looking into '16?",4,"And looking into '16?"
1002291,321212057,922303,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","We expected that the environment will remain stable in '16.",10,"We expected that the environment will remain stable in '16."
1002291,321212057,922303,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Operator","Your next question comes from... Am sorry?",8,"Your next question comes from... Am sorry?"
1002291,321212057,922303,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","I'm just we say we have time for 1 more call so that we're that you're going to pick and will be the last.",25,"I'm just we say we have time for 1 more call so that we're that you're going to pick and will be the last."
1002291,321212057,922303,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Operator","And ask Russian comes from David Hayes would never.",9,"And ask Russian comes from David Hayes would never."
1002291,321212057,922303,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","Just try to pick up on the compensation benefit shift. You obviously made a point margin benefits, I think, we take back end of the year of the compensation, I guess, reversing to some extent through the year in terms of of course, you might've taken begi",136,"Just try to pick up on the compensation benefit shift. You obviously made a point margin benefits, I think, we take back end of the year of the compensation, I guess, reversing to some extent through the year in terms of of course, you might've taken beginning of the year. So just a question on that one can you quantify the impacts of that variable comp dropping out in the second, I guess, more importantly, as you look into next year of his you talked about it more this year you talked about being a transit shoes and your treasure mentioned earlier, would expect that compensation to come back into the numbers or is the organization of the to be not going to pay until the performance for the group steps up the to previous levels?"
1002291,321212057,922303,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","In the composition the dropped in the year 2015 given the lower performance, which had an estimate impact around $30 million. If you look to the numbers for next year, yes, we put it back to normal talking levels. So those ones are included in the numbers",54,"In the composition the dropped in the year 2015 given the lower performance, which had an estimate impact around $30 million. If you look to the numbers for next year, yes, we put it back to normal talking levels. So those ones are included in the numbers that we are provided Q4 for guidance."
1002291,321212057,922303,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","But that's included in the margin?",7,"But that's included in the margin?"
1002291,321212057,922303,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","That's included in the numbers, yes.",7,"That's included in the numbers, yes."
1002291,321212057,922303,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Operator, I think, discloses our call.",6,"Operator, I think, discloses our call."
1002291,321212057,922303,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Operator","Ladies and gentlemen, thank you for your participation in today's conference. This concludes the presentation. You may now disconnect. Good day.",21,"Ladies and gentlemen, thank you for your participation in today's conference. This concludes the presentation. You may now disconnect. Good day."
1002291,321212057,922620,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Operator","Good day, ladies and gentlemen, and welcome to the Mead Johnson Nutrition Fourth Quarter 2015 Earnings Conference Call. My name is Liz, and I'll be your coordinator for today. [Operator Instructions] As a reminder, this conference is being recorded for re",62,"Good day, ladies and gentlemen, and welcome to the Mead Johnson Nutrition Fourth Quarter 2015 Earnings Conference Call. My name is Liz, and I'll be your coordinator for today. [Operator Instructions] As a reminder, this conference is being recorded for replay purposes. I would now like to turn the conference call over to Kathy MacDonald, Vice President, Investor Relations. Please proceed, Kathy."
1002291,321212057,922620,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Thank you, Liz. Good morning, and thank you for joining Mead Johnson's Fourth Quarter and Full Year 2015 Conference Call. With me today are Kasper Jakobsen, our Chief Executive Officer; and Michel Cup, our Chief Financial Officer. Earlier today, we issued",309,"Thank you, Liz. Good morning, and thank you for joining Mead Johnson's Fourth Quarter and Full Year 2015 Conference Call. With me today are Kasper Jakobsen, our Chief Executive Officer; and Michel Cup, our Chief Financial Officer. Earlier today, we issued our earnings release and financial reference slides which are available on our website.
As we start, let me remind everyone that our comments will include forward-looking statements about our future results, including statements about our financial prospects and projections, commodity costs, currency fluctuations, pricing, taxes, capital spending, depreciation and amortization, new product launches, product quality, other growth initiatives and market conditions that constitute forward-looking statements for purposes of the Safe Harbor provisions under the Private Securities Litigation Reform Act of 1995. A more detailed explanation of our forward-looking statements will appear in the materials posted on our website in connection with today's conference call.
Keep in mind that our actual results may differ materially from expectations as of today due to various factors, including those listed in our Annual Report on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K, in each case, as filed with or furnished to, the Securities and Exchange Commission and our earnings release issued this morning, all of which are available upon request or on our website at meadjohnson.com.
Today's comments will include discussion of non-GAAP financial measures. A reconciliation of these measures to comparable GAAP measures, appears in the morning's earnings release posted on our website. In addition, any forward-looking statements represent our estimates only as of today and should not be relied upon as representing our estimates as any subsequent date. While we may elect to update forward-looking statements at some point in the future, we specifically disclaim any obligation to do so even if our estimates change. I will now turn the call over to Kasper."
1002291,321212057,922620,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Thank you, Kathy, and thank you to all of you for listening to our fourth quarter and full year earnings call this morning. Over the next 35 minutes or so, Michel and myself will summarize our fourth quarter and full year 2015 financial results. We'll als",3382,"Thank you, Kathy, and thank you to all of you for listening to our fourth quarter and full year earnings call this morning. Over the next 35 minutes or so, Michel and myself will summarize our fourth quarter and full year 2015 financial results. We'll also outline our expectations for 2016. 
I'll begin by providing an overview focusing on revenue performance, our key strategic initiatives and business drivers and underlying business momentum. I'll then hand over to Michel, who'll give a further analysis of our financial metrics and provide an outlook for key cost drivers. After Michel completes his segment, I will return with a few summary remarks before we give you an opportunity to ask questions. Except when noted otherwise, I'll be referring to non-GAAP results. A full reconciliation to our GAAP results is available in our 10-Q that was filed alongside our earnings release earlier this morning. Both documents are available on our website. 
Let me start with a high-level overview of our fourth quarter 2015 results for the global business before I move on to discuss full year results and then performance of each of our regions. As we exited the year, and I refer now to fourth quarter results specifically, I'm pleased to say we saw a sequential improvement versus the third quarter in our underlying sales performance. Net of withheld shipments to Venezuela, a topic I'll return to later, we saw a sequential growth in constant dollars sales of 1%. This represented a modest reversal of the trend we've seen over the previous 3 quarters, despite sales performance being adversely affected by selected retailer inventory adjustments in Thailand and Malaysia.
Structural changes made to our investment profile in China and the recent launch of our fully imported line of Enfa products helped us deliver on the promise we made in July. At that time, we said we expected to see sequential improvement in China sales as we exited the year. And in the fourth quarter, our China/Hong Kong business grew 2% sequentially over the third quarter. Our North America/Europe segment also grew sequentially by nearly 5% on a constant dollar basis. 
Let me now address our full year results. 2015 was a challenging year for us. We were challenged by a strengthening dollar and the general weakness in many economies throughout Asia and Latin America. GDP growth across Asia and Latin America was lower than prior year and this affected both consumer and retailer confidence. Additionally, in China, we saw increased price-based competition and channel shifts that adversely impacted sales growth and required us to boost investment to protect our competitiveness. 
In Southeast Asia, in particular, we saw slowing economic growth in Thailand and Malaysia. Combined with some company-specific executional issues, this resulted in lower volumes through the year. In the Philippines, where GDP growth remain more robust, we saw relatively better performance. And there, we are satisfied with the progress we made through the year. We continue to benefit from lower dairy costs and an improved gross margin as a consequence. This helped partially offset the EBIT and EPS impact of foreign exchange and lower sales.
For full year 2015, constant dollar net sales were 2% below prior year, largely due to our challenges in China and Hong Kong. Gross sales, however, were in line with 2014. This shows continued solid demand for our brands, though a challenging trading environment saw us report sales below prior year level. 
The impact of a strengthening dollar was significant throughout the year, reducing reported sales by about 6% and earnings per share by $0.26. Where possible, we took price to mitigate the impact of foreign exchange. However, competitor strategies and abnormally low dairy costs made price increases more difficult than we've seen in recent years.
Price consequently contributed 1% -- percentage point of growth to the full year. As we progress through the year, the carryover benefit of price increases taken in 2014 gradually disappeared and price promotional activity became more evident. Against the same quarter of prior year, this increased dynamic adversely affected fourth quarter gross by 1 percentage point. This was largely driven by increased trade promotional activity in China. Global volume was 3% lower than prior year, growth in North America and Europe didn't fully offset weaker performance in Asia and Latin America, and the impact of our decision to slow shipments into Venezuela was also significant.
Infant formula product sales for 2015 were in line with prior year on a constant dollar basis. It follows that we were relatively more challenged within our children's category outside of North America. The children's category is more price-sensitive and, prior to reshaping our competitive stance in the third quarter, we suffered share losses due to competitors' price promotional activity. However, having addressed the price disadvantage as the cohort of infants' age, that consumer brand, this should help sales of our children's franchise going forward.
We understand the recovery of momentum in China and select other emerging markets could take time, and we need to properly fund key growth initiatives. As a consequence, the company invests -- the company's investment in advertising and promotion remained strong in the fourth quarter at 15.6% of sales. This was 190 basis points above prior year's fourth quarter level. 
To help fund these investments and offset the impact of foreign exchange, we accelerated the implementation of some of our operating expense reductions. We refer to this initiative as Fuel for Growth. As a direct result of this focus, our operating expenses came in approximately $20 million favorable versus the forecast that underpinned guidance issued in October. This favorability allowed us to offset the impact of unanticipated dollar strength in the final quarter of the year and still delivered earnings-per-share slightly above the high end of our guidance range.
We delivered $0.78 in non-GAAP earnings per share for the final quarter of 2015. As mentioned, this was slightly better than expected and allowed us to finish 2015 with $3.44 in non-GAAP earnings per share. Even as we grappled with adverse dynamics in many of our markets in 2015, I'm pleased that we avoided any temptation to pull back on investment. We know that continues innovation is critical to our long-term growth prospects.
Here are some examples of new products we introduced around the world. In the United States, we introduced new and more convenient plastic packaging for our 32-ounce ready-to-feed liquid infant formula, building on the success of our 8-ounce launch a couple of years ago. We also responded quickly to competitive activity by introducing a new formulation of infant formula free from genetically-modified raw materials. Across North America, we became the first company to meet newly developed guidance for premature infant formula. And in China, we introduced a fully imported range of Enfa-branded products to complement our locally manufactured range. These fully imported products now account for 35% of our sales within the mainland. 
In Southeast Asia, we upgraded our formulations and added increased levels of DHA to our children's products. We also introduced plastics packaging in several countries, and we added ready-to-drink versions to our lineup of Enfa products. In Latin America, we introduced liquid versions of our key infant formula products; and in Mexico, our Enfagrow Toddler product. For our powdered products, we began the introduction of upgraded plastics packaging. 
Further, over more than 70 years, we worked diligently to develop clinical evidence in support of our specialty portfolio, predominantly our Nutramigen allergy brand. Educating health care professionals about Nutramigen's benefits allowed us to grow constant dollar sales double digits in 2015.
As I complete my comments on overall company performance and before I move to discussing our reporting segments in more detail, I want to mention that, as promised, we executed an accelerated share repurchase program in the most recent quarter. This reflects our commitment to the creation of long-term shareholder value. Michel will revert to this topic later. Let me now briefly comment on the performance within each of our reporting segment, and I begin with Asia. 
Sequentially, Asia's sales were in line with third quarter, with improvements in China, offset by lower sales in Thailand and Malaysia. For fourth quarter, constant dollar sales were 10% below the prior year. Quarter and full year sales compared unfavorably to 2014 by 8%. As mentioned, sequentially, we grew sales in China/Hong Kong by 2% from the third quarter of 2015. A more aggressive trading stance allowed us to stabilize sales of our locally manufactured product line, though we've had to increase our investment we encourage the prices to consumers, appear to have stabilized in the fourth quarter. 
At the same time, demand for our recently introduced fully imported range continued to grow. As mentioned earlier, sales of this product range now accounts to 35% of our sales in Mainland China and a full 22% of our combined China/Hong Kong business. As we expand direct shipments of fully imported products into Mainland China, we expect to see continued cannibalization of our Hong Kong business. Such channel shifts may obscure underlying business progress in the near term, but ultimately should be favorable to the company overall, as we build a stronger, more sustainable portfolio with greater reach inside Mainland China. 
As mentioned at our Investor Day in October, we are committed to make investments in support of our recent introductions. We're advancing digital marketing capabilities, expanding our channel coverage and strengthening our retail chain relationships through focused investments. Beyond the early sales success with our imported product range, as a further sign our strategy is working, we are seeing market share gains in baby stores.
As you know, we've also focused on strengthening our presence in business-to-consumer e-commerce. This represents the fastest growing part of the e-commerce market in China. And the segment is growing at approximately 5x the rate of the rest of the e-commerce channel. In a sign of our commitment to strengthening our presence in web and app-based commerce, we recently signed joint business partnership agreements with Jingdong, owner of leading e-commerce site, JD.com; and Tencent, owner of WeChat, the leading social app in China. Under these agreements, we agreed to cooperate by sharing data and technology platforms to the mutual benefits of our separate businesses. These agreements recognize the expertise of each party, including Mead Johnson China, and we are thrilled to partner with such great companies. 
While our China business began to show progress, our businesses in Malaysia and Thailand experienced challenges as mentioned earlier. Both economies are going through a challenging time due to political uncertainty and weak commodity prices. As a result, both consumer and business confidence is reduced. However, despite this backdrop, I want to acknowledge that we have not executed as well as expected in either country for much of 2015. Though we cannot control economic trends, we can and will control our execution, and we are taking steps to improve performance going forward. In the meantime, we continue to manage trade inventory bills carefully in the fourth quarter. 
In the third quarter, we enhanced our products in Thailand with increased levels of DHA and introduced new packaging, including a plastic tub. Early signs are encouraging, with share increasing in the 3 months following our relaunch. However, it took longer than expected to deplete old inventory in the trade, and consequently, we chose to address this more aggressively in the most recent quarter.
Having discussed some areas of relative challenge, let me now point to our relatively stronger performance in the Philippines. The Philippines' business has delivered solid growth over the past 2 years. We've managed to offset foreign exchange impacts with improved pricing, and we've successfully extended our Lactum children's brand into the infant formula category. This move gives us exposure to a growing economy beyond our traditional premium price position. 
Turning now to Latin America. The region delivered constant dollar sales growth of 3% for the full year compared to 2014. Regional currencies weakened substantially through 2015, with large adverse impacts on sales growth in Brazil, Argentina, Colombia, Venezuela and Mexico. As a consequence, reported sales were 13% below prior year level. For the fourth quarter, excluding Venezuela to where we paused shipments for much of the quarter, sales grew 5% on a our constant dollar basis over the same quarter of prior year. Including Venezuela, the region sales for fourth quarter '15 were 4% lower in constant dollars than the same quarter of 2014. 
As you can tell, our decision to pause shipments to Venezuela was a significant driver of relatively weaker segment performance. As stated in previous calls, we are carefully managing risk associated with our intercompany payables within defined parameters. In the near term, this means matching new shipments to Venezuela to hard currency payments received. We are actually working with the Venezuelan government to address this challenge in order that we can once again help provide much needed nutrition to children in that country. 
Looking at the overall economy of Latin America, over the past decade, these commodity-driven economies benefited substantially from stronger prices. Since the collapse in commodity prices, Latin America's GDP growth has slowed dramatically. Countries beyond the obvious example of Brazil, that's in the recession, are grappling with sharp reductions in their growth rates for the first time since 2009. These macroeconomic conditions, coupled with the strengthening dollar have resulted in sharp depreciation of local currencies.
I'd like to provide a little more detail in today's discussion. And for that purpose, I'll group the region into 3 sessions. I've excluded Venezuela, which I've discussed separately already. I'll now discuss Mexico, the Caribbean and Central America as a distinct area from the Southern Cone area of Brazil and Argentina. And finally, touch briefly on the Andean region, in which we include Peru, Ecuador and Colombia.
In Mexico, the Caribbean and Central America, the Enfa family of premium products grew strongly in constant dollars, both sequentially over the third quarter and in full year 2015, and now represents about 2/3 of sales within the area. Outside of Mexico, much of our business in this area is conducted in U.S. dollars. This helped to partially offset the impact from a decline in the Mexican peso. That said, the Mexican business is our third largest business globally. And many of you already know our Mexican portfolio augments our global Enfa-branded products with 2 very strong local brands milk modifiers, Choco Milk and Cal-C-Tose. 
These 2 milk modifier brands gave us a leading edge -- or a leading share, sorry, of the large Mexican milk modifier market. A large category that's, however, characterize by strong competition from global and local players. With limited potential to expand consumer penetration, competition is tough and occasionally price-based. These dynamics, over the last several years, have caused our milk modifier brands to grow more slowly than our Enfa-branded infant and children's business. In 2015, milk modifiers net sales declined as we expanded trade discounts to protect our competitive position. This impacted the overall Mexico results adversely.
Our performance in the South Cone area was adversely impacted by the economic recession and currency weakness in Brazil. In Argentina, price schemes more than covered the impact of currency depreciation. And across the area, we continue to grow our infant formula and toddler sales strongly in local currency. However, in Brazil, we also sell the Sustagen brand of milk modifiers. And in this category, we saw consumers move to cheaper competitive offerings and we lost sales as a consequence. Within the Andean region, we saw Colombia deliver strong double-digit growth for both the latest quarter and the full year. The smaller market of Ecuador also performed well, but these encouraging results were offset by challenging retail conditions in Peru. 
To wrap up, the key drivers for the Latin America full year results are: volume, which was lower primarily from our intentional constraint of Venezuela shipments and Mexico milk modifier sales reductions; price, that was predominantly from the high inflationary markets of Argentina, Colombia and Venezuela; and finally, foreign exchange that negatively impacted the region. 
I'll now turn to our performance in North America and Europe. In the full year 2015, the North America/Europe segment delivered 4% constant dollar revenue growth over 2014. Volume improved 1%, with price and product mix contributing 3% to our annual growth rate. In the fourth quarter, this segment's sales were in line with the prior year's quarter. Sequentially, as stated earlier, sales increased 5% over the third quarter. With little to no growth in the category in North America, our volume growth was realized through market share gains and our Enfagrow children's business continued double-digit growth. Our premium price specialty and solutions offerings also grew double digits. And our Canadian business continued to execute extremely well and exited the year with record high-market shares.
Europe posted its strongest sales and EBIT performance in the last 5 years, though the sales impact was partially offset by our exit from the Russian market earlier in the year. Overall, 2015 was another strong year for this segment. A year in which we saw profit margins expand to approach historic levels. In many ways, this was proof that our decision to maintain investment levels through the 2009 to 2012 economic downturn was the right one. 
Turning now to our outlook for 2016. Our outlook is broadly similar to that provided at our Investor Day in October. We expect constant dollar sales to continue to show gradual improvement sequentially through the coming quarters. But due to tough comparisons from the first half of 2015, we do not expect to report positive revenue growth over same quarter of prior year till the second half of 2016. For this reason, we expect full year 2016 constant dollar sales growth to be modest in the range of 0% to 2%. 
Based on current exchange rates, we expect currency to reduce sales growth by approximately 600 basis points. As a result, reported sales may decrease by 4% to 6% this year. We now have a good fix on dairy costs, as this item will impact our profit and loss statement through the first 7 or 8 months of the year. Based on this, we are comfortable saying that, again, in 2016, dairy prices would have a favorable impact on our cost of goods.
At our Investor Day event last October, we characterized 2016 as a year of transition. In the context of headwinds from a strengthening dollar, we committed to reduce non-demand-creating operating expenses by $60 million in order to reinvest in select growth initiatives and protect earnings growth. As headwinds from currencies have grown stronger since our October gathering, this initiative has become even more essential to our strategy, and I'm pleased to report, we're making good progress and remain confident in our ability to deliver on our cost-reduction ambition. 
As mentioned in our press release this morning, I believe it's important for us to give you a better picture of the expected evolution in underlying profitability without the polluting effect of currency impact. To this end, let me clarify that we expect to deliver 9% to 12% constant dollar, non-GAAP earnings per share growth. And based on our assumption around foreign exchange, we expect therefore non-GAAP earnings per share, when expressed in U.S. dollars, to be in the range of $3.48 to $3.60. Not included in our estimates of 2016 is any additional benefits that might accrue from a review of efficiency and productivity opportunities within our demand-generating investments. Such a review is currently scheduled for mid-2016.
I must point out that we remain highly focused on further strengthening -- sorry, we must -- we remain highly exposed to the further strengthening of the dollar or selected weakening in foreign currencies. Anticipating that we may continue to see some variability in exchange rates through the year, we've decided to provide you with a reconciliation to growth in non-GAAP constant dollar earnings per share.
I'll now turn the call over to Michel, who will provide some more details on our fourth quarter and full year financials. Michel will also elaborate on our guidance for 2016. And upon the completion of his prepared remarks, I'll return with some summary remarks before we open the lines to questions. Michel, over to you."
1002291,321212057,922620,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Thank you, Kasper, and good morning, everyone. Today, I will discuss our fourth quarter and full year 2015 financial results. I will then briefly highlight segment results and conclude with a summary of our 2016 guidance. Unless otherwise noted, my commen",2233,"Thank you, Kasper, and good morning, everyone. Today, I will discuss our fourth quarter and full year 2015 financial results. I will then briefly highlight segment results and conclude with a summary of our 2016 guidance. Unless otherwise noted, my comments will be on the non-GAAP financial results. References to gross impacts or the effects of currency fluctuations generally refer to the impact on the translation of local currency financial statement into U.S. dollars. 
Let me start with sales. Kasper addressed constant dollar sales growth, I will focus more on the foreign exchange impact. As you can see, from Slide 3, fourth quarter sales on a reported basis were 12% below the prior year quarter. Adverse foreign exchange rates contributed to a decline of 6%, a similar rate to that seen in the third quarter. For the full year, sales on a reported basis were 8% below last year. The adverse foreign exchange impact on sales was 6%, or $229 million.
On Slide 4, we have summarized the impact of foreign exchange for the quarter. The U.S. dollar continue to strengthen in the fourth quarter and its effect on translation of local currency negatively impact all reporting segments. Over 1/3 of the negative currency impact in the fourth quarter were from the Mexican peso and the Chinese renminbi. The balance of the foreign exchange impact was widespread, especially from our large markets like Canada and Malaysia and Thailand. We expect to see additional adverse foreign exchange impact in 2016 based on the continued strengthening of the dollar across a very broad basket of currencies. I'll address this foreign exchange impact in the EPS guidance section as well. 
I will now move on to the factors that impacted our gross margin on Slide 5. Gross margin was 63.9% in the fourth quarter, up 200 basis points from the same quarter of 2014. Lower dairy costs drove the majority of the improvement. However, the benefit was cut in half by adverse foreign exchange impacts. Productivity improvements offset our commodity increases and higher manufacturing costs. In the last earnings call, we highlighted 3 factors that would result in a sequential gross margin decrease: less benefit from new price increases; increased trade investment, especially China; and our annual U.S. plant shutdown. These factors came in as expected during the fourth quarter. 
On a full year basis, gross margin was 64.6%, which is 270 basis points improvement versus the prior year, mainly due to lower dairy costs, which benefited all segments. Supply chain productivity delivered approximately 5% of savings in cost of goods sold, which mitigated other costs as noted previously. 
Moving on to operating expenses on Slide #6. Our advertising and promotion spending was 15.6% of sales in the fourth quarter compared to 13.7% in the prior year quarter. This was an increase of 7% on a constant dollar basis. A&P investment on the fourth quarter includes support for China's fully imported products,   TV media for the U.S. children business and support for new product launches, like the 32-ounce liquid and non-GMO product line that Kasper described earlier. 
SG&A, on a constant dollar basis, was 6% or $14 million lower than the fourth quarter of 2014. Savings were a result of a lower incentive compensation and a reduction in corporate cost, partly driven by our Fuel for Growth initiatives. SG&A, on a full year basis, were flat compared to 2014 on a constant dollar basis. As you can see the from Slide 7, our cost-related research and development, marketing and G&A decreased by 3% in 2015 versus 2014 on a constant dollar basis. When comparing the second half year 2015 to the first half year 2015, the corporate support function decreased 8% mainly driven by the Fuel for Growth program.
In the fourth quarter, we made the first wave of employee reductions. Compared to June, 2015, we reduced approximately 200 FTEs mainly within the corporate support functions, where we reduced 18% of our headcount. We eliminated some outside services and initiated vendor negotiations for key services. The headcount and outside services actions to take to date have allowed us to secure most of our $60 million Fuel for Growth target for 2016. We are very comfortable to deliver this year's savings. 
Turning now to Slide 8. On a constant dollar basis, the fourth quarter EBIT was 3% below the prior year quarter, and the full year EBIT was aligned with 2014. Including currency impact, EBIT was down 13% in the fourth quarter and down 7% for the full year. The EBIT margin as a percent of sales for the fourth quarter was slightly lower than the prior year quarter, as continued investments were not fully offset by the higher gross margin. EBIT margins percentage of sales for the full year increased by 30 basis points. 
I will now discuss EBIT for each segment. Starting with Asia on Slide 9. In Q4, Asia delivered EBIT of $140 million, a decrease of 24% on a constant dollar basis. On a reported basis, EBIT was 28% lower, mainly due to impact of the Chinese renminbi. The EBIT margin at 30% was lower than the fourth quarter 2014 and the third quarter '15. As we continued to invest, especially in China, these investments included price promotions on the locally manufactured products to protect competitiveness, along with A&P support for the fully imported product line introduced earlier this year. As Kasper mentioned, Greater China sales improved sequentially as a result of these investments. For the full year, the Asia EBIT margin at 33% remains the highest of our 3 segments. However, the EBIT margin was lower than in 2014 as lower sales and high-demand generation investments were not fully offset by the dairy benefit.
Latin America, on Slide #10, delivered EBIT of $34 million in the fourth quarter, an increase of 15% on a constant dollar basis. On a reported basis, EBIT declined 26%, as the region continued to have a large negative impact from currencies, most notably the Mexican peso. If we exclude the impact of Venezuela, where we intentionally reduced shipments, the segment's reported EBIT dollars for 2015 would have been in line with 2014 for both the fourth quarter and the full year. For the full year, Latin America EBIT margin improved slightly to 23.1%. Lower dairy costs more than offset the impact of the higher investments. 
Let me address North America and Europe on Slide 11. For the fourth quarter, EBIT was $97 million, an increase of 14% on a constant dollar basis and 8% on a reported basis. In the midst of a tough top line comparison, gross margin continued to be strong. The team managed to maintain operating expense in line with the prior year quarter, while increasing A&P by 9% on a constant-currency basis. For the full year, the North America and European EBIT margin was 28%, benefiting primarily from gross margin. I will now address our financial results from EBIT to net results on Slide #12.
The fourth quarter interest expense increased to approximately $22 million, reflecting the issuance of the new $1.5 billion notes to finance the share repurchase programs. During our October earnings call, we announced a new share repurchase program of our $1.5 billion of the company's common stock, with $1 billion in the form an accelerated share repurchase, or ASR. The ASR was executed after the close of business on that same day. Under the accelerated share repurchase program, 10.7 million shares of stock were delivered in the quarter.
Following this portion of the ASR, the average number of shares in the fourth quarter were 189.8 million. As of December 31, 2015, the outstanding shares were 186.4 million. It is expected that additional shares will be delivered in 2016 under the current ASR program. The ASR program was initially financed by a $1 billion term loan. Shortly thereafter, refinanced by the issuance notes, $750 million 5-year notes at a rate of 3% and $750 million 10-year notes at a rate of 4.125%. 
Taxes. For 2015, our non-GAAP effective tax rate, or ETR, was 24.8% compared to 22.5% in 2014. The 2014 rate was unusually low as a result of $0.05 per share nonrecurring tax benefit. Also, the 2015 ETR was also higher as a result of an unfavorable change in geographic earnings mix. 
Let me briefly address our EPS on Slide 13. Non-GAAP EPS for the fourth quarter was $0.78, a decline of $0.14 versus the prior year quarter. Sales negatively impacted EPS by $0.16 offset by gross margin benefit. Foreign exchange adversely impacted EPS by $0.10. Full year non-GAAP EPS were $3.44, slightly above the high end of our guidance. Versus the prior year, EPS declined by $0.30, the foreign exchange alone negatively impacting EPS by $0.26. The sales decline impacted EPS by $0.26 as well. Gross margin benefit was offset by additional A&P investments to support our innovation, especially our investments in China. 
Specified items. For 2015, specified items were $45 million or $0 17. The largest charge was $25 million. This occurred in the fourth quarter and was related to a restructuring provision for our Fuel for Growth productivity program. This was in line with expectations we highlighted in our third quarter earnings call. Including these specified items, EPS on a non-GAAP basis was $3.27. 
Let me finish the 2015 discussion with a high-level overview of the cash flow and balance sheet. Despite the challenging operating environment, we generated strong cash flow, which further strengthened our balance sheet. As you can see, from Slide 14, free cash flow defined as operating cash flow less capital expenditures was $726 million due in 2015, up 20% from the prior year. For 2015, capital expenditures were $174 million consistent with our long-term goal of about 4% of sales. The most significant capital investment were to expand capacity at our European plant to support demand for the new China fully imported product line, and in the U.S., to support new liquids manufacturing.
Depreciation and amortization expenses was $99 million for the full year. For the full year 2015, we increased our dividends by 10% to $1.65 per share resulting in a total dividend payment of $326 million. The total payout ratio was close to 50% of our net results. Our cash balance, as of December 31, was $1.7 billion, an increase of approximately $400 million compared to December 2014. Nearly 90% of our cash is held outside of the United States. Our net debt position, as of December 31, was less than $1.3 billion. 
I will now wrap up with a summary of our 2016 guidance on a non-GAAP basis on Slide 15. We forecast constant dollar sales in the range of 0% to 2% this year versus 2015. Assuming exchange rate remain at current levels, this would translate into 2016 sales 4% to 6% below the prior year on a reported basis. Please note that we expect tougher sales comparison in the first half of 2016 versus 2015. This is due in part to more favorable performance seen in China, and especially in the first quarter of 2015.
Constant dollar sales in Q1 2016 are expected to be in line or slightly higher above the Q4 2015 performance. The company expects a positive trend in the second half of 2016 on a constant dollar basis. We expect higher investments in A&P in the first half of 2016. As a result, we expect growth of non-GAAP EPS towards the second half of 2016. Please note that quarter 1 2016 non-GAAP EPS will have a tough comparison.
From an EPS guidance perspective, there are several key factors to consider. We expect that our gross margins will be around 64%, similar to the fourth quarter 2015 level. We entered into dairy contracts at attractive prices to secure more than 80% of our expected 2016 dairy needs. Nearly all of the expected $60 million Fuel for Growth savings will be invested in demand-generating activities to enable long-term market share improvement.
The benefits of all share repurchase in 2015, including the ASR program, net of interest expense, is expected to be an $0.11 benefit per share. EPS guidance includes an annual estimated adverse impact of currency rates as of January 2016, which is expected to be approximately $0.40 per share. Another 1% strengthening of the dollar against all currencies where we operate would lead to a further reduction in EPS of about $0.04 per share on a full year basis, just from translation.
Taking all of this into account, non-GAAP EPS guidance is expected to be in the range of $3.48 to $3.60, excluding specified items. On a constant dollar basis, non-GAAP EPS guidance is expected to grow 9% to 12% this excludes $0.11 from the benefit of the share repurchase program in 2015. The company expects to incur charges of approximately $25 million to $30 million associated with the Fuel for Growth program in 2016. Specified items, including charges related to Fuel for Growth are expected to be approximately $0.12 per share. Therefore, GAAP EPS is expected to be in the range of $3.36 to $3.48, excluding future costs related to market-to-market pension adjustments which are not reflected in the guidance.
This concludes my discussion on our quarter 4 and full year 2015 financial results. Thanks again for your time this morning. And with that, I will now turn the call back to Kasper."
1002291,321212057,922620,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Thank you, Michel. Let me briefly provide some summary remarks before we open the lines to your questions. I'm proud of many of the operational adjustments we made in the second half of 2015 when we were faced with significant change. Likewise, I feel goo",363,"Thank you, Michel. Let me briefly provide some summary remarks before we open the lines to your questions. I'm proud of many of the operational adjustments we made in the second half of 2015 when we were faced with significant change. Likewise, I feel good that our key strategies are paying off. Our once-a-year investment much in the United States was made because we believe in the potential of that market. Sales and margins have now rebounded and are helping us overcome challenges abroad. Likewise, our decision to reshape our portfolio in China and focus on new growing sales channels is showing signs of paying off.
Faced with macroeconomic challenges, we're making adjustments in other markets, too. Change is inevitable, and in many ways, businesses should be judged by how well they adjust and adapt, and I'm confident that we'll look back at the end of this year able to acknowledge that we did this quite well. 
Through last year, I repeatedly pointed to 4 important factors that critically influenced company performance. To remind you all, I'm referring to currency movements, dairy cost evolution, our ability to evolve our strategy and portfolio in China and our momentum in North America, particularly in the United States. All of these 4 variables remain as relevant in 2016 as they were to our performance in 2015, but I should add pricing to the list. Our ability to offset, partially or in full, foreign exchange weakness with price increases would be very important. I'd add that I see some encouraging signs that price increases will become easier as we move through the year.
I'll close with message that we'll continue to provide clear visibility on the impact of foreign exchange as we move through 2016. We'll do so by providing updates on both sales and profit growth, net of foreign exchange. In addition to our traditional non-GAAP earnings per share numbers, we hope you'll find this informative.
Operator, I'd now like to open the lines to questions. And because our prepared remarks have taken longer than anticipated, we're prepared to go a few minutes over if the questions merit doing so. Operator, over to you. Thank you."
1002291,321212057,922620,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Operator","[Operator Instructions] The first question comes from David Driscoll with Citi Research.",12,"[Operator Instructions] The first question comes from David Driscoll with Citi Research."
1002291,321212057,922620,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","This is Alexis Borden in for David. So question on China. Kasper, I appreciate your China comments in your prepared remarks. Still, I'd like to ask, just bigger picture. Is your China strategy working? What evidence can you point us to? And are your China",54,"This is Alexis Borden in for David. So question on China. Kasper, I appreciate your China comments in your prepared remarks. Still, I'd like to ask, just bigger picture. Is your China strategy working? What evidence can you point us to? And are your China market shares increasing? And I also have a follow-up."
1002291,321212057,922620,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Well, I think I tried to provide some metrics that would hopefully support my statement, that I believe our strategy is working. I think, we introduced the fully imported line of products into China sort of towards the back half really of the second quart",269,"Well, I think I tried to provide some metrics that would hopefully support my statement, that I believe our strategy is working. I think, we introduced the fully imported line of products into China sort of towards the back half really of the second quarter. And the fact that this product line is now already making up 35% of our sales in the mainland and 22% of our sales in the combined China/Hong Kong business, I think it's fairly impressive progress. I want to remind you also that -- of the message we gave on our Investor Day that we have confirmed our intention to enter the super-high premium category sometime in 2016. I'm sure you can understand that for competitive reasons, I'm not prepared to tell you what our plan timing is, but it goes without saying that we obviously have one. So I feel quite good about that. We now -- if I add the Hong Kong business and our fully imported line together, we've now got more than half of our sales in the China/Hong Kong business coming out of our Netherlands facility, and therefore, meeting consumer desire for imported quality. So I think we're managing that transition quite well. I'm satisfied with the progress we are making in baby stores also. We -- through much of last year, we discussed the fact that we were under-indexing in baby stores, which is one of the faster growing sales channels. But as of late, we've seen some fairly satisfactory improvements to our market shares in this channel, and I'm sure we'll continue to do so going forward."
1002291,321212057,922620,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Great. Alexis, just for the time constraints that we have, I'd like to go on to the next analyst.",19,"Great. Alexis, just for the time constraints that we have, I'd like to go on to the next analyst."
1002291,321212057,922620,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Operator","Your next question comes from Bryan Spillane, Bank of America.",10,"Your next question comes from Bryan Spillane, Bank of America."
1002291,321212057,922620,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","So just one question. I think, in 2015, in certain markets, you were able to price the try to take -- raise prices in order to try to offset some of the negative effects of foreign exchange. I guess, in 2016, as you look at some of these markets that you",119,"So just one question. I think, in 2015, in certain markets, you were able to price the try to take -- raise prices in order to try to offset some of the negative effects of foreign exchange. I guess, in 2016, as you look at some of these markets that you mentioned in terms of -- where currency volatility. Does the cost savings that you're generating this year take some of the pressure off or give you more flexibility and not needing to necessarily -- to try to price for -- to offset the currency? Or are you still going to be looking to sort of price in some of these markets where the currencies have moved so dramatically?"
1002291,321212057,922620,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Brian, thanks for the question. I think, we will definitely look to price in these markets. I think, as you heard us talk about, we were quite some distance off managing to cover the impact of foreign exchange weakness through price in 2015. So that will",230,"Brian, thanks for the question. I think, we will definitely look to price in these markets. I think, as you heard us talk about, we were quite some distance off managing to cover the impact of foreign exchange weakness through price in 2015. So that will a be continued challenge or task for us as we go through 2016. As I was trying to indicate, I think the pricing environment will become so much more friendly. What we saw in '15 was that there was still -- particularly, I would say, in Asia, there were still governments in Asia that were very resistant to price increases in our sector as they still focused very much on kind of inflationary pressure or perceived inflationary pressure, which we think we all know was really a threat that evaporated sometime in 2014, and they would repeatedly point to the fact that we were seeing significant upside from dairy costs coming down as we discussed price increases. I think now that the dairy prices have stabilized, I believe that as both us and our competitors lapped the low dairy costs, it will become a little bit more straightforward to raise prices. But we obviously had to do that in a responsible manner and we have to assess that in the context of general price inflation and wage inflation in the markets we operate in."
1002291,321212057,922620,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Operator","Your next question comes from Amit Sharma with BMO Capital Markets.",11,"Your next question comes from Amit Sharma with BMO Capital Markets."
1002291,321212057,922620,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","Kasper, without asking you to speculate on the timing of it, we've heard that there -- the Chinese government is looking at changing the tariff regulation for cross-border trade online. On a wider context, how do you think about how your positioned in the",61,"Kasper, without asking you to speculate on the timing of it, we've heard that there -- the Chinese government is looking at changing the tariff regulation for cross-border trade online. On a wider context, how do you think about how your positioned in the B2C channels and updated incremental on tax online, how would that impact your positioning in that channel?"
1002291,321212057,922620,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Well, I think there are -- as it relates to China, I expect that we're going to see regulatory adjustments coming sometime in 2016. I don't want to speculate on whether those regulatory adjustments will address all of the imbalances that we are seeing cur",198,"Well, I think there are -- as it relates to China, I expect that we're going to see regulatory adjustments coming sometime in 2016. I don't want to speculate on whether those regulatory adjustments will address all of the imbalances that we are seeing currently in China, but I believe that they will begin to address some of them. At the moment, it's clear that inadvertently, the China regulations have created a tilted playing field, that is very much tilting in favor of imported products sold through e-commerce. I don't believe that, that was the intention of either the regulators or the China government at large, and I think they will find ways to address that. I also think that they remain concerned about the large number of smaller brands that have been created in China that really lack the expertise or the resources to guarantee consumer quality, and I think that would be addressed. So I think you're going to a whole slew of attempts at least by regulators to get at some of these issues through this year, but since you gave me a free pass on the timing, I'll probably take advantage of that, Amit."
1002291,321212057,922620,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Thank you.",2,"Thank you."
1002291,321212057,922620,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Operator","Your next question comes from Ken Goldman with JPMorgan.",9,"Your next question comes from Ken Goldman with JPMorgan."
1002291,321212057,922620,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","Michel, I think, if I'm not wrong, that Mead Johnson locked in a bit more milk supply than usual this early in the year. I know it sometimes goes back and forth, it's hard to tell. But it feels like it's a little more than usual. So first, correct me if I",114,"Michel, I think, if I'm not wrong, that Mead Johnson locked in a bit more milk supply than usual this early in the year. I know it sometimes goes back and forth, it's hard to tell. But it feels like it's a little more than usual. So first, correct me if I'm wrong on that. And second, if that's correct, is that more of a tactical move just based on where milk cost and prices are? Or is it more of a strategic change that you'd like to implement whereby you maybe get a little more visibility there and a little more ability to price in line with where you think you have cost?"
1002291,321212057,922620,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Yes, I think, it is correct. It's a higher level than we used to have. And it's also true that we've taken that position on purpose, given the current benefits that we see. I don't like too much volatility into the P&L, so nobody does that, so the more yo",66,"Yes, I think, it is correct. It's a higher level than we used to have. And it's also true that we've taken that position on purpose, given the current benefits that we see. I don't like too much volatility into the P&L, so nobody does that, so the more you can control the better that is and this was one of the actions we have taken."
1002291,321212057,922620,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","Okay. So should I interpret that as -- I'm trying to figure out whether that's more tactical or strategic, and I kind of heard both in there.",27,"Okay. So should I interpret that as -- I'm trying to figure out whether that's more tactical or strategic, and I kind of heard both in there."
1002291,321212057,922620,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Correct.",1,"Correct."
1002291,321212057,922620,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Operator","Your next question comes from the line of John Baumgartner with Wells Fargo.",13,"Your next question comes from the line of John Baumgartner with Wells Fargo."
1002291,321212057,922620,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","Kasper, I wanted to ask you about North America. So you mentioned the margins being close to record levels here. How much of the margin expansion over the past 2 years is a function of the commodity cost benefits that are more temporary versus maybe somet",73,"Kasper, I wanted to ask you about North America. So you mentioned the margins being close to record levels here. How much of the margin expansion over the past 2 years is a function of the commodity cost benefits that are more temporary versus maybe something more structural in terms of the cost savings or portfolio mix? Should we think of the this high-20s level kind of a new normal for the business?"
1002291,321212057,922620,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Yes, John, I don't think -- if I said record levels, I misspoke. I think I said historic levels. So but it may go back to days before we were a public company, so you may have imperfect visibility. I guess, what I was trying to indicate was that I believe",190,"Yes, John, I don't think -- if I said record levels, I misspoke. I think I said historic levels. So but it may go back to days before we were a public company, so you may have imperfect visibility. I guess, what I was trying to indicate was that I believe that these levels of profitability in the North American business are sustainable, to put it sort of candidly. It's not inconsistent with where we have been. And what we see in the North American business is that we get a lot of leverage on both sales and volume growth in that business. So put another way, our marginal costs are very low in that business, and hence, we see big swings in profitability as sales move up and down. So I'm quite comfortable. I feel good about where the margins are. And I think we've got other parts of our global portfolio where we are working in difficult trading environments and that results in -- perhaps in margin pressure, so it's quite rewarding to see that this part of our portfolio has the opposite dynamic paying in its favor."
1002291,321212057,922620,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Operator","The next question comes from the line of Michael Lavery with CLSA.",12,"The next question comes from the line of Michael Lavery with CLSA."
1002291,321212057,922620,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","Could you talk a little bit more about your prior investments in China and how much of that is trade spending or discounting versus A&P investments? And then also just update your timing, you said at the Investor Day you felt you had about 3 or 4 more qua",59,"Could you talk a little bit more about your prior investments in China and how much of that is trade spending or discounting versus A&P investments? And then also just update your timing, you said at the Investor Day you felt you had about 3 or 4 more quarters of discounting pressure there, is that still your view?"
1002291,321212057,922620,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Our investments in China primarily in the -- I would say, in the second half of 2015, were largely focused on changing our trading profile. That means matching both competitors' pricing and also matching their general profile with retail trade. As we go f",83,"Our investments in China primarily in the -- I would say, in the second half of 2015, were largely focused on changing our trading profile. That means matching both competitors' pricing and also matching their general profile with retail trade. As we go forward, and we look at 2016, we will obviously invest behind our new growth initiatives, so we expect that, that would lead to some increase in both of those lines, both the trade support and the advertising and promotional expense."
1002291,321212057,922620,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Great. Thank you.",3,"Great. Thank you."
1002291,321212057,922620,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Operator","Your next question comes from the line of Matthew Grainger with Morgan Stanley.",13,"Your next question comes from the line of Matthew Grainger with Morgan Stanley."
1002291,321212057,922620,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","Kasper or Michel, I just wanted to clarify a bit further on the EPS guidance. And I joined a bit late, so I may have missed an aspect of the explanation. But you've maintained the expectation of mid-single-digit EPS growth despite the FX headwind being si",76,"Kasper or Michel, I just wanted to clarify a bit further on the EPS guidance. And I joined a bit late, so I may have missed an aspect of the explanation. But you've maintained the expectation of mid-single-digit EPS growth despite the FX headwind being significantly higher. So just curious what the delta was over the past few months that's giving you more confidence in the constant currency outlook or sort of margin flexibility during 2016?"
1002291,321212057,922620,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","I mean, your understanding is correct. We indicated, at Investor Day, mid-single digit and that is in line on what we're confirming now, despite the fact that we will have a higher headwind from currencies. I indicated in Investors Day that at that point",225,"I mean, your understanding is correct. We indicated, at Investor Day, mid-single digit and that is in line on what we're confirming now, despite the fact that we will have a higher headwind from currencies. I indicated in Investors Day that at that point of time, foreign exchange impact would have been around $0.15. Right now, we are looking at -- based on current spot rates, we're looking at the $0.40 impact from currencies. So we clearly looked into how we can mitigate that to still deliver mid-single-digit growth. On one hand side, like Kasper indicated, we clearly looked into pricing because that's an area where we think we need to be very cautious to see what can we do in certain markets, that's one. Two, I highlight specifically, and referred most in an earlier question, on dairy benefits. We secured 80%, which is higher than we expected also in quarter 3. So that's one of the -- whether you call it tactical or strategical initiatives to secure the benefit to avoid volatility. And thirdly, like Kasper also indicated, we are clearly starting further assessments to see what can we do in terms of demand investments, and that will be leaning more towards mid of this year. So all of these initiatives, we accelerated actually, we took actions to mitigate the higher foreign exchange exposure."
1002291,321212057,922620,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","Okay. So it's more the actions you just mentioned as opposed to further acceleration of Fuel for Growth savings?",19,"Okay. So it's more the actions you just mentioned as opposed to further acceleration of Fuel for Growth savings?"
1002291,321212057,922620,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Well, it is. It is a combination, right, I should say. It is the Fuel for Growth savings that's confirmed, significantly confirmed. So that wasn't the case yet in full in Investors Day. But secondly, like I said, we also are going further with further ass",49,"Well, it is. It is a combination, right, I should say. It is the Fuel for Growth savings that's confirmed, significantly confirmed. So that wasn't the case yet in full in Investors Day. But secondly, like I said, we also are going further with further assessment in demand investment."
1002291,321212057,922620,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Operator","Your next question comes from Jason English with Goldman Sachs.",10,"Your next question comes from Jason English with Goldman Sachs."
1002291,321212057,922620,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","A quick housekeeping question. I think that I heard you say that in the first quarter that the sales on constant currency would be flat to may be up 2 versus the fourth quarter of '15. Can you confirm that I heard that right? And also, just mathematically",96,"A quick housekeeping question. I think that I heard you say that in the first quarter that the sales on constant currency would be flat to may be up 2 versus the fourth quarter of '15. Can you confirm that I heard that right? And also, just mathematically as I'm looking at my model, it seems to suggest that sales could be down close to 20% in the first quarter. Is that right? And if so, where -- what should we brace for in terms of pockets of sort of outsize weakness in the first quarter?"
1002291,321212057,922620,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Well, I think -- let me try and repeat what we said. I said in my prepared remarks that we expect to see sequential quarterly improvement in sales, in constant dollar sales. So that would translate into sales in the first quarter as opposed being as or ab",54,"Well, I think -- let me try and repeat what we said. I said in my prepared remarks that we expect to see sequential quarterly improvement in sales, in constant dollar sales. So that would translate into sales in the first quarter as opposed being as or above the level in the fourth quarter."
1002291,321212057,922620,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","And that's with currency?",5,"And that's with currency?"
1002291,321212057,922620,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","No, that was in constant dollars.",6,"No, that was in constant dollars."
1002291,321212057,922620,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","Okay. I'll try to get clarification with Kathy offline on that one then. And I'll pass it on for now.",20,"Okay. I'll try to get clarification with Kathy offline on that one then. And I'll pass it on for now."
1002291,321212057,922620,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","I think for the full year, we will clearly expect to see adverse currency impact. I think, we've said, Jason, that we expect about a 600 basis points adverse impact from foreign exchange, and we also said that we had based that on basically the current ex",74,"I think for the full year, we will clearly expect to see adverse currency impact. I think, we've said, Jason, that we expect about a 600 basis points adverse impact from foreign exchange, and we also said that we had based that on basically the current exchange rates as of this month. So that would stand to reason that, that 600 basis points in adverse impact would start at the beginning of the year."
1002291,321212057,922620,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Operator","Your next question comes from the line of Robert Moskow with Crdit Suisse.",13,"Your next question comes from the line of Robert Moskow with Crdit Suisse."
1002291,321212057,922620,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","This is kind of a follow-up to Matthew's question. I mean, if you do the math, the foreign exchange headwind is significantly more than what you thought in October. And -- but you're kind of maintaining, I think, the same guidance you had before, and that",135,"This is kind of a follow-up to Matthew's question. I mean, if you do the math, the foreign exchange headwind is significantly more than what you thought in October. And -- but you're kind of maintaining, I think, the same guidance you had before, and that guidance implies quite a bit of growth in the core business in order to be achievable. You mentioned pricing, and that's probably the tool that you would use in unlocking in dairy, although I think if you locked in, I'm not sure how that's a benefit from October. So Michel, maybe you can help just a little bit more, don't you have to push the pricing lever harder than you thought in October in order to achieve this guidance? Or are there other levers I'm not aware of?"
1002291,321212057,922620,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","No, it is indeed in combination of price mix, what we need to look into country mix. But yes, I mean, it's a component that is higher than we indicated, that we anticipated in quarter 3.",36,"No, it is indeed in combination of price mix, what we need to look into country mix. But yes, I mean, it's a component that is higher than we indicated, that we anticipated in quarter 3."
1002291,321212057,922620,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","And how is that -- is it is achievable, given the competitive environment? Or do something have to change in the competitive environment in order for that to happen?",29,"And how is that -- is it is achievable, given the competitive environment? Or do something have to change in the competitive environment in order for that to happen?"
1002291,321212057,922620,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Look, part of that is driven by certain new innovation rollouts that we have in schedule. So we're trying to combine that as much as possible to take price further than initially thought.",33,"Look, part of that is driven by certain new innovation rollouts that we have in schedule. So we're trying to combine that as much as possible to take price further than initially thought."
1002291,321212057,922620,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Operator","Your next question comes from Eric Katzman with Deutsche Bank.",10,"Your next question comes from Eric Katzman with Deutsche Bank."
1002291,321212057,922620,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","I guess, let me ask about promotion for a second. Back at our conference in Paris, Kasper, you talked about promotion being kind of the initial signs of being more concerned about it in China, and then I guess it broadened out into Latin America and other",112,"I guess, let me ask about promotion for a second. Back at our conference in Paris, Kasper, you talked about promotion being kind of the initial signs of being more concerned about it in China, and then I guess it broadened out into Latin America and other regions. So I guess, it's been a long call, but just so I frame it, did you kind of end 2015 with what, I think, you had dubbed kind of irrational behavior on the part of competition, was that kind of sequentially flat or did it get worse? And kind of what assumptions are you making around promotion into 2016? And I'll pass it on."
1002291,321212057,922620,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Yes, it's an excellent question, and -- but you caught my comments correctly. I indicated that we've seen the environment stabilize, so there's still -- I would not say it has improved, but the environment has stabilized. And I think having now entered th",112,"Yes, it's an excellent question, and -- but you caught my comments correctly. I indicated that we've seen the environment stabilize, so there's still -- I would not say it has improved, but the environment has stabilized. And I think having now entered the phase, so to speak, in order to protect our competitive position, we saw that pay off in terms of stabilizing and even improving our underlying sales performance in the fourth quarter. So yes, I feel the environment, including in China, is now a little bit more stable. But it's clearly stable at a much higher level of promotion than, say, where we were a couple of years ago."
1002291,321212057,922620,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","And looking into '16?",4,"And looking into '16?"
1002291,321212057,922620,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","We expect that the environment will remain stable in '16.",10,"We expect that the environment will remain stable in '16."
1002291,321212057,922620,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Operator","Your next question comes from -- sorry?",7,"Your next question comes from -- sorry?"
1002291,321212057,922620,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Operator, sorry. I just want to say we have time for one more call, so the one that you're about to place in will be the last.",27,"Operator, sorry. I just want to say we have time for one more call, so the one that you're about to place in will be the last."
1002291,321212057,922620,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Operator","Your next question comes from David Hayes with Nomura.",9,"Your next question comes from David Hayes with Nomura."
1002291,321212057,922620,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","Just trying to pick up on the compensation benefit shift. You obviously made the point that the margin benefited, I think, particularly back end of the year in terms of the compensation, the variable compensation, I guess reversing, to some extent, throug",145,"Just trying to pick up on the compensation benefit shift. You obviously made the point that the margin benefited, I think, particularly back end of the year in terms of the compensation, the variable compensation, I guess reversing, to some extent, through the year in terms of your costs that you might take in beginning of the year. So the question is on that -- one, can you quantify the impacts of that variable comp dropping out? And then secondly, I guess, more importantly, as you look into next year, because you talked about it more this year, you talked about it being a transition year or a transformational year. Would expect that compensation to come back into the numbers? Or is the organization effectively not going to play that rebel pay until the performance for the group steps up back to the previous levels?"
1002291,321212057,922620,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Yes. I mean, in the compensation, that the costs dropped in the year 2015 given the lower performance, which had an estimated impact around $30 million. The -- if you look to the number for next year, yes, we put it back to normal target levels. So those",61,"Yes. I mean, in the compensation, that the costs dropped in the year 2015 given the lower performance, which had an estimated impact around $30 million. The -- if you look to the number for next year, yes, we put it back to normal target levels. So those ones are included in the numbers that we have provided you for guidance."
1002291,321212057,922620,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","I guess, here in the guidance, you'd have that $30 million come back in, but that's included in the margin...",20,"I guess, here in the guidance, you'd have that $30 million come back in, but that's included in the margin..."
1002291,321212057,922620,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","That's included in the numbers, yes.",7,"That's included in the numbers, yes."
1002291,321212057,922620,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Operator, I think this closes our call.",7,"Operator, I think this closes our call."
1002291,321212057,922620,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Operator","Ladies and gentlemen, thank you for your participation in today's conference. This concludes the presentation. You may now disconnect. Good day.",21,"Ladies and gentlemen, thank you for your participation in today's conference. This concludes the presentation. You may now disconnect. Good day."
1002291,321212057,922829,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Operator","Good day, ladies and gentlemen, and welcome to the Mead Johnson Nutrition Fourth Quarter 2015 Earnings Conference Call. My name is Liz, and I'll be your coordinator for today. [Operator Instructions] As a reminder, this conference is being recorded for re",62,"Good day, ladies and gentlemen, and welcome to the Mead Johnson Nutrition Fourth Quarter 2015 Earnings Conference Call. My name is Liz, and I'll be your coordinator for today. [Operator Instructions] As a reminder, this conference is being recorded for replay purposes. I would now like to turn the conference call over to Kathy MacDonald, Vice President, Investor Relations. Please proceed, Kathy."
1002291,321212057,922829,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Thank you, Liz. Good morning, and thank you for joining Mead Johnson's fourth quarter and full year 2015 conference call. With me today are Kasper Jakobsen, our Chief Executive Officer; and Michel Cup, our Chief Financial Officer. Earlier today, we issued",310,"Thank you, Liz. Good morning, and thank you for joining Mead Johnson's fourth quarter and full year 2015 conference call. With me today are Kasper Jakobsen, our Chief Executive Officer; and Michel Cup, our Chief Financial Officer. Earlier today, we issued our earnings release and financial reference slides, which are available on our website.
As we start, let me remind everyone that our comments will include forward-looking statements about our future results, including statements about our financial prospects and projections, commodity costs, currency fluctuations, pricing, taxes, capital spending, depreciation and amortization, new product launches, product quality, other growth initiatives and market conditions that constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. A more detailed explanation of our forward-looking statements will appear in the materials posted on our website in connection with today's conference call.
Keep in mind that our actual results may differ materially from expectations as of today due to various factors, including those listed in our Annual Report on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K, in each case, as filed with or furnished to the Securities and Exchange Commission and our earnings release issued this morning, all of which are available upon request or on our website at meadjohnson.com.
Today's comments will include a discussion of non-GAAP financial measures. A reconciliation of these measures to comparable GAAP measures appears in the morning's earnings release posted on our website. In addition, any forward-looking statements represent our estimates only as of today and should not be relied upon as representing our estimates at any subsequent date. While we may elect to update forward-looking statements at some point in the future, we specifically disclaim any obligation to do so, even if our estimates change. I will now turn the call over to Kasper."
1002291,321212057,922829,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Thank you, Kathy, and thank you to all of you for listening to our fourth quarter and full year earnings call this morning. Over the next 35 minutes or so, Michel and myself will summarize our fourth quarter and full year 2015 financial results. We'll als",3360,"Thank you, Kathy, and thank you to all of you for listening to our fourth quarter and full year earnings call this morning. Over the next 35 minutes or so, Michel and myself will summarize our fourth quarter and full year 2015 financial results. We'll also outline our expectations for 2016. 
I'll begin by providing an overview focusing on revenue performance, our key strategic initiatives and business drivers and underlying business momentum. I'll then hand over to Michel, who'll give a further analysis of our financial metrics and provide an outlook for key cost drivers. After Michel completes his segment, I will return with a few summary remarks before we give you an opportunity to ask questions. Except when noted otherwise, I'll be referring to non-GAAP results. A full reconciliation to our GAAP results is available in our 10-Q that was filed alongside our earnings release earlier this morning. Both documents are available on our website. 
Let me start with a high-level overview of our fourth quarter 2015 results for the global business, before I move on to discuss full year results and then performance of each of our regions. As we exited the year, and I refer now to fourth quarter results specifically, I'm pleased to say we saw a sequential improvement versus the third quarter in our underlying sales performance. Net of withheld shipments to Venezuela, a topic I'll return to later, we saw sequential growth in constant-dollars sales of 1%. This represented a modest reversal of the trend we've seen over the previous 3 quarters, despite sales performance being adversely affected by selective retailer inventory adjustments in Thailand and Malaysia.
Structural changes made to our investment profile in China and the recent launch of our fully imported line of Enfa products helped us deliver on the promise we made in July. At that time, we said we expected to see sequential improvement in China sales as we exited the year. And in the fourth quarter, our China/Hong Kong business grew 2% sequentially over the third quarter. Our North America/Europe segment also grew sequentially by nearly 5% on a constant-dollar basis. 
Let me now address our full year results. 2015 was a challenging year for us. We were challenged by a strengthening dollar and the general weakness in many economies throughout Asia and Latin America. GDP growth across Asia and Latin America was lower than prior year, and this affected both consumer and retailer confidence. Additionally, in China, we saw increased price-based competition and channel shifts that adversely impacted sales growth and required us to boost investment to protect our competitiveness. 
In Southeast Asia, in particular, we saw slowing economic growth in Thailand and Malaysia. Combined with some company-specific executional issues, this resulted in lower volumes through the year. In the Philippines, where GDP growth remained more robust, we saw relatively better performance. And there, we are satisfied with the progress we made through the year. We continue to benefit from lower dairy costs and an improved gross margin as a consequence. This helped partially offset the EBIT and EPS impact of foreign exchange and lower sales.
For full year 2015, constant-dollar net sales were 2% below prior year, largely due to our challenges in China and Hong Kong. Gross sales, however, were in line with 2014. This shows continued solid demand for our brands, though a challenging trading environment saw us report sales below prior-year level. 
The impact of a strengthening dollar was significant throughout the year, reducing reported sales by about 6% and earnings per share by $0.26. Where possible, we took price to mitigate the impact of foreign exchange. However, competitor strategies and abnormally low dairy costs made price increases more difficult than we've seen in recent years.
Price consequently contributed 1% -- percentage point of growth to the full year. As we progressed through the year, the carryover benefit of price increases taken in 2014 gradually disappeared and price promotional activity became more evident. Against the same quarter of prior year, this increased dynamic adversely affected fourth quarter growth by 1 percentage point. This was largely driven by increased trade promotional activity in China. Global volume was 3% lower than prior year, growth in North America and Europe didn't fully offset weaker performance in Asia and Latin America, and the impact of our decision to slow shipments into Venezuela was also significant.
Infant formula product sales for 2015 were in line with prior year on a constant-dollar basis. It follows that we were relatively more challenged within our children's category outside of North America. The children's category is more price-sensitive and, prior to reshaping our competitive stance in the third quarter, we suffered share losses due to competitors' price promotional activity. However, having addressed the price disadvantage, as the cohort of infants' age, that consumer brand, this should help sales of our children's franchise going forward.
We understand the recovery of momentum in China and select other emerging markets could take time, and we need to properly fund key growth initiatives. As a consequence, the company invests -- the company's investment in advertising and promotion remained strong in the fourth quarter at 15.6% of sales. This was 190 basis points above prior-year's fourth quarter level. 
To help fund these investments and offset the impact of foreign exchange, we accelerated the implementation of some of our operating expense reductions. We refer to this initiative as Fuel for Growth. As a direct result of this focus, our operating expenses came in approximately $20 million favorable versus the forecast that underpinned guidance issued in October. This favorability allowed us to offset the impact of unanticipated dollar strength in the final quarter of the year and still deliver earnings per share slightly above the high end of our guidance range.
We delivered $0.78 in non-GAAP earnings per share for the final quarter of 2015. As mentioned, this was slightly better than expected and allowed us to finish 2015 with $3.44 in non-GAAP earnings per share. Even as we grappled with adverse dynamics in many of our markets in 2015, I'm pleased that we avoided any temptation to pull back on investment. We know that continuous innovation is critical to our long-term growth prospects.
Here are some examples of new products we introduced around the world. In the United States, we introduced new and more convenient plastic packaging for our 32-ounce ready-to-feed liquid infant formula, building on the success of our 8-ounce launch a couple of years ago. We also responded quickly to competitive activity by introducing a new formulation of infant formula free from genetically-modified raw materials. Across North America, we became the first company to meet newly developed guidelines for premature infant formula. And in China, we introduced a fully imported range of Enfa-branded products to complement our locally manufactured range. These fully imported products now account for 35% of our sales within the mainland. 
In Southeast Asia, we upgraded our formulations and added increased levels of DHA to our children's products. We also introduced plastics packaging in several countries, and we added ready-to-drink versions to our lineup of Enfa products. In Latin America, we introduced liquid versions of our key infant formula products; and in Mexico, our Enfagrow Toddler product. For our powdered products, we began the introduction of upgraded plastics packaging. 
Further, over more than 70 years, we worked diligently to develop clinical evidence in support of our specialty portfolio, predominantly our Nutramigen allergy brand. Educating health care professionals about Nutramigen's benefits allowed us to grow constant-dollar sales double digits in 2015.
As I complete my comments on overall company performance, and before I move to discussing our reporting segments in more detail, I want to mention that, as promised, we executed an accelerated share repurchase program in the most recent quarter. This reflects our commitment to the creation of long-term shareholder value. Michel will revert to this topic later. Let me now briefly comment on the performance within each of our reporting segments, and I begin with Asia. 
Sequentially, Asia's sales were in line with third quarter, with improvements in China offset by lower sales in Thailand and Malaysia. For fourth quarter, constant-dollar sales were 10% below the prior-year quarter, and full year sales compared unfavorably to 2014 by 8%. As mentioned, sequentially, we grew sales in China/Hong Kong by 2% from the third quarter of 2015. A more aggressive trading stance allowed us to stabilize sales of our locally manufactured product line. Though we've had to increase our investment, we're encouraged that prices to consumers appear to have stabilized in the fourth quarter. 
At the same time, demand for our recently introduced fully imported range continued to grow. As mentioned earlier, sales of this product range now accounts for 35% of our sales in Mainland China and a full 22% of our combined China/Hong Kong business. As we expand direct shipments of fully imported products into Mainland China, we expect to see continued cannibalization of our Hong Kong business. Such channel shifts may obscure underlying business progress in the near term, but ultimately should be favorable to the company overall, as we build a stronger, more sustainable portfolio with greater reach inside Mainland China. 
As mentioned at our Investor Day in October, we are committed to make investments in support of our recent introductions. We're advancing digital marketing capabilities, expanding our channel coverage, and strengthening our retail chain relationships through focused investments. Beyond the early sales success with our imported product range, as a further sign our strategy is working, we are seeing market share gains in baby stores.
As you know, we've also focused on strengthening our presence in business-to-consumer e-commerce. This represents the fastest growing part of the e-commerce market in China, and the segment is growing at approximately 5x the rate of the rest of the e-commerce channel. In a sign of our commitment to strengthening our presence in web and app-based commerce, we recently signed joint business partnership agreements with Jingdong, owner of leading e-commerce site, JD.com; and Tencent, owner of WeChat, the leading social app in China. Under these agreements, we agreed to cooperate by sharing data and technology platforms to the mutual benefits of our separate businesses. These agreements recognize the expertise of each party, including Mead Johnson China, and we are thrilled to partner with such great companies. 
While our China business began to show progress, our businesses in Malaysia and Thailand experienced challenges, as mentioned earlier. Both economies are going through a challenging time due to political uncertainty and weak commodity prices. As a result, both consumer and business confidence is reduced. However, despite this backdrop, I want to acknowledge that we have not executed as well as expected in either country for much of 2015. Though we cannot control economic trends, we can and will control our execution, and we are taking steps to improve performance going forward. In the meantime, we continue to manage trade inventory builds carefully in the fourth quarter. 
In the third quarter, we enhanced our products in Thailand with increased levels of DHA and introduced new packaging, including a plastic tub. Early signs are encouraging, with share increasing in the 3 months following our relaunch. However, it took longer than expected to deplete old inventory in the trade, and consequently, we chose to address this more aggressively in the most recent quarter.
Having discussed some areas of relative challenge, let me now point to our relatively stronger performance in the Philippines. The Philippines' business has delivered solid growth over the past 2 years. We've managed to offset foreign exchange impacts with improved pricing, and we've successfully extended our Lactum children's brand into the infant formula category. This move gives us exposure to a growing economy beyond our traditional premium price position. 
Turning now to Latin America. The region delivered constant-dollar sales growth of 3% for the full year compared to 2014. Regional currencies weakened substantially through 2015, with large adverse impacts on sales growth in Brazil, Argentina, Colombia, Venezuela and Mexico. As a consequence, reported sales were 13% below prior-year level. For the fourth quarter, excluding Venezuela, to where we paused shipments for much of the quarter, sales grew 5% on a constant-dollar basis over the same quarter of prior year. Including Venezuela, the region sales for fourth quarter '15 were 4% lower in constant dollars than the same quarter of 2014. 
As you can tell, our decision to pause shipments to Venezuela was a significant driver of relatively weaker segment performance. As stated in previous calls, we are carefully managing risk associated with our intercompany payables within defined parameters. In the near term, this means matching new shipments to Venezuela to hard currency payments received. We are actually working with the Venezuelan government to address this challenge in order that we can once again help provide much needed nutrition to children in that country. 
Looking at the overall economy of Latin America, over the past decade, these commodity-driven economies benefited substantially from stronger prices. Since the collapse in commodity prices, Latin America's GDP growth has slowed dramatically. Countries, beyond the obvious example of Brazil that's in the recession, are grappling with sharp reductions in their growth rates for the first time since 2009. These macroeconomic conditions, coupled with the strengthening dollar, have resulted in sharp depreciation of local currencies.
I'd like to provide a little more detail in today's discussion. And for that purpose, I'll group the region into 3 sections. I've excluded Venezuela, which I've discussed separately already. I'll now discuss Mexico, the Caribbean and Central America as a distinct area from the Southern Cone area of Brazil and Argentina. And finally, touch briefly on the Andean region, in which we include Peru, Ecuador and Colombia.
In Mexico, the Caribbean and Central America, the Enfa family of premium products grew strongly in constant dollars, both sequentially over the third quarter and in full year 2015, and now represents about 2/3 of sales within the area. Outside of Mexico, much of our business in this area is conducted in U.S. dollars. This helped to partially offset the impact from a decline in the Mexican peso. That said, the Mexican business is our third-largest business globally. And many of you already know our Mexican portfolio augments our global Enfa-branded products with 2 very strong local brands of milk modifiers, Choco Milk and Cal-C-Tose. 
These 2 milk-modifier brands gave us a leading edge -- or a leading share, sorry, of the large Mexican milk-modifier market, a large category that's, however, characterized by strong competition from global and local players. With limited potential to expand consumer penetration, competition is tough and occasionally price-based. These dynamics, over the last several years, have caused our milk-modifier brands to grow more slowly than our Enfa-branded infant and children's business. In 2015, milk modifiers net sales declined as we expanded trade discounts to protect our competitive position. This impacted the overall Mexico result adversely.
Our performance in the South Cone area was adversely impacted by the economic recession and currency weakness in Brazil. In Argentina, price schemes more than covered the impact of currency depreciation. And across the area, we continue to grow our infant formula and toddler sales strongly in local currency. However, in Brazil, we also sell the Sustagen brand of milk modifiers. And in this category, we saw consumers move to cheaper competitive offerings, and we lost sales as a consequence. Within the Andean region, we saw Colombia deliver strong double-digit growth for both the latest quarter and the full year. The smaller market of Ecuador also performed well, but these encouraging results were offset by challenging retail conditions in Peru. 
To wrap up, the key drivers for the Latin America full year results are: volume, which was lower primarily from our intentional constraint of Venezuela shipments and Mexico milk-modifier sales reductions; price, that was predominantly from the high inflationary markets of Argentina, Colombia and Venezuela; and finally, foreign exchange that negatively impacted the region. 
I'll now turn to our performance in North America and Europe. In the full year 2015, the North America/Europe segment delivered 4% constant-dollar revenue growth over 2014. Volume improved 1%, with price and product mix contributing 3% to our annual growth rate. In the fourth quarter, this segment's sales were in line with the prior-year's quarter. Sequentially, as stated earlier, sales increased 5% over the third quarter. With little to no growth in the category in North America, our volume growth was realized through market share gains, and our Enfagrow children's business continued double-digit growth. Our premium price specialty and solutions offerings also grew double digits. And our Canadian business continued to execute extremely well and exited the year with record-high market shares.
Europe posted its strongest sales and EBIT performance in the last 5 years, though the sales impact was partially offset by our exit from the Russian market earlier in the year. Overall, 2015 was another strong year for this segment, a year in which we saw profit margins expand to approach historic levels. In many ways, this was proof that our decision to maintain investment levels through the 2009 to 2012 economic downturn was the right one. 
Turning now to our outlook for 2016. Our outlook is broadly similar to that provided at our Investor Day in October. We expect constant-dollar sales to continue to show gradual improvement sequentially through the coming quarters. But due to tough comparisons from the first half of 2015, we do not expect to report positive revenue growth over same quarter of prior year till the second half of 2016. For this reason, we expect full year 2016 constant-dollar sales growth to be modest, in the range of 0% to 2%. 
Based on current exchange rates, we expect currency to reduce sales growth by approximately 600 basis points. As a result, reported sales may decrease by 4% to 6% this year. We now have a good fix on dairy costs, as this item will impact our profit and loss statement through the first 7 or 8 months of the year. Based on this, we are comfortable saying that, again, in 2016, dairy prices would have a favorable impact on our cost of goods.
At our Investor Day event last October, we characterized 2016 as a year of transition. In the context of headwinds from a strengthening dollar, we committed to reduce non-demand-creating operating expenses by $60 million in order to reinvest in select growth initiatives and protect earnings growth. As headwinds from currencies have grown stronger since our October gathering, this initiative has become even more central to our strategy, and I'm pleased to report we're making good progress and remain confident in our ability to deliver on our cost-reduction ambition. 
As mentioned in our press release this morning, I believe it's important for us to give you a better picture of the expected evolution in underlying profitability without the polluting effect of currency impact. To this end, let me clarify that we expect to deliver 9% to 12% constant-dollar non-GAAP earnings per share growth. And based on our assumption around foreign exchange, we expect therefore non-GAAP earnings per share, when expressed in U.S. dollars, to be in the range of $3.48 to $3.60. Not included in our estimates of 2016 is any additional benefits that might accrue from a review of efficiency and productivity opportunities within our demand-generating investments. Such a review is currently scheduled for mid-2016.
I must point out that we remain highly focused on further strengthening -- sorry, we must -- we remain highly exposed to the further strengthening of the dollar or selected weakening in foreign currencies. Anticipating that we may continue to see some variability in exchange rates through the year, we've decided to provide you with a reconciliation to growth in non-GAAP constant-dollar earnings per share.
I'll now turn the call over to Michel, who will provide some more details on our fourth quarter and full year financials. Michel will also elaborate on our guidance for 2016. And upon the completion of his prepared remarks, I'll return with some summary remarks before we open the lines to questions. Michel, over to you."
1002291,321212057,922829,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Thank you, Kasper, and good morning, everyone. Today, I will discuss our fourth quarter and full year 2015 financial results. I will then briefly highlight segment results, and conclude with a summary of our 2016 guidance. Unless otherwise noted, my comme",2211,"Thank you, Kasper, and good morning, everyone. Today, I will discuss our fourth quarter and full year 2015 financial results. I will then briefly highlight segment results, and conclude with a summary of our 2016 guidance. Unless otherwise noted, my comments will be on the non-GAAP financial results. References to currency impacts or the effects of currency fluctuations generally refer to the impact on the translation of local currency financial statement into U.S. dollars. 
Let me start with sales. Kasper addressed constant-dollar sales growth. I will focus more on the foreign exchange impact. As you can see from Slide 3, fourth quarter sales on a reported basis were 12% below the prior-year quarter. Adverse foreign exchange rates contributed to a decline of 6%, a similar rate to that seen in the third quarter. For the full year, sales on a reported basis were 8% below last year. The adverse foreign exchange impact on sales was 6%, or $229 million.
On Slide 4, we have summarized the impact of foreign exchange for the quarter. The U.S. dollar continued to strengthen in the fourth quarter and its effect on translation of local currency negatively impact all reporting segments. Over 1/3 of the negative currency impact in the fourth quarter were from the Mexican peso and the Chinese renminbi. The balance of the foreign exchange impact was widespread, especially from our large markets like Canada, Malaysia and Thailand. We expect to see additional adverse foreign exchange impact in 2016 based on the continued strengthening of the dollar across a very broad basket of currencies. I'll address this foreign exchange impact in the EPS guidance section as well. 
I will now move on to the factors that impacted our gross margin on Slide 5. Gross margin was 63.9% in the fourth quarter, up 200 basis points from the same quarter of 2014. Lower dairy costs drove the majority of the improvement. However, the benefit was cut in half by adverse foreign exchange impacts. Productivity improvements offset our commodity increases and higher manufacturing costs. In the last earnings call, we highlighted 3 factors that would result in a sequential gross margin decrease: less benefit from new price increases; increased trade investment, especially China; and our annual U.S. plant shutdown. These factors came in as expected during the fourth quarter. 
On a full year basis, gross margin was 64.6%, which is 270 basis points improvement versus the prior year, mainly due to lower dairy costs, which benefited all segments. Supply chain productivity delivered approximately 5% of savings in cost of goods sold, which mitigated other costs, as noted previously. 
Moving on to operating expenses on Slide #6. Our advertising and promotion spending was 15.6% of sales in the fourth quarter compared to 13.7% in the prior-year quarter. This was an increase of 7% on a constant-dollar basis. A&P investment in the fourth quarter includes support for China's fully imported products, TV media for the U.S. children business and support for new product launches, like the 32-ounce liquid and non-GMO product line that Kasper described earlier. 
SG&A, on a constant-dollar basis, was 6% or $14 million lower than the fourth quarter of 2014. Savings were a result of a lower incentive compensation and a reduction in corporate cost, partly driven by our Fuel for Growth initiatives. SG&A, on a full year basis, were flat compared to 2014 on a constant-dollar basis. As you can see from Slide 7, our cost-related research and development, marketing and G&A decreased by 3% in 2015 versus 2014 on a constant-dollar basis. When comparing the second half year 2015 to the first half year 2015, the corporate support function decreased 8%, mainly driven by the Fuel for Growth program.
In the fourth quarter, we made the first wave of employee reductions. Compared to June 2015, we reduced approximately 200 FTEs, mainly within the corporate support functions, where we reduced 18% of our headcount. We eliminated some outside services and initiated vendor negotiations for key services. The headcount and outside services actions to take -- to date have allowed us to secure most of our $60 million Fuel for Growth target for 2016. We are very comfortable to deliver this year's savings. 
Turning now to Slide 8. On a constant-dollar basis, the fourth quarter EBIT was 3% below the prior-year quarter, and the full year EBIT was aligned with 2014. Including currency impact, EBIT was down 13% in the fourth quarter and down 7% for the full year. The EBIT margin as a percent of sales for the fourth quarter was slightly lower than the prior-year quarter, as continued investments were not fully offset by the higher gross margin. EBIT margin as a percentage of sales for the full year increased by 30 basis points. 
I will now discuss EBIT for each segment, starting with Asia on Slide 9. In Q4, Asia delivered EBIT of $140 million, a decrease of 24% on a constant-dollar basis. On a reported basis, EBIT was 28% lower, mainly due to impact of the Chinese renminbi. The EBIT margin at 30% was lower than the fourth quarter 2014 and the third quarter '15. As we continued to invest, especially in China, these investments included price promotions on the locally manufactured products to protect competitiveness, along with A&P support for the fully imported product line introduced earlier this year. As Kasper mentioned, Greater China sales improved sequentially as a result of these investments. For the full year, the Asia EBIT margin at 33% remains the highest of our 3 segments. However, the EBIT margin was lower than in 2014, as lower sales and high demand-generation investments were not fully offset by the dairy benefit.
Latin America, on Slide #10, delivered EBIT of $34 million in the fourth quarter, an increase of 15% on a constant-dollar basis. On a reported basis, EBIT declined 26%, as the region continued to have a large negative impact from currencies, most notably the Mexican peso. If we exclude the impact of Venezuela, where we intentionally reduced shipments, the segment's reported EBIT dollars for 2015 would have been in line with 2014 for both the fourth quarter and the full year. For the full year, Latin America EBIT margin improved slightly to 23.1%. Lower dairy costs more than offset the impact of the higher investments. 
Let me address North America and Europe on Slide 11. For the fourth quarter, EBIT was $97 million, an increase of 14% on a constant-dollar basis and 8% on a reported basis. In the midst of a tough top line comparison, gross margin continued to be strong. The team managed to maintain operating expense in line with the prior-year quarter, while increasing A&P by 9% on a constant-currency basis. For the full year, the North America/European EBIT margin was 28%, benefiting primarily from gross margin. I will now address our financial results from EBIT to net results on Slide #12.
The fourth quarter interest expense increased to approximately $22 million, reflecting the issuance of the new $1.5 billion notes to finance the share repurchase programs. During our October earnings call, we announced a new share repurchase program of $1.5 billion of the company's common stock, with $1 billion in the form an accelerated share repurchase, or ASR. The ASR was executed after the close of business on that same day. Under the accelerated share repurchase program, 10.7 million shares of stock were delivered in the quarter.
Following this portion of the ASR, the average number of shares in the fourth quarter were 189.8 million. As of December 31, 2015, the outstanding shares were 186.4 million. It is expected that additional shares will be delivered in 2016 under the current ASR program. The ASR program was initially financed by a $1 billion term loan. Shortly thereafter, refinanced by the issuance notes, $750 million 5-year notes at a rate of 3% and $750 million 10-year notes at a rate of 4.125%. 
Taxes. For 2015, our non-GAAP effective tax rate, or ETR, was 24.8% compared to 22.5% in 2014. The 2014 rate was unusually low as a result of a $0.05 per share nonrecurring tax benefit. Also, the 2015 ETR was also higher as a result of an unfavorable change in geographic earnings mix. 
Let me briefly address our EPS on Slide 13. Non-GAAP EPS for the fourth quarter was $0.78, a decline of $0.14 versus the prior-year quarter. Sales negatively impacted EPS by $0.16, offset by gross margin benefit. Foreign exchange adversely impacted EPS by $0.10. Full year non-GAAP EPS were $3.44, slightly above the high end of our guidance. Versus the prior year, EPS declined by $0.30, with foreign exchange alone negatively impacting EPS by $0.26. The sales decline impacted EPS by $0.26 as well. Gross margin benefit was offset by additional A&P investments to support our innovation, especially our investments in China. 
Specified items. For 2015, specified items were $45 million or $0.17. The largest charge was $25 million. This occurred in the fourth quarter and was related to a restructuring provision for our Fuel for Growth productivity program. This was in line with expectations we highlighted in our third quarter earnings call. Including these specified items, EPS on a non-GAAP basis was $3.27. 
Let me finish the 2015 discussion with a high-level overview of the cash flow and balance sheet. Despite the challenging operating environment, we generated strong cash flow, which further strengthened our balance sheet. As you can see from Slide 14, free cash flow, defined as operating cash flow less capital expenditures, was $726 million during 2015, up 20% from the prior year. For 2015, capital expenditures were $174 million, consistent with our long-term goal of about 4% of sales. The most significant capital investment were to expand capacity at our European plant to support demand for the new China fully imported product line; and in the U.S., to support new liquids manufacturing.
Depreciation and amortization expenses was $99 million for the full year. For the full year 2015, we increased our dividends by 10% to $1.65 per share, resulting in a total dividend payment of $326 million. The total payout ratio was close to 50% of our net results. Our cash balance as of December 31 was $1.7 billion, an increase of approximately $400 million compared to December 2014. Nearly 90% of our cash is held outside of the United States. Our net debt position as of December 31 was less than $1.3 billion. 
I will now wrap up with a summary of our 2016 guidance on a non-GAAP basis on Slide 15. We forecast constant-dollar sales in the range of 0% to 2% this year versus 2015. Assuming exchange rates remain at current levels, this would translate into 2016 sales 4% to 6% below the prior year on a reported basis. Please note that we expect tougher sales comparison in the first half of 2016 versus 2015. This is due in part to more favorable performance seen in China, and especially in the first quarter of 2015.
Constant-dollar sales in Q1 2016 are expected to be in line or slightly higher above the Q4 2015 performance. The company expects a positive trend in the second half of 2016 on a constant-dollar basis. We expect higher investments in A&P in the first half of 2016. As a result, we expect growth of non-GAAP EPS towards the second half of 2016. Please note that quarter 1 2016 non-GAAP EPS will have a tough comparison.
From an EPS guidance perspective, there are several key factors to consider. We expect that our gross margins will be around 64%, similar to the fourth quarter 2015 level. We entered into dairy contracts at attractive prices to secure more than 80% of our expected 2016 dairy needs. Nearly all of the expected $60 million Fuel for Growth savings will be reinvested in demand-generating activities to enable long-term market share improvement.
The benefit of all share repurchase in 2015, including the ASR program, net of interest expense, is expected to be an $0.11 benefit per share. EPS guidance includes an annual estimated adverse impact of currency rates as of January 2016, which is expected to be approximately $0.40 per share. Another 1% strengthening of the dollar against all currencies where we operate would lead to a further reduction in EPS of about $0.04 per share on a full year basis, just from translation.
Taking all of this into account, non-GAAP EPS guidance is expected to be in the range of $3.48 to $3.60, excluding specified items. On a constant-dollar basis, non-GAAP EPS guidance is expected to grow 9% to 12%. This excludes $0.11 from the benefit of the share repurchase program in 2015. The company expects to incur charges of approximately $25 million to $30 million associated with the Fuel for Growth program in 2016. Specified items, including charges related to Fuel for Growth, are expected to be approximately $0.12 per share. Therefore, GAAP EPS is expected to be in the range of $3.36 to $3.48, excluding future costs related to mark-to-market pension adjustments which are not reflected in the guidance.
This concludes my discussion on our quarter 4 and full year 2015 financial results. Thanks again for your time this morning. And with that, I will now turn the call back to Kasper."
1002291,321212057,922829,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Thank you, Michel. Let me briefly provide some summary remarks before we open the lines to your questions. I'm proud of many of the operational adjustments we made in the second half of 2015, when we were faced with significant change. Likewise, I feel go",363,"Thank you, Michel. Let me briefly provide some summary remarks before we open the lines to your questions. I'm proud of many of the operational adjustments we made in the second half of 2015, when we were faced with significant change. Likewise, I feel good that our key strategies are paying off. Our multi-year investment in the United States was made because we believe in the potential of that market. Sales and margins have now rebounded and are helping us overcome challenges abroad. Likewise, our decision to reshape our portfolio in China and focus on new growing sales channels is showing signs of paying off.
Faced with macroeconomic challenges, we're making adjustments in other markets, too. Change is inevitable, and in many ways, businesses should be judged by how well they adjust and adapt, and I'm confident that we'll look back at the end of this year able to acknowledge that we did this quite well. 
Through last year, I repeatedly pointed to 4 important factors that critically influenced company performance. To remind you all, I'm referring to currency movements, dairy cost evolution, our ability to evolve our strategy and portfolio in China, and our momentum in North America, particularly in the United States. All of these 4 variables remain as relevant in 2016 as they were to our performance in 2015, but I should add pricing to the list. Our ability to offset, partially or in full, foreign exchange weakness with price increases will be very important. I'd add that I see some encouraging signs that price increases will become easier as we move through the year.
I'll close with the message that we'll continue to provide clear visibility on the impact of foreign exchange as we move through 2016. We'll do so by providing updates on both sales and profit growth, net of foreign exchange, in addition to our traditional non-GAAP earnings per share numbers. We hope you'll find this informative.
Operator, I'd now like to open the lines to questions. And because our prepared remarks have taken longer than anticipated, we're prepared to go a few minutes over if the questions merit doing so. Operator, over to you. Thank you."
1002291,321212057,922829,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Operator","[Operator Instructions] The first question comes from David Driscoll with Citi Research.",12,"[Operator Instructions] The first question comes from David Driscoll with Citi Research."
1002291,321212057,922829,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","This is Alexis Borden in for David. So question on China. Kasper, I appreciate your China comments in your prepared remarks. Still, I'd like to ask, just bigger-picture, is your China strategy working? What evidence can you point us to? And are your China",53,"This is Alexis Borden in for David. So question on China. Kasper, I appreciate your China comments in your prepared remarks. Still, I'd like to ask, just bigger-picture, is your China strategy working? What evidence can you point us to? And are your China market shares increasing? And I also have a follow-up."
1002291,321212057,922829,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Well, I think I tried to provide some metrics that would hopefully support my statement that I believe our strategy is working. I think we introduced the fully imported line of products into China sort of towards the back half really of the second quarter",268,"Well, I think I tried to provide some metrics that would hopefully support my statement that I believe our strategy is working. I think we introduced the fully imported line of products into China sort of towards the back half really of the second quarter. And the fact that this product line is now already making up 35% of our sales in the mainland and 22% of our sales in the combined China/Hong Kong business, I think it's fairly impressive progress. I want to remind you also that -- of the message we gave on our Investor Day that we have confirmed our intention to enter the super-high premium category sometime in 2016. I'm sure you can understand that for competitive reasons, I'm not prepared to tell you what our plan timing is, but it goes without saying that we obviously have one. So I feel quite good about that. We now -- if I add the Hong Kong business and our fully imported line together, we've now got more than half of our sales in the China/Hong Kong business coming out of our Netherlands facility, and therefore, meeting consumer desire for imported quality. So I think we're managing that transition quite well. I'm satisfied with the progress we are making in baby stores also. We -- through much of last year, we discussed the fact that we were under-indexing in baby stores, which is one of the faster-growing sales channels. But as of late, we've seen some fairly satisfactory improvements to our market shares in this channel, and I'm sure we'll continue to do so going forward."
1002291,321212057,922829,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Great. Alexis, just for the time constraints that we have, I'd like to go on to the next analyst.",19,"Great. Alexis, just for the time constraints that we have, I'd like to go on to the next analyst."
1002291,321212057,922829,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Operator","Your next question comes from Bryan Spillane, Bank of America.",10,"Your next question comes from Bryan Spillane, Bank of America."
1002291,321212057,922829,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","So just one question. I think, in 2015, in certain markets, you were able to price to the try to take -- raise prices in order to try to offset some of the negative effects of foreign exchange. I guess, in 2016, as you look at some of these markets that y",120,"So just one question. I think, in 2015, in certain markets, you were able to price to the try to take -- raise prices in order to try to offset some of the negative effects of foreign exchange. I guess, in 2016, as you look at some of these markets that you mentioned in terms of where there's currency volatility, does the cost savings that you're generating this year take some of the pressure off or give you more flexibility and not needing to necessarily -- to try to price for -- to offset the currency? Or are you still going to be looking to sort of price in some of these markets where the currencies have moved so dramatically?"
1002291,321212057,922829,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Bryan, thanks for the question. I think we will definitely look to price in these markets. I think, as you heard us talk about, we were quite some distance off managing to cover the impact of foreign exchange weakness through price in 2015. So that will b",229,"Bryan, thanks for the question. I think we will definitely look to price in these markets. I think, as you heard us talk about, we were quite some distance off managing to cover the impact of foreign exchange weakness through price in 2015. So that will be a continued challenge or task for us as we go through 2016. As I was trying to indicate, I think the pricing environment will become somewhat more friendly. What we saw in '15 was that there was still -- particularly, I would say, in Asia, there were still governments in Asia that were very resistant to price increases in our sector, as they still focused very much on kind of inflationary pressure or perceived inflationary pressure, which I think we all know was really a threat that evaporated sometime in 2014. And they would repeatedly point to the fact that we were seeing significant upside from dairy costs coming down as we discussed price increases. I think now that the dairy prices have stabilized, I believe that as both us and our competitors lap the low dairy costs, it will become a little bit more straightforward to raise prices. But we obviously have to do that in a responsible manner and we have to assess that in the context of general price inflation and wage inflation in the markets we operate in."
1002291,321212057,922829,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Operator","Your next question comes from Amit Sharma with BMO Capital Markets.",11,"Your next question comes from Amit Sharma with BMO Capital Markets."
1002291,321212057,922829,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","Kasper, without asking you to speculate on the timing of it, we've heard that there -- the Chinese government is looking at changing the tariff regulation for cross-border trade online. On a wider context, how do you think about how you're positioned in t",65,"Kasper, without asking you to speculate on the timing of it, we've heard that there -- the Chinese government is looking at changing the tariff regulation for cross-border trade online. On a wider context, how do you think about how you're positioned in the B2C channels? And if there is an incremental on tax on online, how would that impact your positioning in that channel?"
1002291,321212057,922829,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Well, I think there are -- as it relates to China, I expect that we're going to see regulatory adjustments coming sometime in 2016. I don't want to speculate on whether those regulatory adjustments will address all of the imbalances that we are seeing cur",198,"Well, I think there are -- as it relates to China, I expect that we're going to see regulatory adjustments coming sometime in 2016. I don't want to speculate on whether those regulatory adjustments will address all of the imbalances that we are seeing currently in China, but I believe that they will begin to address some of them. At the moment, it's clear that, inadvertently, the China regulations have created a tilted playing field that is very much tilting in favor of imported products sold through e-commerce. I don't believe that, that was the intention of either the regulators or the China government at large, and I think they will find ways to address that. I also think that they remain concerned about the large number of smaller brands that have been created in China that really lack the expertise or the resources to guarantee consumer quality, and I think that would be addressed. So I think you're going to a whole slew of attempts, at least, by regulators to get at some of these issues through this year, but since you gave me a free pass on the timing, I'll probably take advantage of that, Amit."
1002291,321212057,922829,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Thank you.",2,"Thank you."
1002291,321212057,922829,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Operator","Your next question comes from Ken Goldman with JPMorgan.",9,"Your next question comes from Ken Goldman with JPMorgan."
1002291,321212057,922829,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","Michel, I think, if I'm not wrong, that Mead Johnson locked in a bit more milk supply than usual this early in the year. I know it sometimes goes back and forth, and it's hard to tell. But it feels like it's a little more than usual. So first, correct me",116,"Michel, I think, if I'm not wrong, that Mead Johnson locked in a bit more milk supply than usual this early in the year. I know it sometimes goes back and forth, and it's hard to tell. But it feels like it's a little more than usual. So first, correct me if I'm wrong on that. And second, if that's correct, is that more of a tactical move just based on where milk cost and prices are? Or is it more of a strategic change that you'd like to implement whereby you maybe get a little more visibility there and a little more ability to price in line with where you think your cost will be?"
1002291,321212057,922829,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Yes, I think it is correct. It's a higher level than we used to have. And it's also true that we've taken that position on purpose, given the current benefits that we see. I don't like too much volatility into the P&L, so nobody does that, so the more you",66,"Yes, I think it is correct. It's a higher level than we used to have. And it's also true that we've taken that position on purpose, given the current benefits that we see. I don't like too much volatility into the P&L, so nobody does that, so the more you can control, the better that is, and this was one of the actions we have taken."
1002291,321212057,922829,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","Okay. So should I interpret that as -- I'm trying to figure out whether that's more tactical or strategic, and I kind of heard both in there.",27,"Okay. So should I interpret that as -- I'm trying to figure out whether that's more tactical or strategic, and I kind of heard both in there."
1002291,321212057,922829,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Correct.",1,"Correct."
1002291,321212057,922829,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Operator","Your next question comes from the line of John Baumgartner with Wells Fargo.",13,"Your next question comes from the line of John Baumgartner with Wells Fargo."
1002291,321212057,922829,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","Kasper, I wanted to ask you about North America. So you mentioned the margins being close to record levels here. How much of the margin expansion over the past 2 years is a function of the commodity cost benefits that are more temporary versus maybe somet",73,"Kasper, I wanted to ask you about North America. So you mentioned the margins being close to record levels here. How much of the margin expansion over the past 2 years is a function of the commodity cost benefits that are more temporary versus maybe something more structural in terms of the cost savings or portfolio mix? Should we think of this high-20s level as kind of a new normal for the business?"
1002291,321212057,922829,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Yes, John, I don't think -- if I said record levels, I misspoke. I think I said historic levels. So -- but it may go back to days before we were a public company, so you may have imperfect visibility. I guess what I was trying to indicate was that I belie",191,"Yes, John, I don't think -- if I said record levels, I misspoke. I think I said historic levels. So -- but it may go back to days before we were a public company, so you may have imperfect visibility. I guess what I was trying to indicate was that I believe that these levels of profitability in the North American business are sustainable, to put it sort of candidly. It's not inconsistent with where we have been. And what we see in the North American business is that we get a lot of leverage on both sales and volume growth in that business. So put another way, our marginal costs are very low in that business, and hence, we see big swings in profitability as sales move up and down. So I'm quite comfortable. I feel good about where the margins are. And I think we've got other parts of our global portfolio where we are working in difficult trading environments, and that results in -- perhaps in margin pressure, so it's quite rewarding to see that this part of our portfolio has the opposite dynamic playing in its favor."
1002291,321212057,922829,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Operator","The next question comes from the line of Michael Lavery with CLSA.",12,"The next question comes from the line of Michael Lavery with CLSA."
1002291,321212057,922829,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","Could you talk a little bit more about your higher investments in China and how much of that is trade spending or discounting versus A&P investments? And then also just update your timing. You said at the Investor Day you felt you had about 3 or 4 more qu",59,"Could you talk a little bit more about your higher investments in China and how much of that is trade spending or discounting versus A&P investments? And then also just update your timing. You said at the Investor Day you felt you had about 3 or 4 more quarters of discounting pressure there. Is that still your view?"
1002291,321212057,922829,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Our investments in China primarily in the -- I would say, in the second half of 2015, were largely focused on changing our trading profile. That means matching both competitors' pricing and also matching their general profile with retail trade. As we go f",83,"Our investments in China primarily in the -- I would say, in the second half of 2015, were largely focused on changing our trading profile. That means matching both competitors' pricing and also matching their general profile with retail trade. As we go forward, and we look at 2016, we will obviously invest behind our new growth initiatives. So we expect that, that would lead to some increase in both of those lines, both the trade support and the advertising and promotional expense."
1002291,321212057,922829,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Great. Thank you.",3,"Great. Thank you."
1002291,321212057,922829,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Operator","Your next question comes from the line of Matthew Grainger with Morgan Stanley.",13,"Your next question comes from the line of Matthew Grainger with Morgan Stanley."
1002291,321212057,922829,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","Kasper or Michel, I just wanted to clarify a bit further on the EPS guidance. And I joined a bit late, so I may have missed an aspect of the explanation. But you've maintained the expectation of mid-single-digit EPS growth despite the FX headwind being si",75,"Kasper or Michel, I just wanted to clarify a bit further on the EPS guidance. And I joined a bit late, so I may have missed an aspect of the explanation. But you've maintained the expectation of mid-single-digit EPS growth despite the FX headwind being significantly higher. So just curious what the delta was over the past few months that's giving you more confidence in the constant-currency outlook or sort of margin flexibility during 2016?"
1002291,321212057,922829,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","I mean, your understanding is correct. We indicated at Investor Day mid-single digit, and that is in line on what we're confirming now, despite the fact that we will have a higher headwind from currencies. I indicated in Investors Day that at that point o",224,"I mean, your understanding is correct. We indicated at Investor Day mid-single digit, and that is in line on what we're confirming now, despite the fact that we will have a higher headwind from currencies. I indicated in Investors Day that at that point of time, foreign exchange impact would have been around $0.15. Right now, we are looking at -- based on current spot rates, we're looking at a $0.40 impact from currencies. So we clearly looked into how we can mitigate that to still deliver mid-single-digit growth. On one hand side, like Kasper indicated, we clearly looked into pricing because that's an area where we think we need to be very cautious to see what can we do in certain markets, that's one. Two, I highlighted specifically, and referred also in an earlier question, on dairy benefits. We secured 80%, which is higher than we expected also in quarter 3. So that's one of the, whether you call it tactical or strategic initiatives, to secure the benefit to avoid volatility. And thirdly, like Kasper also indicated, we are clearly starting further assessments to see what can we do in terms of demand investments, and that will be leaning more towards mid of this year. So all of these initiatives, we accelerated actually, we took actions to mitigate the higher foreign exchange exposure."
1002291,321212057,922829,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","Okay. So it's more the actions you just mentioned as opposed to further acceleration of Fuel for Growth savings?",19,"Okay. So it's more the actions you just mentioned as opposed to further acceleration of Fuel for Growth savings?"
1002291,321212057,922829,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Well, it is. It is a combination, right, I should say. It is the Fuel for Growth savings. That's confirmed, significantly confirmed. So that wasn't the case yet in full in Investors Day. But secondly, like I said, we also are going further with further as",49,"Well, it is. It is a combination, right, I should say. It is the Fuel for Growth savings. That's confirmed, significantly confirmed. So that wasn't the case yet in full in Investors Day. But secondly, like I said, we also are going further with further assessment in demand investment."
1002291,321212057,922829,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Operator","Your next question comes from Jason English with Goldman Sachs.",10,"Your next question comes from Jason English with Goldman Sachs."
1002291,321212057,922829,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","A quick housekeeping question. I think that I heard you say that in the first quarter that the sales on constant currency would be flat to may be up 2% versus the fourth quarter of '15. Can you confirm that I heard that right? And also just mathematically",96,"A quick housekeeping question. I think that I heard you say that in the first quarter that the sales on constant currency would be flat to may be up 2% versus the fourth quarter of '15. Can you confirm that I heard that right? And also just mathematically, as I'm looking at my model, it seems to suggest that sales could be down close to 20% in the first quarter. Is that right? And if so, where -- what should we brace for in terms of pockets of sort of outsize weakness in the first quarter?"
1002291,321212057,922829,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Well, I think -- let me try and repeat what we said. I said in my prepared remarks that we expect to see sequential quarterly improvement in sales, in constant-dollar sales. So that would translate into sales in the first quarter as opposed to being at or",54,"Well, I think -- let me try and repeat what we said. I said in my prepared remarks that we expect to see sequential quarterly improvement in sales, in constant-dollar sales. So that would translate into sales in the first quarter as opposed to being at or above the level in the fourth quarter."
1002291,321212057,922829,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","And that's with currency?",5,"And that's with currency?"
1002291,321212057,922829,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","No, that was in constant dollars.",6,"No, that was in constant dollars."
1002291,321212057,922829,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","Okay. I'll try to get clarification with Kathy offline on that one then. And I'll pass it on for now.",20,"Okay. I'll try to get clarification with Kathy offline on that one then. And I'll pass it on for now."
1002291,321212057,922829,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","I think for the full year, we will clearly expect to see adverse currency impact. I think we've said, Jason, that we expect about a 600 basis point adverse impact from foreign exchange, and we also said that we had based that on basically the current exch",74,"I think for the full year, we will clearly expect to see adverse currency impact. I think we've said, Jason, that we expect about a 600 basis point adverse impact from foreign exchange, and we also said that we had based that on basically the current exchange rates as of this month. So that would stand to reason that, that 600 basis points in adverse impact would start at the beginning of the year."
1002291,321212057,922829,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Operator","Your next question comes from the line of Robert Moskow with Crdit Suisse.",13,"Your next question comes from the line of Robert Moskow with Crdit Suisse."
1002291,321212057,922829,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","This is kind of a follow-up to Matthew's question. I mean, if you do the math, the foreign exchange headwind is significantly more than what you thought in October. And -- but you're kind of maintaining, I think, the same guidance you had before, and that",135,"This is kind of a follow-up to Matthew's question. I mean, if you do the math, the foreign exchange headwind is significantly more than what you thought in October. And -- but you're kind of maintaining, I think, the same guidance you had before, and that guidance implies quite a bit of growth in the core business in order to be achievable. You mentioned pricing, and that's probably the tool that you would use in unlocking in dairy, although I think if you locked in, I'm not sure how that's a benefit from October. So Michel, maybe you can help just a little bit more. Don't you have to push the pricing lever harder than you thought in October in order to achieve this guidance? Or are there other levers I'm not aware of?"
1002291,321212057,922829,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","No, it is indeed a combination of price/mix, what we need to look into, country mix. But yes, I mean, price is a component that is higher than we indicated and that we anticipated in quarter 3.",37,"No, it is indeed a combination of price/mix, what we need to look into, country mix. But yes, I mean, price is a component that is higher than we indicated and that we anticipated in quarter 3."
1002291,321212057,922829,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","And how is that -- is it is achievable, given the competitive environment? Or does something have to change in the competitive environment in order for that to happen?",29,"And how is that -- is it is achievable, given the competitive environment? Or does something have to change in the competitive environment in order for that to happen?"
1002291,321212057,922829,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Look, part of that is driven by certain new innovation rollouts that we're having scheduled. So we're trying to combine that as much as possible to take price further than initially thought.",32,"Look, part of that is driven by certain new innovation rollouts that we're having scheduled. So we're trying to combine that as much as possible to take price further than initially thought."
1002291,321212057,922829,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Operator","Your next question comes from Eric Katzman with Deutsche Bank.",10,"Your next question comes from Eric Katzman with Deutsche Bank."
1002291,321212057,922829,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","I guess, let me ask about promotion for a second. Back at our conference in Paris, Kasper, you talked about promotion being kind of the initial signs of being more concerned about it in China, and then I guess it broadened out into Latin America and other",113,"I guess, let me ask about promotion for a second. Back at our conference in Paris, Kasper, you talked about promotion being kind of the initial signs of being more concerned about it in China, and then I guess it broadened out into Latin America and other regions. So I guess, it's been a long call, but just so I frame it, did you kind of end 2015 -- with what I think you had dubbed kind of irrational behavior on the part of competition, was that kind of sequentially flat or did it get worse? And kind of what assumptions are you making around promotion into 2016? And I'll pass it on."
1002291,321212057,922829,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Yes, it's an excellent question, and -- but you caught my comments correctly. I indicated that we've seen the environment stabilize, so there's still -- I would not say it has improved, but the environment has stabilized. And I think having now entered th",112,"Yes, it's an excellent question, and -- but you caught my comments correctly. I indicated that we've seen the environment stabilize, so there's still -- I would not say it has improved, but the environment has stabilized. And I think having now entered the fray, so to speak, in order to protect our competitive position, we saw that pay off in terms of stabilizing and even improving our underlying sales performance in the fourth quarter. So yes, I feel the environment, including in China, is now a little bit more stable. But it's clearly stable at a much higher level of promotion than, say, where we were a couple of years ago."
1002291,321212057,922829,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","And looking into '16?",4,"And looking into '16?"
1002291,321212057,922829,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","We expect that the environment will remain stable in '16.",10,"We expect that the environment will remain stable in '16."
1002291,321212057,922829,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Operator","Your next question comes from -- sorry?",7,"Your next question comes from -- sorry?"
1002291,321212057,922829,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Operator, sorry. I just want to say we have time for one more call, so the one that you're about to place in will be the last.",27,"Operator, sorry. I just want to say we have time for one more call, so the one that you're about to place in will be the last."
1002291,321212057,922829,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Operator","Your next question comes from David Hayes with Nomura.",9,"Your next question comes from David Hayes with Nomura."
1002291,321212057,922829,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","Just trying to pick up on the compensation benefit shift. You obviously made the point that the margin benefited, I think, particularly back end of the year, in terms of the compensation, the variable compensation, I guess, reversing to some extent throug",147,"Just trying to pick up on the compensation benefit shift. You obviously made the point that the margin benefited, I think, particularly back end of the year, in terms of the compensation, the variable compensation, I guess, reversing to some extent through the year in terms of the accruals that you might take in beginning of the year. So the question is on that -- one, can you quantify the impacts of that variable comp dropping out? And then secondly, I guess, more importantly, as you look into next year, because you talked about it more this year, you talked about it being a transition year or a transformational year, would you expect that compensation to come back into the numbers? Or is the organization effectively not going to pay that variable pay until the performance level for the group steps up back to the previous levels?"
1002291,321212057,922829,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Yes. I mean, in the compensation, accruals dropped in the year 2015 given the lower performance, which had an estimated impact around $30 million. The -- if you look to the number for next year, yes, we put it back to normal target levels. So those ones a",59,"Yes. I mean, in the compensation, accruals dropped in the year 2015 given the lower performance, which had an estimated impact around $30 million. The -- if you look to the number for next year, yes, we put it back to normal target levels. So those ones are included in the numbers that we have provided you for guidance."
1002291,321212057,922829,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","I guess, hitting [ph] the guidance, you'd have that $30 million come back in, but that's included in the margin...",20,"I guess, hitting [ph] the guidance, you'd have that $30 million come back in, but that's included in the margin..."
1002291,321212057,922829,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","That's included in the numbers, yes.",7,"That's included in the numbers, yes."
1002291,321212057,922829,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Operator, I think this closes our call.",7,"Operator, I think this closes our call."
1002291,321212057,922829,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Operator","Ladies and gentlemen, thank you for your participation in today's conference. This concludes the presentation. You may now disconnect. Good day.",21,"Ladies and gentlemen, thank you for your participation in today's conference. This concludes the presentation. You may now disconnect. Good day."
1002291,321212057,923175,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Operator","Good day, ladies and gentlemen, and welcome to the Mead Johnson Nutrition Fourth Quarter 2015 Earnings Conference Call. My name is Liz, and I'll be your coordinator for today. [Operator Instructions] As a reminder, this conference is being recorded for re",62,"Good day, ladies and gentlemen, and welcome to the Mead Johnson Nutrition Fourth Quarter 2015 Earnings Conference Call. My name is Liz, and I'll be your coordinator for today. [Operator Instructions] As a reminder, this conference is being recorded for replay purposes. 
I would now like to turn the conference call over to Kathy MacDonald, Vice President, Investor Relations. Please proceed, Kathy."
1002291,321212057,923175,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Thank you, Liz. Good morning, and thank you for joining Mead Johnson's Fourth Quarter and Full Year 2015 Conference Call. With me today are Kasper Jakobsen, our Chief Executive Officer; and Michel Cup, our Chief Financial Officer. Earlier today, we issued",310,"Thank you, Liz. Good morning, and thank you for joining Mead Johnson's Fourth Quarter and Full Year 2015 Conference Call. With me today are Kasper Jakobsen, our Chief Executive Officer; and Michel Cup, our Chief Financial Officer. Earlier today, we issued our earnings release and financial reference slides, which are available on our website.
As we start, let me remind everyone that our comments will include forward-looking statements about our future results, including statements about our financial prospects and projections, commodity costs, currency fluctuations, pricing, taxes, capital spending, depreciation and amortization, new product launches, product quality, other growth initiatives and market conditions that constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. A more detailed explanation of our forward-looking statements will appear in the materials posted on our website in connection with today's conference call.
Keep in mind that our actual results may differ materially from expectations as of today due to various factors, including those listed in our Annual Report on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K, in each case, as filed with or furnished to the Securities and Exchange Commission and our earnings release issued this morning, all of which are available upon request or on our website at meadjohnson.com.
Today's comments will include a discussion of non-GAAP financial measures. A reconciliation of these measures to comparable GAAP measures appears in the morning's earnings release posted on our website. In addition, any forward-looking statements represent our estimates only as of today and should not be relied upon as representing our estimates at any subsequent date. While we may elect to update forward-looking statements at some point in the future, we specifically disclaim any obligation to do so, even if our estimates change. I will now turn the call over to Kasper."
1002291,321212057,923175,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Thank you, Kathy, and thank you to all of you for listening to our fourth quarter and full year earnings call this morning. Over the next 35 minutes or so, Michel and myself will summarize our fourth quarter and full year 2015 financial results. We'll als",3385,"Thank you, Kathy, and thank you to all of you for listening to our fourth quarter and full year earnings call this morning. Over the next 35 minutes or so, Michel and myself will summarize our fourth quarter and full year 2015 financial results. We'll also outline our expectations for 2016. 
I'll begin by providing an overview focusing on revenue performance, our key strategic initiatives and business drivers and underlying business momentum. I'll then hand over to Michel, who'll give a further analysis of our financial metrics and provide an outlook for key cost drivers. After Michel completes his segment, I will return with a few summary remarks before we give you an opportunity to ask questions. Except when noted otherwise, I'll be referring to non-GAAP results. A full reconciliation to our GAAP results is available in our 10-Q that was filed alongside our earnings release earlier this morning. Both documents are available on our website. 
Let me start with a high-level overview of our fourth quarter 2015 results for the global business, before I move on to discuss full year results and then performance of each of our regions. As we exited the year, and I refer now to fourth quarter results specifically, I'm pleased to say we saw a sequential improvement versus the third quarter in our underlying sales performance. Net of withheld shipments to Venezuela, a topic I'll return to later, we saw sequential growth in constant dollars sales of 1%. This represented a modest reversal of the trend we've seen over the previous 3 quarters, despite sales performance being adversely affected by selective retailer inventory adjustments in Thailand and Malaysia.
Structural changes made to our investment profile in China and the recent launch of our fully imported line of Enfa products helped us deliver on the promise we made in July. At that time, we said we expected to see sequential improvement in China sales as we exited the year. And in the fourth quarter, our China/Hong Kong business grew 2% sequentially over the third quarter. Our North America/Europe segment also grew sequentially by nearly 5% on a constant dollar basis. 
Let me now address our full year results. 2015 was a challenging year for us. We were challenged by a strengthening dollar and the general weakness in many economies throughout Asia and Latin America. GDP growth across Asia and Latin America was lower than prior year, and this affected both consumer and retailer confidence. Additionally, in China, we saw increased price-based competition and channel shifts that adversely impacted sales growth and required us to boost investment to protect our competitiveness. 
In Southeast Asia, in particular, we saw slowing economic growth in Thailand and Malaysia. Combined with some company-specific executional issues, this resulted in lower volumes through the year. In the Philippines, where GDP growth remained more robust, we saw relatively better performance. And there, we are satisfied with the progress we made through the year. We continue to benefit from lower dairy costs and an improved gross margin as a consequence. This helped partially offset the EBIT and EPS impact of foreign exchange and lower sales.
For full year 2015, constant dollar net sales were 2% below prior year, largely due to our challenges in China and Hong Kong. Gross sales, however, were in line with 2014. This shows continued solid demand for our brands, though a challenging trading environment saw us report sales below prior year level. 
The impact of a strengthening dollar was significant throughout the year, reducing reported sales by about 6% and earnings per share by $0.26. Where possible, we took price to mitigate the impact of foreign exchange. However, competitor strategies and abnormally low dairy costs made price increases more difficult than we've seen in recent years.
Price consequently contributed 1% -- percentage point of growth to the full year. As we progressed through the year, the carryover benefit of price increases taken in 2014 gradually disappeared and price promotional activity became more evident. Against the same quarter of prior year, this increased dynamic adversely affected fourth quarter growth by 1 percentage point. This was largely driven by increased trade promotional activity in China. Global volume was 3% lower than prior year, growth in North America and Europe didn't fully offset weaker performance in Asia and Latin America, and the impact of our decision to slow shipments into Venezuela was also significant.
Infant formula product sales for 2015 were in line with prior year on a constant dollar basis. It follows that we were relatively more challenged within our children's category outside of North America. The children's category is more price-sensitive and, prior to reshaping our competitive stance in the third quarter, we suffered share losses due to competitors' price promotional activity. However, having addressed the price disadvantage, as the cohort of infants' age, that consumer brand, this should help sales of our children's franchise going forward.
We understand the recovery of momentum in China and select other emerging markets could take time, and we need to properly fund key growth initiatives. As a consequence, the company invests -- the company's investment in advertising and promotion remained strong in the fourth quarter at 15.6% of sales. This was 190 basis points above prior year 's fourth quarter level. 
To help fund these investments and offset the impact of foreign exchange, we accelerated the implementation of some of our operating expense reductions. We refer to this initiative as Fuel for Growth. As a direct result of this focus, our operating expenses came in approximately $20 million favorable versus the forecast that underpinned guidance issued in October. This favorability allowed us to offset the impact of unanticipated dollar strength in the final quarter of the year and still deliver earnings per share slightly above the high end of our guidance range.
We delivered $0.78 in non-GAAP earnings per share for the final quarter of 2015. As mentioned, this was slightly better than expected and allowed us to finish 2015 with $3.44 in non-GAAP earnings per share. Even as we grappled with adverse dynamics in many of our markets in 2015, I'm pleased that we avoided any temptation to pull back on investment. We know that continuous innovation is critical to our long-term growth prospects.
Here are some examples of new products we introduced around the world. In the United States, we introduced new and more convenient plastic packaging for our 32-ounce ready-to-feed liquid infant formula, building on the success of our 8-ounce launch a couple of years ago. We also responded quickly to competitive activity by introducing a new formulation of infant formula free from genetically-modified raw materials. Across North America, we became the first company to meet newly developed guidelines for premature infant formula. And in China, we introduced a fully imported range of Enfa-branded products to complement our locally manufactured range. These fully imported products now account for 35% of our sales within the mainland. 
In Southeast Asia, we upgraded our formulations and added increased levels of DHA to our children's products. We also introduced plastics packaging in several countries, and we added ready-to-drink versions to our lineup of Enfa products. In Latin America, we introduced liquid versions of our key infant formula products; and in Mexico, our Enfagrow Toddler product. For our powdered products, we began the introduction of upgraded plastics packaging. 
Further, over more than 70 years, we worked diligently to develop clinical evidence in support of our specialty portfolio, predominantly our Nutramigen allergy brand. Educating health care professionals about Nutramigen's benefits allowed us to grow constant dollar sales double digits in 2015.
As I complete my comments on overall company performance, and before I move to discussing our reporting segments in more detail, I want to mention that, as promised, we executed an accelerated share repurchase program in the most recent quarter. This reflects our commitment to the creation of long-term shareholder value. Michel will revert to this topic later. Let me now briefly comment on the performance within each of our reporting segments, and I begin with Asia. 
Sequentially, Asia's sales were in line with third quarter, with improvements in China offset by lower sales in Thailand and Malaysia. For fourth quarter, constant dollar sales were 10% below the prior year quarter, and full year sales compared unfavorably to 2014 by 8%. As mentioned, sequentially, we grew sales in China/Hong Kong by 2% from the third quarter of 2015. A more aggressive trading stance allowed us to stabilize sales of our locally manufactured product line. Though we've had to increase our investment, we're encouraged that prices to consumers appear to have stabilized in the fourth quarter. 
At the same time, demand for our recently introduced fully imported range continued to grow. As mentioned earlier, sales of this product range now accounts for 35% of our sales in Mainland China and a full 22% of our combined China/Hong Kong business. As we expand direct shipments of fully imported products into Mainland China, we expect to see continued cannibalization of our Hong Kong business. Such channel shifts may obscure underlying business progress in the near term, but ultimately should be favorable to the company overall, as we build a stronger, more sustainable portfolio with greater reach inside Mainland China. 
As mentioned at our Investor Day in October, we are committed to make investments in support of our recent introductions. We're advancing digital marketing capabilities, expanding our channel coverage, and strengthening our retail chain relationships through focused investments. Beyond the early sales success with our imported product range, as a further sign our strategy is working, we are seeing market share gains in baby stores.
As you know, we've also focused on strengthening our presence in business-to-consumer e-commerce. This represents the fastest growing part of the e-commerce market in China, and the segment is growing at approximately 5x the rate of the rest of the e-commerce channel. In a sign of our commitment to strengthening our presence in web and app-based commerce, we recently signed joint business partnership agreements with Jingdong, owner of leading e-commerce site, JD.com; and Tencent, owner of WeChat, the leading social app in China. Under these agreements, we agreed to cooperate by sharing data and technology platforms to the mutual benefits of our separate businesses. These agreements recognize the expertise of each party, including Mead Johnson China, and we are thrilled to partner with such great companies. 
While our China business began to show progress, our businesses in Malaysia and Thailand experienced challenges, as mentioned earlier. Both economies are going through a challenging time due to political uncertainty and weak commodity prices. As a result, both consumer and business confidence is reduced. However, despite this backdrop, I want to acknowledge that we have not executed as well as expected in either country for much of 2015. Though we cannot control economic trends, we can and will control our execution, and we are taking steps to improve performance going forward. In the meantime, we continue to manage trade inventory builds carefully in the fourth quarter. 
In the third quarter, we enhanced our products in Thailand with increased levels of DHA and introduced new packaging, including a plastic tub. Early signs are encouraging, with share increasing in the 3 months following our relaunch. However, it took longer than expected to deplete old inventory in the trade, and consequently, we chose to address this more aggressively in the most recent quarter.
Having discussed some areas of relative challenge, let me now point to our relatively stronger performance in the Philippines. The Philippines' business has delivered solid growth over the past 2 years. We've managed to offset foreign exchange impacts with improved pricing, and we've successfully extended our Lactum children's brand into the infant formula category. This move gives us exposure to a growing economy beyond our traditional premium price position. 
Turning now to Latin America. The region delivered constant dollar sales growth of 3% for the full year compared to 2014. Regional currencies weakened substantially through 2015, with large adverse impacts on sales growth in Brazil, Argentina, Colombia, Venezuela and Mexico. As a consequence, reported sales were 13% below prior year level. For the fourth quarter, excluding Venezuela, to where we paused shipments for much of the quarter, sales grew 5% on a constant dollar basis over the same quarter of prior year. Including Venezuela, the region sales for fourth quarter '15 were 4% lower in constant dollars than the same quarter of 2014. 
As you can tell, our decision to pause shipments to Venezuela was a significant driver of relatively weaker segment performance. As stated in previous calls, we are carefully managing risk associated with our intercompany payables within defined parameters. In the near term, this means matching new shipments to Venezuela to hard currency payments received. We are actually working with the Venezuelan government to address this challenge in order that we can once again help provide much needed nutrition to children in that country. 
Looking at the overall economy of Latin America, over the past decade, these commodity-driven economies benefited substantially from stronger prices. Since the collapse in commodity prices, Latin America's GDP growth has slowed dramatically. Countries, beyond the obvious example of Brazil that's in the recession, are grappling with sharp reductions in their growth rates for the first time since 2009. These macroeconomic conditions, coupled with the strengthening dollar, have resulted in sharp depreciation of local currencies.
I'd like to provide a little more detail in today's discussion. And for that purpose, I'll group the region into 3 sections. I've excluded Venezuela, which I've discussed separately already. I'll now discuss Mexico, the Caribbean and Central America as a distinct area from the Southern Cone area of Brazil and Argentina. And finally, touch briefly on the Andean region, in which we include Peru, Ecuador and Colombia.
In Mexico, the Caribbean and Central America, the Enfa family of premium products grew strongly in constant dollars, both sequentially over the third quarter and in full year 2015, and now represents about 2/3 of sales within the area. Outside of Mexico, much of our business in this area is conducted in U.S. dollars. This helped to partially offset the impact from a decline in the Mexican peso. That said, the Mexican business is our third largest business globally. And many of you already know our Mexican portfolio augments our global Enfa-branded products with 2 very strong local brands of milk modifiers, Choco Milk and Cal-C-Tose. 
These 2 milk modifier brands gave us a leading edge -- or a leading share, sorry, of the large Mexican milk modifier market, a large category that's, however, characterized by strong competition from global and local players. With limited potential to expand consumer penetration, competition is tough and occasionally price-based. These dynamics, over the last several years, have caused our milk modifier brands to grow more slowly than our Enfa-branded infant and children's business. In 2015, milk modifiers net sales declined as we expanded trade discounts to protect our competitive position. This impacted the overall Mexico result adversely.
Our performance in the South Cone area was adversely impacted by the economic recession and currency weakness in Brazil. In Argentina, price schemes more than covered the impact of currency depreciation. And across the area, we continue to grow our infant formula and toddler sales strongly in local currency. However, in Brazil, we also sell the Sustagen brand of milk modifiers. And in this category, we saw consumers move to cheaper competitive offerings, and we lost sales as a consequence. Within the Andean region, we saw Colombia deliver strong double-digit growth for both the latest quarter and the full year. The smaller market of Ecuador also performed well, but these encouraging results were offset by challenging retail conditions in Peru. 
To wrap up, the key drivers for the Latin America full year results are: volume, which was lower primarily from our intentional constraint of Venezuela shipments and Mexico milk modifier sales reductions; price, that was predominantly from the high inflationary markets of Argentina, Colombia and Venezuela; and finally, foreign exchange that negatively impacted the region. 
I'll now turn to our performance in North America and Europe. In the full year 2015, the North America/Europe segment delivered 4% constant dollar revenue growth over 2014. Volume improved 1%, with price and product mix contributing 3% to our annual growth rate. In the fourth quarter, this segment's sales were in line with the prior year 's quarter. Sequentially, as stated earlier, sales increased 5% over the third quarter. With little to no growth in the category in North America, our volume growth was realized through market share gains, and our Enfagrow children's business continued double-digit growth. Our premium price specialty and solutions offerings also grew double digits. And our Canadian business continued to execute extremely well and exited the year with record-high market shares.
Europe posted its strongest sales and EBIT performance in the last 5 years, though the sales impact was partially offset by our exit from the Russian market earlier in the year. Overall, 2015 was another strong year for this segment, a year in which we saw profit margins expand to approach historic levels. In many ways, this was proof that our decision to maintain investment levels through the 2009 to 2012 economic downturn was the right one. 
Turning now to our outlook for 2016. Our outlook is broadly similar to that provided at our Investor Day in October. We expect constant dollar sales to continue to show gradual improvement sequentially through the coming quarters. But due to tough comparisons from the first half of 2015, we do not expect to report positive revenue growth over same quarter of prior year till the second half of 2016. For this reason, we expect full year 2016 constant dollar sales growth to be modest, in the range of 0% to 2%. 
Based on current exchange rates, we expect currency to reduce sales growth by approximately 600 basis points. As a result, reported sales may decrease by 4% to 6% this year. We now have a good fix on dairy costs, as this item will impact our profit and loss statement through the first 7 or 8 months of the year. Based on this, we are comfortable saying that, again, in 2016, dairy prices would have a favorable impact on our cost of goods.
At our Investor Day event last October, we characterized 2016 as a year of transition. In the context of headwinds from a strengthening dollar, we committed to reduce non-demand-creating operating expenses by $60 million in order to reinvest in select growth initiatives and protect earnings growth. As headwinds from currencies have grown stronger since our October gathering, this initiative has become even more central to our strategy, and I'm pleased to report we're making good progress and remain confident in our ability to deliver on our cost-reduction ambition. 
As mentioned in our press release this morning, I believe it's important for us to give you a better picture of the expected evolution in underlying profitability without the polluting effect of currency impact. To this end, let me clarify that we expect to deliver 9% to 12% constant dollar non-GAAP earnings per share growth. And based on our assumption around foreign exchange, we expect therefore non-GAAP earnings per share, when expressed in U.S. dollars, to be in the range of $3.48 to $3.60. Not included in our estimates of 2016 is any additional benefits that might accrue from a review of efficiency and productivity opportunities within our demand-generating investments. Such a review is currently scheduled for mid-2016.
I must point out that we remain highly focused on further strengthening -- sorry, we must -- we remain highly exposed to the further strengthening of the dollar or selected weakening in foreign currencies. Anticipating that we may continue to see some variability in exchange rates through the year, we've decided to provide you with a reconciliation to growth in non-GAAP constant dollar earnings per share.
I'll now turn the call over to Michel, who will provide some more details on our fourth quarter and full year financials. Michel will also elaborate on our guidance for 2016. And upon the completion of his prepared remarks, I'll return with some summary remarks before we open the lines to questions. Michel, over to you."
1002291,321212057,923175,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Thank you, Kasper, and good morning, everyone. Today, I will discuss our fourth quarter and full year 2015 financial results. I will then briefly highlight segment results, and conclude with a summary of our 2016 guidance. Unless otherwise noted, my comme",2231,"Thank you, Kasper, and good morning, everyone. Today, I will discuss our fourth quarter and full year 2015 financial results. I will then briefly highlight segment results, and conclude with a summary of our 2016 guidance. Unless otherwise noted, my comments will be on the non-GAAP financial results. References to currency impacts or the effects of currency fluctuations generally refer to the impact on the translation of local currency financial statement into U.S. dollars. 
Let me start with sales. Kasper addressed constant dollar sales growth. I will focus more on the foreign exchange impact. As you can see from Slide 3, fourth quarter sales on a reported basis were 12% below the prior year quarter. Adverse foreign exchange rates contributed to a decline of 6%, a similar rate to that seen in the third quarter. For the full year, sales on a reported basis were 8% below last year. The adverse foreign exchange impact on sales was 6%, or $229 million.
On Slide 4, we have summarized the impact of foreign exchange for the quarter. The U.S. dollar continued to strengthen in the fourth quarter and its effect on translation of local currency negatively impact all reporting segments. Over 1/3 of the negative currency impact in the fourth quarter were from the Mexican peso and the Chinese renminbi. The balance of the foreign exchange impact was widespread, especially from our large markets like Canada, Malaysia and Thailand. We expect to see additional adverse foreign exchange impact in 2016 based on the continued strengthening of the dollar across a very broad basket of currencies. I'll address this foreign exchange impact in the EPS guidance section as well. 
I will now move on to the factors that impacted our gross margin on Slide 5. Gross margin was 63.9% in the fourth quarter, up 200 basis points from the same quarter of 2014. Lower dairy costs drove the majority of the improvement. However, the benefit was cut in half by adverse foreign exchange impacts. Productivity improvements offset our commodity increases and higher manufacturing costs. In the last earnings call, we highlighted 3 factors that would result in a sequential gross margin decrease: less benefit from new price increases; increased trade investment, especially China; and our annual U.S. plant shutdown. These factors came in as expected during the fourth quarter. 
On a full year basis, gross margin was 64.6%, which is 270 basis points improvement versus the prior year, mainly due to lower dairy costs, which benefited all segments. Supply chain productivity delivered approximately 5% of savings in cost of goods sold, which mitigated other costs, as noted previously. 
Moving on to operating expenses on Slide #6. Our advertising and promotion spending was 15.6% of sales in the fourth quarter compared to 13.7% in the prior year quarter. This was an increase of 7% on a constant dollar basis. A&P investment in the fourth quarter includes support for China's fully imported products, TV media for the U.S. children business and support for new product launches, like the 32-ounce liquid and non-GMO product line that Kasper described earlier. 
SG&A, on a constant dollar basis, was 6% or $14 million lower than the fourth quarter of 2014. Savings were a result of a lower incentive compensation and a reduction in corporate cost, partly driven by our Fuel for Growth initiatives. SG&A, on a full year basis, were flat compared to 2014 on a constant dollar basis. As you can see from Slide 7, our cost-related research and development, marketing and G&A decreased by 3% in 2015 versus 2014 on a constant dollar basis. When comparing the second half year 2015 to the first half year 2015, the corporate support function decreased 8%, mainly driven by the Fuel for Growth program.
In the fourth quarter, we made the first wave of employee reductions. Compared to June 2015, we reduced approximately 200 FTEs, mainly within the corporate support functions, where we reduced 18% of our headcount. We eliminated some outside services and initiated vendor negotiations for key services. The headcount and outside services actions to take -- to date have allowed us to secure most of our $60 million Fuel for Growth target for 2016. We are very comfortable to deliver this year's savings. 
Turning now to Slide 8. On a constant dollar basis, the fourth quarter EBIT was 3% below the prior year quarter, and the full year EBIT was aligned with 2014. Including currency impact, EBIT was down 13% in the fourth quarter and down 7% for the full year. The EBIT margin as a percent of sales for the fourth quarter was slightly lower than the prior year quarter, as continued investments were not fully offset by the higher gross margin. EBIT margin as a percentage of sales for the full year increased by 30 basis points. 
I will now discuss EBIT for each segment, starting with Asia on Slide 9. In Q4, Asia delivered EBIT of $140 million, a decrease of 24% on a constant dollar basis. On a reported basis, EBIT was 28% lower, mainly due to impact of the Chinese renminbi. The EBIT margin at 30% was lower than the fourth quarter 2014 and the third quarter '15. As we continued to invest, especially in China, these investments included price promotions on the locally manufactured products to protect competitiveness, along with A&P support for the fully imported product line introduced earlier this year. As Kasper mentioned, Greater China sales improved sequentially as a result of these investments. For the full year, the Asia EBIT margin at 33% remains the highest of our 3 segments. However, the EBIT margin was lower than in 2014, as lower sales and high demand-generation investments were not fully offset by the dairy benefit.
Latin America, on Slide #10, delivered EBIT of $34 million in the fourth quarter, an increase of 15% on a constant dollar basis. On a reported basis, EBIT declined 26%, as the region continued to have a large negative impact from currencies, most notably the Mexican peso. If we exclude the impact of Venezuela, where we intentionally reduced shipments, the segment's reported EBIT dollars for 2015 would have been in line with 2014 for both the fourth quarter and the full year. For the full year, Latin America EBIT margin improved slightly to 23.1%. Lower dairy costs more than offset the impact of the higher investments. 
Let me address North America and Europe on Slide 11. For the fourth quarter, EBIT was $97 million, an increase of 14% on a constant dollar basis and 8% on a reported basis. In the midst of a tough top line comparison, gross margin continued to be strong. The team managed to maintain operating expense in line with the prior year quarter, while increasing A&P by 9% on a constant currency basis. For the full year, the North America/European EBIT margin was 28%, benefiting primarily from gross margin. I will now address our financial results from EBIT to net results on Slide #12.
The fourth quarter interest expense increased to approximately $22 million, reflecting the issuance of the new $1.5 billion notes to finance the share repurchase programs. During our October earnings call, we announced a new share repurchase program of $1.5 billion of the company's common stock, with $1 billion in the form an accelerated share repurchase, or ASR. The ASR was executed after the close of business on that same day. Under the accelerated share repurchase program, 10.7 million shares of stock were delivered in the quarter.
Following this portion of the ASR, the average number of shares in the fourth quarter were 189.8 million. As of December 31, 2015, the outstanding shares were 186.4 million. It is expected that additional shares will be delivered in 2016 under the current ASR program. The ASR program was initially financed by a $1 billion term loan. Shortly thereafter, refinanced by the issuance notes, $750 million 5-year notes at a rate of 3% and $750 million 10-year notes at a rate of 4.125%. 
Taxes. For 2015, our non-GAAP effective tax rate, or ETR, was 24.8% compared to 22.5% in 2014. The 2014 rate was unusually low as a result of a $0.05 per share nonrecurring tax benefit. Also, the 2015 ETR was also higher as a result of an unfavorable change in geographic earnings mix. 
Let me briefly address our EPS on Slide 13. Non-GAAP EPS for the fourth quarter was $0.78, a decline of $0.14 versus the prior year quarter. Sales negatively impacted EPS by $0.16, offset by gross margin benefit. Foreign exchange adversely impacted EPS by $0.10. Full year non-GAAP EPS were $3.44, slightly above the high end of our guidance. Versus the prior year, EPS declined by $0.30, with foreign exchange alone negatively impacting EPS by $0.26. The sales decline impacted EPS by $0.26 as well. Gross margin benefit was offset by additional A&P investments to support our innovation, especially our investments in China. 
Specified items. For 2015, specified items were $45 million or $0.17. The largest charge was $25 million. This occurred in the fourth quarter and was related to a restructuring provision for our Fuel for Growth productivity program. This was in line with expectations we highlighted in our third quarter earnings call. Including these specified items, EPS on a non-GAAP basis was $3.27. 
Let me finish the 2015 discussion with a high-level overview of the cash flow and balance sheet. Despite the challenging operating environment, we generated strong cash flow, which further strengthened our balance sheet. As you can see from Slide 14, free cash flow, defined as operating cash flow less capital expenditures, was $726 million during 2015, up 20% from the prior year. For 2015, capital expenditures were $174 million, consistent with our long-term goal of about 4% of sales. The most significant capital investment were to expand capacity at our European plant to support demand for the new China fully imported product line; and in the U.S., to support new liquids manufacturing.
Depreciation and amortization expenses was $99 million for the full year. For the full year 2015, we increased our dividends by 10% to $1.65 per share, resulting in a total dividend payment of $326 million. The total payout ratio was close to 50% of our net results. Our cash balance as of December 31 was $1.7 billion, an increase of approximately $400 million compared to December 2014. Nearly 90% of our cash is held outside of the United States. Our net debt position as of December 31 was less than $1.3 billion. 
I will now wrap up with a summary of our 2016 guidance on a non-GAAP basis on Slide 15. We forecast constant dollar sales in the range of 0% to 2% this year versus 2015. Assuming exchange rates remain at current levels, this would translate into 2016 sales 4% to 6% below the prior year on a reported basis. Please note that we expect tougher sales comparison in the first half of 2016 versus 2015. This is due in part to more favorable performance seen in China, and especially in the first quarter of 2015.
Constant dollar sales in Q1 2016 are expected to be in line or slightly higher above the Q4 2015 performance. The company expects a positive trend in the second half of 2016 on a constant dollar basis. We expect higher investments in A&P in the first half of 2016. As a result, we expect growth of non-GAAP EPS towards the second half of 2016. Please note that quarter 1 2016 non-GAAP EPS will have a tough comparison.
From an EPS guidance perspective, there are several key factors to consider. We expect that our gross margins will be around 64%, similar to the fourth quarter 2015 level. We entered into dairy contracts at attractive prices to secure more than 80% of our expected 2016 dairy needs. Nearly all of the expected $60 million Fuel for Growth savings will be reinvested in demand-generating activities to enable long-term market share improvement.
The benefit of all share repurchase in 2015, including the ASR program, net of interest expense, is expected to be an $0.11 benefit per share. EPS guidance includes an annual estimated adverse impact of currency rates as of January 2016, which is expected to be approximately $0.40 per share. Another 1% strengthening of the dollar against all currencies where we operate would lead to a further reduction in EPS of about $0.04 per share on a full year basis, just from translation.
Taking all of this into account, non-GAAP EPS guidance is expected to be in the range of $3.48 to $3.60, excluding specified items. On a constant dollar basis, non-GAAP EPS guidance is expected to grow 9% to 12%. This excludes $0.11 from the benefit of the share repurchase program in 2015. The company expects to incur charges of approximately $25 million to $30 million associated with the Fuel for Growth program in 2016. Specified items, including charges related to Fuel for Growth, are expected to be approximately $0.12 per share. Therefore, GAAP EPS is expected to be in the range of $3.36 to $3.48, excluding future costs related to mark-to-market pension adjustments which are not reflected in the guidance.
This concludes my discussion on our quarter 4 and full year 2015 financial results. Thanks again for your time this morning. And with that, I will now turn the call back to Kasper."
1002291,321212057,923175,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Thank you, Michel. Let me briefly provide some summary remarks before we open the lines to your questions. I'm proud of many of the operational adjustments we made in the second half of 2015, when we were faced with significant change. Likewise, I feel go",363,"Thank you, Michel. Let me briefly provide some summary remarks before we open the lines to your questions. I'm proud of many of the operational adjustments we made in the second half of 2015, when we were faced with significant change. Likewise, I feel good that our key strategies are paying off. Our multi-year investment in the United States was made because we believe in the potential of that market. Sales and margins have now rebounded and are helping us overcome challenges abroad. Likewise, our decision to reshape our portfolio in China and focus on new growing sales channels is showing signs of paying off.
Faced with macroeconomic challenges, we're making adjustments in other markets, too. Change is inevitable, and in many ways, businesses should be judged by how well they adjust and adapt, and I'm confident that we'll look back at the end of this year able to acknowledge that we did this quite well. 
Through last year, I repeatedly pointed to 4 important factors that critically influenced company performance. To remind you all, I'm referring to currency movements, dairy cost evolution, our ability to evolve our strategy and portfolio in China, and our momentum in North America, particularly in the United States. All of these 4 variables remain as relevant in 2016 as they were to our performance in 2015, but I should add pricing to the list. Our ability to offset, partially or in full, foreign exchange weakness with price increases will be very important. I'd add that I see some encouraging signs that price increases will become easier as we move through the year.
I'll close with the message that we'll continue to provide clear visibility on the impact of foreign exchange as we move through 2016. We'll do so by providing updates on both sales and profit growth, net of foreign exchange, in addition to our traditional non-GAAP earnings per share numbers. We hope you'll find this informative.
Operator, I'd now like to open the lines to questions. And because our prepared remarks have taken longer than anticipated, we're prepared to go a few minutes over if the questions merit doing so. Operator, over to you. Thank you."
1002291,321212057,923175,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Operator","[Operator Instructions] The first question comes from David Driscoll with Citi Research.",12,"[Operator Instructions] The first question comes from David Driscoll with Citi Research."
1002291,321212057,923175,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","This is Alexis Borden in for David. So question on China. Kasper, I appreciate your China comments in your prepared remarks. Still, I'd like to ask, just bigger picture, is your China strategy working? What evidence can you point us to? And are your China",54,"This is Alexis Borden in for David. So question on China. Kasper, I appreciate your China comments in your prepared remarks. Still, I'd like to ask, just bigger picture, is your China strategy working? What evidence can you point us to? And are your China market shares increasing? And I also have a follow-up."
1002291,321212057,923175,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Well, I think I tried to provide some metrics that would hopefully support my statement that I believe our strategy is working. I think we introduced the fully imported line of products into China sort of towards the back half really of the second quarter",269,"Well, I think I tried to provide some metrics that would hopefully support my statement that I believe our strategy is working. I think we introduced the fully imported line of products into China sort of towards the back half really of the second quarter. And the fact that this product line is now already making up 35% of our sales in the mainland and 22% of our sales in the combined China/Hong Kong business, I think it's fairly impressive progress. I want to remind you also that -- of the message we gave on our Investor Day that we have confirmed our intention to enter the super-high premium category sometime in 2016. I'm sure you can understand that for competitive reasons, I'm not prepared to tell you what our plan timing is, but it goes without saying that we obviously have one. So I feel quite good about that. We now -- if I add the Hong Kong business and our fully imported line together, we've now got more than half of our sales in the China/Hong Kong business coming out of our Netherlands facility, and therefore, meeting consumer desire for imported quality. So I think we're managing that transition quite well. I'm satisfied with the progress we are making in baby stores also. We -- through much of last year, we discussed the fact that we were under-indexing in baby stores, which is one of the faster growing sales channels. But as of late, we've seen some fairly satisfactory improvements to our market shares in this channel, and I'm sure we'll continue to do so going forward."
1002291,321212057,923175,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Great. Alexis, just for the time constraints that we have, I'd like to go on to the next analyst.",19,"Great. Alexis, just for the time constraints that we have, I'd like to go on to the next analyst."
1002291,321212057,923175,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Operator","Your next question comes from Bryan Spillane, Bank of America.",10,"Your next question comes from Bryan Spillane, Bank of America."
1002291,321212057,923175,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","So just one question. I think, in 2015, in certain markets, you were able to price to the try to take -- raise prices in order to try to offset some of the negative effects of foreign exchange. I guess, in 2016, as you look at some of these markets that y",120,"So just one question. I think, in 2015, in certain markets, you were able to price to the try to take -- raise prices in order to try to offset some of the negative effects of foreign exchange. I guess, in 2016, as you look at some of these markets that you mentioned in terms of where there's currency volatility, does the cost savings that you're generating this year take some of the pressure off or give you more flexibility and not needing to necessarily -- to try to price for -- to offset the currency? Or are you still going to be looking to sort of price in some of these markets where the currencies have moved so dramatically?"
1002291,321212057,923175,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Bryan, thanks for the question. I think we will definitely look to price in these markets. I think, as you heard us talk about, we were quite some distance off managing to cover the impact of foreign exchange weakness through price in 2015. So that will b",229,"Bryan, thanks for the question. I think we will definitely look to price in these markets. I think, as you heard us talk about, we were quite some distance off managing to cover the impact of foreign exchange weakness through price in 2015. So that will be a continued challenge or task for us as we go through 2016. As I was trying to indicate, I think the pricing environment will become somewhat more friendly. What we saw in '15 was that there was still -- particularly, I would say, in Asia, there were still governments in Asia that were very resistant to price increases in our sector, as they still focused very much on kind of inflationary pressure or perceived inflationary pressure, which I think we all know was really a threat that evaporated sometime in 2014. And they would repeatedly point to the fact that we were seeing significant upside from dairy costs coming down as we discussed price increases. I think now that the dairy prices have stabilized, I believe that as both us and our competitors lap the low dairy costs, it will become a little bit more straightforward to raise prices. But we obviously have to do that in a responsible manner and we have to assess that in the context of general price inflation and wage inflation in the markets we operate in."
1002291,321212057,923175,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Operator","Your next question comes from Amit Sharma with BMO Capital Markets.",11,"Your next question comes from Amit Sharma with BMO Capital Markets."
1002291,321212057,923175,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","Kasper, without asking you to speculate on the timing of it, we've heard that there -- the Chinese government is looking at changing the tariff regulation for cross-border trade online. On a wider context, how do you think about how you're positioned in t",65,"Kasper, without asking you to speculate on the timing of it, we've heard that there -- the Chinese government is looking at changing the tariff regulation for cross-border trade online. On a wider context, how do you think about how you're positioned in the B2C channels? And if there is an incremental on tax on online, how would that impact your positioning in that channel?"
1002291,321212057,923175,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Well, I think there are -- as it relates to China, I expect that we're going to see regulatory adjustments coming sometime in 2016. I don't want to speculate on whether those regulatory adjustments will address all of the imbalances that we are seeing cur",198,"Well, I think there are -- as it relates to China, I expect that we're going to see regulatory adjustments coming sometime in 2016. I don't want to speculate on whether those regulatory adjustments will address all of the imbalances that we are seeing currently in China, but I believe that they will begin to address some of them. At the moment, it's clear that, inadvertently, the China regulations have created a tilted playing field that is very much tilting in favor of imported products sold through e-commerce. I don't believe that, that was the intention of either the regulators or the China government at large, and I think they will find ways to address that. I also think that they remain concerned about the large number of smaller brands that have been created in China that really lack the expertise or the resources to guarantee consumer quality, and I think that would be addressed. So I think you're going to a whole slew of attempts, at least, by regulators to get at some of these issues through this year, but since you gave me a free pass on the timing, I'll probably take advantage of that, Amit."
1002291,321212057,923175,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Thank you.",2,"Thank you."
1002291,321212057,923175,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Operator","Your next question comes from Ken Goldman with JPMorgan.",9,"Your next question comes from Ken Goldman with JPMorgan."
1002291,321212057,923175,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","Michel, I think, if I'm not wrong, that Mead Johnson locked in a bit more milk supply than usual this early in the year. I know it sometimes goes back and forth, and it's hard to tell. But it feels like it's a little more than usual. So first, correct me",116,"Michel, I think, if I'm not wrong, that Mead Johnson locked in a bit more milk supply than usual this early in the year. I know it sometimes goes back and forth, and it's hard to tell. But it feels like it's a little more than usual. So first, correct me if I'm wrong on that. And second, if that's correct, is that more of a tactical move just based on where milk cost and prices are? Or is it more of a strategic change that you'd like to implement whereby you maybe get a little more visibility there and a little more ability to price in line with where you think your cost will be?"
1002291,321212057,923175,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Yes, I think it is correct. It's a higher level than we used to have. And it's also true that we've taken that position on purpose, given the current benefits that we see. I don't like too much volatility into the P&L, so nobody does that, so the more you",66,"Yes, I think it is correct. It's a higher level than we used to have. And it's also true that we've taken that position on purpose, given the current benefits that we see. I don't like too much volatility into the P&L, so nobody does that, so the more you can control, the better that is, and this was one of the actions we have taken."
1002291,321212057,923175,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","Okay. So should I interpret that as -- I'm trying to figure out whether that's more tactical or strategic, and I kind of heard both in there?",27,"Okay. So should I interpret that as -- I'm trying to figure out whether that's more tactical or strategic, and I kind of heard both in there?"
1002291,321212057,923175,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Correct.",1,"Correct."
1002291,321212057,923175,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Operator","Your next question comes from the line of John Baumgartner with Wells Fargo.",13,"Your next question comes from the line of John Baumgartner with Wells Fargo."
1002291,321212057,923175,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","Kasper, I wanted to ask you about North America. So you mentioned the margins being close to record levels here. How much of the margin expansion over the past 2 years is a function of the commodity cost benefits that are more temporary versus maybe somet",73,"Kasper, I wanted to ask you about North America. So you mentioned the margins being close to record levels here. How much of the margin expansion over the past 2 years is a function of the commodity cost benefits that are more temporary versus maybe something more structural in terms of the cost savings or portfolio mix? Should we think of this high-20s level as kind of a new normal for the business?"
1002291,321212057,923175,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Yes, John, I don't think -- if I said record levels, I misspoke. I think I said historic levels. So -- but it may go back to days before we were a public company, so you may have imperfect visibility. I guess what I was trying to indicate was that I belie",191,"Yes, John, I don't think -- if I said record levels, I misspoke. I think I said historic levels. So -- but it may go back to days before we were a public company, so you may have imperfect visibility. I guess what I was trying to indicate was that I believe that these levels of profitability in the North American business are sustainable, to put it sort of candidly. It's not inconsistent with where we have been. And what we see in the North American business is that we get a lot of leverage on both sales and volume growth in that business. So put another way, our marginal costs are very low in that business, and hence, we see big swings in profitability as sales move up and down. So I'm quite comfortable. I feel good about where the margins are. And I think we've got other parts of our global portfolio where we are working in difficult trading environments, and that results in -- perhaps in margin pressure, so it's quite rewarding to see that this part of our portfolio has the opposite dynamic playing in its favor."
1002291,321212057,923175,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Operator","The next question comes from the line of Michael Lavery with CLSA.",12,"The next question comes from the line of Michael Lavery with CLSA."
1002291,321212057,923175,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","Could you talk a little bit more about your higher investments in China and how much of that is trade spending or discounting versus A&P investments? And then also just update your timing. You said at the Investor Day you felt you had about 3 or 4 more qu",59,"Could you talk a little bit more about your higher investments in China and how much of that is trade spending or discounting versus A&P investments? And then also just update your timing. You said at the Investor Day you felt you had about 3 or 4 more quarters of discounting pressure there. Is that still your view?"
1002291,321212057,923175,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Our investments in China primarily in the -- I would say, in the second half of 2015, were largely focused on changing our trading profile. That means matching both competitors' pricing and also matching their general profile with retail trade. As we go f",83,"Our investments in China primarily in the -- I would say, in the second half of 2015, were largely focused on changing our trading profile. That means matching both competitors' pricing and also matching their general profile with retail trade. As we go forward, and we look at 2016, we will obviously invest behind our new growth initiatives. So we expect that, that would lead to some increase in both of those lines, both the trade support and the advertising and promotional expense."
1002291,321212057,923175,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Great. Thank you.",3,"Great. Thank you."
1002291,321212057,923175,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Operator","Your next question comes from the line of Matthew Grainger with Morgan Stanley.",13,"Your next question comes from the line of Matthew Grainger with Morgan Stanley."
1002291,321212057,923175,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","Kasper or Michel, I just wanted to clarify a bit further on the EPS guidance. And I joined a bit late, so I may have missed an aspect of the explanation. But you've maintained the expectation of mid-single-digit EPS growth despite the FX headwind being si",76,"Kasper or Michel, I just wanted to clarify a bit further on the EPS guidance. And I joined a bit late, so I may have missed an aspect of the explanation. But you've maintained the expectation of mid-single-digit EPS growth despite the FX headwind being significantly higher. So just curious what the delta was over the past few months that's giving you more confidence in the constant currency outlook or sort of margin flexibility during 2016?"
1002291,321212057,923175,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","I mean, your understanding is correct. We indicated at Investor Day mid-single digit, and that is in line on what we're confirming now, despite the fact that we will have a higher headwind from currencies. I indicated in Investors Day that at that point o",224,"I mean, your understanding is correct. We indicated at Investor Day mid-single digit, and that is in line on what we're confirming now, despite the fact that we will have a higher headwind from currencies. I indicated in Investors Day that at that point of time, foreign exchange impact would have been around $0.15. Right now, we are looking at -- based on current spot rates, we're looking at a $0.40 impact from currencies. So we clearly looked into how we can mitigate that to still deliver mid-single-digit growth. On one hand side, like Kasper indicated, we clearly looked into pricing because that's an area where we think we need to be very cautious to see what can we do in certain markets, that's one. Two, I highlighted specifically, and referred also in an earlier question, on dairy benefits. We secured 80%, which is higher than we expected also in quarter 3. So that's one of the, whether you call it tactical or strategic initiatives, to secure the benefit to avoid volatility. And thirdly, like Kasper also indicated, we are clearly starting further assessments to see what can we do in terms of demand investments, and that will be leaning more towards mid of this year. So all of these initiatives, we accelerated actually, we took actions to mitigate the higher foreign exchange exposure."
1002291,321212057,923175,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","Okay. So it's more the actions you just mentioned as opposed to further acceleration of Fuel for Growth savings?",19,"Okay. So it's more the actions you just mentioned as opposed to further acceleration of Fuel for Growth savings?"
1002291,321212057,923175,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Well, it is. It is a combination, right, I should say. It is the Fuel for Growth savings. That's confirmed, significantly confirmed. So that wasn't the case yet in full in Investors Day. But secondly, like I said, we also are going further with further as",49,"Well, it is. It is a combination, right, I should say. It is the Fuel for Growth savings. That's confirmed, significantly confirmed. So that wasn't the case yet in full in Investors Day. But secondly, like I said, we also are going further with further assessment in demand investment."
1002291,321212057,923175,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Operator","Your next question comes from Jason English with Goldman Sachs.",10,"Your next question comes from Jason English with Goldman Sachs."
1002291,321212057,923175,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","A quick housekeeping question. I think that I heard you say that in the first quarter that the sales on constant currency would be flat to may be up 2% versus the fourth quarter of '15. Can you confirm that I heard that right? And also just mathematically",96,"A quick housekeeping question. I think that I heard you say that in the first quarter that the sales on constant currency would be flat to may be up 2% versus the fourth quarter of '15. Can you confirm that I heard that right? And also just mathematically, as I'm looking at my model, it seems to suggest that sales could be down close to 20% in the first quarter. Is that right? And if so, where -- what should we brace for in terms of pockets of sort of outsize weakness in the first quarter?"
1002291,321212057,923175,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Well, I think -- let me try and repeat what we said. I said in my prepared remarks that we expect to see sequential quarterly improvement in sales, in constant dollar sales. So that would translate into sales in the first quarter as opposed to being at or",55,"Well, I think -- let me try and repeat what we said. I said in my prepared remarks that we expect to see sequential quarterly improvement in sales, in constant dollar sales. So that would translate into sales in the first quarter as opposed to being at or above the level in the fourth quarter."
1002291,321212057,923175,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","And that's with currency?",5,"And that's with currency?"
1002291,321212057,923175,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","No, that was in constant dollars.",6,"No, that was in constant dollars."
1002291,321212057,923175,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","Okay. I'll try to get clarification with Kathy offline on that one then. And I'll pass it on for now.",20,"Okay. I'll try to get clarification with Kathy offline on that one then. And I'll pass it on for now."
1002291,321212057,923175,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","I think for the full year, we will clearly expect to see adverse currency impact. I think we've said, Jason, that we expect about a 600 basis point adverse impact from foreign exchange, and we also said that we had based that on basically the current exch",74,"I think for the full year, we will clearly expect to see adverse currency impact. I think we've said, Jason, that we expect about a 600 basis point adverse impact from foreign exchange, and we also said that we had based that on basically the current exchange rates as of this month. So that would stand to reason that, that 600 basis points in adverse impact would start at the beginning of the year."
1002291,321212057,923175,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Operator","Your next question comes from the line of Robert Moskow with Crdit Suisse.",13,"Your next question comes from the line of Robert Moskow with Crdit Suisse."
1002291,321212057,923175,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","This is kind of a follow-up to Matthew's question. I mean, if you do the math, the foreign exchange headwind is significantly more than what you thought in October. And -- but you're kind of maintaining, I think, the same guidance you had before, and that",135,"This is kind of a follow-up to Matthew's question. I mean, if you do the math, the foreign exchange headwind is significantly more than what you thought in October. And -- but you're kind of maintaining, I think, the same guidance you had before, and that guidance implies quite a bit of growth in the core business in order to be achievable. You mentioned pricing, and that's probably the tool that you would use in unlocking in dairy, although I think if you locked in, I'm not sure how that's a benefit from October. So Michel, maybe you can help just a little bit more. Don't you have to push the pricing lever harder than you thought in October in order to achieve this guidance? Or are there other levers I'm not aware of?"
1002291,321212057,923175,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","No, it is indeed a combination of price/mix, what we need to look into, country mix. But yes, I mean, price is a component that is higher than we indicated and that we anticipated in quarter 3.",37,"No, it is indeed a combination of price/mix, what we need to look into, country mix. But yes, I mean, price is a component that is higher than we indicated and that we anticipated in quarter 3."
1002291,321212057,923175,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","And how is that -- is it is achievable, given the competitive environment? Or does something have to change in the competitive environment in order for that to happen?",29,"And how is that -- is it is achievable, given the competitive environment? Or does something have to change in the competitive environment in order for that to happen?"
1002291,321212057,923175,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Look, part of that is driven by certain new innovation rollouts that we're having scheduled. So we're trying to combine that as much as possible to take price further than initially thought.",32,"Look, part of that is driven by certain new innovation rollouts that we're having scheduled. So we're trying to combine that as much as possible to take price further than initially thought."
1002291,321212057,923175,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Operator","Your next question comes from Eric Katzman with Deutsche Bank.",10,"Your next question comes from Eric Katzman with Deutsche Bank."
1002291,321212057,923175,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","I guess, let me ask about promotion for a second. Back at our conference in Paris, Kasper, you talked about promotion being kind of the initial signs of being more concerned about it in China, and then I guess it broadened out into Latin America and other",113,"I guess, let me ask about promotion for a second. Back at our conference in Paris, Kasper, you talked about promotion being kind of the initial signs of being more concerned about it in China, and then I guess it broadened out into Latin America and other regions. So I guess, it's been a long call, but just so I frame it, did you kind of end 2015 -- with what I think you had dubbed kind of irrational behavior on the part of competition, was that kind of sequentially flat or did it get worse? And kind of what assumptions are you making around promotion into 2016? And I'll pass it on."
1002291,321212057,923175,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Yes, it's an excellent question, and -- but you caught my comments correctly. I indicated that we've seen the environment stabilize, so there's still -- I would not say it has improved, but the environment has stabilized. And I think having now entered th",112,"Yes, it's an excellent question, and -- but you caught my comments correctly. I indicated that we've seen the environment stabilize, so there's still -- I would not say it has improved, but the environment has stabilized. And I think having now entered the fray, so to speak, in order to protect our competitive position, we saw that pay off in terms of stabilizing and even improving our underlying sales performance in the fourth quarter. So yes, I feel the environment, including in China, is now a little bit more stable. But it's clearly stable at a much higher level of promotion than, say, where we were a couple of years ago."
1002291,321212057,923175,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","And looking into '16?",4,"And looking into '16?"
1002291,321212057,923175,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","We expect that the environment will remain stable in '16.",10,"We expect that the environment will remain stable in '16."
1002291,321212057,923175,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Operator","Your next question comes from -- sorry?",7,"Your next question comes from -- sorry?"
1002291,321212057,923175,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Operator, sorry. I just want to say we have time for one more call, so the one that you're about to place in will be the last.",27,"Operator, sorry. I just want to say we have time for one more call, so the one that you're about to place in will be the last."
1002291,321212057,923175,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Operator","Your next question comes from David Hayes with Nomura.",9,"Your next question comes from David Hayes with Nomura."
1002291,321212057,923175,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","Just trying to pick up on the compensation benefit shift. You obviously made the point that the margin benefited, I think, particularly back end of the year, in terms of the compensation, the variable compensation, I guess, reversing to some extent throug",147,"Just trying to pick up on the compensation benefit shift. You obviously made the point that the margin benefited, I think, particularly back end of the year, in terms of the compensation, the variable compensation, I guess, reversing to some extent through the year in terms of the accruals that you might take in beginning of the year. So the question is on that -- one, can you quantify the impacts of that variable comp dropping out? And then secondly, I guess, more importantly, as you look into next year, because you talked about it more this year, you talked about it being a transition year or a transformational year, would you expect that compensation to come back into the numbers? Or is the organization effectively not going to pay that variable pay until the performance level for the group steps up back to the previous levels?"
1002291,321212057,923175,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Yes. I mean, in the compensation, accruals dropped in the year 2015 given the lower performance, which had an estimated impact around $30 million. The -- if you look to the number for next year, yes, we put it back to normal target levels. So those ones a",59,"Yes. I mean, in the compensation, accruals dropped in the year 2015 given the lower performance, which had an estimated impact around $30 million. The -- if you look to the number for next year, yes, we put it back to normal target levels. So those ones are included in the numbers that we have provided you for guidance."
1002291,321212057,923175,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","I guess, hitting [ph] the guidance, you'd have that $30 million come back in, but that's included in the margin...",20,"I guess, hitting [ph] the guidance, you'd have that $30 million come back in, but that's included in the margin..."
1002291,321212057,923175,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","That's included in the numbers, yes.",7,"That's included in the numbers, yes."
1002291,321212057,923175,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Operator, I think this closes our call.",7,"Operator, I think this closes our call."
1002291,321212057,923175,"Mead Johnson Nutrition Company, Q4 2015 Earnings Call, Jan 28, 2016",2016-01-28,"Earnings Calls","Mead Johnson Nutrition Company","Operator","Ladies and gentlemen, thank you for your participation in today's conference. This concludes the presentation. You may now disconnect. Good day.",21,"Ladies and gentlemen, thank you for your participation in today's conference. This concludes the presentation. You may now disconnect. Good day."
1002291,329825546,965617,"Mead Johnson Nutrition Company, Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Mead Johnson Nutrition Company","Operator","Good day, ladies and gentlemen, and welcome to the Mead Johnson Nutrition First Quarter 2016 Earnings Conference Call. My name is Nova, and I'll be your coordinator for today. [Operator Instructions] As a reminder, this conference is being recorded for re",61,"Good day, ladies and gentlemen, and welcome to the Mead Johnson Nutrition First Quarter 2016 Earnings Conference Call. My name is Nova, and I'll be your coordinator for today. [Operator Instructions] As a reminder, this conference is being recorded for replay purposes. I would now like to hand the conference over to Kathy Macdonald, Vice President, Investor Relations. Please proceed, Kathy."
1002291,329825546,965617,"Mead Johnson Nutrition Company, Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Thank you, Nova. Good morning and thank you for joining Mead Johnson's First Quarter 2016 Conference Call. With me today are Kasper Jakobsen, our Chief Executive Officer; and Michel Cup, our Chief Financial Officer. Earlier today, we issued our earnings",304,"Thank you, Nova. Good morning and thank you for joining Mead Johnson's First Quarter 2016 Conference Call. With me today are Kasper Jakobsen, our Chief Executive Officer; and Michel Cup, our Chief Financial Officer. 
Earlier today, we issued our earnings release and financial reference slides, which are available on our website. As we start, let me remind everyone that our comments will include forward-looking statements about our future results, including statements about our financial prospects and projections, commodity costs, currency fluctuations, pricing, taxes, capital spending, depreciation and amortization, new product launches, product quality, other growth initiatives and market conditions that constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. A more detailed explanation of our forward-looking statements will appear in the materials posted on our website in connection with today's conference call. 
Keep in mind that our actual results may differ materially from expectations as of today due to various factors, including those listed in our annual reports on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K, in each case, as filed with or furnished to the Securities and Exchange Commission and our earnings release issued this morning, all of which are available upon request or on meadjohnson.com. 
Today's comments will include discussion of non-GAAP financial measures. A reconciliation of these measures to comparable GAAP measures appear in the morning's earnings release posted on our website. In addition, any forward-looking statements represent our estimates only as of today and should not be relied upon as representing our estimates at of any subsequent date. While we may elect to update forward-looking statements at some point in the future, we specifically disclaim any obligation to do so, even if our estimates change. 
I will now turn the call over to Kasper."
1002291,329825546,965617,"Mead Johnson Nutrition Company, Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Thank you, Kathy, and good morning to all of you. Thanks for joining our call. Let me begin by summarizing our first quarter performance before I expand on the headlines with additional detail from each of our reporting segments. My comments will focus on",2689,"Thank you, Kathy, and good morning to all of you. Thanks for joining our call. Let me begin by summarizing our first quarter performance before I expand on the headlines with additional detail from each of our reporting segments. My comments will focus on strategy and top line performance. Michel will then follow-up with additional financial analysis and elaborate on profitability and cash flow. 
Except noted otherwise, I'll be referring to non-GAAP results. At our Investor Day at October of last year, we laid out a three-year plan for value creation. We know that at the time that 2016 would be a year of transition. During our year end earnings call, I identified 3 key milestones we've used to monitor our progress against this plan. 
Firstly, our return to constant dollar sales growth, with the first step being sequential sales growth from fourth quarter 2015 to first quarter 2016. Well today, we're announcing constant dollar sales in the first quarter rose 1.5% above the prior quarter. 
Secondly, we said we'll deliver on our first-year commitments to reduce our overall operating expense base. And in the first quarter, our Fuel for Growth initiative delivered $20 million in expense reductions versus the prior year's first quarter. And we're well on our way to achieve our annual savings target. 
Thirdly, and finally, we said we'd invest a portion of our operating expense savings to fund key growth initiatives, both above and below the net sales line. In the first quarter, we continued to make strong investments in support of our strategy, especially in China. I'll expand on this a little later this morning. 
Turning now to our first quarter 2016 results. First quarter sales came in as expected at $962 million. As anticipated, this represented a sequential improvement in constant dollars over our fourth quarter 2015 number. This was our second successive quarter of sequential improvement in our underlying business, following the difficult second and third quarters of '15. 
Also as anticipated, our financial results were adversely impacted by currency movements to the tune of 600 basis points. Compared to same quarter of prior year's, sales were 6% lower in constant dollars, driven by 8% lower volume while price contributed 2 percentage points of growth. The unfavorable year-over-year comparison was mainly driven by tough base comparisons in our two largest markets and affecting the quarter itself are significantly reduced shipments to Venezuela. 
Given the large adverse currency impact, I'm pleased with the company's continued earnings power. Gross margin for the quarter remained slightly better than 64% and our EBIT margin was above 25% as our cost reduction initiatives began to take hold. 
Investment in advertising and promotion represented 15.8% of sales for the quarter. This was similar to the level seen through the second half of 2015. 
Non-GAAP earnings per share for the quarter were $0.87. Michel will discuss how the most recent devaluation in Venezuela impacted our GAAP earnings. 
Elaborating on the sequential improvement in sales against the prior quarter, improvements in Asia and Latin America were key drivers of growth. I know you're all watching our performance in China closely. So I want to let you know that sequentially, we saw high single-digit percentage improvement in constant dollar sales in the world's biggest market. 
Simultaneously, we saw weaker sequential performance in our North America/Europe segment. I will expand on this in just a moment. 
Let me now briefly discuss progress against some of our major value creating strategic initiatives and let me begin with our growth initiatives before I then address cost reductions and investment optimization. As you know, last year, we began the expansion and transformation of our China brand portfolio to allow us to better meet consumer needs and participate in growing market segments and channels. In late March, we announced the imminent introduction of [indiscernible], a best-in-class premium brand into the China market. I'll return to this topic later. 
In China, we also are making good progress with our Enfamil branded line of fully imported products. And as we closed the quarter, these accounted for fully 45% of our sales in mainland China. 
Outside of China, in Southeast Asia and Latin America, we continued investment in our Enfamil franchise, promoting the benefits of our new plastics packaging and refill system. This is the same system many of you will know from retailer sales here in the United States. 
And domestically, in the United States, we are continuing to invest in our liquids portfolio, a category segment where we've historically underperformed. Our objective is to secure our fair share of this highly profitable market segment. 
Our determination to establish a segment for nutritionally fortified toddler milks in North America is also undiminished. Enfagrow remains a critical part of our growth strategy and we remain excited about its potential. 
Still in the United States, we had begun a test to see how we can leverage big data analysis in our substantial database capability to more precisely target consumers with relevant products and messages. To test this, we've introduced Enfamil Inspire, a new product deploying the same signs used in our China Infinitest products into limited retail distribution. We anticipate learning a great deal from this test and the initiative demonstrates our commitment to innovating our business model over time. 
Let me now turn to our effort to optimize our expense base. Our Fuel for Growth initiative is essential to our ability to sustain investments in growth while generating shareholder value through EPS growth over time. In the first quarter, we began to see the impact. We aim to reduce non-A&P operating expenses by at least $120 million over a 3-year period. We are making good progress against this target. And in the first quarter, reported SG&A expenses alone was 16% lower than a year earlier. We also continue to evaluate opportunities to accelerate or enhance our cost reduction plan. During the coming quarter, we anticipate making progress in our review of advertising and promotion expenditure and other investments in demand creation. We believe new approaches to media and the ongoing conversion to digital will allow for greater efficiency of spend in the mid to long-term. 
But given our substantial investment in new product introductions, we do not expect this initiative to translate into lower A&P percentages towards the end of this year. I'll now discuss in more detail the performance of each of our reporting segments, beginning with the North America and Europe segment. 
Overall, sales in this segment were less strong in the first quarter on both a sequential and year-over-year basis. Measured against the same quarter of 2015, constant dollar sales were weaker by 1% from volume and foreign exchange represented an additional headwind of 2 percentage points. 
The start to the year in our U.S. business was affected by market share losses from the highs we saw on the middle of 2015. On a positive note, we believe the strengthening labor market and workforce participation rates have caused a rise in breastfeeding rates to level off over the last 4 months or so. We are, of course, very focused on what we can control and we are constructing remedial plans to strengthen our market share in the United States, including through pricing actions. 
In Europe and Canada, I'm delighted to report that we are already enjoying record high market shares. As a consequence, we are seeing strong growth both sequentially and year-over-year. In both geographies, we're executing our strategies extremely well, demonstrating that when we do so, we can grow our business even in relatively mature markets. 
Let me now turn to Latin America. In constant dollars and excluding the impact of Venezuela, Latin America growth over the prior quarter, it was 7% higher compared to a year ago. However, when including the impact of suspended shipments to Venezuela, constant dollar sales were lower by 6%. Foreign exchange represented an additional significant headwind of 16%. And improved pricing of 7% was insufficient to fully offset this impact on reported sales. Across the whole region, we are seeing economies impacted by weaker commodity prices and, in several cases, political uncertainty. 
Though both countries are still recovering from currency depreciations, stronger business performance in Mexico and Colombia helped somewhat mitigate the impact of economic recessions in Brazil and Venezuela. We've previously described how we've chosen to make only limited shipments to Venezuela as we are constrained by our limited access locally to hard currency. We are very keen to help alleviate the acute product shortage in Venezuela and restore supply and we're working with the government to find a solution. But until one is found, we expect very limited sales in Venezuela. 
Brazil is going through a well-prophesied economic recession. The impact on consumer and business confidence is manifesting itself in softer demand for discretionary items. And we are feeling the impact most acutely within our children's category. Our infant formula sales are holding up relatively better. We remain excited about the country's long-term potential but we do not anticipate a substantial improvement within this year. 
As mentioned, we enjoyed a strong start to the year in Mexico where our modifier brands recovered somewhat from the weakness in mid-2015. Our infant formula and toddler business gained market share in the first quarter as new packaging and revised messaging behind an improved formulation resonated to consumers. 
Though I recognize we can't quantify the extent to which Colombia may be benefiting from informal parallel exports to neighboring Venezuela, we believe increased market share is the main driver of very strong double-digit sales growth there. 
And finally, our business in the Caribbean and Central America grew by high single digits over the prior year same quarter. In most of these markets, we transacted dollars and, hence, the region remains a stabilizing factor in an inherently volatile segment. 
I'll turn now to our Asia segment. As mentioned in my global overview, we saw a strong single-digit sequential improvement in constant dollar sales in Asia. China grew faster than the segment as a whole, but Thailand and Malaysia also improved over the previous quarter. Despite our strong sequential improvement, year-over-year sales comparison was unfavorable. Volume was lower by 9%, mainly reflecting the fact that we've still not returned to the year ago sales levels in China and Hong Kong. Price was in line with the prior year with improved product mix offsetting the impact of [indiscernible] promotional activity. 
In Thailand and Malaysia, the sequential comparison was helped by nonrepeating retail inventory reductions referenced in our fourth quarter earnings call. Malaysian consumers appear to be adjusting spending habits in response to the VAT introduction and currency-related inflation of 2015. Consequently, we expect more stable performance from Malaysia going forward. The Thai economy remains relatively weaker and we are a little more cautious about a rapid turn around there. We're maintaining investment levels and, in fact, seeking to strengthen our position in anticipation of an eventual recovery in economic growth. Inherently, Thailand is a great market for us and we have a very experienced team on the grand. Longer-term, I'm confident in our prospects there. 
In Vietnam, we've seen opportunities to improve our execution. The market somewhat underperformed against our expectations in 2015 and in the most recent quarter. But our team is focused on the right issues and putting in place plans to strengthen performance in the second half of the year. 
Because our businesses in Indonesia is relatively small, we don't often talk about our performance in this large market. However, over the last 12 months, we've developed a more focused geographic strategy for the country and our improved focused appear to be helping. Sales grew strongly in the first quarter, both sequentially and year-over-year. It's clear that we would like to build a bigger business in this high potential market, but we remain realistic about our scale and the challenges to realizing our ambition organically. 
Let me close on China. The China market continues to evolve quickly and we're still assessing the full impact of recent changes to duty structure and regulatory frameworks. Over the last year or so, I have repeatedly stated my belief that regulatory changes were put in China. And more evenhanded duty structure is in my mind likely to be just the first of several important changes being driven by the Chinese government. The focus remains on consumer safety. And the requirement that all infant formula and children's products, regardless of sales channel, be registered in China, is a key part of the government efforts to safeguard the consumer. We are supportive of these efforts to protect consumers by ensuring products and labels meet Chinese standards, regardless of how and from where they are sold. 
Before I discuss the performance of our China business, I want to remind you of the broad China strategy we laid out for you more than a year ago. We promised we would reshape our product portfolio to better satisfy consumers preference for imported premium products. And once we have the right portfolio, we will then commit the resources to strengthen our performance in higher growth sales channels. Since then, we've introduced a fully imported line of our Enfamil branded products. And after the close of the first quarter, we introduced a new product offering into the highest priced market segment. Enfinitas, as we'd likely call this new offer, contains our best science and was developed incorporating understanding gained from our extensive studies of breast milk, nutrition and metabolism. 
In addition to our long proven industry-leading levels of DHA and AHA, the products contain boosted levels of lactoferrin and milk fat globular membranes, ingredients closely associated with both neuro and immune system development. Though this new technology is costly, we believe Chinese parents would once again confirm that they're willing to invest in their child's future. We now have the right portfolio to win. With both consumers and retailers. Helped by our recent introductions, baby stores became our largest sales channel in the latest quarter and both this channel and the e-commerce channel grew in excess of 20% over the same quarter of last year. 
And despite cannibalization from our imported line, sales of our locally manufactured product line appeared to have stabilized in response to a stronger defensive stops and increased promotional competitiveness. 
I know you all share my interest in the price promotion on the environment in China. Let me give you my perspective. It's clear to us that some competitors push sales aggressively in the fourth quarter of 2015. And as a result, I'm now providing additional discounts to clear inventory overhang from distributors and retailers. Though we will, of course, act to protect our market share, we take a different approach. We simply do not believe Chinese consumers are significantly motivated by lower prices, even though retailers may well be. Rather, Chinese consumers are amongst the world's most discerning and they continue to show a willingness to pay for superior quality and nutrition. This is evidenced by the continued shift towards higher-priced segments. 
Our view is supported by the fact that sequentially, price in fact was a positive contributor to our growth in China in the latest quarter, the positive effect of product mix more than offsetting the effect of promotional spend. 
In response to the successful execution of our strategy, our performance in China improved substantially over the prior quarter with constant dollar sales, as mentioned, showing a high single-digit percentage improvement. 
Commenting now on our outlook for the full year 2016. I reiterate that company guidance for modest constant dollar sales growth between 0% and 2%. Based on current exchange rate assumptions, we expect this to translate into an unfavorable sales comparison in U.S. dollars of between 4% and 6%. 
As advised in our January call, we expect to deliver 9% to 12% growth in constant dollar EPS. Based on this, we also reiterate our guidance for full-year non-GAAP EPS between $3.48 and $3.60. 
I'll now hand over to Michel who will provide additional details on our financial performance. I will then return with a few summary remarks before we take your questions. Michel, over to you."
1002291,329825546,965617,"Mead Johnson Nutrition Company, Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Thank you, Kasper and good morning everyone. Today I will discuss the company's first quarter 2016 financial results. I will then briefly highlight EBIT results by segment and wrap up with a cash flow analysis and summary of our full-year guidance. Unle",2103,"Thank you, Kasper and good morning everyone. Today I will discuss the company's first quarter 2016 financial results. I will then briefly highlight EBIT results by segment and wrap up with a cash flow analysis and summary of our full-year guidance. 
Unless otherwise noted, my comments will be on the non-GAAP financial results. References to currency impacts or the effects of currency fluctuations generally refer to their impact on the translation of local currency, financial statements into the United States dollars. 
Let me start with sales. As shown on Slide 3, on a sequential basis, from the fourth quarter of 2015, constant dollar sales grew by 1.5%. Nearly all of our large markets grew sequentially. And most notably, China. When you review the 5 quarter sequential trend, sales were strongest in the first quarter of 2015 and started to decline in the second quarter. As 2015 progressed, we invested to protect competitiveness, launched new products and we're able to stabilize sales in the fourth quarter. 
In the first quarter, we continued to invest. We rolled out new innovation and selectively increased prices in some markets to compensate for the continued currency devaluations. Consistent with my stated expectation last quarter, I would like to remind you that the second quarter 2016 year-over-year comparison will continue to be tough on a constant dollar basis. Although we should see an improvement in the second quarter performance. 
First quarter sales on a reported basis were 12% below and constant dollar sales were 6% below the prior year quarter. Adverse foreign exchange rate contributed a 600 basis point decline. 
Slide 4 summarizes the impact of foreign exchange on sales and EPS. The U.S. dollar continued to be strong in the first quarter of 2016 and has effect on translation of local currency, [indiscernible] impacted all reporting segments. The first quarter decline of 6% was the same percentage as both the third and fourth quarter of 2015. Half of the negative currency impact in the first quarter were from the Chinese renminbi, the Mexican peso and the Argentinian peso. The balance of the adverse foreign exchange impact was widespread across the regions. We continue to expect an approximately 6% adverse foreign exchange impact on sales for the full year 2016. 
I will address the foreign exchange impact in the EPS guidance section as well. I will now move to factors that impact our gross margins on Slide 5. Gross margins was 64.1% in the first quarter of 2016. This was a similar margin percentage to the first quarter of 2015 and in line with our expectations for the full year. 
Sales impacted from positive mix and pricing was affected by higher trade investments resulting in a slight gross margin decline. Manufacturing cost negatively impacted margin due to lower volume absorption and higher cost of innovation and inflation. 
Low dairy cost was the largest benefit to our gross margin in quarter 1, and more than offset higher conversion costs and of our commodities increases. We expect to see daily benefits in the second quarter. 
As you can see, we continued to deliver productivity savings within our cost of goods sold. Also [indiscernible] had already secured commitments for nearly 90% of our 2016 productivity goals. 
Moving to operating expenses, I will start with advertising and promotion investments on Slide 6. A&P was 15.8% of sales in the first quarter compared to 13.2% in the prior year quarter. This was an increase of 11% on a constant dollar basis. The incremental investments were mainly to support our key China initiatives. Historically, the company had a lower A&P spending in the first quarter of the year. Since our China fully imported product line was launched in the middle of last year, we continued strong investments in the first quarter of 2016, especially fertilization, digital and e-commerce media. In addition, we supported the investment of new innovation rollout in selected markets. 
With the April 2016 launch of our super high premium products, we expect A&P as a percentage of sales to be high in the second quarter  As you can see on this slide, when we launched the China fully import product in the second quarter of 2015, our total A&P as a percentage of sales went up significantly. We can expect that in the second quarter of 2016 as well. 
Turning to Slide 7. The increase in A&P was offset by a reduction in selling, general and administrative expenses. This is in line with the strategy we outlined at Investor Day, that 2016 will be a year of transition with a focus on investments. 
On a constant dollar basis, SG&A was 10% lower than the first quarter of 2015. Approximately $20 million of the SG&A reduction is attributed to our Fuel for Growth initiative, which I will address on the next slide. 
Slide 8 shows that our Fuel for Growth initiative had a strong start in the first quarter. On a constant dollar basis, we delivered cost reduction of 10% for the first quarter of 2015, especially in our support functions. While we have made some reductions in the regional offices, about 3 quarters of the reduction was from corporate headquarter functions, which decreased by approximately 30% on a like-for-like constant-currency basis. Of the corporate headquarter reductions, more than half was from outside services and the balance were personnel related. To date, we have secured over 90% of our planned 2016 reductions. And we are ahead of schedule. At the same time, we constrained sales forces and distribution spending to remain relatively flat to prior year on a constant dollar basis. 
Turning now to Slide 9 for a discussion of EBIT. Let me start this analysis per segment. In the first quarter, Asia delivered an EBIT of $169 million, a decrease of 22% on a constant dollar basis. An incremental 5% decrease came from the adverse foreign exchange impact, largely driven from the Chinese renminbi, Thai baht and the Malaysian ringgit. The Asia EBIT margin at 33.8% improved 390 basis points compared to the fourth quarter of 2015, yet was 600 basis points lower than the first quarter 2015. The main year-over-year drivers were lower sales and increased channel investment and promotional activities. 
Investments continued throughout the Asian region to support our innovation launches. The most significant investments were in China, including competitive price promotions on the locally manufactured products and investments for the fully imported product line. 
Latin America delivered an EBIT of $41 million in the first quarter, a decrease of 11% on a constant dollar basis. The EBIT decline was due to lower sales mainly in Venezuela, yet the decline was somewhat offset by lower A&P investments. Excluding the impact of the Venezuelan business, the Latin America EBIT on a constant dollar basis increased 22% compared to prior year. 
For the segment, adverse foreign exchange impacted EBIT 18%, largely from the Mexican peso. On a reported basis, EBIT was 29% lower than prior year. The Latin America EBIT margin was 25.5% for the first quarter 2016 compared to 28% for the same quarter last year. The 250 basis point decline was from lower sales, mainly Venezuela, somewhat offset by lower A&P and sales force spending. 
For the first quarter, North America and Europe EBIT was $82 million, an increase of 9% on a constant dollar basis. The EBIT margin of 27.2% was 190 basis points better than the prior year quarter. Despite lower sales, gross margin remained strong from the dairy benefit, with an operating expenses reduction in the SG&A was selectively invested to support new product innovations while a portion of the savings drove higher EBIT margins. 
As mentioned on the Fuel for Growth slide, corporate and other delivered significant benefit to EBIT. For the total company, the first quarter EBIT of $244 million was 10% below the prior year quarter on a constant dollar basis. Adverse exchange nearly doubled the impact, resulting in a reported EBIT down 19%. The decline was due to lower sales, somewhat offset by improved operating expenses. The EBIT margin of 25.4% of sales was 200 basis points lower than prior year quarter. The first quarter 2015 EBIT of 27.4% was high due to under spending on A&P. As 2015 progressed, A&P increased and annual 2015 EBIT came in at 24.1%. 
I will now address our financial results from EBIT to net income on Slide 10. The increase in interest expense reflects the full quarterly impact of the November 2015 1.5 billion notes. The significant portion of the proceeds from the notes were used to finance the accelerated share repurchase program. As a reminder, 10.7 million shares of stock were received in the first quarter. The balance of shares will be delivered at the end of the agreement, which is scheduled to conclude in the second quarter of 2016. Our non-GAAP effective tax rate, or ETR, was 23.2% for the first quarter of 2016 compared to 22.5% in the prior year quarter. The first quarter 2015 rate was lower as a result of the more favorable geographic earnings mix that did not prevail for the full year. Non-GAAP EPS for the first quarter was $0.87. 
Let me summarize our financial results by addressing the changes to EPS on Slide 11. In the first quarter, non-GAAP EPS declined $0.12 on a constant dollar basis versus prior year quarter. Sales and related gross profit negatively impacted EPS by $0.16. The increase in A&P was offset by Fuel for Growth savings. The ASR delivered $0.03 benefit net of higher interest expense. Half of the $0.12 decline in non-GAAP EPS on a constant dollar was a result of the temporarily suspension of shipments to Venezuela in the first quarter of 2016. Foreign exchange adversely impact EPS by $0.10. 
Let me address specified items. Since we took a significant specified charge in the first quarter, let me briefly explain what drove the Venezuelan change noted on Slide 12. 
In March 2016, the Venezuelan government changed the exchange rate system from a 3 to a 2-tier structure. There were 2 significant impacts to our business. First, the SICAD rate was eliminated. This was the rate we previously used to translate our net monetary assets of our Venezuelan subsidiary. As a result, we adopted the floating rate now called DCOM. For reference only, the most recent SICAD rate was 13.5 and the DCOM rate at the end of the quarter was approximately 273 and continued to devalue in April. The remeasurement impacts from adopting the DCOM rate was a $32 million loss impacting monetary assets. 
Second, as the DCOM rate also impacts the translation of our local earnings to U.S. dollar, our future results of Venezuela business are impacted. This triggered an impairment review of Venezuelan's long-lived assets. Following that process, we concluded there was $46 million impairment of our long-lived assets. Due to the Venezuelan change, Fuel for Growth and pension remeasurement charges specified items for the first quarter was $0.48 per share, including these specified items, GAAP EPS was $0.39. 
Turning to a high-level overview of cash movement. On Slide 13, the cash balance of $1.7 billion as of March was similar to the year-end balance. Cash from operating activities was lower than the prior-year period. Cash flows reflected lower sales and the negative impact from other working capital. And an unusual item on this chart is the sizable foreign exchange impact on cash. This was mainly due to the abduction of the new exchange rate and the remeasurement of our monetary assets in Venezuela. 
In summary, the cash generated from operations this quarter was used to pay dividends and capital commitments. For the full year, our capital spending goal remains about 4% of sales. 
To summarize, our annual guidance on Slide 14. We expect full year 2015 constant dollar growth in the range of 0% to 2%. We continue to anticipate tough comparisons for the first half year 2016. And we do not expect to report positive revenue growth in the same quarter of prior year until the second half in 2016. We reaffirm our 2016 non-GAAP EPS guidance and the range of $3.48 to $3.60. Primarily due to the first quarter charges rate to Venezuela, fully specified items are now expected to be $0.57 per share. Therefore, our updated 2016 GAAP EPS is expected in the range of $2.91 to $3.03. GAAP EPS will change as a result of future mark-to-market pension adjustments, which we cannot estimate at this time. 
This concludes my discussion on our first quarter financial results. Thanks again for your time this morning and I will now turn the call back to Kasper."
1002291,329825546,965617,"Mead Johnson Nutrition Company, Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Thank you, Michel. Before we take your questions, let me briefly summarize our key messages. Firstly, we are satisfied with the sequential improvement in constant dollar revenue. Secondly, we are pleased with the improvement we're seeing in China and we",218,"Thank you, Michel. Before we take your questions, let me briefly summarize our key messages. 
Firstly, we are satisfied with the sequential improvement in constant dollar revenue. Secondly, we are pleased with the improvement we're seeing in China and we remain focused on the successful execution of our previously outlined China strategy. Thirdly, we do not underestimate the challenges we are facing in an uncertain global economic environment. Despite these challenges, we believe the balance within our global portfolio will allow us to complete 2016, which we've often referred to as a year of transition, as planned. We are therefore reiterating our prior guidance for modest full-year constant dollar sales growth between 0% and 2%. We are confident that sequential constant dollar sales for the first half of 2016 will be stronger than the second half of prior year. And within 2016, sales in the second 6-month period will be stronger than the first half of the year. For the year, we expect foreign exchange to adversely affect translation into our reporting currency by 600 basis points. We also are confirming unchanged non-GAAP EPS guidance of $3.48 to $3.60. 
I'll now hand the call over to our operator, Nova, who will assist us in opening the lines for questions. Nova, I'll hand the call back over to you."
1002291,329825546,965617,"Mead Johnson Nutrition Company, Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Mead Johnson Nutrition Company","Operator","[Operator Instructions] Our first question comes from the line of David Driscoll of Citi.",14,"[Operator Instructions] Our first question comes from the line of David Driscoll of Citi."
1002291,329825546,965617,"Mead Johnson Nutrition Company, Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","I wanted to ask about the super premium product launches. Starting with the China Enfinitas product. And just hear a little bit more about the reception from the mom and baby stores, shelf space, is it incremental to the existing shelf space you have in t",128,"I wanted to ask about the super premium product launches. Starting with the China Enfinitas product. And just hear a little bit more about the reception from the mom and baby stores, shelf space, is it incremental to the existing shelf space you have in there? And then just some comments on kind of what we should expect on the pacing of Enfinitas in China and then kind of fully separately, but still on super premium, just give us a little bit more on Inspire and what's the roll of this product? You said like limited launch in kind of a test, and I suppose, I have the courage to say something like that before. So I just like to hear what role that plays in the U.S.?"
1002291,329825546,965617,"Mead Johnson Nutrition Company, Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Let me just begin by saying that the introduction in China is really proceeding as we speak, David. So it's very early days here. We -- our first initial shipments did not happen until the middle of this month in fact. But reception from retailers has bee",332,"Let me just begin by saying that the introduction in China is really proceeding as we speak, David. So it's very early days here. We -- our first initial shipments did not happen until the middle of this month in fact. But reception from retailers has been very favorable. And we've not had any issues getting the required additional shelf space, be that in baby stores or in other retail channels in China. So I would say we are encouraged by what we see and the engagement we are having, the early engagement we are having with consumers online is also favorable in China. I don't know that we want to get into giving you forecast and expectations by product line. So I don't think I'm prepared to go there. But as you know, it's a project that we've been working on for quite some time, many of you would probably say too long. So obviously, we feel like we are putting our best foot forward and we are optimistic about our prospects. In the U.S., it's a little bit different. And I think what we are doing in the U.S. is really experimenting with a different business model. We believe that based on our increased mastery of, sort of, big data analysis and our own database and our knowledge of the U.S. consumers, we are able to quite precisely target consumers in the market that might be more likely to be interested in a premium nutrition proposition and willing to pay the price that goes with that. So we've begun a test initially with very limited retail distribution. I think we'll assess how that test proceeds through the year and then we'll decide whether we will expand distribution from where we currently are. But the signs used in the two products is identical. There are some minor variations that are required by different regulations and different quality standards needed in the two markets. But the base signs is essentially the same."
1002291,329825546,965617,"Mead Johnson Nutrition Company, Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Mead Johnson Nutrition Company","Operator","Our next question comes from the line of Matthew Grainger of Morgan Stanley.",13,"Our next question comes from the line of Matthew Grainger of Morgan Stanley."
1002291,329825546,965617,"Mead Johnson Nutrition Company, Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","Kasper and Michel, I just wanted to ask about Enfinitas as well. Could you talk a bit more about the formulation and its uniqueness relative to what's currently on the market? Is the value proposition here driven by the ingredients? Or is it really the pr",103,"Kasper and Michel, I just wanted to ask about Enfinitas as well. Could you talk a bit more about the formulation and its uniqueness relative to what's currently on the market? Is the value proposition here driven by the ingredients? Or is it really the proprietary combination? And I guess, what I'm curious is, how quickly do you think fast followers can try and incorporate similar benefits into their products? And just related, from a margin perspective, given the price point, is the expectation that once you hit scale, that margins can ultimately be accretive to your overall Asia region or China business?"
1002291,329825546,965617,"Mead Johnson Nutrition Company, Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Yes, I mean, I think the whole product bundle is quite unique. We -- as you know, we have a large ongoing effort underway within the company to continually enhance our understanding of breastmilk in particular and how we can incorporate the latest signs a",261,"Yes, I mean, I think the whole product bundle is quite unique. We -- as you know, we have a large ongoing effort underway within the company to continually enhance our understanding of breastmilk in particular and how we can incorporate the latest signs associated with breastmilk in enhanced form, in some cases, into formulas. We've acted on some of that. We have raised the levels, as I mentioned, of lactoferrin, which is naturally present in very low levels in all, in most formulas, I shouldn't say all, but most. And we have incorporated elevated levels as well, significantly elevated levels of milk fat globular membranes, which is just what it says it is. Both of these ingredients are sort of closely associated with physiological development, either new or immune system development of -- for infants. The second ingredient is in somewhat scarce supply in the world and we believe that though people can talk about it, it will take some time for people to get to the levels we are at. But most importantly, I think, it's the understanding of how the ingredients work and then we've incorporated that into quite unique packaging in the marketplaces where we packed it with you advertising and digital capabilities. So we're excited about it. I guess, we feel like we've got quite a unique package, which is one of the reasons we've delayed the entry. We wanted to make sure we have the right package. And I don't know if Michel wants to comment on margins. Do you want to add something, Michel?"
1002291,329825546,965617,"Mead Johnson Nutrition Company, Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Yes, the question on margin accretion. I think as Kasper said, we're in the process of rolling that out and so that's our current folks. We're investing in very strong so to drive the awareness and have the right level of distribution and to ensure that m",68,"Yes, the question on margin accretion. I think as Kasper said, we're in the process of rolling that out and so that's our current folks. We're investing in very strong so to drive the awareness and have the right level of distribution and to ensure that moms enter the [indiscernible]. So over time, we expect to see the return on these investments but definitely not at the beginning."
1002291,329825546,965617,"Mead Johnson Nutrition Company, Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Mead Johnson Nutrition Company","Operator","Our next question comes from the line of Rob Moscow from Crdit Suisse.",13,"Our next question comes from the line of Rob Moscow from Crdit Suisse."
1002291,329825546,965617,"Mead Johnson Nutrition Company, Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","A couple of questions about the guidance. First on FX. I think last quarter, you called out $0.40 of headwind. And I don't think I heard it called out on this call. The revenue guidance hasn't changed for FX and I guess I'm a little surprised, most of you",121,"A couple of questions about the guidance. First on FX. I think last quarter, you called out $0.40 of headwind. And I don't think I heard it called out on this call. The revenue guidance hasn't changed for FX and I guess I'm a little surprised, most of your peers are experiencing lighter headwinds, I just wanted to know what the update is on that? And then secondly, your comments about the market in China and inventory, kind of -- or efforts to promote away inventory that's on the shelves. Is it pretty much the same kind of conditions you saw in fourth quarter? Or have things gotten a little worse in the first quarter? How would you characterize it? Thanks."
1002291,329825546,965617,"Mead Johnson Nutrition Company, Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Let me start with addressing the inventory situation. I would say that the promotional environment is certainly not getting better. And I think there is -- it would appear that some people are dealing with the kind of fourth quarter, first quarter dynamic",138,"Let me start with addressing the inventory situation. I would say that the promotional environment is certainly not getting better. And I think there is -- it would appear that some people are dealing with the kind of fourth quarter, first quarter dynamic. I'm very happy with where our inventory levels are, and I think our team on the ground has managed that quite well. I think what we've said before, which may be I should have said in response to Matt's question as well, is that we feel pretty good about our ability to sustain the margins in China at or around the same level as they are today as we see sort of the ability of a favorable product mix as having the ability to offset any additional pressure there might be to increase promotional competitiveness."
1002291,329825546,965617,"Mead Johnson Nutrition Company, Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Yes, let me address the FX question you had. A couple of points, I think you're aware that we are operating in 50 countries. So 2/3 of our revenue in [indiscernible] is exposed to foreign currency fluctuations. And as I highlighted also last year, a part",166,"Yes, let me address the FX question you had. A couple of points, I think you're aware that we are operating in 50 countries. So 2/3 of our revenue in [indiscernible] is exposed to foreign currency fluctuations. And as I highlighted also last year, a part of that is hatched for a certain period. The second point I would like to make is there is -- although there is an improvement, but you still see a significant fluctuation of some currencies, just remind you on the Chinese renminbi mid-April, where you saw a significant change again. And that is impacting our business as we speak. I think you know you've seen that we, in Q1, we delivered our reported sales of a decline of 6%, in line with our expectation. So as it stands today and if we could lock in the whole year as of today, which we can do, we would see some benefits of a couple of cents, I would say, on EPS."
1002291,329825546,965617,"Mead Johnson Nutrition Company, Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","Okay. But you say part of it was hedged. Did you -- the part that was hedged, is that -- were you leaving some money on the table, so to speak? Did that work against you now?",37,"Okay. But you say part of it was hedged. Did you -- the part that was hedged, is that -- were you leaving some money on the table, so to speak? Did that work against you now?"
1002291,329825546,965617,"Mead Johnson Nutrition Company, Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","No, I mean when I gave the guidance of $0.40, in January, I included the hedge position that we had [indiscernible]",21,"No, I mean when I gave the guidance of $0.40, in January, I included the hedge position that we had [indiscernible]"
1002291,329825546,965617,"Mead Johnson Nutrition Company, Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","So is it still $0.40? Or is it different?",9,"So is it still $0.40? Or is it different?"
1002291,329825546,965617,"Mead Johnson Nutrition Company, Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Could you repeat your question?",5,"Could you repeat your question?"
1002291,329825546,965617,"Mead Johnson Nutrition Company, Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","Is the headwind still $0.40? Or is it different?",9,"Is the headwind still $0.40? Or is it different?"
1002291,329825546,965617,"Mead Johnson Nutrition Company, Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","I haven't changed guidance. I haven't changed guidance. The $0.40 is still included.",14,"I haven't changed guidance. I haven't changed guidance. The $0.40 is still included."
1002291,329825546,965617,"Mead Johnson Nutrition Company, Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Mead Johnson Nutrition Company","Operator","Our next question is from the line of Ken Goldman from JPMorgan.",12,"Our next question is from the line of Ken Goldman from JPMorgan."
1002291,329825546,965617,"Mead Johnson Nutrition Company, Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","This is Josh Levine on for Ken. I just had a question on Fuel for Growth. You said that they drove about $20 million in the first quarter, which you said was attributed mostly on cutting out services and overhead. Both of those sound like, I guess, sustai",95,"This is Josh Levine on for Ken. I just had a question on Fuel for Growth. You said that they drove about $20 million in the first quarter, which you said was attributed mostly on cutting out services and overhead. Both of those sound like, I guess, sustainable savings levels. Is it right to assume that level sort of continues through the year? And I guess, obviously, you guided I guess to $60 million savings. That would imply obviously you would beat that number. I guess, can you just help us understand the pacing there?"
1002291,329825546,965617,"Mead Johnson Nutrition Company, Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","I think it's a good question because if you would do your math and as we announced earlier, we would have $60 million savings this year. If you would take $20 million times 4, you have $80 million. I would put some consciousness in there. I think there's",126,"I think it's a good question because if you would do your math and as we announced earlier, we would have $60 million savings this year. If you would take $20 million times 4, you have $80 million. I would put some consciousness in there. I think there's certain fluctuation, especially if you do quarter-on-quarter comparison, especially in the area of third-party services. Having said that, I'm very encouraged by the fact that we secured 90% of the $60 million and I indicated that we are ahead of all plans. And as Kasper also indicated, we are continuing going through a review which we [indiscernible] about -- by the end of the second quarter, on which additional actions we see that we potentially could accelerate."
1002291,329825546,965617,"Mead Johnson Nutrition Company, Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","Got it, thanks. And just on A&P spending. I guess you said that it would be 1 -- 2Q levels will be higher than 1Q, which I guess similar from last year. But just from a year-over-year basis, how is that -- how should we think about that for 2Q? And then j",107,"Got it, thanks. And just on A&P spending. I guess you said that it would be 1 -- 2Q levels will be higher than 1Q, which I guess similar from last year. But just from a year-over-year basis, how is that -- how should we think about that for 2Q? And then just a larger question. When you typically advertise ahead of product launches, ahead of innovations. But I guess, how do you think strategically about when you kind of ramp down that spending, right? Because as we think, sort of when you can let, I guess, the returns on that market investment fall to the bottom-line?"
1002291,329825546,965617,"Mead Johnson Nutrition Company, Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","As Kasper also indicated, don't expect a significant drop in the first half year. We will continue to invest, like I said in my earlier comments, especially in Q2. And you might see some lower A&P expenditures, more towards the end of the year.",44,"As Kasper also indicated, don't expect a significant drop in the first half year. We will continue to invest, like I said in my earlier comments, especially in Q2. And you might see some lower A&P expenditures, more towards the end of the year."
1002291,329825546,965617,"Mead Johnson Nutrition Company, Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Mead Johnson Nutrition Company","Operator","Our next question comes from Amit Sharma of BMO Capital Markets.",11,"Our next question comes from Amit Sharma of BMO Capital Markets."
1002291,329825546,965617,"Mead Johnson Nutrition Company, Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","Kasper, you talked about the baby stores within China are now your biggest or largest channel. Could you just define for us, like, what's the size of the opportunity? And as we become even bigger in that channel, are you fully incorporating the mix benefi",53,"Kasper, you talked about the baby stores within China are now your biggest or largest channel. Could you just define for us, like, what's the size of the opportunity? And as we become even bigger in that channel, are you fully incorporating the mix benefit of having a larger presence in that channel?"
1002291,329825546,965617,"Mead Johnson Nutrition Company, Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","I think we're incorporating benefits. We're certainly thinking about it. As you know, we talked quite a bit about the fact that last year, we were caught in the second and third quarters with a bit of a mismatch between our product offerings, and frankly",188,"I think we're incorporating benefits. We're certainly thinking about it. As you know, we talked quite a bit about the fact that last year, we were caught in the second and third quarters with a bit of a mismatch between our product offerings, and frankly speaking, both the consumer preference and the channel preference in China. We've now addressed that. And we feel very good about the product portfolio we have in place now. And we're beginning to see the returns of that. We've seen a pretty quick improvement in our performance in baby stores. We think there are still opportunities to expand distribution over time and we are doing that in a sort of considered and gradual fashion. And likewise, there are opportunities in e-commerce as well. While we are expanding in those channels and we are growing strongly in those channels, we just like everybody else, I think, are seeing an erosion of sales in the more traditional channels, like supermarkets for instance. But I think, we're doing our best to sort of incorporate these things into our overall forecasting which obviously underpin our guidance."
1002291,329825546,965617,"Mead Johnson Nutrition Company, Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","And is the promotional environment any different in baby channels versus supermarkets?",12,"And is the promotional environment any different in baby channels versus supermarkets?"
1002291,329825546,965617,"Mead Johnson Nutrition Company, Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","No, I wouldn't say so. I think it's fairly consistent.",10,"No, I wouldn't say so. I think it's fairly consistent."
1002291,329825546,965617,"Mead Johnson Nutrition Company, Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Mead Johnson Nutrition Company","Operator","Our next question comes from the line of Pablo Zuanic of Susquehanna Financial Group.",14,"Our next question comes from the line of Pablo Zuanic of Susquehanna Financial Group."
1002291,329825546,965617,"Mead Johnson Nutrition Company, Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","2 questions. One, when you talk about the sequential improvement in your sales growth in the -- compared to the third quarter and compared to the fourth quarter, how does it compare with the market? I just -- I'm just trying to understand how you're growi",102,"2 questions. One, when you talk about the sequential improvement in your sales growth in the -- compared to the third quarter and compared to the fourth quarter, how does it compare with the market? I just -- I'm just trying to understand how you're growing versus the market, that's the first question. And the second question, regarding the new regulations. I understand it's difficult to make judgments and some of them are [indiscernible] not clear. But in terms of the changes, [indiscernible] positive [indiscernible] announcement implies cross-border trade, are you seeing any crackdown or slowdown in terms of [indiscernible] imports? Thanks."
1002291,329825546,965617,"Mead Johnson Nutrition Company, Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Pablo, I think your second question is directed particularly at China. Is that right?",14,"Pablo, I think your second question is directed particularly at China. Is that right?"
1002291,329825546,965617,"Mead Johnson Nutrition Company, Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","Yes, that's right.",3,"Yes, that's right."
1002291,329825546,965617,"Mead Johnson Nutrition Company, Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Okay, okay. I think we are satisfied with the progress we're making vis--vis the market outside of the United States. I did highlight in my sort of prepared remarks, Pablo, that we have clearly lost some market share in the United States.",42,"Okay, okay. I think we are satisfied with the progress we're making vis--vis the market outside of the United States. I did highlight in my sort of prepared remarks, Pablo, that we have clearly lost some market share in the United States."
1002291,329825546,965617,"Mead Johnson Nutrition Company, Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","I'm sorry, because I'm trying to [indiscernible]. But both of my questions are related to China.",17,"I'm sorry, because I'm trying to [indiscernible]. But both of my questions are related to China."
1002291,329825546,965617,"Mead Johnson Nutrition Company, Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Both of them are related to China, okay. We feel that our performance vis--vis the market in China in the first quarter was favorable vis--vis where we began at the beginning of the quarter. And with regards the regulatory framework, we welcome the ne",151,"Both of them are related to China, okay. We feel that our performance vis--vis the market in China in the first quarter was favorable vis--vis where we began at the beginning of the quarter. And with regards the regulatory framework, we welcome the new set of regulations and we think it's a very positive step by the government to continue to regulate a product category, which is -- which sort of carries inherent risks to consumers, if not regulated. So we're very encouraged by what we are seeing. Those of you who have been on call with us before would know that I have been expecting this for quite some time. I think it was [indiscernible]. It is going to act to constrain some other cross-border trades, particularly the cross-border trade which is not organized and not compliant with Chinese regulations, whether that be from an ingredient, quality or labeling perspective."
1002291,329825546,965617,"Mead Johnson Nutrition Company, Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","And just a quick follow-up and last one. Regarding infant milk, the imported range. I understand the benefits and you launched it in December last year and obviously doing well, 45% of your sales. But what are the price point, Kasper? When I see RMB 275 f",81,"And just a quick follow-up and last one. Regarding infant milk, the imported range. I understand the benefits and you launched it in December last year and obviously doing well, 45% of your sales. But what are the price point, Kasper? When I see RMB 275 for Enfamil, it looks pricey compared to a lot of our imported products there. Is that an issue and does that price maybe need to come down in the future? Thanks. And that's all."
1002291,329825546,965617,"Mead Johnson Nutrition Company, Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","You're quite right that it is priced above many other importers -- imported products. But I think it speaks to the strength of our brand equity in China and I think the fact that we are able to grow that product line so strongly, I think supports my asser",90,"You're quite right that it is priced above many other importers -- imported products. But I think it speaks to the strength of our brand equity in China and I think the fact that we are able to grow that product line so strongly, I think supports my assertion that Chinese consumers are fundamentally far more concerned with quality and safety of their nutrition than they are with the cost of it. And if you can give them a premium quality offering, they're willing to pay what it takes."
1002291,329825546,965617,"Mead Johnson Nutrition Company, Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Mead Johnson Nutrition Company","Operator","Our next question comes from the line of Bryan Spillane of Bank of America.",14,"Our next question comes from the line of Bryan Spillane of Bank of America."
1002291,329825546,965617,"Mead Johnson Nutrition Company, Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","Just one question. Can you just give us some sense for, as you're in China specifically, as you've been expanding the distribution of the imported product, just -- is there any pipeline fill? So are you sort of -- are the sales growth now, a little bit ah",82,"Just one question. Can you just give us some sense for, as you're in China specifically, as you've been expanding the distribution of the imported product, just -- is there any pipeline fill? So are you sort of -- are the sales growth now, a little bit ahead of consumption because you're filling pipeline? And I guess as we kind of model going forward with more new product coming into the markets, how should we think about sort of sales versus consumption?"
1002291,329825546,965617,"Mead Johnson Nutrition Company, Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","I think you can assume that it is mostly consumption-based. Most of the distribution build that we experienced happened in late in the second and third quarters of last year.",31,"I think you can assume that it is mostly consumption-based. Most of the distribution build that we experienced happened in late in the second and third quarters of last year."
1002291,329825546,965617,"Mead Johnson Nutrition Company, Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","So we're seeing -- the sequential improvement you've seen in sales is also reflective of the sequential improvement consumption as well?",22,"So we're seeing -- the sequential improvement you've seen in sales is also reflective of the sequential improvement consumption as well?"
1002291,329825546,965617,"Mead Johnson Nutrition Company, Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","We are satisfied it's real, so to speak.",9,"We are satisfied it's real, so to speak."
1002291,329825546,965617,"Mead Johnson Nutrition Company, Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Mead Johnson Nutrition Company","Operator","Our next question comes from the line of John Baumgartner of Wells Fargo.",13,"Our next question comes from the line of John Baumgartner of Wells Fargo."
1002291,329825546,965617,"Mead Johnson Nutrition Company, Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","Kasper, wondering if you can speak a bit to the competitive environment in North America. Is it your sense that this is also some of the dairy cost inflation being realized? Or is it more of maybe just product or innovation-based and you kind of fallen be",75,"Kasper, wondering if you can speak a bit to the competitive environment in North America. Is it your sense that this is also some of the dairy cost inflation being realized? Or is it more of maybe just product or innovation-based and you kind of fallen behind? And then with your A&P being down for the quarter in Q1. Should we expect greater brand support investments coming through to help out volumes as 2016 unfolds?"
1002291,329825546,965617,"Mead Johnson Nutrition Company, Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","I mean, I think we fell a little bit behind on innovation. I think most of you might have listened or read Abbott's earnings call and I commented they've done a great job on their non-GMO line. We are clearly catching up and catching up quite fast in that",187,"I mean, I think we fell a little bit behind on innovation. I think most of you might have listened or read Abbott's earnings call and I commented they've done a great job on their non-GMO line. We are clearly catching up and catching up quite fast in that area. And we'll expect to complete the catch up so to speak later in the year. It's the nature of the U.S. market that the market share tends to sort of oscillate. But over time, the 2 biggest players in the marketplace, are in fact quite stable in their ability to hold onto market share all the time. We go through periods. We had a very good period in the first half of last year where we gained substantial market share and then we gave up some [indiscernible] as they exited the year, we are softening a little bit with that right now. But I'm very confident in our ability to sort of, what we say, restore equilibrium. We've shown again and again that we can do that as the other major player, [indiscernible]. We'll get it back."
1002291,329825546,965617,"Mead Johnson Nutrition Company, Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","And then are you seeing any unusual price discount based on the cost inflation at this point?",17,"And then are you seeing any unusual price discount based on the cost inflation at this point?"
1002291,329825546,965617,"Mead Johnson Nutrition Company, Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","No, I don't see that.",5,"No, I don't see that."
1002291,329825546,965617,"Mead Johnson Nutrition Company, Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Mead Johnson Nutrition Company","Operator","Our next question comes from the line of Jason English of Goldman Sachs.",13,"Our next question comes from the line of Jason English of Goldman Sachs."
1002291,329825546,965617,"Mead Johnson Nutrition Company, Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","I guess I'll pick up where we just left off on the last question. Kasper, you're sort of describing North America actions forward as more of an innovation. But I think in your prepared remarks, you referenced exploring some remedial pricing actions. Can y",51,"I guess I'll pick up where we just left off on the last question. Kasper, you're sort of describing North America actions forward as more of an innovation. But I think in your prepared remarks, you referenced exploring some remedial pricing actions. Can you elaborate a little bit on that?"
1002291,329825546,965617,"Mead Johnson Nutrition Company, Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Well, I think we always -- we're always looking to optimize our value equation in every market we compete in. And I do believe that there's probably opportunities to adapt our value equation in the U.S. in a favorable direction. So we'll look at it on a p",69,"Well, I think we always -- we're always looking to optimize our value equation in every market we compete in. And I do believe that there's probably opportunities to adapt our value equation in the U.S. in a favorable direction. So we'll look at it on a product by product basis and make sure we optimize our pricing. I didn't mean to imply that we imagine pricing going down."
1002291,329825546,965617,"Mead Johnson Nutrition Company, Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","Yes, that's kind of the interpretation I had. So I appreciate the clarification on that.",15,"Yes, that's kind of the interpretation I had. So I appreciate the clarification on that."
1002291,329825546,965617,"Mead Johnson Nutrition Company, Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","I'm sorry. I probably was I'm clearing my communication there.",11,"I'm sorry. I probably was I'm clearing my communication there."
1002291,329825546,965617,"Mead Johnson Nutrition Company, Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","No, I think it was sort of vague which is why I sort of jump to the bad side of the conclusion. So thank you for the clarification on that one that. And then I want to come back to Pablo's question earlier. You're referencing or sort of, foreshadowing mor",142,"No, I think it was sort of vague which is why I sort of jump to the bad side of the conclusion. So thank you for the clarification on that one that. And then I want to come back to Pablo's question earlier. You're referencing or sort of, foreshadowing more regulatory changes on the call. We've obviously had a lot of regulatory changes in terms of registration, labor requirement, duty changes, et cetera. But just -- 1 of his questions was, have you seen an impact yet in terms of the [indiscernible] trade flow into the market? I was hoping you could expand on that. Have you seen any impact? Or is it still sort of hopeful thinking that more change or believed that more change will be necessary from the government before we can actually start to stymie [ph] that flow?"
1002291,329825546,965617,"Mead Johnson Nutrition Company, Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","No. We've seen it. We've seen an impact, almost immediately. Let me rather, let me sort of talk about other people's business, let me perhaps talk about my own business. So we've seen an impact on our Hong Kong business. It's clear that checks at the bord",169,"No. We've seen it. We've seen an impact, almost immediately. Let me rather, let me sort of talk about other people's business, let me perhaps talk about my own business. So we've seen an impact on our Hong Kong business. It's clear that checks at the border between Hong Kong and mainland China has been tightened quite substantially. And there are now efforts underway to collect duty on product ship into the free trade zones. It's still somewhat inconsistent with how duty collection and the new regulations is being implemented. The speed of implementation between the different ports in China have varied quite a bit at the moment as one would expect. But we're definitely seeing, what shall we say, unofficial flows of products becoming more difficult. Now that of course is an opportunity for the products that we bring into China in a more orderly fashion. So we are also seeing a corresponding benefit to our fully imported line and that's definitely helping the growth of that line."
1002291,329825546,965617,"Mead Johnson Nutrition Company, Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","I'm sorry. Nova, we have time for one more call. So this next 1 is the final 1.",19,"I'm sorry. Nova, we have time for one more call. So this next 1 is the final 1."
1002291,329825546,965617,"Mead Johnson Nutrition Company, Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Mead Johnson Nutrition Company","Operator","Our final question comes from the line of Eric Katzman of Deutsche Bank.",13,"Our final question comes from the line of Eric Katzman of Deutsche Bank."
1002291,329825546,965617,"Mead Johnson Nutrition Company, Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","This is Mario Contreras in for Eric. I wanted to ask about Venezuela. Obviously, a number of your CPG peers have deconsolidated their business there. So I wanted to ask if you could quantify the potential EPS risk if you guys were to have to do the same?",72,"This is Mario Contreras in for Eric. I wanted to ask about Venezuela. Obviously, a number of your CPG peers have deconsolidated their business there. So I wanted to ask if you could quantify the potential EPS risk if you guys were to have to do the same? And then maybe that aside, shall we anticipate similar top line headwinds for the next few quarters just in terms of the reduced shipments?"
1002291,329825546,965617,"Mead Johnson Nutrition Company, Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","First of all, let me say that in all, the non-GAAP guidance, as well as the sales guidance that we've given you, we had taken into account the deterioration of Venezuela. So that's very important to note. If you look at it from, the question on deconsolid",138,"First of all, let me say that in all, the non-GAAP guidance, as well as the sales guidance that we've given you, we had taken into account the deterioration of Venezuela. So that's very important to note. If you look at it from, the question on deconsolidation. I think we still see opportunities there, as Kasper indicated going forward, like we are in discussions with the government to see what type of actions we could take. We've had some shipments, but very, very small in the first quarter. And I think we have -- we see, for the near future, still an opportunity to further as we develop that business back to where it was at a certain point of time. So that's the reason why we don't want to consolidate -- deconsolidate at this point in time."
1002291,329825546,965617,"Mead Johnson Nutrition Company, Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","But is there anyway that you could quantify the risk if you were to be in that situation? Or is it just premature to say, or to do that?",29,"But is there anyway that you could quantify the risk if you were to be in that situation? Or is it just premature to say, or to do that?"
1002291,329825546,965617,"Mead Johnson Nutrition Company, Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","No. I mean, if we look at the impairment, from a balance sheet perspective the non monetary and the monetary assets, I think we took the majority of the risk out of the balance sheet, that's one. From an operational point of view, I think I see limited ri",56,"No. I mean, if we look at the impairment, from a balance sheet perspective the non monetary and the monetary assets, I think we took the majority of the risk out of the balance sheet, that's one. From an operational point of view, I think I see limited risk that could impact our EPS going forward."
1002291,329825546,965617,"Mead Johnson Nutrition Company, Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Maybe in closing, Nova, before we close the call, let me take the opportunity just to clarify the ambiguous statement I made on pricing in the U.S. We in fact have announced that we have taken selective price increases on some product lines already, which",80,"Maybe in closing, Nova, before we close the call, let me take the opportunity just to clarify the ambiguous statement I made on pricing in the U.S. We in fact have announced that we have taken selective price increases on some product lines already, which will be effective later this quarter. So I apologize. I was not clear about that. 
So with that, I think we'll sign off for today and thank you very much for joining the call. Kathy?"
1002291,329825546,965617,"Mead Johnson Nutrition Company, Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","That's it. Thank you very much for participating in our First Quarter Conference Call. Operator, I'll leave you to close up the call.",24,"That's it. Thank you very much for participating in our First Quarter Conference Call. Operator, I'll leave you to close up the call."
1002291,329825546,965617,"Mead Johnson Nutrition Company, Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Mead Johnson Nutrition Company","Operator","This concludes the presentation. You may now disconnect. Everyone, have a wonderful day.",13,"This concludes the presentation. You may now disconnect. Everyone, have a wonderful day."
1002291,329825546,966025,"Mead Johnson Nutrition Company, Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Mead Johnson Nutrition Company","Operator","Good day, ladies and gentlemen, and welcome to the Mead Johnson Nutrition First Quarter 2016 Earnings Conference Call. My name is Nova, and I'll be your coordinator for today. [Operator Instructions] As a reminder, this conference is being recorded for re",61,"Good day, ladies and gentlemen, and welcome to the Mead Johnson Nutrition First Quarter 2016 Earnings Conference Call. My name is Nova, and I'll be your coordinator for today. [Operator Instructions] As a reminder, this conference is being recorded for replay purposes.
I would now like to turn the conference over to Kathy MacDonald, Vice President, Investor Relations. Please proceed, Kathy."
1002291,329825546,966025,"Mead Johnson Nutrition Company, Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Thank you, Nova. Good morning and thank you for joining Mead Johnson's First Quarter 2016 Conference Call. With me today are Kasper Jakobsen, our Chief Executive Officer; and Michel Cup, our Chief Financial Officer.Earlier today, we issued our earnings",304,"Thank you, Nova. Good morning and thank you for joining Mead Johnson's First Quarter 2016 Conference Call. With me today are Kasper Jakobsen, our Chief Executive Officer; and Michel Cup, our Chief Financial Officer.
Earlier today, we issued our earnings release and financial reference slides, which are available on our website.
As we start, let me remind everyone that our comments will include forward-looking statements about our future results, including statements about our financial prospects and projection, commodity costs, currency fluctuations, pricing, taxes, capital spending, depreciation and amortization, new product launches, product quality, other growth initiatives and market conditions that constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. A more detailed explanation of our forward-looking statements will appear in the materials posted on our website in connection with today's conference call.
Keep in mind that our actual results may differ materially from expectations as of today due to various factors, including those listed in our annual reports on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K, in each case as filed with or furnished to the Securities and Exchange Commission and our earnings release issued this morning, all of which are available upon request or on meadjohnson.com.
Today's comments will include discussion of non-GAAP financial measures. A reconciliation of these measures to comparable GAAP measures appear in the morning's earnings release posted on our website.
In addition, any forward-looking statements represent our estimates only as of today and should not be relied upon as representing our estimates as of any subsequent date. While we may elect to update forward-looking statements at some point in the future, we specifically disclaim any obligation to do so, even if our estimates change.
I will now turn the call over to Kasper."
1002291,329825546,966025,"Mead Johnson Nutrition Company, Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Thank you, Kathy, and good morning to all of you. Thank you for joining our call. Let me begin by summarizing our first quarter performance before I then expand on the headlines with additional detail from each of our reporting segments. My comments will",2685,"Thank you, Kathy, and good morning to all of you. Thank you for joining our call. Let me begin by summarizing our first quarter performance before I then expand on the headlines with additional detail from each of our reporting segments. My comments will focus on strategy and top line performance. Michel will then follow-up with additional financial analysis and elaborate on profitability and cash flow.
Except noted otherwise, I'll be referring to non-GAAP results.
At our Investor Day in October of last year, we laid out a 3-year plan for value creation. We know that at the time that 2016 would be a year of transition.
During our year-end earnings call, I identified 3 key milestones we've used to monitor our progress against this plan. Firstly, a return to constant dollar sales growth, with the first step being sequential sales growth from fourth quarter 2015 to first quarter 2016. Well, today, we're announcing constant dollar sales in the first quarter rose 1.5% above the prior quarter.
Secondly, we said we'd deliver on our first year commitments to reduce our overall operating expense base. And in the first quarter, our Fuel for Growth initiative delivered $20 million in expense reductions versus the prior year's first quarter, and we are well on our way to achieve our annual savings targets.
Thirdly, and finally, we said we'd invest a portion of our operating expense savings to fund key growth initiatives, both above and below the net sales line. In the first quarter, we continued to make strong investments in support of our strategy, especially in China. I'll expand on this a little later this morning.
Turning now to our first quarter 2016 results. First quarter sales came in as expected at $962 million. As anticipated, this represented a sequential improvement in constant dollars over our fourth quarter 2015 number. This was our second successive quarter of sequential improvement in our underlying business following the difficult second and third quarters of '15.
Also, as anticipated, our financial results were adversely impacted by currency movements to the tune of 600 basis points. Compared to the same quarter of prior year's, sales were 6% lower in constant dollars, driven by 8% lower volume, while price contributed 2 percentage points of growth. The unfavorable year-over-year comparison was mainly driven by tough base comparisons in our 2 largest markets and affecting the quarter itself are significantly reduced shipments to Venezuela.
Given the large adverse currency impact, I'm pleased with the company's continued earnings power. Gross margin for the quarter remained slightly better than 64% and our EBIT margin was above 25% as our cost reduction initiatives began to take hold.
Investment in advertising and promotion represented 15.8% of sales for the quarter. This was similar to the level seen through the second half of 2015.
Non-GAAP earnings per share for the quarter were $0.87. Michel will discuss how the most recent devaluation in Venezuela impacted our GAAP earnings.
Elaborating on the sequential improvement in sales against the prior quarter, improvements in Asia and Latin America were key drivers of growth. I know you're all watching our performance in China closely. So I want to let you know that, sequentially, we saw high single-digit percentage improvement in constant dollar sales in the world's biggest market.
Simultaneously, we saw weaker sequential performance in our North America/Europe segment. I will expand on this in just a moment.
Let me now briefly discuss progress against some of our major value-creating strategic initiatives, and let me begin with our growth initiatives before I then address cost reductions and investment optimization.
As you know, last year, we began the expansion and transformation of our China brand portfolio to allow us to better meet consumer needs and participate in growing market segments and channels. In late March, we announced the immediate introduction of Enfinitas, a best-in-class premium brand, into the China market. I'll return to this topic later.
In China, we also are making good progress with our Enfamil branded line of fully-imported products. And as we closed the quarter, these accounted for fully 45% of our sales in mainland China.
Outside of China, in Southeast Asia and Latin America, we continued investment in our Enfamil franchise, promoting the benefits of our new plastics packaging and refill system. This is the same system many of you would know from retailer sales here in the United States.
And domestically, in the United States, we are continuing to invest in our liquids portfolio, a category segment where we've historically underperformed. Our objective is to secure our fair share of this highly-profitable market segment.
Our determination to establish a segment for nutritionally-fortified toddler milks in North America is also undiminished. Enfagrow remains a critical part of our growth strategy, and we remain excited about its potential.
Still in the United States, we had begun a test to see how we can leverage big data analysis and our substantial database capability to more precisely target consumers with relevant products and messages. To test this, we've introduced Enfamil Enspire, a new product deploying the same science used in our China Enfinitas products, into limited retail distribution. We anticipate learning a great deal from this test, and the initiative demonstrates our commitment to innovating our business model over time.
Let me now turn to our effort to optimize our expense base. Our Fuel for Growth initiative is essential to our ability to sustain investments in growth, while generating shareholder value through EPS growth over time.
In the first quarter, we began to see the impact. We aim to reduce non-A&P operating expenses by at least $120 million over a 3-year period. We are making good progress against this target. And in the first quarter, reported SG&A expenses alone was 16% lower than a year earlier.
We also continue to evaluate opportunities to accelerate or enhance our cost reduction plan. During the coming quarter, we anticipate making progress in our review of advertising and promotion expenditure and other investments in demand creation. We believe new approaches to media and the ongoing conversion to digital will allow for greater efficiency of spend in the mid to long-term. But given our substantial investment in new product introductions, we do not expect this initiative to translate into lower A&P percentages towards the end of this year.
I'll now discuss in more detail the performance of each of our reporting segments, beginning with the North America/Europe segment. Overall, sales in this segment were less strong in the first quarter on both a sequential and year-over-year basis. Measured against the same quarter of 2015, constant dollar sales were weaker by 1% from volume and foreign exchange represented an additional headwind of 2 percentage points.
The start to the year in our U.S. business was affected by market share losses from the highs we saw in the middle of 2015. On a positive note, we believe the strengthening labor market and workforce participation rates have caused a rise in breastfeeding rates to level off over the last 4 months or so. We are, of course, very focused on what we can control and we are constructing remedial plans to strengthen our market share in the United States, including through pricing actions.
In Europe and Canada, I'm delighted to report that we are already enjoying record-high market shares. As a consequence, we are seeing strong growth both sequentially and year-over-year. In both geographies, we are executing our strategies extremely well, demonstrating that, when we do so, we can grow our business even in relatively mature markets.
Let me now turn to Latin America. In constant dollars and excluding the impact of Venezuela, Latin America grows over the prior quarter and was 7% higher compared to a year ago. However, when including the impact of suspended shipments to Venezuela, constant dollar sales were lower by 6%. Foreign exchange represented an additional significant headwind of 16%. An improved pricing of 7% was insufficient to fully offset this impact on reported sales. Across the whole region, we are seeing economies impacted by weaker commodity prices and, in several cases, political uncertainty.
Though both countries are still recovering from currency depreciations, stronger business performance in Mexico and Colombia helped somewhat mitigate the impact of economic recessions in Brazil and Venezuela. We've previously described how we've chosen to make only limited shipments to Venezuela as we are constrained by our limited access locally to hard currency. We are very keen to help alleviate the acute product shortage in Venezuela and restore supply, and we're working with the government to find a solution. But until one is found, we expect very limited sales in Venezuela.
Brazil is going through a well-prophesied economic recession. The impact on consumer and business confidence is manifesting itself in softer demand for discretionary items. And we are feeling the impact most acutely within our children's category. Our infant formula sales are holding up relatively better. We remain excited about the country's long-term potential, but we do not anticipate a substantial improvement within this year.
As mentioned, we enjoyed a strong start to the year in Mexico, where our milk modifier brands recovered somewhat from the weakness in mid-2015. Our infant formula and toddler business gained market share in the first quarter as new packaging and revised messaging behind an improved formulation resonated to consumers.
Though I recognize we can't quantify the extent to which Colombia may be benefiting from informal parallel exports to neighboring Venezuela, we believe increased market share is the main driver of very strong double-digit sales growth there.
And finally, our business in the Caribbean and Central America grew by high single-digits over the prior year's same quarter. In most of these markets, we transacted dollars and, hence, the region remains a stabilizing factor in an inherently volatile segment.
I'll turn now to our Asia segment. As mentioned in my global overview, we saw a strong single-digit sequential improvement in constant dollar sales in Asia. China grew faster than the segment as a whole, but Thailand and Malaysia also improved over the previous quarter.
Despite our strong sequential improvement, year-over-year sales comparison was unfavorable. Volume was lower by 9%, mainly reflecting the fact that we've still not returned to the year ago sales levels in China and Hong Kong. Price was in line with the prior year, with improved product mix offsetting the impact of added promotional activity.
In Thailand and Malaysia, the sequential comparison was helped by non-repeating retail inventory reductions referenced in our fourth quarter earnings call. 
Malaysian consumers appear to be adjusting spending habits in response to the VAT introduction and currency-related inflation of 2015. Consequently, we expect more stable performance from Malaysia going forward.
The Thai economy remains relatively weaker, and we're a little more cautious about a rapid turnaround there. We are maintaining investment levels and, in fact, seeking to strengthen our position in anticipation of an eventual recovery in economic growth. Inherently, Thailand is a great market for us and we have a very experienced team on the ground. Longer-term, I'm confident in our prospects there.
In Vietnam, we have seen opportunities to improve our execution. The market somewhat underperformed against our expectations in 2015 and in the most recent quarter, but our team is focused on the right issues and putting in place plans to strengthen performance in the second half of the year.
Because our businesses in Indonesia is relatively small, we don't often talk about our performance in this large market. However, over the last 12 months, we've developed a more focused geographic strategy for the country, and our improved focus appear to be helping. Sales grew strongly in the first quarter, both sequentially and year-over-year. It's clear that we would like to build a bigger business in this high-potential market, but we remain realistic about our scale and the challenges to realizing our ambition organically.
Let me close on China. The China market continues to evolve quickly and we are still assessing the full impact of recent changes to duty structure and regulatory frameworks. Over the last year or so, I have repeatedly stated my belief that regulatory changes were put in China. And more evenhanded duty structure is, in my mind, likely to be just the first of several important changes being driven by the Chinese government. The focus remains on consumer safety. And the requirement that all infant formula and children's products, regardless of sales channel, be registered in China is a key part of the government's efforts to safeguard the consumer. We're supportive of these efforts to protect consumers by ensuring products and labels meet Chinese standards, regardless of how and from where they are sold.
Before I discuss the performance of our China business, I want to remind you of the broad China strategy we laid out for you more than a year ago. We promised we would reshape our product portfolio to better satisfy consumer's preference for imported premium products. And once we have the right portfolio, we will then commit the resources to strengthen our performance in higher growth sales channels.
Since then, we have introduced a fully-imported line of our Enfamil branded products. And after the close of the first quarter, we introduced a new product offering into the highest priced market segment. Enfinitas, as we have aptly called this new offering, contains our best science and was developed incorporating understanding gained from our extensive studies of breast milk, nutrition and metabolism.
In addition to our long-proven, industry-leading levels of DHA and ARA -- AHA, the products contained boosted levels of lactoferrin and milk fat globular membranes, ingredients closely associated with both neuro and immune system development. Though this new technology is costly, we believe Chinese parents would once again confirm that they're willing to invest in their child's future.
We now have the right portfolio to win with both consumers and retailers. Helped by our recent introductions, baby stores became our largest sales channel in the latest quarter, and both this channel and the e-commerce channel grew in excess of 20% over the same quarter of last year. And despite cannibalization from our imported line, sales of our locally-manufactured product line appeared to have stabilized in response to stronger defensive stops and increased promotional competitiveness.
I know you all share my interest in the price promotional environment in China. Let me give you my perspective. It's clear to us that some competitors push sales aggressively in the fourth quarter of 2015. And as a result, I'm now providing additional discounts to clear inventory overhang from distributors and retailers. Though we will, of course, act to protect our market share, we take a different approach. We simply do not believe Chinese consumers are significantly motivated by lower prices, even though retailers may well be. Rather, Chinese consumers are amongst the world's most discerning and they continue to show a willingness to pay for superior quality and nutrition. This is evidenced by the continued shift towards higher-priced segments.
Our view is supported by the fact that, sequentially, price, in fact, was a positive contributor to our growth in China in the latest quarter, the positive effect of product mix more than offsetting the effect of promotional spend.
In response to the successful execution of our strategy, our performance in China improved substantially over the prior quarter, with constant dollar sales, as mentioned, showing a high single-digit percentage improvement.
Commenting now on our outlook for the full year 2016. I reiterate that company guidance for modest constant dollar sales growth between 0% and 2%. Based on current exchange rate assumptions, we expect this to translate into an unfavorable sales comparison in U.S. dollars of between 4% and 6%.
As advised in our January call, we expect to deliver 9% to 12% growth in constant dollar EPS. Based on this, we also reiterate our guidance for full year non-GAAP EPS between $3.48 and $3.60.
I'll now hand over to Michel who will provide additional details on our financial performance. I will then return with a few summary remarks before we take your questions. Michel, over to you."
1002291,329825546,966025,"Mead Johnson Nutrition Company, Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Thank you, Kasper, and good morning, everyone. Today, I will discuss the company's first quarter 2016 financial results. I will then briefly highlight EBIT results by segment and wrap up with a cash flow analysis and summary of our full year guidance.Un",2102,"Thank you, Kasper, and good morning, everyone. Today, I will discuss the company's first quarter 2016 financial results. I will then briefly highlight EBIT results by segment and wrap up with a cash flow analysis and summary of our full year guidance.
Unless otherwise noted, my comments will be on the non-GAAP financial results. References to currency impacts or the effects of currency fluctuations generally refer to their impact on the translation of local currency, financial statement into the United States dollars.
Let me start with sales. As shown on Slide 3, on a sequential basis, from the fourth quarter of 2015, constant dollar sales grew by 1.5%. Nearly all of our large markets grew sequentially and, most notably, China. When you review the 5-quarter sequential trend, sales were strongest in the first quarter of 2015 and started to decline in the second quarter. As 2015 progressed, we invested to protect competitiveness, launched new products and were able to stabilize sales in the fourth quarter.
In the first quarter, we continued to invest. We rolled out new innovation and selectively increased prices in some markets to compensate for the continued currency devaluations. Consistent with my stated expectation last quarter, I would like to remind you that the second quarter of 2016 year-over-year comparison will continue to be tough on a constant dollar basis, although we should see an improvement in the second quarter performance.
First quarter sales on a reported basis were 12% below and constant dollar sales were 6% below the prior year quarter. Adverse foreign exchange rate contributed a 600 basis point decline.
Slide 4 summarizes the impact of foreign exchange on sales and EPS. The U.S. dollar continued to be strong in the first quarter of 2016 and its effect on the translation of local currency negatively impacted all reporting segments. The first quarter decline of 6% was the same percentage as both the third and the fourth quarter of 2015. Half of the negative currency impact in the first quarter were from the Chinese renminbi, the Mexican peso and the Argentinian peso. The balance of the adverse foreign exchange impact was widespread across the regions. We continue to expect an approximately 6% adverse foreign exchange impact on sales for the full year 2016. I will address the foreign exchange impact in the EPS guidance section as well.
I will now move to factors that impact our gross margins on Slide 5. Gross margins was 64.1% in the first quarter of 2016. This was a similar margin percentage to the first quarter of 2015 and in line with our expectations for the full year.
Sales impacted from positive mix and pricing was affected by higher trade investments resulting in a slight gross margin decline. Manufacturing conversion cost negatively impacted margin due to lower volume absorption and higher cost of innovation and inflation.
Low dairy cost was the largest benefit to our gross margin in quarter 1 and more than offset higher conversion cost and other commodities increases. We expect to see dairy benefits in the second quarter.
As you can see, we continued to deliver productivity savings within our cost of goods sold. Also [indiscernible] has already secured commitments for nearly 90% of our 2016 productivity goals.
Moving to operating expenses, I will start with advertising and promotion investments on Slide 6. A&P was 15.8% of sales in the first quarter compared to 13.2% in the prior year quarter. This was an increase of 11% on a constant dollar basis. The incremental investments were mainly to support our key China initiatives.
Historically, the company had a lower A&P spending in the first quarter of the year. Since our China fully-imported product line was launched in the middle of last year, we continued strong investments in the first quarter of 2016, especially fertilization, digital and e-commerce media. In addition, we supported the investment of new innovation rollout in selected markets.
With the April 2016 launch of our super high premium products, we expect A&P as a percentage of sales to be high in the second quarter. As you can see on this slide, when we launched the China fully-imported product in the second quarter of 2015, our total A&P as a percentage of sales went up significantly. We can expect that in the second quarter of 2016 as well.
Turning to Slide 7. The increase in A&P was offset by reduction in selling, general and administrative expenses. This is in line with the strategy we outlined at Investor Day, that 2016 will be a year of transition with a focus on investments.
On a constant dollar basis, SG&A was 10% lower than the first quarter of 2015. Approximately $20 million of the SG&A reduction is attributed to our Fuel for Growth initiative, which I will address on the next slide.
Slide 8 shows that our Fuel for Growth initiative had a strong start in the first quarter. On a constant dollar basis, we delivered cost reduction of 10% for the first quarter of 2015, especially in our support functions. While we have made some reductions in the region offices, about 3/4 of the reduction was from corporate headquarter functions, which decreased by approximately 30% on a like-for-like constant currency basis. Of the corporate headquarter reductions, more than half was from outside services, and the balance were personnel-related. To-date, we have secured over 90% of our planned 2016 reductions, and we are ahead of schedule. At the same time, we constrained sales forces and distribution spending to remain relatively flat to prior year on a constant dollar basis.
Turning now to Slide 9 for a discussion of EBIT. Let me start this analysis per segment. In the first quarter, Asia delivered an EBIT of $169 million, a decrease of 22% on a constant dollar basis. An incremental 5% decrease came from the adverse foreign exchange impact, largely driven from the Chinese renminbi, Thai baht and the Malaysian ringgit. The Asia EBIT margin, at 33.8%, improved 390 basis points compared to the fourth quarter of 2015, yet was 600 basis points lower than the first quarter of 2015. The main year-over-year drivers were lower sales and increased channel investment and promotional activities.
Investment continued throughout the Asian region to support our innovation launches. The most significant investment were in China, including competitive price promotions on the locally-manufactured products and investment for the fully-imported product line.
Latin America delivered an EBIT of $41 million in the first quarter, a decrease of 11% on a constant dollar basis. The EBIT decline was due to lower sales mainly in Venezuela, yet the decline was somewhat offset by lower A&P investments. Excluding the impact of the Venezuelan business, the Latin America EBIT on a constant dollar basis increased 22% compared to prior year.
For the segment, adverse foreign exchange impacted by EBIT 18%, largely from the Mexican peso. On a reported basis, EBIT was 29% lower than prior year.
The Latin America EBIT margin was 25.5% for the first quarter of 2016 compared to 28% for the same quarter last year. The 250 basis points decline was from lower sales, mainly Venezuela, somewhat offset by lower A&P and sales force spending.
For the first quarter, North America and Europe EBIT was $82 million, an increase of 9% on a constant dollar basis. The EBIT margin of 27.2% was 190 basis points better than the prior year quarter. Despite lower sales, gross margin remained strong from the dairy benefit, with an operating expenses reduction in the SG&A was selectively invested to support new product innovations, while a portion of the savings drove higher EBIT margins.
As mentioned on the Fuel for Growth slide, corporate and other delivered significant benefit to EBIT. For the total company, the first quarter EBIT of $244 million was 10% below the prior year quarter on a constant dollar basis. Adverse exchange nearly doubled the impact, resulting in a reported EBIT down 19%. The decline was due to lower sales somewhat offset by improved operating expenses.
The EBIT margin of 25.4% of sales was 200 basis points lower than prior year quarter. The first quarter 2015 EBIT of 27.4% was high due to underspending on A&P. As 2015 progressed, A&P increased and annual 2015 EBIT came in at 24.1%.
I will now address our financial results from EBIT to net income on Slide 10. The increase in interest expense reflects the full quarterly impact of the November 2015 1.5 billion notes. The significant portion of the proceeds from the notes were used to finance the accelerated share repurchase program. As a reminder, 10.7 million of shares of stock were received in the fourth quarter. The balance of shares will be delivered at the end of the agreement, which is scheduled to conclude in the second quarter of 2016.
Our non-GAAP effective tax rate or ETR was 23.2% for the first quarter of 2016 compared to 22.5% in the prior year quarter. The first quarter 2015 rate was lower as a result of the more favorable geographic earnings mix that did not prevail for the full year. Non-GAAP EPS for the first quarter was $0.87.
Let me summarize our financial results by addressing the changes to EPS on Slide 11. In the first quarter, non-GAAP EPS declined $0.12 on a constant dollar basis versus prior year quarter. Sales and related gross profit negatively impacted EPS by $0.16. The increase in A&P was offset by Fuel for Growth savings. The ASR delivered $0.03 benefit net of higher interest expense. Half of the $0.12 decline in non-GAAP EPS on a constant dollar was a result of the temporary suspension of shipments to Venezuela in the first quarter of 2016. Foreign exchange adversely impact EPS by $0.10.
Let me address specified items. Since we took a significant specified charge in the first quarter, let me briefly explain what drove the Venezuelan change noted on Slide 12.
In March 2016, the Venezuelan government changed the exchange rate system from a 3 to a 2-tier structure. There were 2 significant impacts to our business. First, the SICAD rate was eliminated. This was the rate we previously used to translate our net monetary assets of our Venezuelan subsidiary. As a result, we adopted the floating rate now called DICOM. For reference only, the most recent SICAD rate was 13.5 and the DICOM rate at the end of the quarter was approximately 273 and continued to devalue in April. The remeasurement impact from adopting the DICOM rate was a $32 million loss impacting monetary assets.
Second, as the DICOM rate also impacts the translation of our local earnings to U.S. dollar, our future results of Venezuela business are impacted. This triggered an impairment review of Venezuelan's long-lived assets. Following that process, we concluded there was $46 million impairment of our long-lived assets.
Due to the Venezuela change, Fuel for Growth and pension remeasurement charges specified item for the first quarter was $0.48 per share. Including these specified items, GAAP EPS was $0.39.
Turning to a high-level overview of cash movement. On Slide 13, the cash balance of $1.7 billion as of March was similar to the year-end balance. Cash from operating activities was lower than the prior year period. Cash flows reflected lower sales and the negative impact from other working capital. An unusual item on this chart is the sizable foreign exchange impact on cash. This was mainly due to the adoption of the new exchange rate and the remeasurement of our monetary assets in Venezuela.
In summary, the cash generated from operation this quarter was used to pay dividends and capital commitments. For the full year, our capital spending goal remains about 4% of sales.
To summarize our annual guidance on Slide 14, we expect full year 2015 constant dollar growth in the range of 0% to 2%. We continue to anticipate tough comparisons for the first half year 2016 and we do not expect to report positive revenue growth over the same quarter of prior year until the second half 2016.
We reaffirm our 2016 non-GAAP EPS guidance in the range of $3.48 to $3.60. Primarily due to the first quarter charges rate to Venezuela, full year specified items are now expected to be $0.57 per share. Therefore, our updated 2016 GAAP EPS is expected in the range of $2.91 to $3.03. GAAP EPS will change as a result of future mark-to-market pension adjustments, which we cannot estimate at this time.
This concludes my discussion on our first quarter financial results. Thanks, again, for your time this morning, and I will now turn the call back to Kasper."
1002291,329825546,966025,"Mead Johnson Nutrition Company, Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Thank you, Michel. Before we take your questions, let me briefly summarize our key messages.Firstly, we are satisfied with the sequential improvement in constant dollar revenue. Secondly, we are pleased with the improvement we're seeing in China and we",218,"Thank you, Michel. Before we take your questions, let me briefly summarize our key messages.
Firstly, we are satisfied with the sequential improvement in constant dollar revenue. Secondly, we are pleased with the improvement we're seeing in China and we remain focused on the successful execution of our previously outlined China strategy. Thirdly, we do not underestimate the challenges we are facing in an uncertain global economic environment. Despite these challenges, we believe the balance within our global portfolio will allow us to complete 2016, which we've often referred to as a year of transition, as planned.
We are, therefore, reiterating our prior guidance for modest full year constant dollar sales growth between 0% and 2%. We are confident that sequential constant dollar sales for the first half of 2016 will be stronger than the second half of prior year. And within 2016, sales in the second 6-month period will be stronger than the first half of the year.
For the year, we expect foreign exchange to adversely affect translation into our reporting currency by 600 basis points. We also are confirming unchanged non-GAAP EPS guidance of $3.48 to $3.60.
I'll now hand the call over to our operator, Nova, who will assist us in opening the lines for questions. Nova, I'll hand the call back to you."
1002291,329825546,966025,"Mead Johnson Nutrition Company, Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Mead Johnson Nutrition Company","Operator","[Operator Instructions] Our first question comes from the line of David Driscoll of Citi.",14,"[Operator Instructions] Our first question comes from the line of David Driscoll of Citi."
1002291,329825546,966025,"Mead Johnson Nutrition Company, Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","I wanted to ask about the super premium product launches starting with the China Enfinitas product and just hear a little bit more about the reception from the mom and baby store's shelf space. Is it incremental to the existing shelf space you have in the",129,"I wanted to ask about the super premium product launches starting with the China Enfinitas product and just hear a little bit more about the reception from the mom and baby store's shelf space. Is it incremental to the existing shelf space you have in there? And then, just some comments on kind of what we should expect on the pacing of Enfinitas in China.
And then, kind of fully separately, but still on super premium, just give us a little bit more on Enspire and what's the role of this product? You said like limited launch and kind of a test. And I suppose I haven't heard you ever say something like that before. So I'd just like to hear what role that plays in the U.S."
1002291,329825546,966025,"Mead Johnson Nutrition Company, Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Well, let me just begin by saying that the introduction in China is really proceeding as we speak, David. So it's very early days here. We -- our first initial shipments did not happen until the middle of this month, in fact. But reception from retailers",331,"Well, let me just begin by saying that the introduction in China is really proceeding as we speak, David. So it's very early days here. We -- our first initial shipments did not happen until the middle of this month, in fact. But reception from retailers has been very favorable and we've not had any issues getting the required additional shelf space, be that in baby stores or in other retail channels in China. So I would say we're encouraged by what we see and the engagement we are having. The early engagement we are having with consumers online is also favorable in China.
I don't know that we want to get into giving you forecast and expectations by product line. So I don't think I'm prepared to go there. But as you know, it's a project that we've been working on for quite some time. Many of you would probably say too long. So obviously, we feel like we are putting our best foot forward, and we are optimistic about the prospects.
In the U.S., it's a little bit different. I think what we are doing in the U.S. is really experimenting with a different business model. We believe that, based on our increased mastery of sort of big data analysis and our own database and our knowledge of the U.S. consumers, we are able to quite precisely target consumers in the market that might be more likely to be interested in a premium nutrition proposition and willing to pay the price that goes with that. So we've begun a test initially with very limited retail distribution. I think we'll assess how that test proceeds through the year and then we'll decide whether we will expand distribution from where we currently are. But the science used in the 2 products is identical. There are some minor variations that are required by different regulations and different quality standards needed in the 2 markets, but the base science is essentially the same."
1002291,329825546,966025,"Mead Johnson Nutrition Company, Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Mead Johnson Nutrition Company","Operator","Our next question comes from the line of Matthew Grainger of Morgan Stanley.",13,"Our next question comes from the line of Matthew Grainger of Morgan Stanley."
1002291,329825546,966025,"Mead Johnson Nutrition Company, Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","Kasper and Michel, I just wanted to ask about Enfinitas as well. Could you talk a bit more about the formulation and its uniqueness relative to what's currently on the market? Is the value proposition here driven by the ingredients or is it really the pro",103,"Kasper and Michel, I just wanted to ask about Enfinitas as well. Could you talk a bit more about the formulation and its uniqueness relative to what's currently on the market? Is the value proposition here driven by the ingredients or is it really the proprietary combination? And, I guess, what I'm curious is how quickly do you think fast followers can try and incorporate similar benefits into their products?
And just related, from a margin perspective, given the price point, is the expectation that once you hit scale, that margins can ultimately be accretive to your overall Asia region or China business?"
1002291,329825546,966025,"Mead Johnson Nutrition Company, Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Yes. I mean, I think the whole product bundle is quite unique. We -- as you know, we have a large ongoing effort underway within the company to continually enhance our understanding of breast milk in particular and how we can incorporate the latest scienc",265,"Yes. I mean, I think the whole product bundle is quite unique. We -- as you know, we have a large ongoing effort underway within the company to continually enhance our understanding of breast milk in particular and how we can incorporate the latest science associated with breast milk in enhanced form, in some cases, into formulas. We've acted on some of that. We have raised the levels, as I mentioned, of lactoferrin, which is naturally present in very low levels in all -- in most formulas, I shouldn't say all, but most. And we have incorporated elevated levels as well, significantly elevated levels of milk fat globular membranes, which is just what it says it is. Both of these ingredients are sort of closely associated with physiological development, either neuro or immune system development of -- for infants. The second ingredient is in somewhat scarce supply in the world. And we believe that though people can talk about it, it will take some time for people to get to the levels we are at. But most importantly, I think it's the understanding of how the ingredients work, and then we've incorporated that into quite unique packaging in the marketplaces where we packed it with our advertising and digital capabilities. So we're excited about it and, I guess, we feel like we've got quite a unique package, which is one of the reasons we've delayed the entry. We wanted to make sure we have the right package.
And I don't know if Michel wants to comment on margins. Do you want to add something, Michel?"
1002291,329825546,966025,"Mead Johnson Nutrition Company, Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Yes. The question on margin accretion. I think, as Kasper said, we are in the process of rolling out and that's our current focus. We are investing in, very strong so, to drive the awareness and have the right level of distribution and to ensure that moms",68,"Yes. The question on margin accretion. I think, as Kasper said, we are in the process of rolling out and that's our current focus. We are investing in, very strong so, to drive the awareness and have the right level of distribution and to ensure that moms enter the [indiscernible]. So over time, we expect to see the return on these investments, but definitely not at the beginning."
1002291,329825546,966025,"Mead Johnson Nutrition Company, Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Mead Johnson Nutrition Company","Operator","Our next question comes from the line of Rob Moskow of Crdit Suisse.",13,"Our next question comes from the line of Rob Moskow of Crdit Suisse."
1002291,329825546,966025,"Mead Johnson Nutrition Company, Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","A couple of questions about the guidance, first on FX. I think last quarter you've called out $0.40 of headwind and I don't think I heard it called out on this call. The revenue guidance hasn't changed for FX and, I guess, I'm a little surprised. Most of",119,"A couple of questions about the guidance, first on FX. I think last quarter you've called out $0.40 of headwind and I don't think I heard it called out on this call. The revenue guidance hasn't changed for FX and, I guess, I'm a little surprised. Most of your peers are experiencing lighter headwinds. I just wanted to know what the update is on that.
And then, secondly, your comments about the market in China and inventory kind of -- or efforts to promote away inventory that's on the shelves. Is it pretty much the same kind of conditions you saw in fourth quarter or have things gotten a little worse in first quarter? How would you characterize it?"
1002291,329825546,966025,"Mead Johnson Nutrition Company, Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Let me start with the -- with addressing the inventory situation. I would say that the promotional environment is certainly not getting better. And I think there is a -- it would appear that some people are dealing with the kind of fourth quarter, first q",143,"Let me start with the -- with addressing the inventory situation. I would say that the promotional environment is certainly not getting better. And I think there is a -- it would appear that some people are dealing with the kind of fourth quarter, first quarter dynamic. I'm very happy with where our inventory levels are. And I think we've -- our team on the ground has managed that quite well.
I think what we've said before, which maybe I should have said in response to Matt's question as well, is that we feel pretty good about our ability to sustain the margins in China at or around the same level as they are today as we see sort of the ability of a favorable product mix as having the ability to offset any additional pressure there might be to increase promotional competitiveness."
1002291,329825546,966025,"Mead Johnson Nutrition Company, Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Yes. Let me address the FX question you had. I mean, a couple of points. I think you're aware that we're operating in 50 countries, so 2/3 of our revenue is exposed to foreign currency fluctuations. And as I highlighted also last year, a part of that is h",163,"Yes. Let me address the FX question you had. I mean, a couple of points. I think you're aware that we're operating in 50 countries, so 2/3 of our revenue is exposed to foreign currency fluctuations. And as I highlighted also last year, a part of that is hatched for a certain period.
The second point I would like to make is there is -- although there is an improvement, but you still see a significant fluctuation of some currencies. Just remind you on the Chinese renminbi, mid-April, where you saw a significant change again, and that is impacting our business as we speak. I think you've seen that we, in Q1, we delivered our reported sales of decline of 6%, in line with our expectation. So as it stands of today, and if we could lock in the whole year as of today, which we can do, we would see some benefits of a couple of cents, I would say, on EPS."
1002291,329825546,966025,"Mead Johnson Nutrition Company, Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","Okay. But you say part of it was hedged. Did you -- the part that was hedged, is that -- were you leaving some money on the table, so to speak? Did that work against you now?",37,"Okay. But you say part of it was hedged. Did you -- the part that was hedged, is that -- were you leaving some money on the table, so to speak? Did that work against you now?"
1002291,329825546,966025,"Mead Johnson Nutrition Company, Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","No. I mean, when I gave the guidance of $0.40 in January, I included the hedge position that we had at that point of time.",25,"No. I mean, when I gave the guidance of $0.40 in January, I included the hedge position that we had at that point of time."
1002291,329825546,966025,"Mead Johnson Nutrition Company, Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","Okay. So is it still $0.40 or is it different?",10,"Okay. So is it still $0.40 or is it different?"
1002291,329825546,966025,"Mead Johnson Nutrition Company, Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Could you repeat your question?",5,"Could you repeat your question?"
1002291,329825546,966025,"Mead Johnson Nutrition Company, Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","Is the headwind still $0.40 or is it different?",9,"Is the headwind still $0.40 or is it different?"
1002291,329825546,966025,"Mead Johnson Nutrition Company, Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Well, I haven't changed guidance. So I haven't changed guidance. The $0.40 is still included.",15,"Well, I haven't changed guidance. So I haven't changed guidance. The $0.40 is still included."
1002291,329825546,966025,"Mead Johnson Nutrition Company, Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Mead Johnson Nutrition Company","Operator","Our next question comes from the line of Ken Goldman of JP Morgan.",13,"Our next question comes from the line of Ken Goldman of JP Morgan."
1002291,329825546,966025,"Mead Johnson Nutrition Company, Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","This is Josh Levine on for Ken. Just a question actually on Fuel for Growth. You said that it drove about $20 million in the first quarter, which you said was attributed mostly to cutting out certain services and overhead. Both of those sound like, I gues",100,"This is Josh Levine on for Ken. Just a question actually on Fuel for Growth. You said that it drove about $20 million in the first quarter, which you said was attributed mostly to cutting out certain services and overhead. Both of those sound like, I guess, sustainable savings levels. Is it right to assume that level sort of continues through the year? And, I guess -- and obviously, you guided, I guess, to $60 million savings. That would imply, obviously, you would beat that number. I'm just -- I guess, can you just help us on the pacing there?"
1002291,329825546,966025,"Mead Johnson Nutrition Company, Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Yes. I think it's a good question because if you would do your math and, as we announced earlier, we would have $60 million savings this year. If you would take $20 million times 4, you have $80 million. I would put some cautiousness in there. I think the",132,"Yes. I think it's a good question because if you would do your math and, as we announced earlier, we would have $60 million savings this year. If you would take $20 million times 4, you have $80 million. I would put some cautiousness in there. I think there is certain fluctuation, especially if you do quarter-on-quarter comparison, especially in the area of third party services.
Having said that, I'm very encouraged by the fact that we secured 90% of the $60 million, and I indicated that we're ahead of our plan. So -- and as Kasper also indicated, we are continuing going through a review which we -- just talks more about -- by the end of the second quarter on which additional actions we see that we potentially could accelerate."
1002291,329825546,966025,"Mead Johnson Nutrition Company, Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","Got it. And then, just on A&P spending, I guess, you said that it would be one -- 2Q levels will be higher than 1Q, which, I guess, is similar to last year. But just from a year-over-year basis, how is that -- how should we think about that for 2Q?And t",111,"Got it. And then, just on A&P spending, I guess, you said that it would be one -- 2Q levels will be higher than 1Q, which, I guess, is similar to last year. But just from a year-over-year basis, how is that -- how should we think about that for 2Q?
And then, just a larger question, when you typically advertise ahead of product launches, ahead of innovations, but, I guess, how do you think strategically about when you kind of ramp down that spending, right? Just because as we think -- sort of when you can let, I guess, the returns on that market investment fall on the bottom line."
1002291,329825546,966025,"Mead Johnson Nutrition Company, Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Well, as Kasper also indicated, that -- don't expect a significant drop in the first half year. We will continue to invest, like I said in my earlier comments, especially in Q2. And you might see some lower A&P expenditures more towards the end of the yea",47,"Well, as Kasper also indicated, that -- don't expect a significant drop in the first half year. We will continue to invest, like I said in my earlier comments, especially in Q2. And you might see some lower A&P expenditures more towards the end of the year."
1002291,329825546,966025,"Mead Johnson Nutrition Company, Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Mead Johnson Nutrition Company","Operator","Our next question comes from the line of Amit Sharma of BMO Capital Markets.",14,"Our next question comes from the line of Amit Sharma of BMO Capital Markets."
1002291,329825546,966025,"Mead Johnson Nutrition Company, Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","Kasper, you talked about baby stores in China are now your biggest or largest channel. Could you just define for us, like, what's the size of the opportunity? And as we become even bigger in that channel, are you fully incorporating the mix benefit of hav",52,"Kasper, you talked about baby stores in China are now your biggest or largest channel. Could you just define for us, like, what's the size of the opportunity? And as we become even bigger in that channel, are you fully incorporating the mix benefit of having a larger presence in that channel?"
1002291,329825546,966025,"Mead Johnson Nutrition Company, Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","I think we're incorporating the benefits. We are certainly thinking about it. As you know, we talked quite a bit about the fact that, last year, we were caught in the second and third quarters with a bit of a mismatch between our product offerings and, fr",191,"I think we're incorporating the benefits. We are certainly thinking about it. As you know, we talked quite a bit about the fact that, last year, we were caught in the second and third quarters with a bit of a mismatch between our product offerings and, frankly speaking, both the consumer preference and the channel preference in China. We've now addressed that. And we feel very good about the product portfolio we have in place now. And we are beginning to see the returns of that. We've seen a pretty quick improvement in our performance in baby stores. We think there are still opportunities to expand distribution over time, and we are doing that in a sort of considered and gradual fashion. And likewise, there are opportunities in e-commerce as well. While we are expanding in those channels and we are growing strongly in those channels, we, just like everybody else, I think are seeing an erosion of sales in the more traditional channels, like supermarkets for instance. But I think we're doing our best to sort of incorporate these things into our overall forecasting, which obviously underpin our guidance."
1002291,329825546,966025,"Mead Johnson Nutrition Company, Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","And is the promotional environment any different in baby channels versus supermarkets?",12,"And is the promotional environment any different in baby channels versus supermarkets?"
1002291,329825546,966025,"Mead Johnson Nutrition Company, Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","No. I wouldn't say so. I think it's fairly consistent.",10,"No. I wouldn't say so. I think it's fairly consistent."
1002291,329825546,966025,"Mead Johnson Nutrition Company, Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Mead Johnson Nutrition Company","Operator","Our next question comes from the line of Pablo Zuanic of Susquehanna Financial Group.",14,"Our next question comes from the line of Pablo Zuanic of Susquehanna Financial Group."
1002291,329825546,966025,"Mead Johnson Nutrition Company, Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","Look, 2 questions. One, when you talk about the sequential improvement in your sales growth in the -- compared to the third quarter and compared to the fourth quarter, how does it compare with the market? I just -- I'm just trying to get an understanding",107,"Look, 2 questions. One, when you talk about the sequential improvement in your sales growth in the -- compared to the third quarter and compared to the fourth quarter, how does it compare with the market? I just -- I'm just trying to get an understanding of how you're growing versus the market. That's the first question.
And the second question, regarding the new regulations. I understand it's difficult to make judgments and some of them are still not clear. But in terms of the changes of the positive list announcement implies for cross-border trade, are you seeing any crackdown or slowdown in terms of parallel imports?"
1002291,329825546,966025,"Mead Johnson Nutrition Company, Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Pablo, I take it your second question is directed particularly at China, is that right?",15,"Pablo, I take it your second question is directed particularly at China, is that right?"
1002291,329825546,966025,"Mead Johnson Nutrition Company, Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","Yes, that's right.",3,"Yes, that's right."
1002291,329825546,966025,"Mead Johnson Nutrition Company, Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Okay. Okay. Well, I think we are satisfied with the progress we are making vis--vis the market outside of the United States. I did highlight in my sort of prepared remarks, Pablo, that we have clearly lost some market share in the United States and...",45,"Okay. Okay. Well, I think we are satisfied with the progress we are making vis--vis the market outside of the United States. I did highlight in my sort of prepared remarks, Pablo, that we have clearly lost some market share in the United States and..."
1002291,329825546,966025,"Mead Johnson Nutrition Company, Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","No. I'm sorry because -- I mean, I don't mean to interrupt, but my question -- both of them are related to China. I'm sorry.",25,"No. I'm sorry because -- I mean, I don't mean to interrupt, but my question -- both of them are related to China. I'm sorry."
1002291,329825546,966025,"Mead Johnson Nutrition Company, Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Both of them are related to China. Okay. We feel that our performance vis--vis the market in China in the first quarter was favorable, vis--vis where we began at the beginning of the quarter.And with regards to the regulatory framework, we welcome t",153,"Both of them are related to China. Okay. We feel that our performance vis--vis the market in China in the first quarter was favorable, vis--vis where we began at the beginning of the quarter.
And with regards to the regulatory framework, we welcome the new set of regulations and we think it's a very positive step by the government to continue to regulate a product category, which is -- which sort of carries inherent risks to consumers if not regulated. So we're very encouraged by what we are seeing. Those of you who have been on calls with us before know that I've been expecting this for quite some time. So I think it was inevitable. I think it is going to act to constrain some other cross-border trades, particularly the cross-border trade which is not organized and not compliant with Chinese regulations, whether that be from an ingredient, quality or labeling perspective."
1002291,329825546,966025,"Mead Johnson Nutrition Company, Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","And just a quick follow-up and last one. Regarding infant milk, the imported range. I understand the benefits, and you launched it in December last year and obviously doing well, 45% of your sales. But what are the other price point, Kasper? I mean, when",84,"And just a quick follow-up and last one. Regarding infant milk, the imported range. I understand the benefits, and you launched it in December last year and obviously doing well, 45% of your sales. But what are the other price point, Kasper? I mean, when I see a RMB 275 for Enfamil, it looks pricey compared to a lot of our imported products there. Is that an issue? And does that price may need to come down in the future? And that's all."
1002291,329825546,966025,"Mead Johnson Nutrition Company, Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Well, you're quite right that it is priced above many other importers -- imported products, but I think it speaks to the strength of our brand equity in China. And I think the fact that we are able to grow that product line so strongly, I think, supports",90,"Well, you're quite right that it is priced above many other importers -- imported products, but I think it speaks to the strength of our brand equity in China. And I think the fact that we are able to grow that product line so strongly, I think, supports my assertion that Chinese consumers are fundamentally far more concerned with quality and safety of their nutrition than they are with the cost of it. And if you can give them a premium quality offering, they're willing to pay what it takes."
1002291,329825546,966025,"Mead Johnson Nutrition Company, Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Mead Johnson Nutrition Company","Operator","Our next question comes from the line of Bryan Spillane of Bank of America.",14,"Our next question comes from the line of Bryan Spillane of Bank of America."
1002291,329825546,966025,"Mead Johnson Nutrition Company, Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","Just one question. Can you just give us some sense for -- as you're -- in China specifically, as you've been expanding the distribution of the imported product, just -- is there any pipeline fill? So are you sort of -- the sales growth now a little bit ah",83,"Just one question. Can you just give us some sense for -- as you're -- in China specifically, as you've been expanding the distribution of the imported product, just -- is there any pipeline fill? So are you sort of -- the sales growth now a little bit ahead of consumption because you're filling pipeline? And, I guess, as we kind of model going forward with more new product coming into the market, how should we think about sort of sales versus consumption?"
1002291,329825546,966025,"Mead Johnson Nutrition Company, Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","I think you can assume that it is mostly consumption-based. Most of the distribution build that we experienced happened late in the second and third quarters of last year.",30,"I think you can assume that it is mostly consumption-based. Most of the distribution build that we experienced happened late in the second and third quarters of last year."
1002291,329825546,966025,"Mead Johnson Nutrition Company, Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","So we're seeing -- the sequential improvement you've seen in sales is also reflective of a sequential improvement in consumption as well?",23,"So we're seeing -- the sequential improvement you've seen in sales is also reflective of a sequential improvement in consumption as well?"
1002291,329825546,966025,"Mead Johnson Nutrition Company, Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","We are satisfied it's real, so to speak.",9,"We are satisfied it's real, so to speak."
1002291,329825546,966025,"Mead Johnson Nutrition Company, Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Mead Johnson Nutrition Company","Operator","Our next question comes from the line of John Baumgartner of Wells Fargo.",13,"Our next question comes from the line of John Baumgartner of Wells Fargo."
1002291,329825546,966025,"Mead Johnson Nutrition Company, Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","Kasper, wondering if you can just speak a bit to the competitive environment in North America. Is it your sense that this is also some of the dairy cost deflation being realized? Or is it more maybe just product and innovation-based where you've kind of f",75,"Kasper, wondering if you can just speak a bit to the competitive environment in North America. Is it your sense that this is also some of the dairy cost deflation being realized? Or is it more maybe just product and innovation-based where you've kind of fallen behind?
And then, with your A&P being down for the quarter in Q1, should we expect greater brand support investments coming through to help out volumes as 2016 unfolds?"
1002291,329825546,966025,"Mead Johnson Nutrition Company, Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","I mean, I think we fell a little bit behind on innovation. I think most of you might have listened or read Abbott's earnings call, and I commend them. They've done a great job on their non-GMO line. We are clearly catching up and catching up quite fast in",190,"I mean, I think we fell a little bit behind on innovation. I think most of you might have listened or read Abbott's earnings call, and I commend them. They've done a great job on their non-GMO line. We are clearly catching up and catching up quite fast in that area. And we'll expect to complete the catch-up, so to speak, later in the year. It's the nature of the U.S. market that the market share tends to sort of oscillate. But over time, the 2 biggest players in the marketplace are, in fact, quite stable in their ability to hold onto market share all the time.
We go through periods. We had a very good period in the first half of last year where we gained substantial market share. And then, we gave up some as we exited the year and we are suffering a little bit for that right now. But I'm very confident in our ability to sort of, what we say, restore equilibrium. We've shown again and again that we can do that as the other major player here. So you -- we'll get it back."
1002291,329825546,966025,"Mead Johnson Nutrition Company, Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","And then, are you just seeing any unusual price discounting based on the dairy cost deflation at this point?",19,"And then, are you just seeing any unusual price discounting based on the dairy cost deflation at this point?"
1002291,329825546,966025,"Mead Johnson Nutrition Company, Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","No. I don't see that.",5,"No. I don't see that."
1002291,329825546,966025,"Mead Johnson Nutrition Company, Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Mead Johnson Nutrition Company","Operator","Our next question comes from the line of Jason English of Goldman Sachs.",13,"Our next question comes from the line of Jason English of Goldman Sachs."
1002291,329825546,966025,"Mead Johnson Nutrition Company, Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","I guess, I'll pick up where we just left off on the last question. Kasper, you're sort of describing North America actions forward as more of an innovation. But I think, in prepared remarks, you referenced exploring some remedial pricing actions. Can you",49,"I guess, I'll pick up where we just left off on the last question. Kasper, you're sort of describing North America actions forward as more of an innovation. But I think, in prepared remarks, you referenced exploring some remedial pricing actions. Can you elaborate a little bit around that?"
1002291,329825546,966025,"Mead Johnson Nutrition Company, Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Well, I think we always -- we are always looking to optimize our value equation in every market we compete in. And I do believe that there's probably opportunities to adapt our value equation in the U.S. in a favorable direction. So we'll look at it on a",68,"Well, I think we always -- we are always looking to optimize our value equation in every market we compete in. And I do believe that there's probably opportunities to adapt our value equation in the U.S. in a favorable direction. So we'll look at it on a product-by-product basis and make sure we optimize our pricing. I didn't mean to imply that we imagine pricing going down."
1002291,329825546,966025,"Mead Johnson Nutrition Company, Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","Yes, that's kind of the interpretation I had. So I appreciate the clarification on that.",15,"Yes, that's kind of the interpretation I had. So I appreciate the clarification on that."
1002291,329825546,966025,"Mead Johnson Nutrition Company, Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","I'm sorry. I probably was unclear in my communication then.",11,"I'm sorry. I probably was unclear in my communication then."
1002291,329825546,966025,"Mead Johnson Nutrition Company, Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","Well, no. I think it was sort of vague, which is why I sort of jumped to the bad side of the conclusion.And then, I want to come back to Pablo's question earlier. You're referencing or sort of foreshadowing more regulatory changes on the come. We've obv",134,"Well, no. I think it was sort of vague, which is why I sort of jumped to the bad side of the conclusion.
And then, I want to come back to Pablo's question earlier. You're referencing or sort of foreshadowing more regulatory changes on the come. We've obviously had a lot of regulatory changes in terms of registration, regulatory requirements, duty changes, et cetera. But his -- one of his questions was have you seen an impact yet in terms of the illegitimate trade flow into the market? I was hoping you could expound on that. Have you seen any impact? Or is it still sort of hopeful thinking that more change -- or I believe that more change will be necessary from the government before we can actually start to stymie that flow?"
1002291,329825546,966025,"Mead Johnson Nutrition Company, Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","No. We've seen it. We've seen an impact almost immediately. Let me -- rather than sort of talk about other people's business, let me perhaps talk about my own business. So we've seen an impact on our Hong Kong business. It's clear that checks at the borde",167,"No. We've seen it. We've seen an impact almost immediately. Let me -- rather than sort of talk about other people's business, let me perhaps talk about my own business. So we've seen an impact on our Hong Kong business. It's clear that checks at the border between Hong Kong and mainland China has been tightened quite substantially. And there are now efforts underway to collect duty on products shipped into the free trade zones. It's still somewhat inconsistent with how duty collection and the new regulation is being implemented. The speed of implementation between different ports in China vary quite a bit at the moment as one would expect. But we are definitely seeing, what shall we say, unofficial flows of products becoming more difficult.
Now that, of course, is an opportunity for the products that we bring into China in a more orderly fashion. So we are also seeing a corresponding benefit to our fully-imported line, and that's definitely helping the growth of that line."
1002291,329825546,966025,"Mead Johnson Nutrition Company, Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","I'm sorry. Nova, we have time for one more call. So this next one is the final one.",19,"I'm sorry. Nova, we have time for one more call. So this next one is the final one."
1002291,329825546,966025,"Mead Johnson Nutrition Company, Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Mead Johnson Nutrition Company","Operator","Our final question comes from the line of Eric Katzman of Deutsche Bank.",13,"Our final question comes from the line of Eric Katzman of Deutsche Bank."
1002291,329825546,966025,"Mead Johnson Nutrition Company, Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","This is Mario Contreras on for Eric. I wanted to ask about Venezuela. Obviously, a number of your CPG peers have de-consolidated their business there. So I wanted to ask if you could quantify the potential EPS risk if you guys were to have to do the same?",72,"This is Mario Contreras on for Eric. I wanted to ask about Venezuela. Obviously, a number of your CPG peers have de-consolidated their business there. So I wanted to ask if you could quantify the potential EPS risk if you guys were to have to do the same?
And then, maybe that aside, shall we anticipate similar top line headwinds for the next few quarters just in terms of the reduced shipments?"
1002291,329825546,966025,"Mead Johnson Nutrition Company, Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","First of all, let me say that in all the non-GAAP guidance as well as the sales guidance that we have given you, we have taken into account deterioration of Venezuela. So that's very important to note.If you look at it from -- and the question on de-con",138,"First of all, let me say that in all the non-GAAP guidance as well as the sales guidance that we have given you, we have taken into account deterioration of Venezuela. So that's very important to note.
If you look at it from -- and the question on de-consolidation, I think we still see opportunities there, as Kasper indicated going forward, right? We are in discussions with the government to see what type of actions we could take. We had some shipments, but very, very small in the first quarter. And I think we have -- we see, for the near future, still an opportunity to further develop the business back to where it was at a certain point of time. So that's the reason why we don't want to consolidate -- de-consolidate at this point of time."
1002291,329825546,966025,"Mead Johnson Nutrition Company, Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","But is there any way that you could quantify the risk if you were to be in that situation? Or is it just premature to do that?",27,"But is there any way that you could quantify the risk if you were to be in that situation? Or is it just premature to do that?"
1002291,329825546,966025,"Mead Johnson Nutrition Company, Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","No. I mean, I think if you look at the impairment, from the balance sheet perspective, the monetary and the nonmonetary assets, clearly, I think the -- we took the majority of the risk out of the balance sheet, that's one.From an operational point of vi",60,"No. I mean, I think if you look at the impairment, from the balance sheet perspective, the monetary and the nonmonetary assets, clearly, I think the -- we took the majority of the risk out of the balance sheet, that's one.
From an operational point of view, I think I see limited risk that could impact our EPS going forward."
1002291,329825546,966025,"Mead Johnson Nutrition Company, Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Maybe in closing, Nova, just before we close the call, let me take the opportunity just to clarify the ambiguous statement I made on pricing in the U.S. We, in fact, have announced that we have taken selected price increases on some product lines already,",81,"Maybe in closing, Nova, just before we close the call, let me take the opportunity just to clarify the ambiguous statement I made on pricing in the U.S. We, in fact, have announced that we have taken selected price increases on some product lines already, which will be effective later this quarter. So I apologize. I was not clear about that.
So with that, I think we'll sign off for today. And thank you very much for joining the call. Kathy?"
1002291,329825546,966025,"Mead Johnson Nutrition Company, Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","That's it. Thank you very much for participating in our first quarter conference call. Operator, I'll leave you to close out the call.",24,"That's it. Thank you very much for participating in our first quarter conference call. Operator, I'll leave you to close out the call."
1002291,329825546,966025,"Mead Johnson Nutrition Company, Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Mead Johnson Nutrition Company","Operator","This concludes the presentation. You may now disconnect. Everyone, have a wonderful day.",13,"This concludes the presentation. You may now disconnect. Everyone, have a wonderful day."
1002291,329825546,966207,"Mead Johnson Nutrition Company, Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Mead Johnson Nutrition Company","Operator","Good day, ladies and gentlemen, and welcome to the Mead Johnson Nutrition First Quarter 2016 Earnings Conference Call. My name is Nova, and I'll be your coordinator for today. [Operator Instructions] As a reminder, this conference is being recorded for re",61,"Good day, ladies and gentlemen, and welcome to the Mead Johnson Nutrition First Quarter 2016 Earnings Conference Call. My name is Nova, and I'll be your coordinator for today. [Operator Instructions] As a reminder, this conference is being recorded for replay purposes.
I would now like to turn the conference over to Kathy MacDonald, Vice President, Investor Relations. Please proceed, Kathy."
1002291,329825546,966207,"Mead Johnson Nutrition Company, Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Thank you, Nova. Good morning and thank you for joining Mead Johnson's First Quarter 2016 Conference Call. With me today are Kasper Jakobsen, our Chief Executive Officer; and Michel Cup, our Chief Financial Officer.Earlier today, we issued our earnings",304,"Thank you, Nova. Good morning and thank you for joining Mead Johnson's First Quarter 2016 Conference Call. With me today are Kasper Jakobsen, our Chief Executive Officer; and Michel Cup, our Chief Financial Officer.
Earlier today, we issued our earnings release and financial reference slides, which are available on our website.
As we start, let me remind everyone that our comments will include forward-looking statements about our future results, including statements about our financial prospects and projection, commodity costs, currency fluctuations, pricing, taxes, capital spending, depreciation and amortization, new product launches, product quality, other growth initiatives and market conditions that constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. A more detailed explanation of our forward-looking statements will appear in the materials posted on our website in connection with today's conference call.
Keep in mind that our actual results may differ materially from expectations as of today due to various factors, including those listed in our annual reports on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K, in each case as filed with or furnished to the Securities and Exchange Commission and our earnings release issued this morning, all of which are available upon request or on meadjohnson.com.
Today's comments will include discussion of non-GAAP financial measures. A reconciliation of these measures to comparable GAAP measures appear in the morning's earnings release posted on our website.
In addition, any forward-looking statements represent our estimates only as of today and should not be relied upon as representing our estimates as of any subsequent dates. While we may elect to update forward-looking statements at some point in the future, we specifically disclaim any obligation to do so, even if our estimates change.
I will now turn the call over to Kasper."
1002291,329825546,966207,"Mead Johnson Nutrition Company, Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Thank you, Kathy, and good morning to all of you. Thank you for joining our call. Let me begin by summarizing our first quarter performance before I then expand on the headlines with additional detail from each of our reporting segments. My comments will",2687,"Thank you, Kathy, and good morning to all of you. Thank you for joining our call. Let me begin by summarizing our first quarter performance before I then expand on the headlines with additional detail from each of our reporting segments. My comments will focus on strategy and top line performance. Michel will then follow-up with additional financial analysis and elaborate on profitability and cash flow.
Except where I note otherwise, I'll be referring to non-GAAP results.
At our Investor Day in October of last year, we laid out a 3-year plan for value creation. We know that at the time that 2016 would be a year of transition.
During our year-end earnings call, I identified 3 key milestones we've used to monitor our progress against this plan. Firstly, a return to constant dollar sales growth, with the first step being sequential sales growth from fourth quarter 2015 to first quarter 2016. Well, today, we're announcing constant dollar sales in the first quarter rose 1.5% above the prior quarter.
Secondly, we said we'd deliver on our first year commitments to reduce our overall operating expense base. And in the first quarter, our Fuel for Growth initiative delivered $20 million in expense reductions versus the prior year's first quarter, and we are well on our way to achieve our annual savings targets.
Thirdly, and finally, we said we'd invest a portion of our operating expense savings to fund key growth initiatives, both above and below the net sales line. In the first quarter, we continued to make strong investments in support of our strategy, especially in China. I'll expand on this a little later this morning.
Turning now to our first quarter 2016 results. First quarter sales came in as expected at $962 million. As anticipated, this represented a sequential improvement in constant dollars over our fourth quarter 2015 number. This was our second successive quarter of sequential improvement in our underlying business following the difficult second and third quarters of '15.
Also, as anticipated, our financial results were adversely impacted by currency movements to the tune of 600 basis points. Compared to the same quarter of prior year's, sales were 6% lower in constant dollars, driven by 8% lower volume, while price contributed 2 percentage points of growth. The unfavorable year-over-year comparison was mainly driven by tough base comparisons in our 2 largest markets and affecting the quarter itself are significantly reduced shipments to Venezuela.
Given the large adverse currency impact, I'm pleased with the company's continued earnings power. Gross margin for the quarter remained slightly better than 64% and our EBIT margin was above 25% as our cost reduction initiatives began to take hold.
Investment in advertising and promotion represented 15.8% of sales for the quarter. This was similar to the level seen through the second half of 2015.
Non-GAAP earnings per share for the quarter were $0.87. Michel will discuss how the most recent devaluation in Venezuela impacted our GAAP earnings.
Elaborating on the sequential improvement in sales against the prior quarter, improvements in Asia and Latin America were key drivers of growth. I know you're all watching our performance in China closely. So I want to let you know that, sequentially, we saw high single-digit percentage improvement in constant dollar sales in the world's biggest market.
Simultaneously, we saw weaker sequential performance in our North America/Europe segment. I will expand on this in just a moment.
Let me now briefly discuss progress against some of our major value-creating strategic initiatives, and let me begin with our growth initiatives before I then address cost reductions and investment optimization.
As you know, last year, we began the expansion and transformation of our China brand portfolio to allow us to better meet consumer needs and participate in growing market segments and channels. In late March, we announced the immediate introduction of Enfinitas, a best-in-class premium brand, into the China market. I'll return to this topic later.
In China, we are also making good progress with our Enfamil branded line of fully-imported products. And as we closed the quarter, these accounted for fully 45% of our sales in mainland China.
Outside of China, in Southeast Asia and Latin America, we continued investment in our Enfamil franchise, promoting the benefits of our new plastics packaging and refill system. This is the same system many of you would know from retailer sales here in the United States.
And domestically, in the United States, we are continuing to invest in our liquids portfolio, a category segment where we've historically underperformed. Our objective is to secure our fair share of this highly-profitable market segment.
Our determination to establish a segment for nutritionally-fortified toddler milks in North America is also undiminished. Enfagrow remains a critical part of our growth strategy, and we remain excited about its potential.
Still in the United States, we had begun a test to see how we can leverage big data analysis and our substantial database capability to more precisely target consumers with relevant products and messages. To test this, we've introduced Enfamil Enspire, a new product deploying the same science used in our China Enfinitas products, into limited retail distribution. We anticipate learning a great deal from this test, and the initiative demonstrates our commitment to innovating our business model over time.
Let me now turn to our effort to optimize our expense base. Our Fuel for Growth initiative is essential to our ability to sustain investments in growth, while generating shareholder value through EPS growth over time.
In the first quarter, we began to see the impact. We aim to reduce non-A&P operating expenses by at least $120 million over a 3-year period. We are making good progress against this target. And in the first quarter, reported SG&A expenses alone was 16% lower than a year earlier.
We also continue to evaluate opportunities to accelerate or enhance our cost reduction plan. During the coming quarter, we anticipate making progress in our review of advertising and promotion expenditure and other investments in demand creation. We believe new approaches to media and the ongoing conversion to digital will allow for greater efficiency of spend in the mid to long-term. But given our substantial investment in new product introductions, we do not expect this initiative to translate into lower A&P percentages towards the end of this year.
I'll now discuss in more detail the performance of each of our reporting segments, beginning with the North America/Europe segment. Overall, sales in this segment were less strong in the first quarter on both a sequential and year-over-year basis. Measured against the same quarter of 2015, constant dollar sales were weaker by 1% from volume and foreign exchange represented an additional headwind of 2 percentage points.
The start to the year in our U.S. business was affected by market share losses from the highs we saw in the middle of 2015. On a positive note, we believe the strengthening labor market and workforce participation rates have caused a rise in breastfeeding rates to level off over the last 4 months or so. We are, of course, very focused on what we can control and we are constructing remedial plans to strengthen our market share in the United States, including through pricing actions.
In Europe and Canada, I'm delighted to report that we are already enjoying record-high market shares. As a consequence, we are seeing strong growth both sequentially and year-over-year. In both geographies, we are executing our strategies extremely well, demonstrating that, when we do so, we can grow our business even in relatively mature markets.
Let me now turn to Latin America. In constant dollars and excluding the impact of Venezuela, Latin America grows over the prior quarter and was 7% higher compared to a year ago. However, when including the impact of suspended shipments to Venezuela, constant dollar sales were lower by 6%. Foreign exchange represented an additional significant headwind of 16%. An improved pricing of 7% was insufficient to fully offset this impact on reported sales. Across the whole region, we are seeing economies impacted by weaker commodity prices and, in several cases, political uncertainty.
Though both countries are still recovering from currency depreciations, stronger business performance in Mexico and Colombia helped somewhat mitigate the impact of economic recessions in Brazil and Venezuela. We've previously described how we've chosen to make only limited shipments to Venezuela as we are constrained by our limited access locally to hard currency. We are very keen to help alleviate the acute product shortage in Venezuela and restore supply, and we're working with the government to find a solution. But until one is found, we expect very limited sales in Venezuela.
Brazil is going through a well-prophesied economic recession. The impact on consumer and business confidence is manifesting itself in softer demand for discretionary items. And we are feeling the impact most acutely within our children's category. Our infant formula sales are holding up relatively better. We remain excited about the country's long-term potential, but we do not anticipate a substantial improvement within this year.
As mentioned, we enjoyed a strong start to the year in Mexico, where our milk modifier brands recovered somewhat from the weakness in mid-2015. Our infant formula and toddler business gained market share in the first quarter as new packaging and revised messaging behind an improved formulation resonated to consumers.
Though I recognize we can't quantify the extent to which Colombia may be benefiting from informal parallel exports to neighboring Venezuela, we believe increased market share is the main driver of very strong double-digit sales growth there.
And finally, our business in the Caribbean and Central America grew by high single-digits over the prior year's same quarter. In most of these markets, we transacted dollars and, hence, the region remains a stabilizing factor in an inherently volatile segment.
I'll turn now to our Asia segment. As mentioned in my global overview, we saw a strong single-digit sequential improvement in constant dollar sales in Asia. China grew faster than the segment as a whole, but Thailand and Malaysia also improved over the previous quarter.
Despite our strong sequential improvement, year-over-year sales comparison was unfavorable. Volume was lower by 9%, mainly reflecting the fact that we've still not returned to the year ago sales levels in China and Hong Kong. Price was in line with the prior year, with improved product mix offsetting the impact of added promotional activity.
In Thailand and Malaysia, the sequential comparison was helped by non-repeating retail inventory reductions referenced in our fourth quarter earnings call. 
Malaysian consumers appear to be adjusting spending habits in response to the VAT introduction and currency-related inflation of 2015. Consequently, we expect more stable performance from Malaysia going forward.
The Thai economy remains relatively weaker, and we're a little more cautious about a rapid turnaround there. We are maintaining investment levels and, in fact, seeking to strengthen our position in anticipation of an eventual recovery in economic growth. Inherently, Thailand is a great market for us and we have a very experienced team on the ground. Longer-term, I'm confident in our prospects there.
In Vietnam, we have seen opportunities to improve our execution. The market somewhat underperformed against our expectations in 2015 and in the most recent quarter, but our team is focused on the right issues and putting in place plans to strengthen performance in the second half of the year.
Because our businesses in Indonesia is relatively small, we don't often talk about our performance in this large market. However, over the last 12 months, we've developed a more focused geographic strategy for the country, and our improved focus appear to be helping. Sales grew strongly in the first quarter, both sequentially and year-over-year. It's clear that we would like to build a bigger business in this high-potential market, but we remain realistic about our scale and the challenges to realizing our ambition organically.
Let me close on China. The China market continues to evolve quickly and we are still assessing the full impact of recent changes to duty structure and regulatory frameworks. Over the last year or so, I have repeatedly stated my belief that regulatory changes were put in China. And more evenhanded duty structure is, in my mind, likely to be just the first of several important changes being driven by the Chinese government. The focus remains on consumer safety. And the requirement that all infant formula and children's products, regardless of sales channel, be registered in China is a key part of the government's efforts to safeguard the consumer. We're supportive of these efforts to protect consumers by ensuring products and labels meet Chinese standards, regardless of how and from where they are sold.
Before I discuss the performance of our China business, I want to remind you of the broad China strategy we laid out for you more than a year ago. We promised we would reshape our product portfolio to better satisfy consumer's preference for imported premium products. And once we have the right portfolio, we will then commit the resources to strengthen our performance in higher growth sales channels.
Since then, we have introduced a fully-imported line of our Enfamil branded products. And after the close of the first quarter, we introduced a new product offering into the highest priced market segment. Enfinitas, as we have aptly called this new offering, contains our best science and was developed incorporating understanding gained from our extensive studies of breast milk, nutrition and metabolism.
In addition to our long-proven, industry-leading levels of DHA and ARA -- AHA, the products contained boosted levels of lactoferrin and milk fat globular membranes, ingredients closely associated with both neuro and immune system development. Though this new technology is costly, we believe Chinese parents would once again confirm that they're willing to invest in their child's future.
We now have the right portfolio to win with both consumers and retailers. Helped by our recent introductions, baby stores became our largest sales channel in the latest quarter, and both this channel and the e-commerce channel grew in excess of 20% over the same quarter of last year. And despite cannibalization from our imported line, sales of our locally-manufactured product line appeared to have stabilized in response to stronger defensive stops and increased promotional competitiveness.
I know you all share my interest in the price promotional environment in China. Let me give you my perspective. It's clear to us that some competitors push sales aggressively in the fourth quarter of 2015. And as a result, I'm now providing additional discounts to clear inventory overhang from distributors and retailers. Though we will, of course, act to protect our market share, we take a different approach. We simply do not believe Chinese consumers are significantly motivated by lower prices, even though retailers may well be. Rather, Chinese consumers are amongst the world's most discerning and they continue to show a willingness to pay for superior quality and nutrition. This is evidenced by the continued shift towards higher-priced segments.
Our view is supported by the fact that, sequentially, price, in fact, was a positive contributor to our growth in China in the latest quarter, the positive effect of product mix more than offsetting the effect of promotional spend.
In response to the successful execution of our strategy, our performance in China improved substantially over the prior quarter, with constant dollar sales, as mentioned, showing a high single-digit percentage improvement.
Commenting now on our outlook for the full year 2016. I reiterate that company guidance for modest constant dollar sales growth between 0% and 2%. Based on current exchange rate assumptions, we expect this to translate into an unfavorable sales comparison in U.S. dollars of between 4% and 6%.
As advised in our January call, we expect to deliver 9% to 12% growth in constant dollar EPS. Based on this, we also reiterate our guidance for full year non-GAAP EPS between $3.48 and $3.60.
I'll now hand over to Michel who will provide additional details on our financial performance. I will then return with a few summary remarks before we take your questions. Michel, over to you."
1002291,329825546,966207,"Mead Johnson Nutrition Company, Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Thank you, Kasper, and good morning, everyone. Today, I will discuss the company's first quarter 2016 financial results. I will then briefly highlight EBIT results by segment and wrap up with a cash flow analysis and summary of our full year guidance.Un",2102,"Thank you, Kasper, and good morning, everyone. Today, I will discuss the company's first quarter 2016 financial results. I will then briefly highlight EBIT results by segment and wrap up with a cash flow analysis and summary of our full year guidance.
Unless otherwise noted, my comments will be on the non-GAAP financial results. References to currency impacts or the effects of currency fluctuations generally refer to their impact on the translation of local currency, financial statement into the United States dollars.
Let me start with sales. As shown on Slide 3, on a sequential basis, from the fourth quarter of 2015, constant dollar sales grew by 1.5%. Nearly all of our large markets grew sequentially and, most notably, China. When you review the 5-quarter sequential trend, sales were strongest in the first quarter of 2015 and started to decline in the second quarter. As 2015 progressed, we invested to protect competitiveness, launched new products and were able to stabilize sales in the fourth quarter.
In the first quarter, we continued to invest. We rolled out new innovation and selectively increased prices in some markets to compensate for the continued currency devaluations. Consistent with my stated expectation last quarter, I would like to remind you that the second quarter of 2016 year-over-year comparison will continue to be tough on a constant dollar basis, although we should see an improvement in the second quarter performance.
First quarter sales on a reported basis were 12% below and constant dollar sales were 6% below the prior year quarter. Adverse foreign exchange rate contributed a 600 basis point decline.
Slide 4 summarizes the impact of foreign exchange on sales and EPS. The U.S. dollar continued to be strong in the first quarter of 2016 and its effect on the translation of local currency negatively impacted all reporting segments. The first quarter decline of 6% was the same percentage as both the third and the fourth quarter of 2015. Half of the negative currency impact in the first quarter were from the Chinese renminbi, the Mexican peso and the Argentinian peso. The balance of the adverse foreign exchange impact was widespread across the regions. We continue to expect an approximately 6% adverse foreign exchange impact on sales for the full year 2016. I will address the foreign exchange impact in the EPS guidance section as well.
I will now move to factors that impact our gross margins on Slide 5. Gross margins was 64.1% in the first quarter of 2016. This was a similar margin percentage to the first quarter of 2015 and in line with our expectations for the full year.
Sales impacted from positive mix and pricing was affected by higher trade investments resulting in a slight gross margin decline. Manufacturing conversion cost negatively impacted margin due to lower volume absorption and higher cost of innovation and inflation.
Low dairy cost was the largest benefit to our gross margin in quarter 1 and more than offset higher conversion cost and other commodities increases. We expect to see dairy benefits in the second quarter.
As you can see, we continued to deliver productivity savings within our cost of goods sold. Also Biostime has already secured commitments for nearly 90% of our 2016 productivity goals.
Moving to operating expenses, I will start with advertising and promotion investments on Slide 6. A&P was 15.8% of sales in the first quarter compared to 13.2% in the prior year quarter. This was an increase of 11% on a constant dollar basis. The incremental investments were mainly to support our key China initiatives.
Historically, the company had a lower A&P spending in the first quarter of the year. Since our China fully-imported product line was launched in the middle of last year, we continued strong investments in the first quarter of 2016, especially fertilization, digital and e-commerce media. In addition, we supported the investment of new innovation rollout in selected markets.
With the April 2016 launch of our super high premium products, we expect A&P as a percentage of sales to be high in the second quarter. As you can see on this slide, when we launched the China fully-imported product in the second quarter of 2015, our total A&P as a percentage of sales went up significantly. We can expect that in the second quarter of 2016 as well.
Turning to Slide 7. The increase in A&P was offset by reduction in selling, general and administrative expenses. This is in line with the strategy we outlined at Investor Day, that 2016 will be a year of transition with a focus on investments.
On a constant dollar basis, SG&A was 10% lower than the first quarter of 2015. Approximately $20 million of the SG&A reduction is attributed to our Fuel for Growth initiative, which I will address on the next slide.
Slide 8 shows that our Fuel for Growth initiative had a strong start in the first quarter. On a constant dollar basis, we delivered cost reduction of 10% for the first quarter of 2015, especially in our support functions. While we have made some reductions in the region offices, about 3/4 of the reduction was from corporate headquarter functions, which decreased by approximately 30% on a like-for-like constant currency basis. Of the corporate headquarter reductions, more than half was from outside services, and the balance were personnel-related. To-date, we have secured over 90% of our planned 2016 reductions, and we are ahead of schedule. At the same time, we constrained sales forces and distribution spending to remain relatively flat to prior year on a constant dollar basis.
Turning now to Slide 9 for a discussion of EBIT. Let me start this analysis per segment. In the first quarter, Asia delivered an EBIT of $169 million, a decrease of 22% on a constant dollar basis. An incremental 5% decrease came from the adverse foreign exchange impact, largely driven from the Chinese renminbi, Thai baht and the Malaysian ringgit. The Asia EBIT margin, at 33.8%, improved 390 basis points compared to the fourth quarter of 2015, yet was 600 basis points lower than the first quarter of 2015. The main year-over-year drivers were lower sales and increased channel investment and promotional activities.
Investment continued throughout the Asian region to support our innovation launches. The most significant investment were in China, including competitive price promotions on the locally-manufactured products and investment for the fully-imported product line.
Latin America delivered an EBIT of $41 million in the first quarter, a decrease of 11% on a constant dollar basis. The EBIT decline was due to lower sales mainly in Venezuela, yet the decline was somewhat offset by lower A&P investments. Excluding the impact of the Venezuelan business, the Latin America EBIT on a constant dollar basis increased 22% compared to prior year.
For the segment, adverse foreign exchange impacted EBIT by 18%, largely from the Mexican peso. On a reported basis, EBIT was 29% lower than prior year.
The Latin America EBIT margin was 25.5% for the first quarter of 2016 compared to 28% for the same quarter last year. The 250 basis points decline was from lower sales, mainly Venezuela, somewhat offset by lower A&P and sales force spending.
For the first quarter, North America and Europe EBIT was $82 million, an increase of 9% on a constant dollar basis. The EBIT margin of 27.2% was 190 basis points better than the prior year quarter. Despite lower sales, gross margin remained strong from the dairy benefit, with an operating expenses reduction in the SG&A was selectively invested to support new product innovations, while a portion of the savings drove higher EBIT margins.
As mentioned on the Fuel for Growth slide, corporate and other delivered significant benefit to EBIT. For the total company, the first quarter EBIT of $244 million was 10% below the prior year quarter on a constant dollar basis. Adverse exchange nearly doubled the impact, resulting in a reported EBIT down 19%. The decline was due to lower sales somewhat offset by improved operating expenses.
The EBIT margin of 25.4% of sales was 200 basis points lower than prior year quarter. The first quarter 2015 EBIT of 27.4% was high due to underspending on A&P. As 2015 progressed, A&P increased and annual 2015 EBIT came in at 24.1%.
I will now address our financial results from EBIT to net income on Slide 10. The increase in interest expense reflects the full quarterly impact of the November 2015 1.5 billion notes. The significant portion of the proceeds from the notes were used to finance the accelerated share repurchase program. As a reminder, 10.7 million of shares of stock were received in the fourth quarter. The balance of shares will be delivered at the end of the agreement, which is scheduled to conclude in the second quarter of 2016.
Our non-GAAP effective tax rate or ETR was 23.2% for the first quarter of 2016 compared to 22.5% in the prior year quarter. The first quarter 2015 rate was lower as a result of the more favorable geographic earnings mix that did not prevail for the full year. Non-GAAP EPS for the first quarter was $0.87.
Let me summarize our financial results by addressing the changes to EPS on Slide 11. In the first quarter, non-GAAP EPS declined $0.12 on a constant dollar basis versus prior year quarter. Sales and related gross profit negatively impacted EPS by $0.16. The increase in A&P was offset by Fuel for Growth savings. The ASR delivered $0.03 benefit net of higher interest expense. Half of the $0.12 decline in non-GAAP EPS on a constant dollar was a result of the temporary suspension of shipments to Venezuela in the first quarter of 2016. Foreign exchange adversely impact EPS by $0.10.
Let me address specified items. Since we took a significant specified charge in the first quarter, let me briefly explain what drove the Venezuelan change noted on Slide 12.
In March 2016, the Venezuelan government changed the exchange rate system from a 3 to a 2-tier structure. There were 2 significant impacts to our business. First, the SICAD rate was eliminated. This was the rate we previously used to translate our net monetary assets of our Venezuelan subsidiary. As a result, we adopted the floating rate now called DICOM. For reference only, the most recent SICAD rate was 13.5 and the DICOM rate at the end of the quarter was approximately 273 and continued to devalue in April. The remeasurement impact from adopting the DICOM rate was a $32 million loss impacting monetary assets.
Second, as the DICOM rate also impacts the translation of our local earnings to U.S. dollar, our future results of Venezuela business are impacted. This triggered an impairment review of Venezuelan's long-lived assets. Following that process, we concluded there was $46 million impairment of our long-lived assets.
Due to the Venezuela change, Fuel for Growth and pension remeasurement charges specified item for the first quarter was $0.48 per share. Including these specified items, GAAP EPS was $0.39.
Turning to a high-level overview of cash movement. On Slide 13, the cash balance of $1.7 billion as of March was similar to the year-end balance. Cash from operating activities was lower than the prior year period. Cash flows reflected lower sales and the negative impact from other working capital. An unusual item on this chart is the sizable foreign exchange impact on cash. This was mainly due to the adoption of the new exchange rate and the remeasurement of our monetary assets in Venezuela.
In summary, the cash generated from operation this quarter was used to pay dividends and capital commitments. For the full year, our capital spending goal remains about 4% of sales.
To summarize our annual guidance on Slide 14, we expect full year 2015 constant dollar growth in the range of 0% to 2%. We continue to anticipate tough comparisons for the first half year 2016 and we do not expect to report positive revenue growth over the same quarter of prior year until the second half 2016.
We reaffirm our 2016 non-GAAP EPS guidance in the range of $3.48 to $3.60. Primarily due to the first quarter charges rate to Venezuela, full year specified items are now expected to be $0.57 per share. Therefore, our updated 2016 GAAP EPS is expected in the range of $2.91 to $3.03. GAAP EPS will change as a result of future mark-to-market pension adjustments, which we cannot estimate at this time.
This concludes my discussion on our first quarter financial results. Thanks, again, for your time this morning, and I will now turn the call back to Kasper."
1002291,329825546,966207,"Mead Johnson Nutrition Company, Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Thank you, Michel. Before we take your questions, let me briefly summarize our key messages.Firstly, we are satisfied with the sequential improvement in constant dollar revenue. Secondly, we are pleased with the improvement we're seeing in China and we",218,"Thank you, Michel. Before we take your questions, let me briefly summarize our key messages.
Firstly, we are satisfied with the sequential improvement in constant dollar revenue. Secondly, we are pleased with the improvement we're seeing in China and we remain focused on the successful execution of our previously outlined China strategy. Thirdly, we do not underestimate the challenges we are facing in an uncertain global economic environment. Despite these challenges, we believe the balance within our global portfolio will allow us to complete 2016, which we've often referred to as a year of transition, as planned.
We are, therefore, reiterating our prior guidance for modest full year constant dollar sales growth between 0% and 2%. We are confident that sequential constant dollar sales for the first half of 2016 will be stronger than the second half of prior year. And within 2016, sales in the second 6-month period will be stronger than the first half of the year.
For the year, we expect foreign exchange to adversely affect translation into our reporting currency by 600 basis points. We also are confirming unchanged non-GAAP EPS guidance of $3.48 to $3.60.
I'll now hand the call over to our operator, Nova, who will assist us in opening the lines for questions. Nova, I'll hand the call back to you."
1002291,329825546,966207,"Mead Johnson Nutrition Company, Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Mead Johnson Nutrition Company","Operator","[Operator Instructions] Our first question comes from the line of David Driscoll of Citi.",14,"[Operator Instructions] Our first question comes from the line of David Driscoll of Citi."
1002291,329825546,966207,"Mead Johnson Nutrition Company, Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","I wanted to ask about the super premium product launches starting with the China Enfinitas product and just hear a little bit more about the reception from the mom and baby store's shelf space. Is it incremental to the existing shelf space you have in the",129,"I wanted to ask about the super premium product launches starting with the China Enfinitas product and just hear a little bit more about the reception from the mom and baby store's shelf space. Is it incremental to the existing shelf space you have in there? And then, just some comments on kind of what we should expect on the pacing of Enfinitas in China.
And then, kind of fully separately, but still on super premium, just give us a little bit more on Enspire and what's the role of this product? You said like limited launch and kind of a test. And I suppose I haven't heard you ever say something like that before. So I'd just like to hear what role that plays in the U.S."
1002291,329825546,966207,"Mead Johnson Nutrition Company, Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Well, let me just begin by saying that the introduction in China is really proceeding as we speak, David. So it's very early days here. We -- our first initial shipments did not happen until the middle of this month, in fact. But reception from retailers",331,"Well, let me just begin by saying that the introduction in China is really proceeding as we speak, David. So it's very early days here. We -- our first initial shipments did not happen until the middle of this month, in fact. But reception from retailers has been very favorable and we've not had any issues getting the required additional shelf space, be that in baby stores or in other retail channels in China. So I would say we're encouraged by what we see and the engagement we are having. The early engagement we are having with consumers online is also favorable in China.
I don't know that we want to get into giving you forecast and expectations by product line. So I don't think I'm prepared to go there. But as you know, it's a project that we've been working on for quite some time. Many of you would probably say too long. So obviously, we feel like we are putting our best foot forward, and we are optimistic about the prospects.
In the U.S., it's a little bit different. I think what we are doing in the U.S. is really experimenting with a different business model. We believe that, based on our increased mastery of sort of big data analysis and our own database and our knowledge of the U.S. consumers, we are able to quite precisely target consumers in the market that might be more likely to be interested in a premium nutrition proposition and willing to pay the price that goes with that. So we've begun a test initially with very limited retail distribution. I think we'll assess how that test proceeds through the year and then we'll decide whether we will expand distribution from where we currently are. But the science used in the 2 products is identical. There are some minor variations that are required by different regulations and different quality standards needed in the 2 markets, but the base science is essentially the same."
1002291,329825546,966207,"Mead Johnson Nutrition Company, Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Mead Johnson Nutrition Company","Operator","Our next question comes from the line of Matthew Grainger of Morgan Stanley.",13,"Our next question comes from the line of Matthew Grainger of Morgan Stanley."
1002291,329825546,966207,"Mead Johnson Nutrition Company, Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","Kasper and Michel, I just wanted to ask about Enfinitas as well. Could you talk a bit more about the formulation and its uniqueness relative to what's currently on the market? Is the value proposition here driven by the ingredients or is it really the pro",103,"Kasper and Michel, I just wanted to ask about Enfinitas as well. Could you talk a bit more about the formulation and its uniqueness relative to what's currently on the market? Is the value proposition here driven by the ingredients or is it really the proprietary combination? And, I guess, what I'm curious is how quickly do you think fast followers can try and incorporate similar benefits into their products?
And just related, from a margin perspective, given the price point, is the expectation that once you hit scale, that margins can ultimately be accretive to your overall Asia region or China business?"
1002291,329825546,966207,"Mead Johnson Nutrition Company, Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Yes. I mean, I think the whole product bundle is quite unique. We -- as you know, we have a large ongoing effort underway within the company to continually enhance our understanding of breast milk in particular and how we can incorporate the latest scienc",265,"Yes. I mean, I think the whole product bundle is quite unique. We -- as you know, we have a large ongoing effort underway within the company to continually enhance our understanding of breast milk in particular and how we can incorporate the latest science associated with breast milk in enhanced form, in some cases, into formulas. We've acted on some of that. We have raised the levels, as I mentioned, of lactoferrin, which is naturally present in very low levels in all -- in most formulas, I shouldn't say all, but most. And we have incorporated elevated levels as well, significantly elevated levels of milk fat globular membranes, which is just what it says it is. Both of these ingredients are sort of closely associated with physiological development, either neuro or immune system development of -- for infants. The second ingredient is in somewhat scarce supply in the world. And we believe that though people can talk about it, it will take some time for people to get to the levels we are at. But most importantly, I think it's the understanding of how the ingredients work, and then we've incorporated that into quite unique packaging in the marketplaces where we packed it with our advertising and digital capabilities. So we're excited about it and, I guess, we feel like we've got quite a unique package, which is one of the reasons we've delayed the entry. We wanted to make sure we have the right package.
And I don't know if Michel wants to comment on margins. Do you want to add something, Michel?"
1002291,329825546,966207,"Mead Johnson Nutrition Company, Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Yes. The question on margin accretion. I think, as Kasper said, we are in the process of rolling out and that's our current focus. We are investing in, very strong so, to drive the awareness and have the right level of distribution and to ensure that moms",69,"Yes. The question on margin accretion. I think, as Kasper said, we are in the process of rolling out and that's our current focus. We are investing in, very strong so, to drive the awareness and have the right level of distribution and to ensure that moms enter the cadbury [indiscernible]. So over time, we expect to see the return on these investments, but definitely not at the beginning."
1002291,329825546,966207,"Mead Johnson Nutrition Company, Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Mead Johnson Nutrition Company","Operator","Our next question comes from the line of Rob Moskow of Crdit Suisse.",13,"Our next question comes from the line of Rob Moskow of Crdit Suisse."
1002291,329825546,966207,"Mead Johnson Nutrition Company, Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","A couple of questions about the guidance, first on FX. I think last quarter you called out $0.40 of headwind and I don't think I heard it called out on this call. The revenue guidance hasn't changed for FX and, I guess, I'm a little surprised. Most of you",119,"A couple of questions about the guidance, first on FX. I think last quarter you called out $0.40 of headwind and I don't think I heard it called out on this call. The revenue guidance hasn't changed for FX and, I guess, I'm a little surprised. Most of your peers are experiencing lighter headwinds. I just wanted to know what the update is on that.
And then, secondly, your comments about the market in China and inventory kind of -- or efforts to promote away inventory that's on the shelves. Is it pretty much the same kind of conditions you saw in fourth quarter or have things gotten a little worse in first quarter? How would you characterize it?"
1002291,329825546,966207,"Mead Johnson Nutrition Company, Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Let me start with the -- with addressing the inventory situation. I would say that the promotional environment is certainly not getting better. And I think there is a -- it would appear that some people are dealing with the kind of fourth quarter, first q",143,"Let me start with the -- with addressing the inventory situation. I would say that the promotional environment is certainly not getting better. And I think there is a -- it would appear that some people are dealing with the kind of fourth quarter, first quarter dynamic. I'm very happy with where our inventory levels are. And I think we've -- our team on the ground has managed that quite well.
I think what we've said before, which maybe I should have said in response to Matt's question as well, is that we feel pretty good about our ability to sustain the margins in China at or around the same level as they are today as we see sort of the ability of a favorable product mix as having the ability to offset any additional pressure there might be to increase promotional competitiveness."
1002291,329825546,966207,"Mead Johnson Nutrition Company, Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Yes. Let me address the FX question you had. I mean, a couple of points. I think you're aware that we're operating in 50 countries, so 2/3 of our revenue is exposed to foreign currency fluctuations. And as I highlighted also last year, a part of that is h",163,"Yes. Let me address the FX question you had. I mean, a couple of points. I think you're aware that we're operating in 50 countries, so 2/3 of our revenue is exposed to foreign currency fluctuations. And as I highlighted also last year, a part of that is hatched for a certain period.
The second point I would like to make is there is -- although there is an improvement, but you still see a significant fluctuation of some currencies. Just remind you on the Chinese renminbi, mid-April, where you saw a significant change again, and that is impacting our business as we speak. I think you know we've seen in Q1, we delivered our reported sales of decline of 6%, in line with our expectation. So as it stands of today, and if we could lock in the whole year as of today, which we can do, we would see some benefits of a couple of cents, I would say, on EPS."
1002291,329825546,966207,"Mead Johnson Nutrition Company, Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","Okay. But you say part of it was hedged. Did you -- the part that was hedged, is that -- were you leaving some money on the table, so to speak? Did that work against you now?",37,"Okay. But you say part of it was hedged. Did you -- the part that was hedged, is that -- were you leaving some money on the table, so to speak? Did that work against you now?"
1002291,329825546,966207,"Mead Johnson Nutrition Company, Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","No. I mean, when I gave the guidance of $0.40 in January, I included the hedge position that we had at that point of time.",25,"No. I mean, when I gave the guidance of $0.40 in January, I included the hedge position that we had at that point of time."
1002291,329825546,966207,"Mead Johnson Nutrition Company, Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","Okay. So is it still $0.40 or is it different?",10,"Okay. So is it still $0.40 or is it different?"
1002291,329825546,966207,"Mead Johnson Nutrition Company, Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Could you repeat your question?",5,"Could you repeat your question?"
1002291,329825546,966207,"Mead Johnson Nutrition Company, Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","Is the headwind still $0.40 or is it different?",9,"Is the headwind still $0.40 or is it different?"
1002291,329825546,966207,"Mead Johnson Nutrition Company, Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Well, I haven't changed guidance. So I haven't changed guidance. The $0.40 is still included.",15,"Well, I haven't changed guidance. So I haven't changed guidance. The $0.40 is still included."
1002291,329825546,966207,"Mead Johnson Nutrition Company, Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Mead Johnson Nutrition Company","Operator","Our next question comes from the line of Ken Goldman of JP Morgan.",13,"Our next question comes from the line of Ken Goldman of JP Morgan."
1002291,329825546,966207,"Mead Johnson Nutrition Company, Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","This is Josh Levine on for Ken. Just a question actually on Fuel for Growth. You said that it drove about $20 million in the first quarter, which you said was attributed mostly to cutting out certain services and overhead. Both of those sound like, I gues",101,"This is Josh Levine on for Ken. Just a question actually on Fuel for Growth. You said that it drove about $20 million in the first quarter, which you said was attributed mostly to cutting out certain services and overhead. Both of those sound like, I guess like sustainable savings levels. Is it right to assume that level sort of continues through the year? And, I guess -- and obviously, you guided, I guess, to $60 million savings. That would imply, obviously, you would beat that number. I'm just -- I guess, can you just help us on the pacing there?"
1002291,329825546,966207,"Mead Johnson Nutrition Company, Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Yes. I think it's a good question because if you would do your math and, as we announced earlier, we would have $60 million savings this year. If you would take $20 million times 4, you have $80 million. I would put some cautiousness in there. I think the",132,"Yes. I think it's a good question because if you would do your math and, as we announced earlier, we would have $60 million savings this year. If you would take $20 million times 4, you have $80 million. I would put some cautiousness in there. I think there is certain fluctuation, especially if you do quarter-on-quarter comparison, especially in the area of third party services.
Having said that, I'm very encouraged by the fact that we secured 90% of the $60 million, and I indicated that we're ahead of our plan. So -- and as Kasper also indicated, we are continuing going through a review which we -- just talks more about -- by the end of the second quarter on which additional actions we see that we potentially could accelerate."
1002291,329825546,966207,"Mead Johnson Nutrition Company, Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","Got it. And then, just on A&P spending, I guess, you said that it would be one -- 2Q levels will be higher than 1Q, which, I guess, is similar to last year. But just from a year-over-year basis, how is that -- how should we think about that for 2Q?And t",110,"Got it. And then, just on A&P spending, I guess, you said that it would be one -- 2Q levels will be higher than 1Q, which, I guess, is similar to last year. But just from a year-over-year basis, how is that -- how should we think about that for 2Q?
And then, just a larger question, when you typically advertise ahead of product launches, ahead of innovations, but, I guess, how do you think strategically about when you kind of ramp down that spending, right? Just as we think -- sort of when you can let, I guess, the returns on that market investment fall on the bottom line."
1002291,329825546,966207,"Mead Johnson Nutrition Company, Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Well, as Kasper also indicated, that -- don't expect a significant drop in the first half year. We will continue to invest, like I said in my earlier comments, especially in Q2. And you might see some lower A&P expenditures more towards the end of the yea",47,"Well, as Kasper also indicated, that -- don't expect a significant drop in the first half year. We will continue to invest, like I said in my earlier comments, especially in Q2. And you might see some lower A&P expenditures more towards the end of the year."
1002291,329825546,966207,"Mead Johnson Nutrition Company, Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Mead Johnson Nutrition Company","Operator","Our next question comes from the line of Amit Sharma of BMO Capital Markets.",14,"Our next question comes from the line of Amit Sharma of BMO Capital Markets."
1002291,329825546,966207,"Mead Johnson Nutrition Company, Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","Kasper, you talked about baby stores in China are now your biggest or largest channel. Could you just define for us, like, what's the size of the opportunity? And as we become even bigger in that channel, are you fully incorporating the mix benefit of hav",52,"Kasper, you talked about baby stores in China are now your biggest or largest channel. Could you just define for us, like, what's the size of the opportunity? And as we become even bigger in that channel, are you fully incorporating the mix benefit of having a larger presence in that channel?"
1002291,329825546,966207,"Mead Johnson Nutrition Company, Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","I think we're incorporating the benefits. We are certainly thinking about it. As you know, we talked quite a bit about the fact that, last year, we were caught in the second and third quarters with a bit of a mismatch between our product offerings and, fr",191,"I think we're incorporating the benefits. We are certainly thinking about it. As you know, we talked quite a bit about the fact that, last year, we were caught in the second and third quarters with a bit of a mismatch between our product offerings and, frankly speaking, both the consumer preference and the channel preference in China. We've now addressed that. And we feel very good about the product portfolio we have in place now. And we are beginning to see the returns of that. We've seen a pretty quick improvement in our performance in baby stores. We think there are still opportunities to expand distribution over time, and we are doing that in a sort of considered and gradual fashion. And likewise, there are opportunities in e-commerce as well. While we are expanding in those channels and we are growing strongly in those channels, we, just like everybody else, I think are seeing an erosion of sales in the more traditional channels, like supermarkets for instance. But I think we're doing our best to sort of incorporate these things into our overall forecasting, which obviously underpin our guidance."
1002291,329825546,966207,"Mead Johnson Nutrition Company, Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","And is the promotional environment any different in baby channels versus supermarkets?",12,"And is the promotional environment any different in baby channels versus supermarkets?"
1002291,329825546,966207,"Mead Johnson Nutrition Company, Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","No. I wouldn't say so. I think it's fairly consistent.",10,"No. I wouldn't say so. I think it's fairly consistent."
1002291,329825546,966207,"Mead Johnson Nutrition Company, Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Mead Johnson Nutrition Company","Operator","Our next question comes from the line of Pablo Zuanic of Susquehanna Financial Group.",14,"Our next question comes from the line of Pablo Zuanic of Susquehanna Financial Group."
1002291,329825546,966207,"Mead Johnson Nutrition Company, Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","Look, 2 questions. One, when you talk about the sequential improvement in your sales growth in the -- compared to the third quarter and compared to the fourth quarter, how does it compare with the market? I just -- I'm just trying to get an understanding",107,"Look, 2 questions. One, when you talk about the sequential improvement in your sales growth in the -- compared to the third quarter and compared to the fourth quarter, how does it compare with the market? I just -- I'm just trying to get an understanding of how you're growing versus the market. That's the first question.
And the second question, regarding the new regulations. I understand it's difficult to make judgments and some of them are still not clear. But in terms of the changes of the positive list announcement implies for cross-border trade, are you seeing any crackdown or slowdown in terms of parallel imports?"
1002291,329825546,966207,"Mead Johnson Nutrition Company, Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Pablo, I take it your second question is directed particularly at China, is that right?",15,"Pablo, I take it your second question is directed particularly at China, is that right?"
1002291,329825546,966207,"Mead Johnson Nutrition Company, Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","Yes, that's right.",3,"Yes, that's right."
1002291,329825546,966207,"Mead Johnson Nutrition Company, Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Okay. Okay. Well, I think we are satisfied with the progress we are making vis--vis the market outside of the United States. I did highlight in my sort of prepared remarks, Pablo, that we have clearly lost some market share in the United States and...",45,"Okay. Okay. Well, I think we are satisfied with the progress we are making vis--vis the market outside of the United States. I did highlight in my sort of prepared remarks, Pablo, that we have clearly lost some market share in the United States and..."
1002291,329825546,966207,"Mead Johnson Nutrition Company, Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","No. I'm sorry because -- I mean, I don't mean to interrupt, but my question -- both of them are related to China. I'm sorry.",25,"No. I'm sorry because -- I mean, I don't mean to interrupt, but my question -- both of them are related to China. I'm sorry."
1002291,329825546,966207,"Mead Johnson Nutrition Company, Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Both of them are related to China. Okay. We feel that our performance vis--vis the market in China in the first quarter was favorable, vis--vis where we began at the beginning of the quarter.And with regards to the regulatory framework, we welcome t",153,"Both of them are related to China. Okay. We feel that our performance vis--vis the market in China in the first quarter was favorable, vis--vis where we began at the beginning of the quarter.
And with regards to the regulatory framework, we welcome the new set of regulations and we think it's a very positive step by the government to continue to regulate a product category, which is -- which sort of carries inherent risks to consumers if not regulated. So we're very encouraged by what we are seeing. Those of you who have been on calls with us before know that I've been expecting this for quite some time. So I think it was inevitable. I think it is going to act to constrain some other cross-border trades, particularly the cross-border trade which is not organized and not compliant with Chinese regulations, whether that be from an ingredient, quality or labeling perspective."
1002291,329825546,966207,"Mead Johnson Nutrition Company, Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","And just a quick follow-up and last one. Regarding Enfamil, the imported range. I understand the benefits, and you launched it in December last year and obviously doing well, 45% of your sales. But what are the other price point, Kasper? I mean, when I se",83,"And just a quick follow-up and last one. Regarding Enfamil, the imported range. I understand the benefits, and you launched it in December last year and obviously doing well, 45% of your sales. But what are the other price point, Kasper? I mean, when I see a RMB 275 for Enfamil, it looks pricey compared to a lot of our imported products there. Is that an issue? And does that price may need to come down in the future? And that's all."
1002291,329825546,966207,"Mead Johnson Nutrition Company, Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Well, you're quite right that it is priced above many other importers -- imported products, but I think it speaks to the strength of our brand equity in China. And I think the fact that we are able to grow that product line so strongly, I think, supports",90,"Well, you're quite right that it is priced above many other importers -- imported products, but I think it speaks to the strength of our brand equity in China. And I think the fact that we are able to grow that product line so strongly, I think, supports my assertion that Chinese consumers are fundamentally far more concerned with quality and safety of their nutrition than they are with the cost of it. And if you can give them a premium quality offering, they're willing to pay what it takes."
1002291,329825546,966207,"Mead Johnson Nutrition Company, Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Mead Johnson Nutrition Company","Operator","Our next question comes from the line of Bryan Spillane of Bank of America.",14,"Our next question comes from the line of Bryan Spillane of Bank of America."
1002291,329825546,966207,"Mead Johnson Nutrition Company, Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","Just one question. Can you just give us some sense for -- as you're -- in China specifically, as you've been expanding the distribution of the imported product, just -- is there any pipeline fill? So are you sort of -- the sales growth now a little bit ah",83,"Just one question. Can you just give us some sense for -- as you're -- in China specifically, as you've been expanding the distribution of the imported product, just -- is there any pipeline fill? So are you sort of -- the sales growth now a little bit ahead of consumption because you're filling pipeline? And, I guess, as we kind of model going forward with more new product coming into the market, how should we think about sort of sales versus consumption?"
1002291,329825546,966207,"Mead Johnson Nutrition Company, Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","I think you can assume that it is mostly consumption-based. Most of the distribution build that we experienced happened late in the second and third quarters of last year.",30,"I think you can assume that it is mostly consumption-based. Most of the distribution build that we experienced happened late in the second and third quarters of last year."
1002291,329825546,966207,"Mead Johnson Nutrition Company, Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","So we're seeing -- the sequential improvement you've seen in sales is also reflective of a sequential improvement in consumption as well?",23,"So we're seeing -- the sequential improvement you've seen in sales is also reflective of a sequential improvement in consumption as well?"
1002291,329825546,966207,"Mead Johnson Nutrition Company, Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","We are satisfied it's real, so to speak.",9,"We are satisfied it's real, so to speak."
1002291,329825546,966207,"Mead Johnson Nutrition Company, Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Mead Johnson Nutrition Company","Operator","Our next question comes from the line of John Baumgartner of Wells Fargo.",13,"Our next question comes from the line of John Baumgartner of Wells Fargo."
1002291,329825546,966207,"Mead Johnson Nutrition Company, Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","Kasper, wondering if you can just speak a bit to the competitive environment in North America. Is it your sense that this is also some of the dairy cost deflation being realized? Or is it more maybe just product and innovation-based where you've kind of f",75,"Kasper, wondering if you can just speak a bit to the competitive environment in North America. Is it your sense that this is also some of the dairy cost deflation being realized? Or is it more maybe just product and innovation-based where you've kind of fallen behind?
And then, with your A&P being down for the quarter in Q1, should we expect greater brand support investments coming through to help out volumes as 2016 unfolds?"
1002291,329825546,966207,"Mead Johnson Nutrition Company, Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","I mean, I think we fell a little bit behind on innovation. I think most of you might have listened or read Abbott's earnings call, and I commend them. They've done a great job on their non-GMO line. We are clearly catching up and catching up quite fast in",189,"I mean, I think we fell a little bit behind on innovation. I think most of you might have listened or read Abbott's earnings call, and I commend them. They've done a great job on their non-GMO line. We are clearly catching up and catching up quite fast in that area. And we'll expect to complete the catch-up, so to speak, later in the year. It's the nature of the U.S. market that the market share tends to sort of oscillate. But over time, the 2 biggest players in the marketplace are, in fact, quite stable in their ability to hold onto market share over time.
We go through periods. We had a very good period in the first half of last year where we gained substantial market share. And then, we gave up some as we exited the year and we are suffering a little bit for that right now. But I'm very confident in our ability to sort of, what we say, restore equilibrium. We've shown again and again that we can do that as the other major player here. So you -- we'll get it back."
1002291,329825546,966207,"Mead Johnson Nutrition Company, Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","And then, are you just seeing any unusual price discounting based on the dairy cost deflation at this point?",19,"And then, are you just seeing any unusual price discounting based on the dairy cost deflation at this point?"
1002291,329825546,966207,"Mead Johnson Nutrition Company, Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","No. I don't see that.",5,"No. I don't see that."
1002291,329825546,966207,"Mead Johnson Nutrition Company, Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Mead Johnson Nutrition Company","Operator","Our next question comes from the line of Jason English of Goldman Sachs.",13,"Our next question comes from the line of Jason English of Goldman Sachs."
1002291,329825546,966207,"Mead Johnson Nutrition Company, Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","I guess, I'll pick up where we just left off on the last question. Kasper, you're sort of describing North America actions forward as more of an innovation. But I think, in prepared remarks, you referenced exploring some remedial pricing actions. Can you",49,"I guess, I'll pick up where we just left off on the last question. Kasper, you're sort of describing North America actions forward as more of an innovation. But I think, in prepared remarks, you referenced exploring some remedial pricing actions. Can you elaborate a little bit around that?"
1002291,329825546,966207,"Mead Johnson Nutrition Company, Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Well, I think we always -- we are always looking to optimize our value equation in every market we compete in. And I do believe that there's probably opportunities to adapt our value equation in the U.S. in a favorable direction. So we'll look at it on a",68,"Well, I think we always -- we are always looking to optimize our value equation in every market we compete in. And I do believe that there's probably opportunities to adapt our value equation in the U.S. in a favorable direction. So we'll look at it on a product-by-product basis and make sure we optimize our pricing. I didn't mean to imply that we imagine pricing going down."
1002291,329825546,966207,"Mead Johnson Nutrition Company, Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","Yes, that's kind of the interpretation I had. So I appreciate the clarification on that.",15,"Yes, that's kind of the interpretation I had. So I appreciate the clarification on that."
1002291,329825546,966207,"Mead Johnson Nutrition Company, Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","I'm sorry. I probably was unclear in my communication then.",11,"I'm sorry. I probably was unclear in my communication then."
1002291,329825546,966207,"Mead Johnson Nutrition Company, Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","Well, no. I think it was sort of vague, which is why I sort of jumped to the bad side of the conclusion.And then, I want to come back to Pablo's question earlier. You're referencing or sort of foreshadowing more regulatory changes on the come. We've obv",134,"Well, no. I think it was sort of vague, which is why I sort of jumped to the bad side of the conclusion.
And then, I want to come back to Pablo's question earlier. You're referencing or sort of foreshadowing more regulatory changes on the come. We've obviously had a lot of regulatory changes in terms of registration, labeling requirements, duty changes, et cetera. But his -- one of his questions was have you seen an impact yet in terms of the illegitimate trade flow into the market? I was hoping you could expound on that. Have you seen any impact? Or is it still sort of hopeful thinking that more change -- or I believe that more change will be necessary from the government before we can actually start to stymie that flow?"
1002291,329825546,966207,"Mead Johnson Nutrition Company, Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","No. We've seen it. We've seen an impact almost immediately. Let me -- rather than sort of talk about other people's business, let me perhaps talk about my own business. So we've seen an impact on our Hong Kong business. It's clear that checks at the borde",167,"No. We've seen it. We've seen an impact almost immediately. Let me -- rather than sort of talk about other people's business, let me perhaps talk about my own business. So we've seen an impact on our Hong Kong business. It's clear that checks at the border between Hong Kong and mainland China has been tightened quite substantially. And there are now efforts underway to collect duty on products shipped into the free trade zones. It's still somewhat inconsistent with how duty collection and the new regulation is being implemented. The speed of implementation between different ports in China vary quite a bit at the moment as one would expect. But we are definitely seeing, what shall we say, unofficial flows of products becoming more difficult.
Now that, of course, is an opportunity for the products that we bring into China in a more orderly fashion. So we are also seeing a corresponding benefit to our fully-imported line, and that's definitely helping the growth of that line."
1002291,329825546,966207,"Mead Johnson Nutrition Company, Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","I'm sorry. Nova, we have time for one more call. So this next one is the final one.",19,"I'm sorry. Nova, we have time for one more call. So this next one is the final one."
1002291,329825546,966207,"Mead Johnson Nutrition Company, Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Mead Johnson Nutrition Company","Operator","Our final question comes from the line of Eric Katzman of Deutsche Bank.",13,"Our final question comes from the line of Eric Katzman of Deutsche Bank."
1002291,329825546,966207,"Mead Johnson Nutrition Company, Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","This is Mario Contreras on for Eric. I wanted to ask about Venezuela. Obviously, a number of your CPG peers have de-consolidated their business there. So I wanted to ask if you could quantify the potential EPS risk if you guys were to have to do the same?",72,"This is Mario Contreras on for Eric. I wanted to ask about Venezuela. Obviously, a number of your CPG peers have de-consolidated their business there. So I wanted to ask if you could quantify the potential EPS risk if you guys were to have to do the same?
And then, maybe that aside, shall we anticipate similar top line headwinds for the next few quarters just in terms of the reduced shipments?"
1002291,329825546,966207,"Mead Johnson Nutrition Company, Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","First of all, let me say that in all the non-GAAP guidance as well as the sales guidance that we have given you, we have taken into account deterioration of Venezuela. So that's very important to note.If you look at it from -- and the question on de-con",138,"First of all, let me say that in all the non-GAAP guidance as well as the sales guidance that we have given you, we have taken into account deterioration of Venezuela. So that's very important to note.
If you look at it from -- and the question on de-consolidation, I think we still see opportunities there, as Kasper indicated going forward, right? We are in discussions with the government to see what type of actions we could take. We had some shipments, but very, very small in the first quarter. And I think we have -- we see, for the near future, still an opportunity to further develop the business back to where it was at a certain point of time. So that's the reason why we don't want to consolidate -- de-consolidate at this point of time."
1002291,329825546,966207,"Mead Johnson Nutrition Company, Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","But is there any way that you could quantify the risk if you were to be in that situation? Or is it just premature to do that?",27,"But is there any way that you could quantify the risk if you were to be in that situation? Or is it just premature to do that?"
1002291,329825546,966207,"Mead Johnson Nutrition Company, Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","No. I mean, I think if you look at the impairment, from the balance sheet perspective, the monetary and the nonmonetary assets, clearly, I think the -- we took the majority of the risk out of the balance sheet, that's one.From an operational point of vi",60,"No. I mean, I think if you look at the impairment, from the balance sheet perspective, the monetary and the nonmonetary assets, clearly, I think the -- we took the majority of the risk out of the balance sheet, that's one.
From an operational point of view, I think I see limited risk that could impact our EPS going forward."
1002291,329825546,966207,"Mead Johnson Nutrition Company, Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Maybe in closing, Nova, just before we close the call, let me take the opportunity just to clarify the ambiguous statement I made on pricing in the U.S. We, in fact, have announced that we have taken selected price increases on some product lines already,",81,"Maybe in closing, Nova, just before we close the call, let me take the opportunity just to clarify the ambiguous statement I made on pricing in the U.S. We, in fact, have announced that we have taken selected price increases on some product lines already, which will be effective later this quarter. So I apologize. I was not clear about that.
So with that, I think we'll sign off for today. And thank you very much for joining the call. Kathy?"
1002291,329825546,966207,"Mead Johnson Nutrition Company, Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","That's it. Thank you very much for participating in our first quarter conference call. Operator, I'll leave you to close out the call.",24,"That's it. Thank you very much for participating in our first quarter conference call. Operator, I'll leave you to close out the call."
1002291,329825546,966207,"Mead Johnson Nutrition Company, Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Mead Johnson Nutrition Company","Operator","This concludes the presentation. You may now disconnect. Everyone, have a wonderful day.",13,"This concludes the presentation. You may now disconnect. Everyone, have a wonderful day."
1002291,367328591,1015187,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Operator","Good day, ladies and gentlemen, and welcome to the Mead Johnson Nutrition Second Quarter and First Half 2016 Earnings Conference Call. My name is Liz, and I will be your coordinator for today. [Operator Instructions] As a reminder, this conference is bein",66,"Good day, ladies and gentlemen, and welcome to the Mead Johnson Nutrition Second Quarter and First Half 2016 Earnings Conference Call. My name is Liz, and I will be your coordinator for today. [Operator Instructions] As a reminder, this conference is being recorded for replay purposes. I would now like to turn the conference call over to Kathy Macdonald, Vice President, Investor Relations. Please proceed, Kathy."
1002291,367328591,1015187,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Thank you, Liz. Good morning and thank you for joining Mead Johnson's Second Quarter and First Half 2016 Conference Call. With me today are Kasper Jakobsen, our Chief Executive Officer; and Michel Cup, our Chief Financial Officer. Earlier today, we issu",304,"Thank you, Liz. Good morning and thank you for joining Mead Johnson's Second Quarter and First Half 2016 Conference Call. With me today are Kasper Jakobsen, our Chief Executive Officer; and Michel Cup, our Chief Financial Officer. 
Earlier today, we issued our 10-Q, earnings release and financial reference slides. If you have the slides in front of you, please turn to Slide #2. A detailed explanation of our forward-looking statements appears in the materials posted on our website in connection with today's conference call. 
As we start, let me remind everyone that our comments will include forward-looking statements about our future results, including statements about our financial prospects and projection, commodity costs, currency fluctuations, pricing, taxes, capital spending, new product launches, other growth initiatives and market conditions that constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Keep in mind that our actual results may differ materially from expectations as of today due to various factors, including those listed in our annual report on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K, and each case is filed with or furnished to the Securities and Exchange Commission in our earnings release issued this morning. 
Today's comments will include discussion of non-GAAP financial measures. A reconciliation of these measures to comparable GAAP measures appears in this morning's earnings release and financial reference slides, which are available at meadjohnson.com. In addition, any forward-looking statements represent our estimates only as of today and should not be relied upon as representing our estimates as of any subsequent date. While we may elect to update forward-looking statements at some point in the future, we specifically disclaim any obligation to do so, even if our estimates change. 
I will now turn the call over to Kasper."
1002291,367328591,1015187,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Thank you, Kathy and good morning to all of you. Thank you for joining us on our earnings call. My comments will focus on our strategy and top line performance. And then Michel will follow up with some additional financial information and [indiscernible",2467,"Thank you, Kathy and good morning to all of you. Thank you for joining us on our earnings call. 
My comments will focus on our strategy and top line performance. And then Michel will follow up with some additional financial information and [indiscernible] on segment profitability and our company's cash flow. 
Let me begin by summarizing the company's second quarter performance before I provide additional details on each of our reporting segments. Except where I noted otherwise, I'll be referring to non-GAAP results. At the end of last year, we laid out a three-year plan for value creation, with this year being a year of transition. I also identified three key milestones we use to monitor our profits against this value creation plan. I referenced these plans in our last earnings call, so let me reference them again today. 
Of the three milestones we laid out, the first was to return the business to constant dollar sales growth. Today, you'll hear as we reiterate expectations for 2016 sales that anticipates that we'll return to growth in the coming quarters. Within the most recently completed quarter, demand in China for new products continued to grow. Actual shipments this quarter however were constrained by supply shortage caused by newly introduced additional import processes at Chinese border points. More about this later. 
Despite these constraints, the gross sales before trade support and discounts were in line with prior quarter. Net sales were lower than the quarter before as trade support for new product introductions increased. Michel will elaborate on this a little bit later. 
Our second milestone centered around our commitment to reduce our operating expense base. Year-to-date, we've delivered $47 million in expense reductions. We've already achieved nearly 80% of our annual target of $60 million. We are ahead of schedule. And in this call, we are announcing a revised, more ambitious target. 
We are both accelerating and expanding our cost initiatives by increasing our 2016 target to $75 million to $80 million in savings from the previously announced $60 million. We're also raising our three-year cumulative savings goals from $120 million to $180 million. 
Our third and final milestone we said will be to invest a portion of our expense savings to fund key growth initiatives. To date, we've invested substantially behind the introduction of a fully imported Enfamil into China and the building of a [indiscernible] franchise in North America. This latest quarter, we made strong investments in support of our Enfinitas launch in China and the expansion of distribution reach. Overtime, we'll demonstrate to you that these investments are central to us delivering on our commitment to shareholder value creation. 
Turning now to our second quarter 2016 results. We continue to manage through a challenging global operating environment. Economic growth in many emerging and developing economies of Asia and Latin America has slowed over the past 18 to 24 months. Simultaneously, political uncertainty affects many markets in both Asia and South America. These affects they present near-term headwinds for us. That said, we continue to find opportunities amidst the uncertainty. We continue to invest to put ourselves in the best possible position for when a turnaround and economic growth eventually materializes and come it will. 
For the second quarter, sales for the company was $942 million. Reported net sales were $9 million lower than the prior year quarter. Currency adversely impacted our results by 500 basis points. Consequently, constant dollar sales were below -- excuse me, consequently, constant dollar sales were 4% below those of the second quarter of 2015. Price was favorable by 1% despite added trade support in China, while volume was 5% unfavorable. 
Second quarter sales were impacted by significant investments to secure trade support and distribution of Enfinitas in China. Though costly in the near term, these investments will help establish the brand and drive long-term revenue growth. I'll return to the topic of Enfinitas a little later. 
In China, a requirement for additional product testing prior to implication to affect towards the end of the second quarter, causing delays to the importation process. I want to commend the Chinese government for its actions to enhance food safety standards and importation guidelines to ensure imported products can be safely used by Chinese parents and children. 
During the quarter, the government implemented new testing standards for imported products within our category. The effect of this change was a temporary delay in the importation of some of our fastest-growing products from our Netherlands facility. This drove some near-term volatility in our sales results. In the mid to long-term, we, however, believe these additional processes will benefit both Chinese children and responsible operators within the industry. 
Outside of China, the deteriorating circumstances in Venezuela that so tragically impacted the people and our colleagues there have resulted in significantly reduced shipments to the country. When comparing to the second quarter of last year, this adversely impacted the company sales by 130 basis points in the latest quarter. 
Despite the challenging operating environment, I'm pleased with the company's earnings power. Gross margin remained strong. Our strategy to drive growth of higher value product and product forms is working and helps offset the impact of increased investments above the net sales line. Investments in advertising and promotion represented 17.6% of net sales in the quarter. 
Our Fuel for Growth cost reduction initiative drove significant reduction in SG&A. Overall, these costs were down 9% from constant dollars in the second quarter compared to the same quarter of the prior year. 
While we made significant investments in key growth initiatives, our EBIT margin was 24.4% in the quarter and non-GAAP earnings per share for the quarter were $0.88. Michel will expand on our earnings delivery a little later. 
I'll now discuss the performance of each of our reporting segments, beginning with the North America and Europe segment. 
Net sales in the North America and Europe segment were in line with the second quarter of 2015. On a constant dollar basis, and improved sequentially from the first quarter, a 1% benefit from price was offset by lower volumes. Additionally, we experienced additional headwind of 1% from foreign exchange. 
The Center for Disease Control recently issued their report on 2015 U.S. birth and birth rates. Reported annual birth was 0.3% below the 2014 level. Breastfeeding rates however, appeared to have stabilized. Our market share in the U.S. business stabilized in the second quarter but remained at a level lower than the prior year. In our outlook, we're recognizing it will likely take longer than [indiscernible] to recover market share. Much of our share loss was within the specialty and solution segment of the infant formula market. But we are confident we understand our challenges and we are addressing them. 
There are bright spots within this reporting segment also. Last October, we introduced a new 32-ounce liquids packaging. This product line is now growing double digits and we are gaining share in the high-value liquids category. 
It's still early days for our premium priced Inspire product but reception from retailers has been favorable and we expect to see distribution increase in the coming quarters as we build consumer demand. 
Our North American toddler business, defined as products targeting children more than 1 year of age, continues to grow at an annual rate in double digits. 
And turning to Canada. I continue to be pleased with our progress. Second quarter sales grew double digits based on strong market share gains in both the infant and children segments. We've executed extremely well over the past year or 2 and our Canadian team is deservingly receiving much internal recognition. 
Our European business remains strong based on a leading position in the growing [indiscernible] segment there. We are well-positioned to benefit from future increases in diagnosis ahead of strong innovation pipeline to support our growth in Europe. 
Let me now turn to Latin America. Constant dollar sales for the total region was 3% lower than the prior year same quarter. Pricing benefits of 9% was insufficient to fully offset foreign exchange impact of 13%. Excluding the impact of our sharply reduced business in Venezuela, Latin America sales grew 4% in constant dollars over the same quarter of 2015. 
Mexico and Colombia were the biggest contributors to growth. In Mexico, we're seeing improved momentum in both our premium pediatric nutrition business and our milk modifier business. We enjoy strong market shares in our milk modifier business and retain our #1 position in this category. In infant formulas, we recently rolled out a product containing milk fat globular membranes, the same key ingredient contained in Enfinitas and its by-products launched in China and the U.S. 
Trends in other parts of Latin America remain broadly unchanged from the prior quarter. In Brazil, the economic challenges continue to hurt demand for discretionary items by our midpriced children's products. The infant premium infant formula products are less discretionary and they continue to grow. We continue to benefit from strong sales in our Colombian unit which maintained strong market shares and in addition, is benefiting from cross-border demand from Venezuela. 
We are rolling out our new plastics packaging and refill systems across Latin America. And in some markets, we are testing ready-to-drink versions of our children's products. These initiatives would allow us to take advantage of segment growth opportunities and support selective increases in price. 
I'll turn now to the Asia segment. Constant dollar growth sales in Asia were in line with the second quarter of 2015. In support of the Enfinitas launch in China, trade investments however were significantly higher when compared to the prior year. Partly as a result of this, price was unfavorable by 2% as the increased trade investments in China more than offset the impact of price increases in Southeast Asia. 
Across the region, product mix continued to improve with sales of our premium priced products going faster than those of our lower-priced variants. Volume was unfavorable by 5% as we experienced delays to importation in China and dealt with some market share weakness in the Philippines. Despite improving momentum in China, the Asia region has not yet recovered to sales levels seen in the early part of 2015. 
In the Philippines, we've seen softer markets share in sales of Lactum, our midpriced children's brand. We feel we've identified the root causes behind our share loss and have a remedial plan that will allow us to get back on track. 
Our Malaysia business is growing both volume and price. We recently introduced a new formulation and improved packaging that will allow us to recover market share over time. 
Across South East Asia, we are rolling out new product formulations and promoting the benefits of our new plastics packaging. Supported by an improved value equation, we are raising prices behind this innovation. 
I will finish my discussion of the Asia segment with China. In my introductory headlines, I described the import delays caused by increased processes at all border points. In Mainland China, the government implemented a new requirement that every batch be extensively tested prior to release to Chinese consumers. Previously, a sampling approach has been applied. The increase in the number of test required caused temporary delays as testing and verification capacity was stretched. The effect of this was a temporary delay in the importation and shortage of supply of many of our fastest-growing imported line items, as I mentioned earlier. We nevertheless are pleased to see these measures implemented. 
Similarly, increased constant monitoring and reduced visitor numbers have adversely impacted our Hong Kong business. It's become more challenging for our Hong Kong business to compete for visiting Chinese tourists but now connects these imported products more easily from within the Mainland. These challenges confirm our China strategy, pursuing increased flexibilities through a broader product portfolio so through more diverse set of sales channels. 
Turning to our Mainland China where our fully imported products continues to gather momentum and we're seeing stronger demand from consumers. Through the second quarter, we continued to grow market share via the imported segment. In the baby store channel, we've increased our distributional supported by our most recent new product introductions. We are seeing both our ability to make progress and the substantial runway we have ahead of us. 
As of the second quarter, we are no longer under indexing versus the market in the fast-growing baby store channel. Our new Enfinitas product line is off to a solid start. 3 months after introductions, we're still building distribution and demand but we're encouraged by the early signs. 
In totality, I'm satisfied with the progress we've made with our portfolio and channel transformation in China. I also recognize we've got a long way to go and a lot of opportunities ahead of us. It's hard not to be excited about the immense potential of not only our China business but our global business. 
Before I hand over to Michel, I want to provide an updated outlook for full-year 2016, our year of transition, a year in which we're addressing several structural opportunities within both our brand portfolio, our product line-up and our cost structure. 
At the beginning of the year, we knew comparisons in the first half 2016 would be challenging. I'm satisfied that many of our critical initiatives have gone as planned and we are expecting growth over prior year in the second half of the year. However, we've seen three developments causing us to revisit our estimate for full year 2016 constant dollar sales growth. It's taking us longer-than-expected to recover the market share we lost in the U.S. towards the end of 2015. 
Secondly, the import-related challenges in China, Hong Kong in the second quarter caused us sales we won't fully recapture until next year. 
Thirdly, we're supporting our imported portfolio in China with additional trade support. In light of these factors, we now expect constant dollar sales in line with or not more than 2% below the 2015 level. 
Through the first half of the year, we've identified several opportunities within our cost structure. In doing so, we found additional opportunities to both reduce cost and increase efficiencies. In a moment, Michel will outline an expanded ambition and scope for our operating expense initiatives, the project we refer to as Fuel for Growth. Despite lower sales, a slightly improved outlook for gross margin, expense optimization and the benefit realized from a lower tax rate in the just completed quarter allows to reiterate our expectation for non-GAAP earnings per share of $3 -- of between $3.48 and $3.60 for the full year 2016. 
I'll now hand over to Michel, who will provide additional details on our second quarter and first half financial performance. I'll then return with a few summary remarks before we take your questions. Michel, over to you."
1002291,367328591,1015187,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Thank you, Kasper and good morning everyone. Today I will discuss the company's second quarter and first half 2016 financial results. I will then briefly highlight EBIT results for each segments, cash flow and liquidity items and conclude with a summary o",2843,"Thank you, Kasper and good morning everyone. Today I will discuss the company's second quarter and first half 2016 financial results. I will then briefly highlight EBIT results for each segments, cash flow and liquidity items and conclude with a summary of full year guidance. 
Unless otherwise noted, my comments will be on the non-GAAP financial results. References to currency impacts or the effects of currency fluctuations generally refer to the impact on the translation of local currency, financial statement into U.S. dollars. In addition, my comment about sales refer to net sales, unless I explicitly call out gross sales. 
Let me start with sales as shown on Slide 3. Kasper addressed the constant dollar change. I will focus on the reported sales and the foreign currency impact. For both the second quarter and first half year, adverse foreign exchange rates contributed to the 500 basis points decline compared to the same period of the prior year. Second quarter net sales on a reported dollar basis grew 9% below prior year quarter. Reduced shipments to Venezuela impacted net sales negatively by 1% in the second quarter versus the prior year quarter. 
Slide 4 summarizes the impact of foreign exchange on sales. U.S. dollar continues to be strong and effects of translation of local currencies negatively impacted all [ph] our reporting segments. However, the impact was slightly less significant in the second quarter of 2016 when compared to the trend from the last 3 quarters. Nearly 2/3 of the second quarter negative currency impact on sales were from the Chinese renminbi, the Mexican peso and the Argentine peso. The balance of the adverse foreign exchange impact was widespread across regions. 
As a result of the year-to-date foreign exchange impact, our outstanding currency hedges for the remainder of the year and the current forward rate, we are revising our currency expectations from minus 6% to minus 5% adverse foreign exchange impact on sales for the full year 2016. I will address foreign exchange impact in the EPS guidance section as well. 
I'm introducing Slide 5 for better transparency of gross sales, which reflects sales to customers before trade investment and other items, which are recorded as gross to net sales adjustment. We reallocated some investments in the second quarter from advertising and promotion to trade investments, in support of the rollout of Enfinitas and build on our momentum of the fully imported premium products that were introduced in the second quarter of last year. Gross sales on a constant dollar basis were flat compared to the prior year quarter and down 2% for the first half year of 2016 versus the same period last year. The significant gross sales improvement in the second quarter has been realized. 
Slide 6. The second quarter EBIT of $230 million was 10% above the prior-year quarter on a constant dollar basis. Foreign exchange adversely impacted EBIT by 6%, including currency impacts. EBIT increased 4% on a reported basis in the second quarter. 
If you would exclude Venezuela, our EBIT on constant dollar basis improved by 14% versus prior year quarter. The second quarter EBIT margin of 24.4% of sales was 290 basis points better than the prior year quarter. Despite macroeconomic and country-specific challenges which impacted our sales, we made excellent progress to reduce operating expenses as part of our Fuel for Growth program which allowed continued investments and, at the same time, improve the underlying profitability. Year-to-date EBIT was $474 million, a decline of 1% versus previous year on a constant dollar basis. Foreign exchange, an adverse impact of 8%. 
Excluding Venezuela, EBIT in the first half year improved by 3% versus previous year period on a constant dollar basis, mainly driven by a higher gross margin and our cost savings realized in the first half year, partly offset by the mine generating investments. 
I will now move to the factors that impact gross margin on Slide 7. Gross margin was 65.1% in the second quarter of 2016, or 66% on a constant dollar non-GAAP basis. Adverse foreign exchange impact the gross margin by 150 basis points in the second quarter. We were able to deliver a nearly flat gross margin on a reported basis in both the second quarter and the first half year compared to the previous year periods despite the significant currency headwind. 
Sales had a slightly negative impact on gross margin from higher trade investment, especially in China. Low dairy cost continued to be the large benefit to gross margin in the second quarter and first half of 2016. Our key dairy components have been secured through supply contracts for the remainder of the year and we expect some further benefits. Although the daily benefits for the remainder of the year will be smaller compared to the first half year. 
We continue to deliver productivity savings within cost of goods sold. Year-to-date, the supply chain team delivered productivity savings of around 3.5% of cost of goods sold, in line with our expectation. We're very secured for the full year. We expect full year gross margin to be slightly better than our prior year guidance of 64%. 
Moving to operating expenses. I will start with advertising and promotions expenses [ph] on Slide 8. Advertising and promotion was 17.6% of sales in the second quarter compared to 18.4% in the prior year quarter. As previously mentioned, in the second quarter, we reallocated a portion of investments from A&P to trade investments which are recognized in gross to net sales. Despite the year-over-year savings, the second quarter of both years marked noticeably higher investments. The incremental investments were mainly to support key China initiatives, last year for the launch of our fully imported products and for April of this year, the launch of the Enfinitas product line and the continued support of our greater China strategy. 
In the second quarter, we purposefully delayed some A&P investments due to delays in the importation of some of our China product impacting our sales. As such, we expect the third quarter may continue to be at elevated level before it normalizes in the fourth quarter. 
Slide 9 provides the combined spending of the mine generating investments, both as trade investments classified in gross to  net sales and advertising and promotion. Some of the key trade investment activities include trade support, customer programs and promotional pricing. For the second quarter, the combined investment increased above the prior-year quarter and was also higher than it was the last few quarters. 
Trade spending is focused closer to our consumer and to ensure our products are present with strong distribution in the key growing channels. In the past few quarters, we've increased these investments, especially in China, to be more competitive in the baby store and e-commerce channels. While we increased trade investments, we plan to reduce the A&P as a percentage of sales over the next few years. 
Last quarter, we committed to provide an update on our view of advertising and promotion expenditures. At Investor's Day last year, when I spoke about advertising and promotion, I stated that we should be able to optimize a lower A&P by 50 to 100 basis points over 3 years. We can now confirm that we expect to be at the top of that range and reduced our A&P by 100 basis points by 2018. We will realize this by prioritizing investment choices that maximize our return on investments of key influence drivers. 
We will continue to optimize our non media expenses and leverage our decision supporting tools better. In addition, we will strengthen our focus on digital marketing versus the traditional media. 
Slide 10, we reduced our SG&A cost by 9% on a constant dollar basis in the second quarter of 2016 versus the previous year quarter and by 10% year-to-date compared to the prior-year period. Like we indicated before, our Fuel for Growth program is focused on cost reduction within our support functions and marketing. 
Areas of focus were the reduction of key vendor contracts, eliminates discretionary spend and optimize organizational errors. As you can see from Slide 11, we are significantly ahead of schedule on the original 2016 Fuel for Growth target. Our Fuel for Growth target for this year was $60 million. By midyear, we've delivered 79% of this year's target savings, or $47 million already. Especially in the corporate overhead functions, we're able to reduce our cost by $30 million in the first half year of 2016 versus the first half year of 2015. Significant progress had been made by systematically renegotiating contracts with our largest vendors. 
Slide 12. Over the last few months, we performed a more extended deep dive review of our expenses as well as our organizational structure. We concluded, based also on the success of our results to date, to accelerate certain cost savings programs identified earlier and to expand the scope to all operating expenses functions, including sales force and distribution. We now expect to deliver $75 million to $80 million of savings in 2016. This is an increase of $15 million to $20 million versus our original 2016 target. Taking into account the savings realized in 2015 of $20 million, cumulative savings by the end of 2016 are expected to be around $95 million to $100 million. 
In addition to the original program of $120 million, we expect an incremental $60 million of cost savings opportunities by 2018. The combined Fuel for Growth program will deliver $180 million savings by 2018. 
The incremental Fuel for Growth savings will provide additional flexibility to invest in the company's future growth. 
Turning to Slide 13 for a discussion of EBIT by segment. Let me start with Asia. In the second quarter, Asia delivered an EBIT of $137 million, a decrease of 4% on a constant dollar basis compared to prior year quarter. Foreign exchange adversely impacted EBIT by additional 8%. Lastly from the Chinese renminbi, the Thai baht and the Malaysian ringgit. The Asia EBIT margin at 30% declined 50 basis points compared to the second quarter of 2015. The main drivers were lower sales and an increase in trade investment in gross to net sales. The lower net sales impact was somewhat offset by a favorable dairy cost and some lower A&P expenses. 
For the first half-year of 2016, the Asian EBIT margin of 32% were 350 basis points lower than the prior year, as the lower sales and higher demand generation investments were not fully offset by the dairy benefit. A&P as a percentage of sales increased in the first half-year versus the previous period. 
Turning to Slide 14. Latin America delivered an EBIT of $36 million in the second quarter, a decrease of 7% on a constant dollar basis compared to the prior year quarter. For this segment, foreign exchange adversely impacted EBIT by 12%, largely from the Mexican peso. Excluding our Venezuela business, EBIT on a constant dollar increased by 9% in the second quarter -- for the previous year quarter. And EBIT on a constant dollar increased 16% in the first half year of 2016 versus the previous year period. 
For the balance of the business, lower sales were somewhat offset by lower demand generating expenses. The year-to-date Latin America EBIT margin was 23.6% compared to 25.3% for the same period last year. Lower EBIT margin is mainly a result of lower gross margin from the deteriorating situation in Brazil and Venezuela, so when offset by cost reduction program. 
Slide 15 shows North America and Europe segment results. For the second quarter, North America and Europe EBIT was $99 million, an increase of 21% on a constant dollar basis. The EBIT margin of 31.1% was 450 basis points better than previous year quarter. Gross margin remained strong from the benefit of low dairy costs. With the operating expenses, reduction in A&P and SG&A cost savings helped fund the stack of investments and drove high EBIT margins. Year-to-date, EBIT margin was 29.2%, an improvement of 300 basis points versus the previous year period. Fuel for Growth savings programs and the dairy benefit contributed to improved EBIT margin. 
I will now address the financial results from EBIT to EPS on Slide 16. The interest expense of $26 million in the second quarter was similar to the first quarter of 2016 expense. When compared to the prior year quarter, the interest expense increase reflects the impact of the November 2015 $1.5 billion notes issuance. A significant portion of the proceeds from the notes were used to finance the accelerated share repurchase program, or ASR. 
Since the ASR concluded on June 30, let me briefly provide you a summary of the transaction. During our Investor Day, we announced the new $1.5 billion share repurchase program, of which $1 billion would be in the form of an ASR. 10.7 million shares of stock were received in the fourth quarter of 2015, an additional 2.1 million of shares of stock were received on June 30, 2016. In total, 12.8 million shares of stock were repurchased through the ASR program at an average price of $78.05 per share. Since the IPO, the company bought back 23.4 million of shares, with a total value of $1.8 billion. There are 184.7 million shares outstanding as of June 30. And in the last 12 months, this is a reduction of 18.5 million shares. 
The benefit from all share repurchase in 2015 and the full ASR program net of interest expense delivered almost $0.05 year-to-date and is in line with our full year guidance of $0.11 benefit per share in 2016. 
As part of the $1.5 billion share buyback program announced in 2015, we still have $500 million available for an additional repurchase program. We continue to focus on shareholder value creation. This includes EBIT margin accretion, sales and EPS growth, along with the return of cash to shareholders through both dividends and share repurchases. 
Next, non-GAAP effective tax rate, or EPR was 18.3% for the second quarter of 2016 compared to 25.6% in the prior year quarter. In the second quarter of 2016, there was about $0.05 per share benefit as a result of utilizing foreign tax credits on dividends from our foreign operations. We expect the balance of the year to normalize. 
Non-GAAP EPS for the second quarter was $0.88, an increase of 16% on a reported basis and 24% on a constant dollar basis. Year-to-date non-GAAP EPS was $1.75, a decrease of 5% on a reported basis and an increase of 3% on a constant dollar basis. 
Let me summarize our financial results by addressing the change to EPS on Slide 17. In the second quarter, non-GAAP EPS increased $0.18 to $0.94 per share on a constant dollar basis versus the prior year quarter. Sales and related gross profit negatively impacted EPS by $0.07. Our Fuel for Growth savings delivered $0.11 benefit. Advertising and promotions were $0.06 lower in the quarter. And the share repurchase program delivered a $0.02 benefit net of higher interest expense. Techs and other contributed the $0.06 benefit. Despite the negative impact of foreign currency of $0.06 per share, EPS increased by $0.12 versus second quarter last year on a non-GAAP basis. 
Turning to a high-level overview of cash movements. On Slide 18, the cash balance of $1.7 billion as of June 30 was similar to the beginning of the year balance. Cash flow from operations was negatively impacted by $94 million as a result of timing of tax payments and other working capital movements. Our CapEx investments were $81 million, mainly in our U.S. and Europe manufacturing facility. For the full year ago, our capital spending goal remains about 4% of sales. Dividend payments were $155 million in the first half-year. The negative impact of foreign exchange impact of $32 million was related to the currency devaluation in Venezuela. 
To summarize our forward-looking annual guidance on Slide 19, our sales outlook for 2016 on a constant dollar basis expected to be 0 to 2% below the prior year. The foreign currency reducing sales growth by about 5%, reported sales are estimated to be 5% to 7% below 2015. 
We reaffirm our 2016 GAAP EPS guidance of $2.91 to $3.03. And our non-GAAP guidance of $3.48 to $3.60 per share for the following reasons: First, we expect the gross margin improvement from our previous guidance of 64%; second, our Fuel for Growth savings are well ahead of plan and will only partly be reinvested in our business; thirdly, we have an ETR benefit around $0.05 in the second quarter; and fourth, the foreign exchange impact is expected to be approximately $0.35 per share from our previous guidance of $0.40 per share. 
GAAP EPS guidance is slightly impacted by potentially significant future mark-to-market potential adjustments which cannot be estimated and classified as specified items. Specified items include charges related to Fuel for Growth and our Venezuela business. 
This concludes my discussion on the second quarter and first half year 2016 financial results. Thanks again for your time this morning. I'll now hand over the call back to Kasper."
1002291,367328591,1015187,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Thank you, Michel. Before we open the lines for questions, let me briefly reiterate our expectations that our relative performance will improve as we move into the second half of 2016. We expect to see the company return to positive growth in the coming q",151,"Thank you, Michel. Before we open the lines for questions, let me briefly reiterate our expectations that our relative performance will improve as we move into the second half of 2016. We expect to see the company return to positive growth in the coming quarters and our guidance reflects that. Our efforts to reshape our product and brand portfolio in China are progressing well, so is our initiative to strengthen our presence in the fast-growing channels there. We are gaining momentum in Mexico, Canada and Malaysia while we are addressing our performance shortfalls in the U.S. and the Philippines. We are protecting our ability to invest to maximize our opportunities by improving our gross margins to improve product mix and by lowering our expense base. And finally, we remain as committed as ever to shareholder value creation. 
With that, Liz, could I ask you to open the lines for questions, please?"
1002291,367328591,1015187,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Operator","[Operator Instructions] Your first question comes from David Driscoll with Citi.",11,"[Operator Instructions] Your first question comes from David Driscoll with Citi."
1002291,367328591,1015187,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","Kasper, can you comment on your retail performance in China? And distinguish it from all the various shipment issues that I think you were talking about? Can you give us some color on market share? And maybe a little bit more on the imported product gains",86,"Kasper, can you comment on your retail performance in China? And distinguish it from all the various shipment issues that I think you were talking about? Can you give us some color on market share? And maybe a little bit more on the imported product gains? And then to kind of round all this question out, will the third quarter see China shipments pick up because of the problems of shipments within the second quarter because of the customs issues that you talked about? Thank you."
1002291,367328591,1015187,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Thanks, David. It's an excellent question. So what I was implying in my prepared remarks, but I'm quite prepared to be more specific is that we are very satisfied with the consumer demand trends that we are observing in China. So we feel that we are gaini",192,"Thanks, David. It's an excellent question. So what I was implying in my prepared remarks, but I'm quite prepared to be more specific is that we are very satisfied with the consumer demand trends that we are observing in China. So we feel that we are gaining share in the -- with our new products both in our -- in the super high premium segment where we obviously came from a standing start and in the imported product segment where we've now been at it for a little while. However, the difficulty of getting product into China in this latest quarter did result in some selected out of stocks situations at retail as well as lower inventories in many of our distributors. So to the extent of the latter, we expect that we will gradually recover that over the second half of the year. A little bit hard to say whether we will recover it all in the third quarter because that involves speculating on how the importation process evolves. But we are quite encouraged and we are confident that some of these issues are sort of relatively short term in nature."
1002291,367328591,1015187,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","Then just to follow up, would you say then that the retail performance and the market share gains are more indicative of the success of the strategy rather than the shipment number you're reporting today?",35,"Then just to follow up, would you say then that the retail performance and the market share gains are more indicative of the success of the strategy rather than the shipment number you're reporting today?"
1002291,367328591,1015187,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","That's certainly the way we look at it. So I hope I brought [indiscernible] cost in my prepared remarks.",20,"That's certainly the way we look at it. So I hope I brought [indiscernible] cost in my prepared remarks."
1002291,367328591,1015187,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Operator","Your next question comes from Michael Lavery from CLSA.",9,"Your next question comes from Michael Lavery from CLSA."
1002291,367328591,1015187,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","I had just 2 quick ones. One on Enfinitas, I was wondering if you could give some sense of -- I know it was early there still, but for the distribution, is that skewed more towards tier 1 cities or is it broad geographically and just how is that progressi",87,"I had just 2 quick ones. One on Enfinitas, I was wondering if you could give some sense of -- I know it was early there still, but for the distribution, is that skewed more towards tier 1 cities or is it broad geographically and just how is that progressing? And then just second in Indonesia, we saw a premium competitor cut prices by about 10%. What are the market dynamics there for you? Are you seeing pricing pressure or share pressure or opportunities in that market?"
1002291,367328591,1015187,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Let me start with Enfinitas. It really is early to say how that brand is performing. And particularly, as this last month or so, was affected by these temporary delays in importation that I referenced now repeatedly in China. We are aiming for a pretty br",130,"Let me start with Enfinitas. It really is early to say how that brand is performing. And particularly, as this last month or so, was affected by these temporary delays in importation that I referenced now repeatedly in China. We are aiming for a pretty broad distribution but obviously with an emphasis on the baby store channel which is a primary outlet for these high-quality premium priced products in China. In Indonesia, we typically don't mention it very often in our earnings call, that's not because it's not a great market, it's simply because we have a very small business there and our market participation is relatively low. So I suspect there are other people that are far more qualified than I do to discuss the market trends in Indonesia."
1002291,367328591,1015187,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Thank you, Michael.",3,"Thank you, Michael."
1002291,367328591,1015187,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Operator","Your next question comes from Bryan Spillane with Bank of America.",11,"Your next question comes from Bryan Spillane with Bank of America."
1002291,367328591,1015187,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","Just one question related to the increased investment in trade spend. I guess Kasper, the question is just, it was that in reaction to some of your competitors promoting more? Was it a reaction? Is it really a mix, channel mix issue, that you're increasin",119,"Just one question related to the increased investment in trade spend. I guess Kasper, the question is just, it was that in reaction to some of your competitors promoting more? Was it a reaction? Is it really a mix, channel mix issue, that you're increasing your sales in the baby store and that just tends to need more trade promotion? I guess the reason I ask is it seems sort of inconsistent that you got a bottleneck at the border, so you're not getting product across, yet you're promoting more, which would seem to increase the incidence of out of stock. So if you can just kind of tie those things together, I think, it will be helpful thanks."
1002291,367328591,1015187,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Bryan, thanks for the question, I mean, the trade support is not always, in any case, tied directly to volume. The certain amount of sort of fixed expenses that are incurred in order to support the trade and particularly create sufficient presence and awa",97,"Bryan, thanks for the question, I mean, the trade support is not always, in any case, tied directly to volume. The certain amount of sort of fixed expenses that are incurred in order to support the trade and particularly create sufficient presence and awareness in the early stage of a brand launch. So it really reflects that. It is very directly connected to the launch of Enfinitas and it is directly connected to the fact that trade support in the baby store channel tends to be the higher than it is, for instance, in the food channel."
1002291,367328591,1015187,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","Okay, so it seems like you've got -- you've made more progress maybe than you would've originally -- or it's progressing faster than you thought and so the need for the trade spend has kind of increased sooner than you thought as well, is that a fair way",51,"Okay, so it seems like you've got -- you've made more progress maybe than you would've originally -- or it's progressing faster than you thought and so the need for the trade spend has kind of increased sooner than you thought as well, is that a fair way to put it?"
1002291,367328591,1015187,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Well, I think as a better way to look at it is that we have chosen to rebalance our investment between A&P and trade support to some degree in this latest quarter. We expect that that balance would change from quarter-to-quarter depending on what our acti",68,"Well, I think as a better way to look at it is that we have chosen to rebalance our investment between A&P and trade support to some degree in this latest quarter. We expect that that balance would change from quarter-to-quarter depending on what our activities are and whether they are booked in one line of the sort of brand investments or booked above the net sales line."
1002291,367328591,1015187,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Operator","Your next question comes from Amit Sharma with BMO Capital.",10,"Your next question comes from Amit Sharma with BMO Capital."
1002291,367328591,1015187,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","Kasper, just to continue what you just said, so if you -- if we are going to shift funding between above the line and below the line, how should we can reconcile that with Michel's said earlier comments about 100 basis points decline in R&D spending over",59,"Kasper, just to continue what you just said, so if you -- if we are going to shift funding between above the line and below the line, how should we can reconcile that with Michel's said earlier comments about 100 basis points decline in R&D spending over the next few years? Is that net of higher based funding? Potentially?"
1002291,367328591,1015187,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Michel, you want to [indiscernible]",5,"Michel, you want to [indiscernible]"
1002291,367328591,1015187,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Yes, when I was referring to A&P, clearly, we were referring to the A&P line as a percent of sales. Yes, we stepped up the gross to net investments in the second half of the year and as Kasper said, it was really to support trade and reiterated the rollou",99,"Yes, when I was referring to A&P, clearly, we were referring to the A&P line as a percent of sales. Yes, we stepped up the gross to net investments in the second half of the year and as Kasper said, it was really to support trade and reiterated the rollout of certain new product launch like Enfinitas and to get the distribution line. So that gave us, I would say, especially in the second quarter, a temporary step up and we will continue this from higher trade investment. But I don't expect a further strong increase in that line."
1002291,367328591,1015187,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","So it's just -- I understand it well. So trade spending slightly up this quarter without looking for a sustained increase in that. And then A&P spend savings should accrue or should be available for you to reinvest or drop to the bottom line?",45,"So it's just -- I understand it well. So trade spending slightly up this quarter without looking for a sustained increase in that. And then A&P spend savings should accrue or should be available for you to reinvest or drop to the bottom line?"
1002291,367328591,1015187,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","A&P savings should be reinvested into gross net or should be dropped to the bottom line.",17,"A&P savings should be reinvested into gross net or should be dropped to the bottom line."
1002291,367328591,1015187,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Thank you, Amit.",3,"Thank you, Amit."
1002291,367328591,1015187,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Operator","Your next question comes from Ken Goldman, JPMorgan.",8,"Your next question comes from Ken Goldman, JPMorgan."
1002291,367328591,1015187,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","Forgive my -- the length of my question here, but from my perspective, the guidance on Fuel for Growth has been a bit confusing. And maybe I'm wrong. But I'm just hoping you can clear it up for me. So you explicitly said in your slides in the Investor Day",208,"Forgive my -- the length of my question here, but from my perspective, the guidance on Fuel for Growth has been a bit confusing. And maybe I'm wrong. But I'm just hoping you can clear it up for me. So you explicitly said in your slides in the Investor Day that you're looking for 300 basis points of margin improvement, not savings but margin improvement. And that implies your EBIT margin will get around 27% by 2018, all else equal. And that's an outlook that I think I've confirmed with the company in recent weeks. But you've also thought, including today, about how you're going to reinvest some of your savings back into your business which suggests that maybe that model of that $120 million, now $180 million is going to flow to the bottom-line. So I'm clearly just trying to figure out, Michel, how do I reconcile what seems to be some conflicting information out there? And I know it's not guidance. But from a rough outlook, is it long for us in the outside to think that margins are expected to go up by 300 basis points or more net of reinvestments over the next few [ph] years? I think that's a key question for people."
1002291,367328591,1015187,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Yes, so let me clarify to avoid any confusion, because I want to be consistent with the messages that I gave at Investor Day. So at Investor Day, we said we will deliver $120 million of Fuel for Growth savings. And we also indicated that we will partly re",141,"Yes, so let me clarify to avoid any confusion, because I want to be consistent with the messages that I gave at Investor Day. So at Investor Day, we said we will deliver $120 million of Fuel for Growth savings. And we also indicated that we will partly reinvest that and partly will be rolled through profitability. And in combination with a couple of other initiatives that we announced at Investor Day, we indicated that that will deliver a 300 basis points margin improvement from 24% to 27% indeed. So what we announced today is an incremental program of $60 million which should give us $180 million by 2018. From the $60 million, we indicate that we will use that to reinvest in our business to strengthen our future growth. So that will be not part of the growth to profitability."
1002291,367328591,1015187,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","Okay, so...",2,"Okay, so..."
1002291,367328591,1015187,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Did that clarified your question?",5,"Did that clarified your question?"
1002291,367328591,1015187,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","I think so, I'm on myself. I apologize. But I just want to make sure. Those of us who are modeling, I'm not looking for guidance. But modeling 27% roughly in 2018, I know it so far out. But are we absolutely insane to do that? Or is that kind of what the",62,"I think so, I'm on myself. I apologize. But I just want to make sure. Those of us who are modeling, I'm not looking for guidance. But modeling 27% roughly in 2018, I know it so far out. But are we absolutely insane to do that? Or is that kind of what the company thinking as well, all else equal [indiscernible] ?"
1002291,367328591,1015187,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","I think, what we laid out in Investor Day, we increased our EBIT margin by 300 basis points to 27%.",20,"I think, what we laid out in Investor Day, we increased our EBIT margin by 300 basis points to 27%."
1002291,367328591,1015187,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","I think you're right, Ken, with the way you're thinking about it, with all the normal caveats about being 2.5 years into the future. But the majority of the market increase will come from a combination of the impact of the Fuel for Growth initiatives that",86,"I think you're right, Ken, with the way you're thinking about it, with all the normal caveats about being 2.5 years into the future. But the majority of the market increase will come from a combination of the impact of the Fuel for Growth initiatives that we are discussing now and of course, we would expect over that time horizon also, aligned with what we communicated at the Investor Day, to see a return to sales growth which will also help the margin accretion exercise."
1002291,367328591,1015187,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Thank you, Ken.",3,"Thank you, Ken."
1002291,367328591,1015187,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Operator","Your next question comes from Matthew Grainger of Morgan Stanley.",10,"Your next question comes from Matthew Grainger of Morgan Stanley."
1002291,367328591,1015187,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","So Kasper, I wanted to just better understand the issue with the testing standards that you mentioned and the anticipated impact, if there is any, that these could have going forward? And I guess, do you think that this had a similar impact across your pe",95,"So Kasper, I wanted to just better understand the issue with the testing standards that you mentioned and the anticipated impact, if there is any, that these could have going forward? And I guess, do you think that this had a similar impact across your peer set during the quarter? Was it idiosyncratic to you? And ask only because we haven't heard any mention of it from 2 of your larger competitors that have already reported? And related just, are there any kind of carryforward costs associated with that that would be meaningful in anyway?"
1002291,367328591,1015187,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","I -- so let me -- I normally don't comment on what my competitors say. But I think it depends on how you read the statements they made. I guess we read them a little bit differently from how you may have read them. I do think that it has impacted everybod",205,"I -- so let me -- I normally don't comment on what my competitors say. But I think it depends on how you read the statements they made. I guess we read them a little bit differently from how you may have read them. I do think that it has impacted everybody in pretty much the same manner. So I think other people have referenced the fact that informal exports or imports into China have slowed, et cetera, et cetera. And I think that we probably all have seen the same impact. I do want to reiterate just that we see this as an incredibly favorable development over the midterm. And a clear sort of sign of the Chinese government's commitment to ensure the safety of products that are being sold in China and ensure that these products, in every case, conform with Chinese quality standards. So you've heard me mention this a number of times before. So I'm frankly, though I will openly admit that we have hope that we would report slightly better sales results in the second quarter due to this issue, I'm actually very happy with it from the potential for it to impact our business favorably as we move forward."
1002291,367328591,1015187,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","Thanks, Kasper. And just I'm sure you're well placed to me whatever requirements there are. But just the costs associated with that, with the requirements, is it material in any way?",31,"Thanks, Kasper. And just I'm sure you're well placed to me whatever requirements there are. But just the costs associated with that, with the requirements, is it material in any way?"
1002291,367328591,1015187,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","No. I mean, the -- I should perhaps have been more explicit. But actually, the additional testing that is happening is actually done by the Chinese government. And of course, we have invested substantially in ensuring that we can, in every case, meet the",58,"No. I mean, the -- I should perhaps have been more explicit. But actually, the additional testing that is happening is actually done by the Chinese government. And of course, we have invested substantially in ensuring that we can, in every case, meet the Chinese quality standards on products that we sell in China, whether directly or indirectly."
1002291,367328591,1015187,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Operator","Your next question comes from John Baumgartner from Wells Fargo.",10,"Your next question comes from John Baumgartner from Wells Fargo."
1002291,367328591,1015187,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","Michel, I wanted to touch on the incremental sales force and distribution savings you mentioned. Can you speak more to the specifics of that? In terms of what it entails? And maybe what types of risks, if any, that may present to your top line going forwa",56,"Michel, I wanted to touch on the incremental sales force and distribution savings you mentioned. Can you speak more to the specifics of that? In terms of what it entails? And maybe what types of risks, if any, that may present to your top line going forward? Just in terms of balancing your in-market resources. Thanks."
1002291,367328591,1015187,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Maybe I'll give one comment and then I'll let Michel expand on it. John, I think as fast as it comes to the sales force, the organizations and reductions in the spend, first, you should not necessarily infer that greater efficiency in our sales force expe",152,"Maybe I'll give one comment and then I'll let Michel expand on it. John, I think as fast as it comes to the sales force, the organizations and reductions in the spend, first, you should not necessarily infer that greater efficiency in our sales force expenses means a reduction in force. Indeed, in many cases, it's an optimized station of discretionary spends that we have in the sales force that sit in the same line of the P&L. But it's also true to say that outside of the sort of frontline sales force, there are probably opportunities selectively across our global organizations to organize ourselves a bit differently. So I would say that. I think maybe the -- on the A&P P side, I think we're simply recognizing that there are efficiencies available to us as the world is changing that we order, put more energy to take advantage of. Michel?"
1002291,367328591,1015187,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","2 my comments to add. The $60 million [indiscernible] additional Fuel for Growth savings that we announced, it is not only related to sales force and distribution, just to make that clear, right? It is a further optimization also of the supporting functio",87,"2 my comments to add. The $60 million [indiscernible] additional Fuel for Growth savings that we announced, it is not only related to sales force and distribution, just to make that clear, right? It is a further optimization also of the supporting functions. And I would say, even the majority will come from the supporting roles. And to your point, let's be clear. We always said, we'll be very careful with salesforce optimizations because we don't want to jeopardize our momentum in certain markets that we're having."
1002291,367328591,1015187,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Operator","Your next question comes from Robert Moskow Crdit Suisse.",9,"Your next question comes from Robert Moskow Crdit Suisse."
1002291,367328591,1015187,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","I was wondering, when you talked about the inspections on the borders, are you talking about all boarders? It's not just the Hong Kong border? But it's just any product kind of coming into the country? And also, I mean, is there anything that you can do t",108,"I was wondering, when you talked about the inspections on the borders, are you talking about all boarders? It's not just the Hong Kong border? But it's just any product kind of coming into the country? And also, I mean, is there anything that you can do to expedite it, expedite those inspections and why can't we think of it more as just kind of like a one time hit to those debt incoming product that kind of slows you down temporarily but then is kind of solved maybe a month or 2 later? It's like a tape [ph] going going through a snake or something like that."
1002291,367328591,1015187,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Rob, I think it's a good question. And actually, you can think about it sort of like that. There isn't anything we can really do to expedite it because, as I've said, it applies to the formal importation process into China. And the testing is handled by t",402,"Rob, I think it's a good question. And actually, you can think about it sort of like that. There isn't anything we can really do to expedite it because, as I've said, it applies to the formal importation process into China. And the testing is handled by the Chinese, by Chinese government agencies outside of the control and involvement of the importing party. So you simply have to wait for your turn, so to speak, and for your individual import batch to be tested and then released through the importation process. It's clear that this created a very -- this was a very large undertaking by these responsible agencies in China. And there was some short-term backup. I'm absolutely confident that they are working day and night to resolve that. And sort of, as usual, I have great confidence in the fact that the Chinese government will resolve that and get back to more than normal importation flow as they refine these processes. So I do think that that part of it is sort of temporary. I think the part that will impact us is that of course, our financial year inevitably cuts off on the 31st of December. And there are two impacts in the near term from this. Firstly, there are the sales that we lost through supply shortages in the second quarter already. That -- an element of that, we will probably be able to recapture because we'll be able to replenish inventory in our distributors. But as I referenced, in response to David's question, at the outset of this Q&A session, there were out of stocks that occurred at the retail level which means that we did lose sales to consumers. And those are, if you wanted, permanently lost, so to speak. They're not going to be recovered. The second impact of it is that if you think about this, it effectively puts our kind of growth plans behind these products 2 months back because we have been in this constraint supply situation for the last couple of months, which means that the, given the rather steep growth curve that we have anticipated for these products, we'll be exiting the year, we'll be cutting off the year on the 31st of December at a point of lower sales than we would otherwise have done given the 2 months that we have sort of inevitably lost or partially lost."
1002291,367328591,1015187,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","And does this put at all the Enfinitas concept at risk in any way, shape or form? Like are customers who have been notified of the product launching, are they upset that it's not available? Or have they noticed it's not available? Do you have any feedback",49,"And does this put at all the Enfinitas concept at risk in any way, shape or form? Like are customers who have been notified of the product launching, are they upset that it's not available? Or have they noticed it's not available? Do you have any feedback on that?"
1002291,367328591,1015187,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","I've never had a customer who was entirely happy when you can't supply their orders. But I think we have a great relationship with the vast majority of our customers in China. And they understand the situation. As I said, it's not completely unique to our",72,"I've never had a customer who was entirely happy when you can't supply their orders. But I think we have a great relationship with the vast majority of our customers in China. And they understand the situation. As I said, it's not completely unique to our company and I think we managed to explain it to them. And I feel confident that we still have the support of our customer base."
1002291,367328591,1015187,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Operator","Your next question comes from Jon Andersen with William Blair.",10,"Your next question comes from Jon Andersen with William Blair."
1002291,367328591,1015187,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","I just want to put the discrete import testing issue aside for a minute and just Kasper, if you could comment maybe on some of the broader regulatory changes that are happening in China. I'm thinking here about things that may ultimately resolve in volume",89,"I just want to put the discrete import testing issue aside for a minute and just Kasper, if you could comment maybe on some of the broader regulatory changes that are happening in China. I'm thinking here about things that may ultimately resolve in volume migration away from some of the gray market into more responsible producers or registered product hands. Can you talk a little about what's happening there? The timing of some of those events? and when do you think there's a benefit here to meet? Thanks."
1002291,367328591,1015187,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Well, I mean, we've been talking about this topic, I guess, it's a broad topic now, for at least a couple of years. I remain very, very optimistic about the way the Chinese government is going about this. It's natural that we would always wish that things",255,"Well, I mean, we've been talking about this topic, I guess, it's a broad topic now, for at least a couple of years. I remain very, very optimistic about the way the Chinese government is going about this. It's natural that we would always wish that things could happen faster than they do. But what I see is a very clear determination by the Chinese government to ensure that products that are sold to China, for consumption by Chinese children, are all safe and in compliance with their standards. And that's a very reasonable goal. There are various initiatives that intersect as they pursue this latest one to try to get a handle on imported products, at least through the formal channels and making sure that those products comply with Chinese standards. I think it's a very positive one. I think there's still a significant amount of product going through sort of informal channels imported into China in small parcels, mainly through what we have previously called consumer-to-consumer e-commerce or what we can perhaps call unofficial exports out of say, Europe or Australia. I would expect the Chinese government, just looking at that. And overtime, they will determine a way to ensure that you can't have different quality standards applying to that sales channel than you had to the official sales channels. So overall, I'm very -- I'm very encouraged by what I'm seeing, recognizing that is challenging us in the short-term but it's a good thing for the long-term development of the China market."
1002291,367328591,1015187,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Thank you.",2,"Thank you."
1002291,367328591,1015187,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Operator","Your next question comes from Mario Contreras with Deutsche Bank.",10,"Your next question comes from Mario Contreras with Deutsche Bank."
1002291,367328591,1015187,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","So I wanted to ask on North America. Earlier in your remarks, you mentioned the share recovery there has been a bit slower than expected. And then later, you also mentioned that A&P was down in that region. So I guess my first question is, is there any co",69,"So I wanted to ask on North America. Earlier in your remarks, you mentioned the share recovery there has been a bit slower than expected. And then later, you also mentioned that A&P was down in that region. So I guess my first question is, is there any correlation there? And second, and more broadly, what does it take to get share to a more acceptable level? Thank you."
1002291,367328591,1015187,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Well, Mario, I think first of all, let me start by stating that the market share comments are all relative and they are relative to where we were to a month ago. And there's no doubt that we've lost some market share, probably about 100 basis points or so",209,"Well, Mario, I think first of all, let me start by stating that the market share comments are all relative and they are relative to where we were to a month ago. And there's no doubt that we've lost some market share, probably about 100 basis points or so in market share versus where we were a year ago, at least the way that we look at the profitable part of the U.S. market. We -- I'm not sure I'm prepared to comment on what our plans are exactly for recovering that market share. But you can imagine that it's receiving a fair amount of attention. And I did talk about the particular product segments where we've seen the -- our share develop unfavorably. So it's still -- we're spending at very healthy levels against it. And I'm confident that if we felt that, it was a question of simply investing more money in order to sell more and therefore, gain more share, we would do so. However, I'm not convinced that this is a question of absolute investment levels. I think there have been some execution of issues that we are working through and I'm confident my team in the U.S. are addressing those issues as we speak."
1002291,367328591,1015187,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Operator, we will take one more question.",7,"Operator, we will take one more question."
1002291,367328591,1015187,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Operator","Your last question comes from Pablo Zuanic from SAG.",9,"Your last question comes from Pablo Zuanic from SAG."
1002291,367328591,1015187,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","Look, just one question on the import and local mix. In previous presentations, you've given the mix. Can you give us as an update on where you are in China in terms of imports and local? And related to that, this trade promotion question, it would be nic",110,"Look, just one question on the import and local mix. In previous presentations, you've given the mix. Can you give us as an update on where you are in China in terms of imports and local? And related to that, this trade promotion question, it would be nice if you can break it by the three product categories, right? And what I mean by that, the local products, the unfamiliar imported range and then Enfinitas launch. Because the way I understand it, you're having to promote your old inventory on the shelves, the local product. So if you can just give some color in that regard, will be helpful. Thanks."
1002291,367328591,1015187,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","I'm going to try and strike a balance and make sure that I don't give way more information to my competitors than I would like, Pablo. So please be understanding of that. So I don't know that [indiscernible] identify how we're spending our trade support.",146,"I'm going to try and strike a balance and make sure that I don't give way more information to my competitors than I would like, Pablo. So please be understanding of that. So I don't know that [indiscernible] identify how we're spending our trade support. On the import versus local business, I think we've been very clear that the imported part of our portfolio is still the fastest-growing part of our portfolio. And we see us being in the kind of transition phase where over the long -- over the midterm, at least we will see our Hong Kong products and our locally produced products probably decline and you will see us making up for that decline with growth with our imported product portfolio. That assumes that there are no unforeseen changes to the regulatory environment in China that would somehow cause that to change."
1002291,367328591,1015187,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","Right. If I may, just to make a follow up. On the margin question, whether people project 26%, 27%, 28% by 2018, my question is you had guided for a 300 net gain. But today, you increased your cost savings from $120 million to $180 million, that's 100 bps",114,"Right. If I may, just to make a follow up. On the margin question, whether people project 26%, 27%, 28% by 2018, my question is you had guided for a 300 net gain. But today, you increased your cost savings from $120 million to $180 million, that's 100 bps on sales, and your A&P efficiency went from $50 million to $100 million to $100 million now, so that amounts to almost another $175 million of margin expansion. But you're still sticking to 27%. So my read of that is great, you have more cost savings. But you have recognize that the reinvestment is great than you had expected. Is that the right, the correctly?"
1002291,367328591,1015187,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Pablo, before Michel answers, could you put your phone on mute when he answers, we're getting an echo from you.",20,"Pablo, before Michel answers, could you put your phone on mute when he answers, we're getting an echo from you."
1002291,367328591,1015187,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","I'm sorry, okay.",4,"I'm sorry, okay."
1002291,367328591,1015187,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Pablo, yes, the major part of that incremental $60 [ph] million will be reinvested in the business, especially [indiscernible], especially also for the A&P, 100 basis points decrease. Is there a posting at reinvestment and like we said, we also potentiall",75,"Pablo, yes, the major part of that incremental $60 [ph] million will be reinvested in the business, especially [indiscernible], especially also for the A&P, 100 basis points decrease. Is there a posting at reinvestment and like we said, we also potentially, expect over time some for the headwinds in gross to margin in line with what I indicated at Investor Day in October. That's the reason why you don't see it go through the benefit."
1002291,367328591,1015187,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Thank you for participating in Mead Johnson's earnings conference call. I will now turn it back to the operator.",20,"Thank you for participating in Mead Johnson's earnings conference call. I will now turn it back to the operator."
1002291,367328591,1015187,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Operator","This concludes the presentation. You may now disconnect. Good day.",10,"This concludes the presentation. You may now disconnect. Good day."
1002291,367328591,1015680,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Operator","Good day, ladies and gentlemen, and welcome to the Mead Johnson Nutrition Second Quarter and First Half 2016 Earnings Conference Call. My name is Liz, and I will be your coordinator for today. [Operator Instructions] As a reminder, this conference is bein",66,"Good day, ladies and gentlemen, and welcome to the Mead Johnson Nutrition Second Quarter and First Half 2016 Earnings Conference Call. My name is Liz, and I will be your coordinator for today. [Operator Instructions] As a reminder, this conference is being recorded for replay purposes. 
I would now like to turn the conference call over to Kathy Macdonald, Vice President, Investor Relations. Please proceed, Kathy."
1002291,367328591,1015680,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Thank you, Liz. Good morning, and thank you for joining Mead Johnson's Second Quarter and First Half 2016 Conference Call. With me today are Kasper Jakobsen, our Chief Executive Officer; and Michel Cup, our Chief Financial Officer. Earlier today, we iss",304,"Thank you, Liz. Good morning, and thank you for joining Mead Johnson's Second Quarter and First Half 2016 Conference Call. With me today are Kasper Jakobsen, our Chief Executive Officer; and Michel Cup, our Chief Financial Officer. 
Earlier today, we issued our 10-Q, earnings release and financial reference slides. If you have the slides in front of you, please turn to Slide #2. A detailed explanation of our forward-looking statements appears in the materials posted on our website in connection with today's conference call. 
As we start, let me remind everyone that our comments will include forward-looking statements about our future results, including statements about our financial prospects and projection, commodity costs, currency fluctuations, pricing, taxes, capital spending, new product launches, other growth initiatives and market conditions that constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Keep in mind that our actual results may differ materially from expectations as of today due to various factors, including those listed in our annual report on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K, and each case is filed with or furnished to the Securities and Exchange Commission in our earnings release issued this morning. 
Today's comments will include discussion of non-GAAP financial measures. A reconciliation of these measures to comparable GAAP measures appears in this morning's earnings release and financial reference slides, which are available at meadjohnson.com. In addition, any forward-looking statements represent our estimates only as of today and should not be relied upon as representing our estimates as of any subsequent date. While we may elect to update forward-looking statements at some point in the future, we specifically disclaim any obligation to do so, even if our estimates change. 
I will now turn the call over to Kasper."
1002291,367328591,1015680,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Thank you, Kathy, and good morning to all of you. Thank you for joining us on our earnings call. My comments will focus on our strategy and top line performance. And then Michel will follow up with some additional financial information on segment profit",2459,"Thank you, Kathy, and good morning to all of you. Thank you for joining us on our earnings call. 
My comments will focus on our strategy and top line performance. And then Michel will follow up with some additional financial information on segment profitability and our company's cash flow. 
Let me begin by summarizing the company's second quarter performance before I provide additional details on each of our reporting segments. Except where I note otherwise, I'll be referring to non-GAAP results. At the end of last year, we laid out a 3-year plan for value creation, with this year being a year of transition. I also identified 3 key milestones we'd use to monitor our profits against this value-creation plan. I referenced these plans in our last earnings call, so let me reference them again today. 
Of the 3 milestones we laid out, the first was to return the business to constant-dollar sales-growth. Today, you'll hear us reiterate expectations for 2016 sales that anticipates that we'll return to growth in the coming quarters. Within the most recently completed quarter, demand in China for new products continued to grow. Actual shipments this quarter, however, were constrained by supply shortage caused by newly introduced, additional import processes at Chinese border points. More about this later. 
Despite these constraints, gross sales before trade support and discounts were in line with prior quarter. Net sales were lower than the quarter before, as trade support for new product introductions increased. Michel will elaborate on this a little bit later. 
Our second milestone is centered around our commitment to reduce our operating expense base. Year-to-date, we've delivered $47 million in expense reductions. We've already achieved nearly 80% of our annual target of $60 million. We are ahead of schedule. And in this call, we're announcing a revised, more ambitious target. 
We are both accelerating and expanding our cost initiatives by increasing our 2016 target to $75 million to $80 million in savings from the previously announced $60 million. We're also raising our 3-year cumulative savings goals from $120 million to $180 million. 
Our third and final milestone we said would be to invest a portion of our expense savings to fund key growth initiatives. To date, we've invested substantially behind the introduction of a fully imported Enfamil into China and the building of a toddler franchise in North America. This latest quarter, we made strong investments in support of our Enfinitas launch in China and the expansion of distribution reach. Over time, we'll demonstrate to you that these investments are essential to us delivering on our commitment to shareholder value creation. 
Turning now to our second quarter 2016 results. We continue to manage through a challenging global operating environment. Economic growth in many emerging and developing economies of Asia and Latin America has slowed over the past 18 to 24 months. Simultaneously, political uncertainty affects many markets in both Asia and South America. These effects present near-term headwinds for us. That said, we continue to find opportunity amidst the uncertainty. We continue to invest to put ourselves in the best possible position for when a turnaround and economic growth eventually materializes, and come, it will. 
For the second quarter, sales for the company was $942 million. Reported net sales were $9 million lower than the prior year quarter. Currency adversely impacted our results by 500 basis points. Consequently, constant-dollar sales were below -- excuse me, consequently, constant-dollar sales were 4% below those of the second quarter of 2015. Price was favorable by 1% despite added trade support in China, while volume was 5% unfavorable. 
Second quarter sales were impacted by significant investments to secure trade support and distribution of Enfinitas in China. Though costly in the near term, these investments will help establish the brand and drive long-term revenue growth. I'll return to the topics of Enfinitas a little later. 
In China, a requirement for additional product testing prior to importation took effect towards the end of the second quarter, causing delays to the importation process. I want to commend the Chinese government for its actions to enhance food safety standards and importation guidelines to ensure imported products can be safely used by Chinese parents and children. 
During the quarter, the government implemented new testing standards for imported products within our category. The effect of this change was a temporary delay in the importation of some of our fastest-growing products from our Netherlands facility. This drove some near-term volatility in our sales results. In the mid to long term, we, however, believe these additional processes will benefit both Chinese children and responsible operators within the industry. 
Outside of China, the deteriorating circumstances in Venezuela, that so tragically impacted the people and our colleagues there, have resulted in significantly reduced shipments to the country. When comparing to the second quarter of last year, this adversely impacted the company's sales by 130 basis points in the latest quarter. 
Despite the challenging operating environment, I'm pleased with the company's earnings power. Gross margin remained strong. Our strategy to drive growth of higher-value products and product forms is working and helps offset the impact of increased investments above the net sales line. Investments in advertising and promotion represented 17.6% of net sales in the quarter. 
Our Fuel for Growth cost-reduction initiative drove significant reduction in SG&A. Overall, these costs were down 9% in constant dollars in the second quarter compared to the same quarter of prior year. 
While we made significant investments in key growth initiatives, our EBIT margin was 24.4% in the quarter, and non-GAAP earnings per share for the quarter were $0.88. Michel will expand on our earnings delivery a little later. 
I'll now discuss the performance of each of our reporting segments, beginning with the North America/Europe segment. 
Net sales in the North America/Europe segment were in line with the second quarter of 2015 on a constant-dollar basis and improved sequentially from the first quarter. A 1% benefit from price was offset by lower volumes. Additionally, we experienced additional headwind of 1% from foreign exchange. 
The Center for Disease Control recently issued their report on 2015 U.S. birth and birth rates. Reported annual birth was 0.3% below the 2014 level. Breastfeeding rates, however, appeared to have stabilized. Our market share in the U.S. business stabilized in the second quarter but remained at a level lower than the prior year. In our outlook, we are recognizing it will likely take longer than hoped for to recover market share. Much of our share loss was within the specialty and solution segment of the infant formula market. But we are confident we understand our challenges and we're addressing them. 
There are bright spots within this reporting segment also. Last October, we introduced a new 32-ounce liquids packaging. This product line is now growing double digits, and we are gaining share in the high-value liquids category. 
It's still early days for our premium-priced Inspire products but reception from retailers has been favorable, and we expect to see distribution increase in the coming quarters as we build consumer demand. 
Our North American toddler business, defined as products targeting children more than 1 year of age, continues to grow at an annual rate in double digits. 
And turning to Canada. I continue to be pleased with our progress. Second quarter sales grew double digits based on strong market share gains in both the infant and children segments. We've executed extremely well over the past year or 2, and our Canadian team is deservedly receiving much internal recognition. 
Our European business remains strong based on a leading position in the growing allergy segment there. We are well positioned to benefit from future increases in diagnosis and have a strong innovation pipeline to support our growth in Europe. 
Let me now turn to Latin America. Constant-dollar sales for the total region was 3% lower than the prior year same quarter. Pricing benefits of 9% was insufficient to fully offset foreign exchange impacts of 13%. Excluding the impact of our sharply reduced business in Venezuela, Latin America sales grew 4% in constant dollars over the same quarter of 2015. 
Mexico and Colombia were the biggest contributors to growth. In Mexico, we are seeing improved momentum in both our premium pediatric nutrition business and our milk modifier business. We enjoy strong market shares in our milk modifier business and retain our #1 position in this category. In infant formulas, we recently rolled out a product containing Milk Fat Globular Membranes (sic) [Milk Fat Globule Membranes], the same key ingredient contained in Enfinitas and its by-products launched in China and the U.S. 
Trends in other parts of Latin America remain broadly unchanged from the prior quarter. In Brazil, the economic challenges continue to hurt demand for discretionary items by our mid-priced children's products. The infant premium formula products are less discretionary, and they continue to grow. We continue to benefit from strong sales in our Colombian unit, which maintained strong market shares, and in addition, is benefiting from cross-border demand from Venezuela. 
We are rolling out our new plastics packaging and refill systems across Latin America. And in some markets, we are testing ready-to-drink versions of our children's products. These initiatives will allow us to take advantage of segment growth opportunities and support selective increases in price. 
I'll turn now to the Asia segment. Constant-dollar-growth sales in Asia were in line with the second quarter of 2015. In support of the Enfinitas launch in China, trade investments, however, were significantly higher when compared to the prior year. Partly as a result of this, price was unfavorable by 2%, as the increased trade investments in China more than offset the impact of price increases in Southeast Asia. 
Across the region, product mix continued to improve with sales of our premium-priced products going faster than those of our lower-priced variants. Volume was unfavorable by 5%, as we experienced delays to importation in China and dealt with some market share weakness in the Philippines. Despite improving momentum in China, the Asia region has not yet recovered to sales levels seen in the early part of 2015. 
In the Philippines, we've seen softer market share in sales of Lactum, our mid-priced children's brand. We feel we've identified the root causes behind our share loss and have a remedial plan that will allow us to get back on track. 
Our Malaysia business is growing both volume and price. We recently introduced a new formulation and improved packaging that will allow us to recover market share over time. 
Across Southeast Asia, we are rolling out new product formulations and promoting the benefits of our new plastics packaging. Supported by an improved value equation, we are raising prices behind this innovation. 
I will finish my discussion of the Asia segment with China. In my introductory headlines, I described the import delays caused by increased processes at all border points. In Mainland China, the government implemented a new requirement that every batch be extensively tested prior to release to Chinese consumers. Previously, a sampling approach has been applied. The increase in the number of tests required caused temporary delays as testing and verification capacity was stretched. The effect of this was a temporary delay in the importation and shortage of supply of many of our fastest-growing imported line items, as I mentioned earlier. We, nevertheless, are pleased to see these measures implemented. 
Similarly, increased customs monitoring and reduced visitor numbers have adversely impacted our Hong Kong business. It's become more challenging for our Hong Kong business to compete for visiting Chinese tourists that now connects these imported products more easily from within the Mainland. These challenges confirm our China strategy pursuing increased flexibilities through a broader product portfolio sold through a more diverse set of sales channels. 
Turning now to Mainland China, where our fully imported products continues to gather momentum, and we're seeing stronger demand from consumers. Through the second quarter, we continued to grow market share of the imported segment. In the baby store channel, we've increased our distribution, supported by our most recent, new product introductions. We are seeing both our ability to make progress and the substantial runway we have ahead of us. 
As of the second quarter, we are no longer under indexing versus the market in the fast-growing baby store channel. Our new Enfinitas product line is off to a solid start. Three months after introductions, we are still building distribution and demand, but we are encouraged by the early signs. 
In totality, I'm satisfied with the progress we've made with our portfolio and channel transformation in China. I also recognize we've got a long way to go and a lot of opportunities ahead of us. It's hard not to be excited about the immense potential of not only our China business but our global business. 
Before I hand over to Michel, I want to provide an updated outlook for full year 2016,  our year of transition, a year in which we are addressing several structural opportunities within both our brand portfolio, our product lineup and our cost structure. 
At the beginning of the year, we knew comparisons in the first half 2016 would be challenging. I'm satisfied that many of our critical initiatives have gone as planned, and we are expecting growth over prior year in the second half of the year. However, we've seen 3 developments causing us to revisit our estimate for full year 2016 constant-dollar-sales growth. It's taking us longer than expected to recover the market share we lost in the U.S. towards the end of 2015. 
Secondly, the import-related challenges in China, Hong Kong in the second quarter cost of sales we won't fully recapture until next year. 
Thirdly, we are supporting our imported portfolio in China with additional trade support. In light of these factors, we now expect constant-dollar sales in line with or not more than 2% below the 2015 level. 
Through the first half of the year, we've identified several opportunities within our cost structure. In doing so, we found additional opportunities to both reduce cost and increase efficiencies. In a moment, Michel will outline an expanded ambition and scope for our operating expense initiative, the project we refer to as Fuel for Growth. Despite lower sales, a slightly improved outlook for gross margin, expense optimization and the benefit realized from a lower tax rate in the just completed quarter allow us to reiterate our expectation for non-GAAP earnings per share of $3 -- of between $3.48 and $3.60 for the full year 2016. 
I'll now hand over to Michel, who will provide additional details on our second quarter and first half financial performance. I'll then return with a few summary remarks before we take your questions. Michel, over to you."
1002291,367328591,1015680,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Thank you, Kasper, and good morning, everyone. Today, I will discuss the company's second quarter and first half 2016 financial results. I will then briefly highlight EBIT results for each segment, cash flow and liquidity items and conclude with a summary",2809,"Thank you, Kasper, and good morning, everyone. Today, I will discuss the company's second quarter and first half 2016 financial results. I will then briefly highlight EBIT results for each segment, cash flow and liquidity items and conclude with a summary of full year guidance. 
Unless otherwise noted, my comments will be on the non-GAAP financial results. References to currency impacts or the effects of currency fluctuations generally refer to the impact on the translation of local currency financial statement into U.S. dollars. In addition, my comment about sales will refer to net sales, unless I explicitly call out gross sales. 
Let me start with sales as shown on Slide 3. Kasper addressed the constant-dollar change. I will focus on the reported sales and the foreign currency impact. For both the second quarter and first half year, adverse foreign exchange rates contributed to a 500 basis points decline compared to the same period of the prior year. Second quarter net sales on a reported dollar basis grew 9% below prior year quarter. Reduced shipments to Venezuela impacted net sales negatively by 1% in the second quarter versus the prior year quarter. 
Slide 4 summarizes the impact of foreign exchange on sales. U.S. dollar continued to be strong and effects of translation of local currencies negatively impacted all reporting segments. However, the impact was slightly less significant in the second quarter of 2016 when compared to the trend from the last 3 quarters. Nearly 2/3 of the second quarter negative currency impact on sales were from the Chinese renminbi, the Mexican peso and the Argentine peso. The balance of the adverse foreign exchange impact was widespread across regions. 
As a result of the year-to-date foreign exchange impact, our outstanding currency hedges for the remaining of the year and the current forward rate, we are revising our currency expectations from minus 6% to minus 5% adverse foreign exchange impact on sales for the full year 2016. I will address foreign exchange impact in the EPS guidance section as well. 
I'm introducing Slide 5 for better transparency of gross sales, which reflects sales to customers before trade investment and other items, which are recorded as gross to net sales adjustments. We reallocated some investments in the second quarter from advertising and promotion to trade investments, in support of the rollout of Enfinitas and build on our momentum of the fully imported premium products that were introduced in the second quarter of last year. Gross sales on a constant-dollar basis were flat compared to the prior year quarter and down 2% for the first half year of 2016 versus the same period last year. The significant gross sales improvement in the second quarter has been realized. 
Slide 6. The second quarter EBIT of $230 million was 10% above the prior year quarter on a constant-dollar basis. Foreign exchange adversely impacted EBIT by 6%, including currency impacts. EBIT increased 4% on a reported basis in the second quarter. 
If you would exclude Venezuela, our EBIT on constant-dollar basis improved by 14% versus prior year quarter. The second quarter EBIT margin of 24.4% of sales was 290 basis points better than the prior year quarter. Despite macroeconomic and country-specific challenges which impacted our sales, we made excellent progress to reduce operating expenses as part of our Fuel for Growth program which allowed continued investments and, at the same time, improve the underlying profitability. Year-to-date EBIT was $474 million, a decline of 1% versus previous year on a constant-dollar basis. Foreign exchange, an adverse impact of 8%. 
Excluding Venezuela, EBIT in the first half year improved by 3% versus previous year period on a constant-dollar basis, mainly driven by a higher gross margin and our cost savings realized in the first half year, partly offset by demand-generating investments. 
I will now move to the factors that impact gross margin on Slide 7. Gross margin was 65.1% in the second quarter of 2016, or 66% on a constant-dollar non-GAAP basis. Adverse foreign exchange impacted the gross margin by 150 basis points in the second quarter. We were able to deliver a nearly flat gross margin on a reported basis in both the second quarter and the first half year compared to the previous-year periods despite the significant currency headwind. 
Sales had a slightly negative impact on gross margin from higher-trade investment, especially in China. Low dairy cost continued to be the large benefit to gross margin in the second quarter and first half of 2016. Our key dairy components have been secured through supply contracts for the remainder of the year, and we expect some further benefits, although the dairy benefits for the remainder of the year will be smaller compared to the first half year. 
We continue to deliver productivity savings within cost of goods sold. Year-to-date, the supply chain team delivered productivity savings of around 3.5% of cost of goods sold, in line with our expectation. With dairy secured for the full year, we expect full year gross margin to be slightly better than our prior year guidance of 64%. 
Moving to operating expenses. I will start with advertising and promotion investments  on Slide 8. Advertising and promotion was 17.6% of sales in the second quarter compared to 18.4% in the prior year quarter. As previously mentioned, in the second quarter, we reallocated a portion of investments from A&P to trade investments, which are recognized in gross to net sales. Despite the year-over-year savings, the second quarter of both years marked noticeably higher investments. The incremental investments were mainly to support key China initiatives, last year for the launch of our fully imported products and in April of this year, the launch of the Enfinitas product line and the continued support of our greater China strategy. 
In the second quarter, we purposefully delayed some A&P investments due to delays in the importation of some of our China product impacting our sales. As such, we expect that third quarter may continue to be in elevated level before it normalizes in the fourth quarter. 
Slide 9 provides the combined spending of the mine-generating investments, both as trade investments classified in gross to net sales and advertising and promotion. Some of the key trade investment activities include trade support, customer programs and promotional pricing. For the second quarter, the combined investment increased above the prior year quarter and was also higher versus the last few quarters. 
Trade spending is focused close to our consumer and to ensure our products are present with strong distribution in the key growing channels. In the past few quarters, we've increased these investments, especially in China, to be more competitive in the baby store and e-commerce channels. While we increased trade investments, we plan to reduce the A&P as a percentage of sales over the next few years. 
Last quarter, we committed to provide an update on our review of advertising and promotion expenditures. At Investor's Day last year, when I spoke about advertising and promotion, I stated that we should be able to optimize a lower A&P by 50 to 100 basis points over 3 years. We can now confirm that we expect to be at the top of that range and reduce our A&P by 100 basis points by 2018. We will realize this by prioritizing investment choices that maximize our return on investments of key influence drivers. 
We will continue to optimize our nonmedia expenses and leverage our decision-supporting tools better. In addition, we will strengthen our focus on digital marketing versus the traditional media. 
Slide 10. We reduced our SG&A cost by 9% on a constant-dollar basis in the second quarter of 2016 versus the previous-year quarter and by 10% year-to-date compared to the prior year period. Like we indicated before, our Fuel for Growth program is focused on cost reduction within our support functions and marketing. 
Areas of focus were the reduction of key vendor contracts, eliminates discretionary spend and optimize organization layers. As you can see from Slide 11, we are significantly ahead of schedule on the original 2016 Fuel for Growth target. Our Fuel for Growth target for this year was $60 million. By mid-year, we've delivered 79% of this year's target savings, or $47 million already. Especially in the corporate overhead functions, we were able to reduce our cost by $30 million in the first half year of 2016 versus the first half year of 2015. Significant progress has been made by systematically renegotiating contracts with our largest vendors. 
Slide 12. Over the last few months, we performed a more extended, deep-dive review of our expenses as well as our organizational structure. We concluded, based also on the success of our results to-date, to accelerate certain cost-savings programs identified earlier and to expand the scope to all operating expenses functions, including sales force and distribution. We now expect to deliver $75 million to $80 million of savings in 2016. This is an increase of $15 million to $20 million versus our original 2016 target. Taking into account the savings realized in 2015 of $20 million, cumulative savings by the end of 2016 are expected to be around $95 million to $100 million. 
In addition to the original program of $120 million, we expect an incremental $60 million of cost-savings opportunities by 2018. The combined Fuel for Growth program will now deliver $180 million savings by 2018. 
The incremental Fuel for Growth savings will provide additional flexibility to invest in the company's future growth. 
Turning to Slide 13 for a discussion of EBIT by segment. Let me start with Asia. In the second quarter, Asia delivered an EBIT of $137 million, a decrease of 4% on a constant-dollar basis compared to prior year quarter. Foreign exchange adversely impacted EBIT by additional 8%. Lastly, from the Chinese renminbi, the Thai baht and the Malaysian ringgit. The Asia EBIT margin at 30% declined 50 basis points compared to the second quarter of 2015. The main drivers were lower sales and an increase in trade investment in gross to net sales. The lower net sales impact was somewhat offset by a favorable dairy cost and some lower A&P expenses. 
For the first half year of 2016, the Asian EBIT margin of 32% were 350 basis points lower than the prior year, as lower sales and higher-demand-generation investments were not fully offset by the dairy benefit. A&P as a percentage of sales increased in the first half year versus the previous period. 
Turning to Slide 14. Latin America delivered EBIT of $36 million in the second quarter, a decrease of 7% on a constant-dollar basis compared to the prior year quarter. For this segment, foreign exchange adversely impacted EBIT by 12%, largely from the Mexican peso. Excluding our Venezuela business, EBIT on a constant dollar increased by 9% in the second quarter -- for the previous year quarter. And EBIT on a constant dollar increased 16% in the first half year of 2016 versus the previous-year period. 
For the balance of the business, lower sales were somewhat offset by lower-demand-generating expenses. The year-to-date Latin America EBIT margin was 23.6% compared to 25.3% for the same period last year. Lower EBIT margin is mainly a result of lower gross margin from the deteriorating situation in Brazil and Venezuela, somewhat offset by cost-reduction programs. 
Slide 15 shows the North America/Europe segment results. For the second quarter, North America/Europe EBIT was $99 million, an increase of 21% on a constant-dollar basis. The EBIT margin of 31.1% was 450 basis points better than previous year quarter. Gross margin remained strong from the benefit of low dairy costs. Within operating expenses, reduction in A&P and SG&A cost savings helped fund selective investments and drove high EBIT margins. Year-to-date, EBIT margin was 29.2%, an improvement of 300 basis points versus previous-year period. Fuel for Growth savings programs and the dairy benefit contributed to the improved EBIT margin. 
I will now address the financial results from EBIT to EPS on Slide 16. The interest expense of $26 million in the second quarter was similar to the first quarter of 2016 expense. When compared to the prior year quarter, the interest expense increase reflects the impact of the November 2015 $1.5 billion notes issuance. A significant portion of the proceeds from the notes were used to finance the accelerated share repurchase program, or ASR. 
Since the ASR concluded on June 30, let me briefly provide you a summary of the transaction. During our Investor Day, we announced the new $1.5 billion share repurchase program, of which $1 billion would be in the form of an ASR. 10.7 million shares of stock were received in the fourth quarter of 2015, an additional 2.1 million of shares of stock were received on June 30, 2016. In total, 12.8 million shares of stock were repurchased through the ASR program at an average price of $78.05 per share. Since the IPO, the company bought back 23.4 million of shares, with a total value of $1.8 billion. There are 184.7 million shares outstanding as of June 30. And in the last 12 months, this is a reduction of 18.5 million shares. 
The benefit from all share repurchase in 2015 and the full ASR program, net of interest expense, delivered almost $0.05 year-to-date and is in line with our full year guidance of $0.11 benefit per share in 2016. 
As part of the $1.5 billion share buyback program announced in 2015, we still have $500 million available for an additional repurchase program. We continue to focus on shareholder value creation. This includes EBIT margin accretion, sales and EPS growth, along with the return of cash to shareholders through both dividends and share repurchases. 
Next, non-GAAP effective tax rate, or EPR, was 18.3% for the second quarter of 2016 compared to 25.6% in the prior year quarter. In the second quarter of 2016, there was about $0.05 per share benefit as a result of utilizing foreign tax credits on dividends from our foreign operations. We expect the EPR for the balance of the year to normalize. 
Non-GAAP EPS for the second quarter was $0.88, an increase of 16% on a reported basis and 24% on a constant-dollar basis. Year-to-date non-GAAP EPS was $1.75, a decrease of 5% on a reported basis and an increase of 3% on a constant-dollar basis. 
Let me summarize our financial results by addressing the change to EPS on Slide 17. In the second quarter, non-GAAP EPS increased $0.18 to $0.94 per share on a constant-dollar basis versus the prior year quarter. Sales and related gross profit negatively impacted EPS by $0.07. Our Fuel for Growth savings delivered $0.11 benefit. Advertising and promotions were $0.06 lower in the quarter, and that share repurchase program delivered a $0.02 benefit, net of higher interest expense. Tax and other contributed a $0.06 benefit. Despite the negative impact of foreign currency of $0.06 per share, EPS increased by $0.12 versus second quarter last year on a non-GAAP basis. 
Turning to a high-level overview of cash movements. On Slide 18, the cash balance of $1.7 billion as of June 30 was similar to the beginning-of-the-year balance. Cash flow from operations was negatively impacted by $94 million as a result of timing of tax payments and other working capital movements. Our CapEx investments were $81 million, mainly in our U.S. and Europe manufacturing facilities. For the full year ago, our capital spending goal remains about 4% of sales. Dividend payments were $155 million in the first half year. The negative impact of foreign exchange impact of $32 million was related to the currency devaluation in Venezuela. 
To summarize our forward-looking annual guidance on Slide 19, our sales outlook for 2016 on a constant-dollar basis is expected to be 0 to 2% below the prior year. With foreign currency reducing sales growth by about 5%, reported sales are estimated to be 5% to 7% below 2015. 
We reaffirm our 2016 GAAP EPS guidance of $2.91 to $3.03 and our non-GAAP guidance of $3.48 to $3.60 per share for the following reasons: First, we expect a gross margin improvement from our previous guidance of 64%; second, our Fuel for Growth savings are well ahead of plan and will only partly be reinvested in our business; thirdly, we have an ETR benefit around $0.05 in the second quarter; and fourth, the foreign exchange impact is expected to be approximately $0.35 per share from our previous guidance of $0.40 per share. 
GAAP EPS guidance is slightly to be impacted by potentially significant future market-to-market pension adjustments, which cannot be estimated and are classified as specified items. Specified items include charges related to Fuel for Growth and our Venezuela business. 
This concludes my discussion on the second quarter and first half year 2016 financial results. Thanks again for your time this morning. I will now hand over the call back to Kasper."
1002291,367328591,1015680,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Thank you, Michel. Before we open the lines for questions, let me briefly reiterate our expectations that our relative performance will improve as we move into the second half of 2016. We expect to see the company return to positive growth in the coming q",150,"Thank you, Michel. Before we open the lines for questions, let me briefly reiterate our expectations that our relative performance will improve as we move into the second half of 2016. We expect to see the company return to positive growth in the coming quarters and our guidance reflects that. Our efforts to reshape our product and brand portfolio in China are progressing well, so is our initiative to strengthen our presence in the fast-growing channels there. We're gaining momentum in Mexico, Canada and Malaysia while we are addressing our performance shortfalls in the U.S. and the Philippines. We are partaking our ability to invest to maximize our opportunities by improving our gross margins to improve product mix and by lowering our expense base. And finally, we remain as committed as ever to shareholder value creation. 
With that, Liz, could I ask you to open the lines for questions, please?"
1002291,367328591,1015680,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Operator","[Operator Instructions] Your first question comes from David Driscoll with Citi.",11,"[Operator Instructions] Your first question comes from David Driscoll with Citi."
1002291,367328591,1015680,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","Kasper, can you comment on your retail performance in China? And distinguish it from all the various shipment issues that I think you were talking about? Can you give us some color on market share? And maybe a little bit more on the imported product gains",86,"Kasper, can you comment on your retail performance in China? And distinguish it from all the various shipment issues that I think you were talking about? Can you give us some color on market share? And maybe a little bit more on the imported product gains? And then to kind of round all this question out, will the third quarter see China shipments pick up because of the problems of shipments within the second quarter because of the customs issues that you talked about? Thank you."
1002291,367328591,1015680,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Thanks, David. It's an excellent question. So what I was implying in my prepared remarks, but I'm quite prepared to be more specific, is that we are very satisfied with the consumer demand trends that we are observing in China. So we feel that we are gain",190,"Thanks, David. It's an excellent question. So what I was implying in my prepared remarks, but I'm quite prepared to be more specific, is that we are very satisfied with the consumer demand trends that we are observing in China. So we feel that we are gaining share in the -- with our new products, both in our -- in the super high-premium segment where we obviously came from a standing start and in the imported product segment where we've now been at it for a little while. However, the difficulty of getting product into China in this latest quarter did result -- did some selective out-of-stocks situations at retail as well as lower inventories in many of our distributors. So to the extent of the latter, we expect that we will gradually recover that over the second half of the year. A little bit hard to say whether we will recover it all in the third quarter because that involves speculating on how the importation process evolves. But we are quite encouraged and we are confident that some of these issues are sort of relatively short term in nature."
1002291,367328591,1015680,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","Then just to follow up, would you say then that the retail performance and the market share gains are more indicative of the success of the strategy rather than the shipment number you're reporting today?",35,"Then just to follow up, would you say then that the retail performance and the market share gains are more indicative of the success of the strategy rather than the shipment number you're reporting today?"
1002291,367328591,1015680,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","That's certainly the way we look at it. So I hope I brought that across in my prepared remarks.",20,"That's certainly the way we look at it. So I hope I brought that across in my prepared remarks."
1002291,367328591,1015680,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Operator","Your next question comes from Michael Lavery from CLSA.",9,"Your next question comes from Michael Lavery from CLSA."
1002291,367328591,1015680,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","I just have 2 quick ones. One on Enfinitas, I was wondering if you could give some sense of -- I know it's early there still, but for the distribution, is that skewed more towards tier 1 cities or is it broad geographically and just how is that progressin",86,"I just have 2 quick ones. One on Enfinitas, I was wondering if you could give some sense of -- I know it's early there still, but for the distribution, is that skewed more towards tier 1 cities or is it broad geographically and just how is that progressing? And then just second in Indonesia, we saw a premium competitor cut prices by about 10%. What are the market dynamics there for you? Are you seeing pricing pressure or share pressure or opportunities in that market?"
1002291,367328591,1015680,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Let me start with Enfinitas. It really is early to say how that brand is performing. And particularly, as this last months or so was affected by these temporary delays in importation that I've referenced now repeatedly in China. We are aiming for a pretty",129,"Let me start with Enfinitas. It really is early to say how that brand is performing. And particularly, as this last months or so was affected by these temporary delays in importation that I've referenced now repeatedly in China. We are aiming for a pretty broad distribution but obviously with an emphasis on the baby store channel which is the primary outlet for these high-quality, premium-priced products in China. In Indonesia, we typically don't mention it very often in our earnings call, that's not because it's not a great market, it's simply because we have a very small business there and our market participation is relatively low. So I suspect there are other people that are far more qualified than I do to discuss the market trends in Indonesia."
1002291,367328591,1015680,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Thank you, Michael.",3,"Thank you, Michael."
1002291,367328591,1015680,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Operator","Your next question comes from Bryan Spillane with Bank of America.",11,"Your next question comes from Bryan Spillane with Bank of America."
1002291,367328591,1015680,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","Just one question related to the increased investment in trade spend. I guess, Kasper, the question is just, it was that in reaction to some of your competitors promoting more? Was it a reaction? Is it really a mix, channel mix issue, that you're increasi",121,"Just one question related to the increased investment in trade spend. I guess, Kasper, the question is just, it was that in reaction to some of your competitors promoting more? Was it a reaction? Is it really a mix, channel mix issue, that you're increasing your sales in the baby store and that just tends to need more trade promotion? I guess the reason why I ask is just -- it seems sort of inconsistent that you've got a bottleneck at the border, so you're not getting product across, yet you're promoting more, which would seem to increase the incidence of out of stock. So if you can just kind of tie those things together, I think that would  be helpful."
1002291,367328591,1015680,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Bryan, thanks for the question. I mean, the trade support is not always, in any case, tied directly to volume. There are certain amount of sort of fixed expenses that are incurred in order to support the trade and particularly create sufficient presence a",97,"Bryan, thanks for the question. I mean, the trade support is not always, in any case, tied directly to volume. There are certain amount of sort of fixed expenses that are incurred in order to support the trade and particularly create sufficient presence and awareness in the early stage of a brand launch. So it really reflects that. It is very directly connected to the launch of Enfinitas, and it is directly connected to the fact that trade support in the baby store channel tends to be higher than it is, for instance, in the food channel."
1002291,367328591,1015680,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","Okay. So it seems like you've got -- you've made more progress maybe than you would've original -- or it's progressing faster than you thought and so the need for the trade spend is kind of increased sooner than you thought as well. Is that a fair way to",51,"Okay. So it seems like you've got -- you've made more progress maybe than you would've original -- or it's progressing faster than you thought and so the need for the trade spend is kind of increased sooner than you thought as well. Is that a fair way to put it?"
1002291,367328591,1015680,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Well, I think it's -- a better way to look at it is that we have chosen to rebalance our investment between A&P and trade support to some degree in this latest quarter. We expect that, that balance would change from quarter-to-quarter depending on what ou",69,"Well, I think it's -- a better way to look at it is that we have chosen to rebalance our investment between A&P and trade support to some degree in this latest quarter. We expect that, that balance would change from quarter-to-quarter depending on what our activities are and whether they are booked in one line of the sort of brand investments or booked above the net sales line."
1002291,367328591,1015680,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Operator","Your next question comes from Amit Sharma with BMO Capital.",10,"Your next question comes from Amit Sharma with BMO Capital."
1002291,367328591,1015680,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","Kasper, just to continue what you just said, so if we -- if you are going to shift funding between above the line and below the line, how should we reconcile that with what Michel said earlier in his comments about 100 basis points decline in R&D spending",61,"Kasper, just to continue what you just said, so if we -- if you are going to shift funding between above the line and below the line, how should we reconcile that with what Michel said earlier in his comments about 100 basis points decline in R&D spending over the next few years? Is that net of higher based funding? Potentially?"
1002291,367328591,1015680,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Michel, do you want to take it [indiscernible]",8,"Michel, do you want to take it [indiscernible]"
1002291,367328591,1015680,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Yes, when I was referring to A&P, clearly, we were referring to the A&P line as a percentage of sales. Yes, we have -- stepped up the gross to net investments in the second half of the year, and like Kasper said, it was really to support trade and reitera",100,"Yes, when I was referring to A&P, clearly, we were referring to the A&P line as a percentage of sales. Yes, we have -- stepped up the gross to net investments in the second half of the year, and like Kasper said, it was really to support trade and reiterated the rollout of certain new product launch like Enfinitas and to get the distribution rights. So that gave us, I would say, especially in the second quarter, a temporary step-up, and we will continue this from higher trade investment. But I don't expect a further strong increase in that line."
1002291,367328591,1015680,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","So it's just -- I understand it well. So trade spending slightly up this quarter without looking for a sustained increase in that. And then A&P spend savings should accrue or should be available for you to reinvest or drop to the bottom line?",45,"So it's just -- I understand it well. So trade spending slightly up this quarter without looking for a sustained increase in that. And then A&P spend savings should accrue or should be available for you to reinvest or drop to the bottom line?"
1002291,367328591,1015680,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","A&P savings should be reinvested into gross net or should be dropped to the bottom line.",17,"A&P savings should be reinvested into gross net or should be dropped to the bottom line."
1002291,367328591,1015680,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Thank you, Amit.",3,"Thank you, Amit."
1002291,367328591,1015680,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Operator","Your next question comes from Ken Goldman, JPMorgan.",8,"Your next question comes from Ken Goldman, JPMorgan."
1002291,367328591,1015680,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Analysts",".Forgive my -- the length of my question here. But from my perspective, the guidance on Fuel for Growth is a bit confusing. And maybe I'm wrong. But I'm just hoping you can clear it up for me. So you explicitly said in your slides from the Investor Day",209,".
Forgive my -- the length of my question here. But from my perspective, the guidance on Fuel for Growth is a bit confusing. And maybe I'm wrong. But I'm just hoping you can clear it up for me. So you explicitly said in your slides from the Investor Day that you're looking for 300 basis points of margin improvement, not savings but margin improvement. And that implies that your EBIT margin will get to around 27% by 2018, all else equal. And that's an outlook that I think I've confirmed with the company in recent weeks. But you've also talked, including today, about how you're going to reinvest some of your savings back into the business, which suggests that maybe model all of that $120 million, now $180 million, is going to flow to the bottom line. So I'm clearly just trying to figure out, Michel, how do I reconcile what seems to be some conflicting information out there? And I know it's not guidance, but from a rough outlook, is it wrong for us on the outside to think that margins are expected to go up by 300 basis points or more net of reinvestments over the next few years? I think that's a key question for people."
1002291,367328591,1015680,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Yes, so let me clarify to avoid any confusion, because I want to be consistent with the messages that I gave at Investor's Day. So at Investor's Day, we said we will deliver $120 million of Fuel for Growth savings. And we also indicated that we will partl",141,"Yes, so let me clarify to avoid any confusion, because I want to be consistent with the messages that I gave at Investor's Day. So at Investor's Day, we said we will deliver $120 million of Fuel for Growth savings. And we also indicated that we will partly reinvest that and partly will be rolled through profitability. And in combination with a couple of other initiatives that we announced at Investor Day, we indicated that, that will deliver a 300 basis points margin improvement from 24% to 27% indeed. So what we announced today is an incremental program of $60 million, which should give us $180 million by 2018. From the $60 million, we indicate that we will use that to reinvest in our business to strengthen our future growth. So that will be not part of the growth through profitability."
1002291,367328591,1015680,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","Okay, so...",2,"Okay, so..."
1002291,367328591,1015680,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Did that clarify your question?",5,"Did that clarify your question?"
1002291,367328591,1015680,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","I think so. I'm on myself, so I apologize. but I just want to make sure. Those of us who are modeling, I'm not asking for guidance. But modeling 27% roughly in 2018, I know it's so far out. But are we absolutely insane to do that? Or is that kind of what",67,"I think so. I'm on myself, so I apologize. but I just want to make sure. Those of us who are modeling, I'm not asking for guidance. But modeling 27% roughly in 2018, I know it's so far out. But are we absolutely insane to do that? Or is that kind of what the company is thinking as well, all else equal, if it goes as planned?"
1002291,367328591,1015680,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","I think that the line what we laid out in Investor's Day that we increased our EBIT margin by 300 basis points to 27%.",25,"I think that the line what we laid out in Investor's Day that we increased our EBIT margin by 300 basis points to 27%."
1002291,367328591,1015680,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","I think you're right, Ken, with the way you're thinking about it, with all the normal caveats about being 2.5 years into the future. But the majority of the margin increase will come from a combination of the impact for the Fuel for Growth initiatives tha",86,"I think you're right, Ken, with the way you're thinking about it, with all the normal caveats about being 2.5 years into the future. But the majority of the margin increase will come from a combination of the impact for the Fuel for Growth initiatives that we are discussing now and, of course, we would expect over that time horizon also, aligned with what we communicated at the Investor Day, to see a return to sales growth which will also help the margin accretion exercise."
1002291,367328591,1015680,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Thank you, Ken.",3,"Thank you, Ken."
1002291,367328591,1015680,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Operator","Your next question comes from Matthew Grainger of Morgan Stanley.",10,"Your next question comes from Matthew Grainger of Morgan Stanley."
1002291,367328591,1015680,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","So, Kasper, I wanted to just better understand the issue with the testing standards that you mentioned and the anticipated impact, if there is any, that these could have going forward? And I guess, do you think that this had a similar impact across your p",98,"So, Kasper, I wanted to just better understand the issue with the testing standards that you mentioned and the anticipated impact, if there is any, that these could have going forward? And I guess, do you think that this had a similar impact across your peer set during the quarter? Was it idiosyncratic to you? And I asked only because we haven't heard any mention of it from 2 of your larger competitors that have already reported. And related just -- are there any kind of carryforward costs associated with that, that would be meaningful in any way?"
1002291,367328591,1015680,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","I -- so let me -- I normally don't comment on what my competitors say. But I think it depends on how you read the statements they made. I guess we read them a little bit differently from how you may have read them. I do think that it has impacted everybod",205,"I -- so let me -- I normally don't comment on what my competitors say. But I think it depends on how you read the statements they made. I guess we read them a little bit differently from how you may have read them. I do think that it has impacted everybody in pretty much the same manner. So I think other people have referenced the fact that informal exports or imports into China have slowed, et cetera, et cetera. And I think that we probably all have seen the same impact. I do want to reiterate just that we see this as an incredibly favorable development over the mid-term and a clear sort of sign of the Chinese government's commitment to ensure the safety of products that are being sold in China and ensure that these products, in every case, conform with Chinese-quality standards. So you've heard me mention this a number of times before. So I'm frankly -- though I will openly admit that we had hoped that we would report slightly better sales results in the second quarter due to this issue, I'm actually very happy with it from the potential for it to impact our business favorably as we move forward."
1002291,367328591,1015680,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","Thanks, Kasper. And just -- I'm sure you're well placed to me whatever requirements there are. But just the costs associated with that, with the requirements, is it material in any way?",32,"Thanks, Kasper. And just -- I'm sure you're well placed to me whatever requirements there are. But just the costs associated with that, with the requirements, is it material in any way?"
1002291,367328591,1015680,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","No. I mean, the -- I should perhaps have been more explicit. But actually, the additional testing that is happening is actually done by the Chinese government. And of course, we have invested substantially in ensuring that we can, in every case, meet the",57,"No. I mean, the -- I should perhaps have been more explicit. But actually, the additional testing that is happening is actually done by the Chinese government. And of course, we have invested substantially in ensuring that we can, in every case, meet the Chinese-quality standards on products that we sell in China, whether directly or indirectly."
1002291,367328591,1015680,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Operator","Your next question comes from John Baumgartner with Wells Fargo.",10,"Your next question comes from John Baumgartner with Wells Fargo."
1002291,367328591,1015680,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","Michel, I wanted to touch on the incremental sales force and distribution savings you mentioned. Can you speak more to the specifics of that? In terms of what it entails? And maybe what types of risks, if any, that may present to your top line going forwa",54,"Michel, I wanted to touch on the incremental sales force and distribution savings you mentioned. Can you speak more to the specifics of that? In terms of what it entails? And maybe what types of risks, if any, that may present to your top line going forward in terms of balancing your end-market resources."
1002291,367328591,1015680,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Maybe I'll give one comment and then I'll let Michel expand on it. John, I think as fast it comes to the sales force, the organizations and reductions in spend, firstly, you should not necessarily infer that greater efficiency in our sales force expenses",150,"Maybe I'll give one comment and then I'll let Michel expand on it. John, I think as fast it comes to the sales force, the organizations and reductions in spend, firstly, you should not necessarily infer that greater efficiency in our sales force expenses means a reduction in force. Indeed, in many cases, it's an optimization of discretionary spends that we have in the sales force that sit in the same line of the P&L. But it's also true to say that outside of the sort of frontline sales force, there are probably opportunities selectively across our global organizations to organize ourselves a bit differently. So I would say that. I think maybe the -- on the A&P side, I think we're simply recognizing that there are efficiencies available to us as the world is changing that we all have to put more energy into taking advantage of. Michel?"
1002291,367328591,1015680,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Yes, 2 my comments to add. The $60 million a year of additional Fuel for Growth savings that we announced, it is not only related to sales force and distribution, just to make that clear, right? It's a further optimization also of the supporting functions",91,"Yes, 2 my comments to add. The $60 million a year of additional Fuel for Growth savings that we announced, it is not only related to sales force and distribution, just to make that clear, right? It's a further optimization also of the supporting functions. And I would say, even the majority will come from the supporting roles. And your point -- let's be clear. We always said we will be very careful with sales force optimizations because we don't want to jeopardize our momentum in certain markets that we're having."
1002291,367328591,1015680,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Operator","Your next question comes from Robert Moskow, Crdit Suisse.",9,"Your next question comes from Robert Moskow, Crdit Suisse."
1002291,367328591,1015680,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","I was wondering, when you talked about the inspections on the borders, are you talking about all borders? It's not just the Hong Kong border? But it's just any product kind of coming into the country? And also, I mean, is there anything that you can do to",105,"I was wondering, when you talked about the inspections on the borders, are you talking about all borders? It's not just the Hong Kong border? But it's just any product kind of coming into the country? And also, I mean, is there anything that you can do to expedite it, expedite those inspections and why can't we think of it more as just kind of like a onetime hit to those debt incoming product that kind of slows you down temporarily but then is kind of solved maybe a month or 2 later? It's like a pig going to a snake or something like that."
1002291,367328591,1015680,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Rob, I think it's a good question. And actually, you can think about it sort of like that. There isn't anything we can really do to expedite it because, as I've said, it applies to the formal importation process into China. And the testing is handled by t",405,"Rob, I think it's a good question. And actually, you can think about it sort of like that. There isn't anything we can really do to expedite it because, as I've said, it applies to the formal importation process into China. And the testing is handled by the Chinese -- by Chinese government agencies outside of the control and involvement of the importing party. So you simply have to wait for your turn, so to speak, and for your individual import batch to be tested and then released through the importation process. It's clear that this created a very -- this was a very large undertaking by these responsible agencies in China. And there was some short-term backup. I'm absolutely confident that they are working day and night to resolve that. And sort of, as usual, I have great confidence in the fact that the Chinese government will resolve that and get back to more of a normal importation flow as they refine these processes. So I do think that, that part of it is sort of temporary. I think the part that will impact us is that, of course, our financial year inevitably cuts off on the 31st of December. And there are 2 impacts in the near term from this. Firstly, there are the sales that we lost through supply shortages in the second quarter already. That -- an element of that, we will probably be able to recapture because we'll be able to replenish inventory in our distributors. But as I referenced, in response to David's question at the outset of this Q&A session, there were out of stocks that occurred at the retail level, which means that we did lose sales to consumers. And those are, if you wanted, permanently lost, so to speak. They're not going to be recovered. The second impact of it is that if you think about this, it effectively puts our kind of growth plans behind these products 2 months back because we've been in this constrained supply situation for the last couple of months, which means that the -- given the rather steep growth curve that we had anticipated for these products, we'll be exiting the year, we'll be cutting off the year on the 31st of December at a point of lower sales than we would otherwise have done, given the 2 months that we have sort of inevitably [ph]  Lost or partially lost."
1002291,367328591,1015680,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","And does this put at all the Enfinitas concept at risk in any way, shape or form? Like are customers who have been notified of the product launching, are they upset that it's not available? Or have they noticed it's not available? Do you -- if you have an",52,"And does this put at all the Enfinitas concept at risk in any way, shape or form? Like are customers who have been notified of the product launching, are they upset that it's not available? Or have they noticed it's not available? Do you -- if you have any feedback on that?"
1002291,367328591,1015680,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","I've never had a customer who was entirely happy when you can't supply their orders. But I think we have a great relationship with the vast majority of our customers in China. And they understand the situation. As I said, it's not completely unique to our",72,"I've never had a customer who was entirely happy when you can't supply their orders. But I think we have a great relationship with the vast majority of our customers in China. And they understand the situation. As I said, it's not completely unique to our company and I think we managed to explain it to them. And I feel confident that we still have the support of our customer base."
1002291,367328591,1015680,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Operator","Your next question comes from Jon Andersen with William Blair.",10,"Your next question comes from Jon Andersen with William Blair."
1002291,367328591,1015680,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","I just want to put the discrete import testing issue aside for a minute and just, Kasper, if you could comment maybe on some of the broader regulatory changes that are happening in China. I'm thinking here about things that may ultimately resolve in volum",88,"I just want to put the discrete import testing issue aside for a minute and just, Kasper, if you could comment maybe on some of the broader regulatory changes that are happening in China. I'm thinking here about things that may ultimately resolve in volume migration away from some of the gray market into more responsible producers or registered product hands. Can you talk a little about what's happening there, the timing of some of those events and where do you think there's a benefit here to meet?"
1002291,367328591,1015680,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Well, I mean, we've been talking about this topic, I guess, it's a broad topic now, for at least a couple of years. I remain very, very optimistic about the way the Chinese government is going about this. It's natural that we would always wish that things",257,"Well, I mean, we've been talking about this topic, I guess, it's a broad topic now, for at least a couple of years. I remain very, very optimistic about the way the Chinese government is going about this. It's natural that we would always wish that things could happen faster than they do. But what I see is a very clear determination by the Chinese government to ensure that products that are sold to China -- for consumption by Chinese children are all safe and in compliance with their standards. And that's a very reasonable goal. There are various initiatives that intersect as they pursue this latest one to try to get a handle on imported products, at least through the formal channels and making sure that those products comply with Chinese standards. I think it's a very positive one. I think there's still a significant amount of product going through sort of informal channels imported into China in small parcels, mainly through what we have previously called consumer-to-consumer e-commerce or what we can perhaps call unofficial exports out of say, Europe or Australia. I would expect the Chinese government just looking at that. And over time,  they will determine a way to ensure that you can't have different quality standards applying to that sales channel than you have to the official sales channels. So overall, I'm very -- I'm very encouraged by what I'm seeing, recognizing that is challenging us in the short-term but it's a good thing for the long-term development of the China market."
1002291,367328591,1015680,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Thank you.",2,"Thank you."
1002291,367328591,1015680,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Operator","Your next question comes from Mario Contreras from Deutsche Bank.",10,"Your next question comes from Mario Contreras from Deutsche Bank."
1002291,367328591,1015680,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","So I wanted to ask on North America. Earlier in your remarks, you mentioned the share recovery there has been a bit slower than expected. And then later, you also mentioned that A&P was down in that region. So I guess my first question is, is there any co",67,"So I wanted to ask on North America. Earlier in your remarks, you mentioned the share recovery there has been a bit slower than expected. And then later, you also mentioned that A&P was down in that region. So I guess my first question is, is there any correlation there? And second, and more broadly, what does it take to get share to a more acceptable level?"
1002291,367328591,1015680,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Well, Mario, I think first of all, let me start by stating that the market share comments are all relative and they are relative to where we were 12 months ago. And there's no doubt that we've lost some market share, probably about 100 basis points or so",209,"Well, Mario, I think first of all, let me start by stating that the market share comments are all relative and they are relative to where we were 12 months ago. And there's no doubt that we've lost some market share, probably about 100 basis points or so in market share versus where we were a year ago, at least the way that we look at the profitable part of the U.S. market. We -- I'm not sure I'm prepared to comment on what our plans are exactly for recovering that market share. But you can imagine that it's receiving a fair amount of attention. And I did talk about the particular product segments where we've seen the -- our share develop unfavorably. So it's still -- we are spending at very healthy levels against it. And I'm confident that if we felt that, it was a question of simply investing more money in order to sell more and therefore, gain more share, we would do so. However, I'm not convinced that this is a question of absolute investment levels. I think there have been some execution of issues that we are working through and I'm confident my team in the U.S. are addressing those issues as we speak."
1002291,367328591,1015680,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Operator","Your last question comes from Pablo Zuanic with SIG.",9,"Your last question comes from Pablo Zuanic with SIG."
1002291,367328591,1015680,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","Look, just one question on the import and local mix. In previous presentations, you've given the mix. Can you give us as an update on where you are in China in terms of imports and local? And related to that, this trade promotion question, it would be nic",109,"Look, just one question on the import and local mix. In previous presentations, you've given the mix. Can you give us as an update on where you are in China in terms of imports and local? And related to that, this trade promotion question, it would be nice if you can break it by the 3 product categories, right? And what I mean by that, the local products, the Enfamil imported range and then Enfinitas launch. Because the way I understand it, you're having to promote your old inventory on the shelves, the local product. So if you can just give some color in that regard would be helpful."
1002291,367328591,1015680,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","I'm going to try and strike a balance and make sure that I don't give way more information to my competitors than I would like, Pablo. So please be understanding of that. So I don't know that I will go further to identify how we're spending our trade supp",151,"I'm going to try and strike a balance and make sure that I don't give way more information to my competitors than I would like, Pablo. So please be understanding of that. So I don't know that I will go further to identify how we're spending our trade support. On the import versus local business, I think we've been very clear that the imported part of our portfolio is still the fastest-growing part of our portfolio. And we see us being in the kind of transition phase where over the long -- over the mid-term, at least we will see our Hong Kong products and our locally produced products probably in decline and you will see us making up for that decline with growth through our imported product portfolio. That assumes that there are no unforeseen changes to the regulatory environment in China that would somehow cause that to change."
1002291,367328591,1015680,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","Right. And if I may, just a very quick follow-up. On the margin question, whether people project 26%, 27%, 28% by 2018, my question is, you had guided for a 300 net gain. But today, you increased your cost savings from $120 million to $180 million, that's",116,"Right. And if I may, just a very quick follow-up. On the margin question, whether people project 26%, 27%, 28% by 2018, my question is, you had guided for a 300 net gain. But today, you increased your cost savings from $120 million to $180 million, that's 100 bps on sales, and your A&P efficiency went from $50 million to $100 million to $100 million now. So that amounts to almost another $175 million of margin expansion. But you're still sticking to 27%. So that my read of that is great, you have more cost savings. But you have recognize that the reinvestment is greater than you had expected. Is that the right, the correctly read?"
1002291,367328591,1015680,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Pablo, before Michel answers, could you put your phone on mute when he answers, we're getting an echo from you.",20,"Pablo, before Michel answers, could you put your phone on mute when he answers, we're getting an echo from you."
1002291,367328591,1015680,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","I'm sorry, okay.",4,"I'm sorry, okay."
1002291,367328591,1015680,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Yes, Pablo, the major part of that incremental $60 million will be reinvested in the business, especially gross to net, especially also for the A&P, 100 basis points decrease. So is it gross to net reinvestments? and like we said, we also potentially, exp",78,"Yes, Pablo, the major part of that incremental $60 million will be reinvested in the business, especially gross to net, especially also for the A&P, 100 basis points decrease. So is it gross to net reinvestments? and like we said, we also potentially, expect over time some further headwinds in gross to margin in line with what I indicated at Investor's Day in October. That's the reason why you don't see that pulled through -- fall to benefit."
1002291,367328591,1015680,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Thank you for participating in Mead Johnson's earnings conference call. I will now turn it back to the operator.",20,"Thank you for participating in Mead Johnson's earnings conference call. I will now turn it back to the operator."
1002291,367328591,1015680,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Operator","This concludes the presentation. You may now disconnect. Good day.",10,"This concludes the presentation. You may now disconnect. Good day."
1002291,367328591,1016263,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Operator","Good day, ladies and gentlemen, and welcome to the Mead Johnson Nutrition Second Quarter and First Half 2016 Earnings Conference Call. My name is Liz, and I will be your coordinator for today. [Operator Instructions] As a reminder, this conference is bein",66,"Good day, ladies and gentlemen, and welcome to the Mead Johnson Nutrition Second Quarter and First Half 2016 Earnings Conference Call. My name is Liz, and I will be your coordinator for today. [Operator Instructions] As a reminder, this conference is being recorded for replay purposes. 
I would now like to turn the conference call over to Kathy MacDonald, Vice President, Investor Relations. Please proceed, Kathy."
1002291,367328591,1016263,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Thank you, Liz. Good morning, and thank you for joining Mead Johnson's Second Quarter and First Half 2016 Conference Call. With me today are Kasper Jakobsen, our Chief Executive Officer; and Michel Cup, our Chief Financial Officer. Earlier today, we iss",304,"Thank you, Liz. Good morning, and thank you for joining Mead Johnson's Second Quarter and First Half 2016 Conference Call. With me today are Kasper Jakobsen, our Chief Executive Officer; and Michel Cup, our Chief Financial Officer. 
Earlier today, we issued our 10-Q, earnings release and financial reference slides. If you have the slides in front of you, please turn to Slide #2. A detailed explanation of our forward-looking statements appears in the materials posted on our website in connection with today's conference call. 
As we start, let me remind everyone that our comments will include forward-looking statements about our future results, including statements about our financial prospects and projection, commodity costs, currency fluctuations, pricing, taxes, capital spending, new product launches, other growth initiatives and market conditions that constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Keep in mind that our actual results may differ materially from expectations as of today due to various factors, including those listed in our annual report on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K, and each case is filed with or furnished to the Securities and Exchange Commission and our earnings release issued this morning. 
Today's comments will include discussion of non-GAAP financial measures. A reconciliation of these measures to comparable GAAP measures appears in this morning's earnings release and financial reference slides, which are available at meadjohnson.com. In addition, any forward-looking statements represent our estimates only as of today and should not be relied upon as representing our estimates as of any subsequent date. While we may elect to update forward-looking statements at some point in the future, we specifically disclaim any obligation to do so, even if our estimates change. 
I will now turn the call over to Kasper."
1002291,367328591,1016263,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Thank you, Kathy, and good morning to all of you. Thank you for joining us on our earnings call. My comments will focus on our strategy and top line performance. And then Michel will follow up with some additional financial information and elaborate on",2457,"Thank you, Kathy, and good morning to all of you. Thank you for joining us on our earnings call. 
My comments will focus on our strategy and top line performance. And then Michel will follow up with some additional financial information and elaborate on segment profitability and our company's cash flow. 
Let me begin by summarizing the company's second quarter performance before I provide additional details on each of our reporting segments. Except where I note otherwise, I'll be referring to non-GAAP results. At the end of last year, we laid out a 3-year plan for value creation, with this year being a year of transition. I also identified 3 key milestones we'd use to monitor our profits against this value-creation plan. I referenced these plans in our last earnings call, so let me reference them again today. 
Of the 3 milestones we laid out, the first was to return the business to constant-dollar sales-growth. Today, you'll hear us reiterate expectations for 2016 sales that anticipates that we'll return to growth in the coming quarters. Within the most recently completed quarter, demand in China for new products continued to grow. Actual shipments this quarter, however, were constrained by supply shortage caused by newly introduced, additional import processes at Chinese border points. More about this later. 
Despite these constraints, gross sales before trade support and discounts were in line with prior quarter. Net sales were lower than the quarter before, as trade support for new product introductions increased. Michel will elaborate on this a little bit later. 
Our second milestone is centered around our commitment to reduce our operating expense base. Year-to-date, we've delivered $47 million in expense reductions. We've already achieved nearly 80% of our annual target of $60 million. We are ahead of schedule. And in this call, we're announcing a revised, more ambitious target. 
We are both accelerating and expanding our cost initiatives by increasing our 2016 target to $75 million to $80 million in savings from the previously announced $60 million. We're also raising our 3-year cumulative savings goals from $120 million to $180 million. 
Our third and final milestone we said would be to invest a portion of our expense savings to fund key growth initiatives. To date, we've invested substantially behind the introduction of a fully imported Enfamil into China and the building of a toddler franchise in North America. This latest quarter, we made strong investments in support of our Enfinitas launch in China and the expansion of distribution reach. Over time, we'll demonstrate to you that these investments are essential to us delivering on our commitment to shareholder value creation. 
Turning now to our second quarter 2016 results. We continue to manage through a challenging global operating environment. Economic growth in many emerging and developing economies of Asia and Latin America has slowed over the past 18 to 24 months. Simultaneously, political uncertainty affects many markets in both Asia and South America. These effects present near-term headwinds for us. That said, we continue to find opportunity amidst the uncertainty. We continue to invest to put ourselves in the best possible position for when a turnaround and economic growth eventually materializes, and come, it will. 
For the second quarter, sales for the company was $942 million. Reported net sales were $9 million lower than the prior year quarter. Currency adversely impacted our results by 500 basis points. Consequently, constant-dollar sales were below -- excuse me, consequently, constant-dollar sales were 4% below those of the second quarter of 2015. Price was favorable by 1% despite added trade support in China, while volume was 5% unfavorable. 
Second quarter sales were impacted by significant investments to secure trade support and distribution of Enfinitas in China. Though costly in the near term, these investments will help establish the brand and drive long-term revenue growth. I'll return to the topics of Enfinitas a little later. 
In China, a requirement for additional product testing prior to importation took effect towards the end of the second quarter, causing delays to the importation process. I want to commend the Chinese government for its actions to enhance food safety standards and importation guidelines to ensure imported products can be safely used by Chinese parents and children. 
During the quarter, the government implemented new testing standards for imported products within our category. The effect of this change was a temporary delay in the importation of some of our fastest-growing products from our Netherlands facility. This drove some near-term volatility in our sales results. In the mid to long term, we, however, believe these additional processes will benefit both Chinese children and responsible operators within the industry. 
Outside of China, the deteriorating circumstances in Venezuela, that so tragically impact the people and our colleagues there, have resulted in significantly reduced shipments to the country. When comparing to the second quarter of last year, this adversely impacted the company's sales by 130 basis points in the latest quarter. 
Despite the challenging operating environment, I'm pleased with the company's earnings power. Gross margin remained strong. Our strategy to drive growth of higher-value products and product forms is working and helps offset the impact of increased investments above the net sales line. Investments in advertising and promotion represented 17.6% of net sales in the quarter. 
Our Fuel for Growth cost-reduction initiative drove significant reduction in SG&A. Overall, these costs were down 9% in constant dollars in the second quarter compared to the same quarter of prior year. 
While we made significant investments in key growth initiatives, our EBIT margin was 24.4% in the quarter, and non-GAAP earnings per share for the quarter were $0.88. Michel will expand on our earnings delivery a little later. 
I'll now discuss the performance of each of our reporting segments, beginning with the North America/Europe segment. 
Net sales in the North America/Europe segment were in-line with the second quarter of 2015 on a constant-dollar basis and improved sequentially from the first quarter. A 1% benefit from price was offset by lower volumes. Additionally, we experienced additional headwind of 1% from foreign exchange. 
The Center for Disease Control recently issued their report on 2015 U.S. birth and birth rates. Reported annual birth was 0.3% below the 2014 level. Breastfeeding rates, however, appeared to have stabilized. Our market share in the U.S. business stabilized in the second quarter but remained at a level lower than the prior year. In our outlook, we are recognizing it will likely take longer than hoped for to recover market share. Much of our share loss was within the specialty and solution segment of the infant formula market. But we are confident we understand our challenges and we're addressing them. 
There are bright spots within this reporting segment also. Last October, we introduced a new 32-ounce liquids packaging. This product line is now growing double digits, and we are gaining share in the high-value liquids category. 
It's still the early days for our premium-priced Enspire products but reception from retailers has been favorable, and we expect to see distribution increase in the coming quarters as we build consumer demand. 
Our North American toddler business, defined as products targeting children more than 1 year of age, continues to grow at an annual rate in double digits. 
And turning to Canada. I continue to be pleased with our progress. Second quarter sales grew double digits based on strong market share gains in both the infant and children segments. We've executed extremely well over the past year or 2, and our Canadian team is deservedly receiving much internal recognition. 
Our European business remains strong based on a leading position in the growing allergy segment there. We are well-positioned to benefit from future increases in diagnosis and have a strong innovation pipeline to support our growth in Europe. 
Let me now turn to Latin America. Constant-dollar sales for the total region was 3% lower than the prior year same quarter. Pricing benefits of 9% was insufficient to fully offset foreign exchange impacts of 13%. Excluding the impact of our sharply reduced business in Venezuela, Latin America sales grew 4% in constant dollars over the same quarter of 2015. 
Mexico and Colombia were the biggest contributors to growth. In Mexico, we are seeing improved momentum in both our premium pediatric nutrition business and our milk modifier business. We enjoy strong market shares in our milk modifier business and retain our #1 position in this category. In infant formulas, we recently rolled out a product containing Milk Fat Globular Membranes (sic) [Milk Fat Globule Membranes], the same key ingredient contained in Enfinitas and Enspire products launched in China and the U.S. 
Trends in other parts of Latin America remain broadly unchanged from the prior quarter. In Brazil, economic challenges continue to hurt demand for discretionary items like our mid-priced children's products. The premium infant formula products are less discretionary, and they continue to grow. We continue to benefit from strong sales in our Colombian unit, which maintains strong market shares, and in addition, is benefiting from cross-border demand from Venezuela. 
We are rolling out our new plastics packaging and refill systems across Latin America. And in some markets, we are testing ready-to-drink versions of our children's products. These initiatives will allow us to take advantage of segment growth opportunities and support selective increases in price. 
I'll turn now to the Asia segment. Constant-dollar-growth sales in Asia were in-line with the second quarter of 2015. In support of the Enfinitas launch in China, trade investments, however, were significantly higher when compared to the prior year. Partly as a result of this, price was unfavorable by 2%, as the increased trade investments in China more than offset the impact of price increases in Southeast Asia. 
Across the region, product mix continued to improve with sales of our premium-priced products going faster than those of our lower-priced variants. Volume was unfavorable by 5%, as we experienced delays to importation in China and dealt with some market share weakness in the Philippines. Despite improving momentum in China, the Asia region has not yet recovered to sales levels seen in the early part of 2015. 
In the Philippines, we've seen softer market share in sales of Lactum, our mid-priced children's brand. We feel we've identified the root causes behind our share loss and have a remedial plan that will allow us to get back on track. 
Our Malaysia business is growing both volume and price. We recently introduced a new formulation and improved packaging that will allow us to recover market share over time. 
Across Southeast Asia, we are rolling out new product formulations and promoting the benefits of our new plastics packaging. Supported by an improved value equation, we are raising prices behind this innovation. 
I will finish my discussion of the Asia segment with China. In my introductory headlines, I described the import delays caused by increased processes at all border points. In Mainland China, the government implemented a new requirement that every batch be extensively tested prior to release to Chinese consumers. Previously, a sampling approach has been applied. The increase in the number of tests required caused temporary delays as testing and verification capacity was stretched. The effect of this was a temporary delay in the importation and shortage of supply of many of our fastest-growing imported line items, as I mentioned earlier. We, nevertheless, are pleased to see these measures implemented. 
Similarly, increased customs monitoring and reduced visitor numbers have adversely impacted our Hong Kong business. It's become more challenging for our Hong Kong business to compete for visiting Chinese tourists that now connects these imported products more easily from within the Mainland. These challenges confirm our China strategy pursuing increased flexibilities through a broader product portfolio sold through a more diverse set of sales channels. 
Turning now to Mainland China, where our fully imported products continues to gather momentum, and we're seeing strong demand from consumers. Through the second quarter, we continued to grow market share of the imported segment. In the baby store channel, we've increased our distribution, supported by our most recent, new product introductions. We are seeing both our ability to make progress and the substantial runway we have ahead of us. 
As of the second quarter, we are no longer under indexing versus the market in the fast-growing baby store channel. Our new Enfinitas product line is off to a solid start. Three months after introductions, we are still building distribution and demand, but we are encouraged by the early signs. 
In totality, I'm satisfied with the progress we've made with our portfolio and channel transformation in China. I also recognize we've got a long way to go and a lot of opportunities ahead of us. It's hard not to be excited about the immense potential of not only our China business but our global business. 
Before I hand over to Michel, I want to provide an updated outlook for full year 2016,  our year of transition, a year in which we are addressing several structural opportunities within both our brand portfolio, our product lineup and our cost structure. 
At the beginning of the year, we knew comparisons in the first half 2016 would be challenging. I'm satisfied that many of our critical initiatives have gone as planned, and we are expecting growth over prior year in the second half of the year. However, we've seen 3 developments causing us to revisit our estimate for full year 2016 constant-dollar-sales growth. It's taking us longer than expected to recover the market share we lost in the U.S. towards the end of 2015. 
Secondly, the import-related challenges in China, Hong Kong in the second quarter cost of sales we won't fully recapture until next year. 
Thirdly, we are supporting our imported portfolio in China with additional trade support. In light of these factors, we now expect constant-dollar sales in-line with or not more than 2% below the 2015 level. 
Through the first half of the year, we've identified several opportunities within our cost structure. In doing so, we found additional opportunities to both reduce cost and increase efficiencies. In a moment, Michel will outline an expanded ambition and scope for our operating expense initiative, the project we refer to as Fuel for Growth. Despite lower sales, a slightly improved outlook for gross margin, expense optimization and the benefit realized from a lower tax rate in the just completed quarter allow us to reiterate our expectation for non-GAAP earnings per share of $3 -- of between $3.48 and $3.60 for the full year 2016. 
I'll now hand over to Michel, who will provide additional details on our second quarter and first half financial performance. I'll then return with a few summary remarks before we take your questions. Michel, over to you."
1002291,367328591,1016263,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Thank you, Kasper, and good morning, everyone. Today, I will discuss the company's second quarter and first half 2016 financial results. I will then briefly highlight EBIT results for each segment, cash flow and liquidity items and conclude with a summary",2807,"Thank you, Kasper, and good morning, everyone. Today, I will discuss the company's second quarter and first half 2016 financial results. I will then briefly highlight EBIT results for each segment, cash flow and liquidity items and conclude with a summary of full year guidance. 
Unless otherwise noted, my comments will be on the non-GAAP financial results. References to currency impacts or the effects of currency fluctuations generally refer to the impact on the translation of local currency financial statement into U.S. dollars. In addition, my comments about sales will refer to net sales, unless I explicitly call out gross sales. 
Let me start with sales as shown on Slide 3. Kasper addressed the constant-dollar change. I will focus on the reported sales and the foreign currency impact. For both the second quarter and first half year, adverse foreign exchange rates contributed to a 500 basis points decline compared to the same period of the prior year. Second quarter net sales on a reported dollar basis grew 9% below prior year quarter. Reduced shipments to Venezuela impacted net sales negatively by 1% in the second quarter versus the prior year quarter. 
Slide 4 summarizes the impact of foreign exchange on sales. U.S. dollar continued to be strong and effects of translation of local currencies negatively impacted all reporting segments. However, the impact was slightly less significant in the second quarter of 2016 when compared to the trend from the last 3 quarters. Nearly 2/3 of the second quarter negative currency impact on sales were from the Chinese renminbi, the Mexican peso and the Argentine peso. The balance of the adverse foreign exchange impact was widespread across regions. 
As a result of the year-to-date foreign exchange impact, our outstanding currency hedges for the remaining of the year and the current forward rate, we are revising our currency expectations from minus 6% to minus 5% adverse foreign exchange impact on sales for the full year 2016. I will address foreign exchange impact in the EPS guidance section as well. 
I'm introducing Slide 5 for better transparency of gross sales, which reflects sales to customers before trade investment and other items, which are recorded as gross to net sales adjustments. We reallocated some investments in the second quarter from advertising and promotion to trade investments, in support of the rollout of Enfinitas and build on our momentum of the fully imported premium products which were introduced in the second quarter of last year. Gross sales on a constant-dollar basis were flat compared to the prior year quarter and down 2% for the first half year of 2016 versus the same period last year. The significant gross sales improvement in the second quarter has been realized. 
Slide 6. The second quarter EBIT of $230 million was 10% above the prior year quarter on a constant-dollar basis. Foreign exchange adversely impacted EBIT by 6%, including currency impacts. EBIT increased 4% on a reported basis in the second quarter. 
If you would exclude Venezuela, our EBIT on constant-dollar basis improved by 14% versus prior year quarter. The second quarter EBIT margin of 24.4% of sales was 290 basis points better than the prior year quarter. Despite macroeconomic and country-specific challenges which impacted our sales, we made excellent progress to reduce operating expenses as part of our Fuel for Growth program which allowed continued investments and, at the same time, improve the underlying profitability. Year-to-date EBIT was $474 million, a decline of 1% versus previous year on a constant-dollar basis. Foreign exchange, an adverse impact of 8%. 
Excluding Venezuela, EBIT in the first half year improved by 3% versus previous year period on a constant-dollar basis, mainly driven by a higher gross margin and our cost savings realized in the first half year, partly offset by demand-generating investments. 
I will now move to the factors that impact gross margin on Slide 7. Gross margin was 65.1% in the second quarter of 2016, or 66% on a constant-dollar non-GAAP basis. Adverse foreign exchange impacted the gross margin by 150 basis points in the second quarter. We were able to deliver a nearly flat gross margin on a reported basis in both the second quarter and the first half year compared to the previous-year periods despite the significant currency headwind. 
Sales had a slightly negative impact on gross margin from higher-trade investment, especially in China. Low dairy cost continued to be the large benefit to gross margin in the second quarter and first half of 2016. Our key dairy components have been secured through supply contracts for the remainder of the year, and we expect some further benefits, although the dairy benefits for the remainder of the year will be smaller compared to the first half year. 
We continue to deliver productivity savings within cost of goods sold. Year-to-date, the supply chain team delivered productivity savings of around 3.5% of cost of goods sold, in-line with our expectation. With dairy secured for the full year, we expect full year gross margin to be slightly better than our prior year guidance of 64%. 
Moving to operating expenses. I will start with advertising and promotion investments  on Slide 8. Advertising and promotion was 17.6% of sales in the second quarter compared to 18.4% in the prior year quarter. As previously mentioned, in the second quarter, we reallocated a portion of investments from A&P to trade investments, which are recognized in gross to net sales. Despite the year-over-year savings, the second quarter of both years marked noticeably higher investments. The incremental investments were mainly to support key China initiatives, last year for the launch of our fully imported products and in April of this year, the launch of the Enfinitas product line and the continued support of our greater China strategy. 
In the second quarter, we purposefully delayed some A&P investments due to delays in the importation of some of our China product impacting our sales. As such, we expect the third quarter may continue to be in elevated level before it normalizes in the fourth quarter. 
Slide 9 provides the combined spending of the mine-generating investments, both as trade investments classified in gross to net sales and advertising and promotion. Some of the key trade investment activities include trade support, customer programs and promotional pricing. For the second quarter, the combined investment increased above the prior year quarter and was also higher for the last few quarters. 
Trade spending is focused close to our consumer and to ensure our products are present with strong distribution in the key growing channels. In the past few quarters, we've increased these investments, especially in China, to be more competitive in the baby store and e-commerce channels. While we increased trade investments, we plan to reduce the A&P as a percentage of sales over the next few years. 
Last quarter, we committed to provide an update on our review of advertising and promotion expenditures. At Investor's Day last year, when I spoke about advertising and promotion, I stated that we should be able to optimize a lower A&P by 50 to 100 basis points over 3 years. We can now confirm that we expect to be at the top of that range and reduce our A&P by 100 basis points by 2018. We will realize this by prioritizing investment choices that maximize our return on investments of key influence drivers. 
We will continue to optimize our non-media expenses and leverage our decision-supporting tools better. In addition, we will strengthen our focus on digital marketing versus the traditional media. 
Slide 10. We reduced our SG&A cost by 9% on a constant-dollar basis in the second quarter of 2016 versus the previous-year quarter and by 10% year-to-date compared to the prior year period. Like we indicated before, our Fuel for Growth program is focused on cost reduction within our support functions and marketing. 
Areas of focus were the reduction of key vendor contracts, eliminates discretionary spend and optimize organization layers. As you can see from Slide 11, we are significantly ahead of schedule on the original 2016 Fuel for Growth target. Our Fuel for Growth target for this year was $60 million. By mid-year, we've delivered 79% of this year's target savings, or $47 million already. Especially in the corporate overhead functions, we were able to reduce our cost by $30 million in the first half year of 2016 versus the first half year of 2015. Significant progress has been made by systematically renegotiating contracts with our largest vendors. 
Slide 12. Over the last few months, we performed a more extended, deep-dive review of our expenses as well as our organizational structure. We concluded, based also on the success of our results to-date, to accelerate certain cost-savings programs identified earlier and to expand the scope to all operating expenses functions, including sales force and distribution. We now expect to deliver $75 million to $80 million of savings in 2016. This is an increase of $15 million to $20 million versus our original 2016 target. Taking into account the savings realized in 2015 of $20 million, cumulative savings by the end of 2016 are expected to be around $95 million to $100 million. 
In addition to the original program of $120 million, we expect an incremental $60 million of cost-savings opportunities by 2018. The combined Fuel for Growth program will now deliver $180 million savings by 2018. 
The incremental Fuel for Growth savings will provide additional flexibility to invest in the company's future growth. 
Turning to Slide 13 for a discussion of EBIT by segment. Let me start with Asia. In the second quarter, Asia delivered an EBIT of $137 million, a decrease of 4% on a constant-dollar basis compared to prior year quarter. Foreign exchange adversely impacted EBIT by additional 8%. Lastly, from the Chinese renminbi, the Thai baht and the Malaysian ringgit. The Asia EBIT margin at 30% declined 50 basis points compared to the second quarter of 2015. The main drivers were lower sales and an increase in trade investment in gross to net sales. The lower net sales impact was somewhat offset by a favorable dairy cost and some lower A&P expenses. 
For the first half year of 2016, the Asian EBIT margin of 32% were 350 basis points lower than the prior year, as lower sales and higher-demand-generation investments were not fully offset by the dairy benefit. A&P as a percentage of sales increased in the first half year versus the previous period. 
Turning to Slide 14. Latin America delivered EBIT of $36 million in the second quarter, a decrease of 7% on a constant-dollar basis compared to the prior year quarter. For this segment, foreign exchange adversely impacted EBIT by 12%, largely from the Mexican peso. Excluding our Venezuela business, EBIT on a constant dollar increased by 9% in the second quarter -- for the previous year quarter. And EBIT on a constant dollar increased 16% in the first half year of 2016 versus the previous-year period. 
For the balance of the business, lower sales were somewhat offset by lower-demand-generating expenses. The year-to-date Latin America EBIT margin was 23.6% compared to 25.3% for the same period last year. Lower EBIT margin is mainly a result of lower gross margin from the deteriorating situation in Brazil and Venezuela, somewhat offset by cost-reduction programs. 
Slide 15 shows the North America/Europe segment results. For the second quarter, North America/Europe EBIT was $99 million, an increase of 21% on a constant-dollar basis. The EBIT margin of 31.1% was 450 basis points better than previous year quarter. Gross margin remained strong from the benefit of low dairy costs. Within operating expenses, reduction in A&P and SG&A cost savings helped fund selective investments and drove high EBIT margins. Year-to-date, EBIT margin was 29.2%, an improvement of 300 basis points versus previous-year period. Fuel for Growth savings programs and the dairy benefit contributed to the improved EBIT margin. 
I will now address the financial results from EBIT to EPS on Slide 16. The interest expense of $26 million in the second quarter was similar to the first quarter of 2016 expense. When compared to the prior year quarter, the interest expense increase reflects the impact of the November 2015 $1.5 billion notes issuance. A significant portion of the proceeds from the notes were used to finance the accelerated share repurchase program, or ASR. 
Since the ASR concluded on June 30, let me briefly provide you a summary of the transaction. During our Investor Day, we announced the new $1.5 billion share repurchase program, of which $1 billion would be in the form of an ASR. 10.7 million shares of stock were received in the fourth quarter of 2015, an additional 2.1 million of shares of stock were received on June 30, 2016. In total, 12.8 million shares of stock were repurchased through the ASR program at an average price of $78.05 per share. Since the IPO, the company bought back 23.4 million of shares, with a total value of $1.8 billion. There are 184.7 million shares outstanding as of June 30. And in the last 12 months, this is a reduction of 18.5 million shares. 
The benefit from all share repurchase in 2015 and the full ASR program, net of interest expense, delivered almost $0.05 year-to-date and is in-line with our full year guidance of $0.11 benefit per share in 2016. 
As part of the $1.5 billion share buyback program announced in 2015, we still have $500 million available for an additional repurchase program. We continue to focus on shareholder value creation. This includes EBIT margin accretion, sales and EPS growth, along with the return of cash to shareholders through both dividends and share repurchases. 
Next, non-GAAP effective tax rate, or ETR, was 18.3% for the second quarter of 2016 compared to 25.6% in the prior year quarter. In the second quarter of 2016, there was about $0.05 per share benefit as a result of utilizing foreign tax credits on dividends from our foreign operations. We expect the ETR for the balance of the year to normalize. 
Non-GAAP EPS for the second quarter was $0.88, an increase of 16% on a reported basis and 24% on a constant-dollar basis. Year-to-date non-GAAP EPS was $1.75, a decrease of 5% on a reported basis and an increase of 3% on a constant-dollar basis. 
Let me summarize our financial results by addressing the change to EPS on Slide 17. In the second quarter, non-GAAP EPS increased $0.18 to $0.94 per share on a constant-dollar basis versus the prior year quarter. Sales and related gross profit negatively impacted EPS by $0.07. Our Fuel for Growth savings delivered $0.11 benefit. Advertising and promotions were $0.06 lower in the quarter, and that share repurchase program delivered a $0.02 benefit, net of higher interest expense. Tax and other contributed a $0.06 benefit. Despite the negative impact of foreign currency of $0.06 per share, EPS increased by $0.12 versus second quarter last year on a non-GAAP basis. 
Turning to a high-level overview of cash movements. On Slide 18, the cash balance of $1.7 billion as of June 30 was similar to the beginning-of-the-year balance. Cash flow from operations was negatively impacted by $94 million as a result of timing of tax payments and other working capital movements. Our CapEx investments were $81 million, mainly in our U.S. and Europe manufacturing facilities. For the full year ago, our capital spending goal remains about 4% of sales. Dividend payments were $155 million in the first half year. The negative impact of foreign exchange impact of $32 million was related to the currency devaluation in Venezuela. 
To summarize our forward-looking annual guidance on Slide 19, our sales outlook for 2016 on a constant-dollar basis is expected to be 0 to 2% below the prior year. With foreign currency reducing sales growth by about 5%, reported sales are estimated to be 5% to 7% below 2015. 
We reaffirm our 2016 GAAP EPS guidance of $2.91 to $3.03 and our non-GAAP guidance of $3.48 to $3.60 per share for the following reasons: First, we expect a gross margin improvement from our previous guidance of 64%; second, our Fuel for Growth savings are well ahead of plan and will only partly be reinvested in our business; thirdly, we have an ETR benefit around $0.05 in the second quarter; and fourth, the foreign exchange impact is expected to be approximately $0.35 per share from our previous guidance of $0.40 per share. 
GAAP EPS guidance is likely to be impacted by potentially significant future market-to-market pension adjustments, which cannot be estimated and are classified as specified items. Specified items include charges related to Fuel for Growth and our Venezuela business. 
This concludes my discussion on the second quarter and first half year 2016 financial results. Thanks again for your time this morning. I will now hand over the call back to Kasper."
1002291,367328591,1016263,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Thank you, Michel. Before we open the lines for questions, let me briefly reiterate our expectations that our relative performance will improve as we move into the second half of 2016. We expect to see the company return to positive growth in the coming q",150,"Thank you, Michel. Before we open the lines for questions, let me briefly reiterate our expectations that our relative performance will improve as we move into the second half of 2016. We expect to see the company return to positive growth in the coming quarters and our guidance reflects that. Our efforts to reshape our product and brand portfolio in China are progressing well, so is our initiative to strengthen our presence in the fast-growing channels there. We're gaining momentum in Mexico, Canada and Malaysia while we are addressing our performance shortfalls in the U.S. and the Philippines. We are partaking our ability to invest to maximize our opportunities by improving our gross margins to improve product mix and by lowering our expense base. And finally, we remain as committed as ever to shareholder value creation. 
With that, Liz, could I ask you to open the lines for questions, please?"
1002291,367328591,1016263,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Operator","[Operator Instructions] Your first question comes from David Driscoll with Citi.",11,"[Operator Instructions] Your first question comes from David Driscoll with Citi."
1002291,367328591,1016263,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","Kasper, can you comment on your retail performance in China? And distinguish it from all the various shipment issues that I think you were talking about? Can you give us some color on market share? And maybe a little bit more on the imported product gains",86,"Kasper, can you comment on your retail performance in China? And distinguish it from all the various shipment issues that I think you were talking about? Can you give us some color on market share? And maybe a little bit more on the imported product gains? And then to kind of round all this question out, will the third quarter see China shipments pick up because of the problems of shipments within the second quarter because of the customs issues that you talked about? Thank you."
1002291,367328591,1016263,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Thanks, David. It's an excellent question. So what I was implying in my prepared remarks, but I'm quite prepared to be more specific, is that we are very satisfied with the consumer demand trends that we are observing in China. So we feel that we are gain",190,"Thanks, David. It's an excellent question. So what I was implying in my prepared remarks, but I'm quite prepared to be more specific, is that we are very satisfied with the consumer demand trends that we are observing in China. So we feel that we are gaining share in the -- with our new products, both in our -- in the super high-premium segment where we obviously came from a standing start and in the imported product segment where we've now been at it for a little while. However, the difficulty of getting product into China in this latest quarter did result -- with some selective out-of-stocks situations at retail as well as lower inventories in many of our distributors. So to the extent of the latter, we expect that we will gradually recover that over the second half of the year. A little bit hard to say whether we will recover it all in the third quarter because that involves speculating on how the importation process evolves. But we are quite encouraged and we are confident that some of these issues are sort of relatively short term in nature."
1002291,367328591,1016263,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","Then just to follow up, would you say then that the retail performance and the market share gains are more indicative of the success of the strategy rather than the shipment number you're reporting today?",35,"Then just to follow up, would you say then that the retail performance and the market share gains are more indicative of the success of the strategy rather than the shipment number you're reporting today?"
1002291,367328591,1016263,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","That's certainly the way we look at it. So I hope I brought that across in my prepared remarks.",20,"That's certainly the way we look at it. So I hope I brought that across in my prepared remarks."
1002291,367328591,1016263,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Operator","Your next question comes from Michael Lavery from CLSA.",9,"Your next question comes from Michael Lavery from CLSA."
1002291,367328591,1016263,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","I just have 2 quick ones. One on Enfinitas, I was wondering if you could give some sense of -- I know it's early there still, but for the distribution, is that skewed more towards tier 1 cities or is it broad geographically and just how is that progressin",86,"I just have 2 quick ones. One on Enfinitas, I was wondering if you could give some sense of -- I know it's early there still, but for the distribution, is that skewed more towards tier 1 cities or is it broad geographically and just how is that progressing? And then just second in Indonesia, we saw a premium competitor cut prices by about 10%. What are the market dynamics there for you? Are you seeing pricing pressure or share pressure or opportunities in that market?"
1002291,367328591,1016263,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Let me start with Enfinitas. It really is early to say how that brand is performing. And particularly, as these last months or so was affected by these temporary delays in importation that I've referenced now repeatedly in China. We are aiming for a prett",128,"Let me start with Enfinitas. It really is early to say how that brand is performing. And particularly, as these last months or so was affected by these temporary delays in importation that I've referenced now repeatedly in China. We are aiming for a pretty broad distribution but obviously with an emphasis on the baby store channel which is the primary outlet for these high-quality, premium-priced products in China. In Indonesia, we typically don't mention it very often in our earnings call, that's not because it's not a great market, it's simply because we have a very small business there and our market participation is relatively low. So I suspect there are other people that are far more qualified than I  to discuss the market trends in Indonesia."
1002291,367328591,1016263,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Thank you, Michael.",3,"Thank you, Michael."
1002291,367328591,1016263,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Operator","Your next question comes from Bryan Spillane with Bank of America.",11,"Your next question comes from Bryan Spillane with Bank of America."
1002291,367328591,1016263,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","Just one question related to the increased investment in trade spend. I guess, Kasper, the question is just,  was that in reaction to some of your competitors promoting more? Was it a reaction? Is it really a mix, channel mix issue, that you're increasing",120,"Just one question related to the increased investment in trade spend. I guess, Kasper, the question is just,  was that in reaction to some of your competitors promoting more? Was it a reaction? Is it really a mix, channel mix issue, that you're increasing your sales in the baby store and that just tends to need more trade promotion? I guess the reason why I ask is just -- it seems sort of inconsistent that you've got a bottleneck at the border, so you're not getting product across, yet you're promoting more, which would seem to increase the incidence of out of stock. So if you can just kind of tie those things together, I think that would  be helpful."
1002291,367328591,1016263,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Bryan, thanks for the question. I mean, the trade support is not always, in every case, tied directly to volume. There are certain amount of sort of fixed expenses that are incurred in order to support the trade and particularly create sufficient presence",97,"Bryan, thanks for the question. I mean, the trade support is not always, in every case, tied directly to volume. There are certain amount of sort of fixed expenses that are incurred in order to support the trade and particularly create sufficient presence and awareness in the early stage of a brand launch. So it really reflects that. It is very directly connected to the launch of Enfinitas, and it is directly connected to the fact that trade support in the baby store channel tends to be higher than it is, for instance, in the food channel."
1002291,367328591,1016263,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","Okay. So it seems like you've got -- you've made more progress maybe than you would've original -- or it's progressing faster than you thought and so the need for the trade spend is kind of increased sooner than you thought as well. Is that a fair way to",51,"Okay. So it seems like you've got -- you've made more progress maybe than you would've original -- or it's progressing faster than you thought and so the need for the trade spend is kind of increased sooner than you thought as well. Is that a fair way to put it?"
1002291,367328591,1016263,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Well, I think it's -- a better way to look at it is that we have chosen to rebalance our investment between A&P and trade support to some degree in this latest quarter. We expect that, that balance would change from quarter-to-quarter depending on what ou",69,"Well, I think it's -- a better way to look at it is that we have chosen to rebalance our investment between A&P and trade support to some degree in this latest quarter. We expect that, that balance would change from quarter-to-quarter depending on what our activities are and whether they are booked in one line of the sort of brand investments or booked above the net sales line."
1002291,367328591,1016263,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Operator","Your next question comes from Amit Sharma with BMO Capital.",10,"Your next question comes from Amit Sharma with BMO Capital."
1002291,367328591,1016263,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","Kasper, just to continue what you just said, so if we -- if you are going to shift funding between above the line and below the line, how should we reconcile that with what Michel said earlier in his comments about 100 basis points decline in R&D spending",61,"Kasper, just to continue what you just said, so if we -- if you are going to shift funding between above the line and below the line, how should we reconcile that with what Michel said earlier in his comments about 100 basis points decline in R&D spending over the next few years? Is that net of higher based funding? Potentially?"
1002291,367328591,1016263,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Michel, do you want to take it [indiscernible]",8,"Michel, do you want to take it [indiscernible]"
1002291,367328591,1016263,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Yes, when I was referring to A&P, clearly, we were referring to the A&P line as a percentage of sales. Yes, we have -- stepped up the gross to net investments in the second half  year, and like Kasper said, it was really to support trade and reiterated th",98,"Yes, when I was referring to A&P, clearly, we were referring to the A&P line as a percentage of sales. Yes, we have -- stepped up the gross to net investments in the second half  year, and like Kasper said, it was really to support trade and reiterated the rollout of certain new product launch like Enfinitas and to get the distribution rights. So that gave us, I would say, especially in the second quarter, a temporary step-up, and we will continue this from higher trade investment. But I don't expect a further strong increase in that line."
1002291,367328591,1016263,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","So  just so I understand it well. So trade spending slightly up this quarter without looking for a sustained increase in that. And then A&P spend savings should accrue or should be available for you to reinvest or drop to the bottom line?",43,"So  just so I understand it well. So trade spending slightly up this quarter without looking for a sustained increase in that. And then A&P spend savings should accrue or should be available for you to reinvest or drop to the bottom line?"
1002291,367328591,1016263,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","A&P savings should be reinvested into gross net or should be dropped to the bottom line.",17,"A&P savings should be reinvested into gross net or should be dropped to the bottom line."
1002291,367328591,1016263,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Thank you, Amit.",3,"Thank you, Amit."
1002291,367328591,1016263,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Operator","Your next question comes from Ken Goldman, JPMorgan.",8,"Your next question comes from Ken Goldman, JPMorgan."
1002291,367328591,1016263,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Analysts",".Forgive my -- the length of my question here. But from my perspective, the guidance on Fuel for Growth is a bit confusing. And maybe I'm wrong. But I'm just hoping you can clear it up for me. So you explicitly said in your slides from the Investor Day",209,".
Forgive my -- the length of my question here. But from my perspective, the guidance on Fuel for Growth is a bit confusing. And maybe I'm wrong. But I'm just hoping you can clear it up for me. So you explicitly said in your slides from the Investor Day that you're looking for 300 basis points of margin improvement, not savings but margin improvement. And that implies that your EBIT margin will get to around 27% by 2018, all else equal. And that's an outlook that I think I've confirmed with the company in recent weeks. But you've also talked, including today, about how you're going to reinvest some of your savings back into the business, which suggests that maybe model all of that $120 million, now $180 million, is going to flow to the bottom line. So I'm clearly just trying to figure out, Michel, how do I reconcile what seems to be some conflicting information out there? And I know it's not guidance, but from a rough outlook, is it wrong for us on the outside to think that margins are expected to go up by 300 basis points or more net of reinvestments over the next few years? I think that's a key question for people."
1002291,367328591,1016263,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Yes, so let me clarify to avoid any confusion, because I want to be consistent with the messages that I gave at Investor's Day. So at Investor's Day, we said we will deliver $120 million of Fuel for Growth savings. And we also indicated that we will partl",141,"Yes, so let me clarify to avoid any confusion, because I want to be consistent with the messages that I gave at Investor's Day. So at Investor's Day, we said we will deliver $120 million of Fuel for Growth savings. And we also indicated that we will partly reinvest that and partly will be rolled through profitability. And in combination with a couple of other initiatives that we announced at Investor Day, we indicated that, that will deliver a 300 basis points margin improvement from 24% to 27% indeed. So what we announced today is an incremental program of $60 million, which should give us $180 million by 2018. From the $60 million, we indicate that we will use that to reinvest in our business to strengthen our future growth. So that will be not part of the growth through profitability."
1002291,367328591,1016263,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","Okay, so...",2,"Okay, so..."
1002291,367328591,1016263,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Did that clarify your question?",5,"Did that clarify your question?"
1002291,367328591,1016263,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","I think so. I'm on myself, so I apologize, but I just want to make sure. Those of us who are modeling, I'm not asking for guidance. But modeling 27% roughly in 2018, I know it's so far out. But are we absolutely insane to do that? Or is that kind of what",67,"I think so. I'm on myself, so I apologize, but I just want to make sure. Those of us who are modeling, I'm not asking for guidance. But modeling 27% roughly in 2018, I know it's so far out. But are we absolutely insane to do that? Or is that kind of what the company is thinking as well, all else equal, if it goes as planned?"
1002291,367328591,1016263,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","I think that the line what we laid out in Investor's Day that we increased our EBIT margin by 300 basis points to 27%.",25,"I think that the line what we laid out in Investor's Day that we increased our EBIT margin by 300 basis points to 27%."
1002291,367328591,1016263,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","I think you're right, Ken, with the way you're thinking about it, with all the normal caveats about being 2.5 years into the future. But the majority of the margin increase will come from a combination of the impact for the Fuel for Growth initiatives tha",86,"I think you're right, Ken, with the way you're thinking about it, with all the normal caveats about being 2.5 years into the future. But the majority of the margin increase will come from a combination of the impact for the Fuel for Growth initiatives that we are discussing now and, of course, we would expect over that time horizon also, aligned with what we communicated at the Investor Day, to see a return to sales growth which will also help the margin accretion exercise."
1002291,367328591,1016263,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Thank you, Ken.",3,"Thank you, Ken."
1002291,367328591,1016263,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Operator","Your next question comes from Matthew Grainger of Morgan Stanley.",10,"Your next question comes from Matthew Grainger of Morgan Stanley."
1002291,367328591,1016263,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","So, Kasper, I wanted to just better understand the issue with the testing standards that you mentioned and the anticipated impact, if there is any, that these could have going forward? And I guess, do you think that this had a similar impact across your p",98,"So, Kasper, I wanted to just better understand the issue with the testing standards that you mentioned and the anticipated impact, if there is any, that these could have going forward? And I guess, do you think that this had a similar impact across your peer set during the quarter? Was it idiosyncratic to you? And I ask only because we haven't heard any mention of it from 2 of your larger competitors that have already reported. And related just -- are there any kind of carryforward costs associated with that, that would be meaningful in any way?"
1002291,367328591,1016263,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","I -- so let me -- I normally don't comment on what my competitors say. But I think it depends on how you read the statements they made. I guess we read them a little bit differently from how you may have read them. I do think that it has impacted everybod",205,"I -- so let me -- I normally don't comment on what my competitors say. But I think it depends on how you read the statements they made. I guess we read them a little bit differently from how you may have read them. I do think that it has impacted everybody in pretty much the same manner. So I think other people have referenced the fact that informal exports or imports into China have slowed, et cetera, et cetera. And I think that we probably all have seen the same impact. I do want to reiterate just that we see this as an incredibly favorable development over the mid-term and a clear sort of sign of the Chinese government's commitment to ensure the safety of products that are being sold in China and ensure that these products, in every case, conform with Chinese-quality standards. So you've heard me mention this a number of times before. So I'm frankly -- though I will openly admit that we had hoped that we would report slightly better sales results in the second quarter due to this issue, I'm actually very happy with it from the potential for it to impact our business favorably as we move forward."
1002291,367328591,1016263,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","Thanks, Kasper. And just -- I'm sure you're well placed to me whatever requirements there are. But just the costs associated with that, with the requirements, is it material in any way?",32,"Thanks, Kasper. And just -- I'm sure you're well placed to me whatever requirements there are. But just the costs associated with that, with the requirements, is it material in any way?"
1002291,367328591,1016263,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","No. I mean, the -- I should perhaps have been more explicit. But actually, the additional testing that is happening is actually done by the Chinese government. And of course, we have invested substantially in ensuring that we can, in every case, meet the",57,"No. I mean, the -- I should perhaps have been more explicit. But actually, the additional testing that is happening is actually done by the Chinese government. And of course, we have invested substantially in ensuring that we can, in every case, meet the Chinese-quality standards on products that we sell in China, whether directly or indirectly."
1002291,367328591,1016263,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Operator","Your next question comes from John Baumgartner with Wells Fargo.",10,"Your next question comes from John Baumgartner with Wells Fargo."
1002291,367328591,1016263,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","Michel, I wanted to touch on the incremental sales force and distribution savings you mentioned. Can you speak more to the specifics of that? In terms of what it entails? And maybe what types of risks, if any, that may present to your top line going forwa",54,"Michel, I wanted to touch on the incremental sales force and distribution savings you mentioned. Can you speak more to the specifics of that? In terms of what it entails? And maybe what types of risks, if any, that may present to your top line going forward in terms of balancing your end-market resources."
1002291,367328591,1016263,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Maybe I'll give one comment and then I'll let Michel expand on it. John, I think as fast it comes to the sales force, the organizations and reductions in spend, firstly, you should not necessarily infer that greater efficiency in our sales force expenses",149,"Maybe I'll give one comment and then I'll let Michel expand on it. John, I think as fast it comes to the sales force, the organizations and reductions in spend, firstly, you should not necessarily infer that greater efficiency in our sales force expenses means a reduction in force. Indeed, in many cases, it's an optimization of discretionary spends that we have in the sales force that sit in the same line of the P&L. But it's also true to say that outside of the sort of frontline sales force, there are probably opportunities selectively across our global organizations to organize ourselves a bit differently. So I would say that. I think maybe the -- on the A&P side, I think we're simply recognizing that there are efficiencies available to us as the world is changing that we ought to put more energy into taking advantage of. Michel?"
1002291,367328591,1016263,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Yes, 2 comments to add. The $60 million additional Fuel for Growth savings that we announced, it is not only related to sales force and distribution, just to make that clear, right? It's a further optimization also of the supporting functions. And I would",87,"Yes, 2 comments to add. The $60 million additional Fuel for Growth savings that we announced, it is not only related to sales force and distribution, just to make that clear, right? It's a further optimization also of the supporting functions. And I would say, even the majority will come from the supporting roles. And your point -- let's be clear. We always said we will be very careful with sales force optimizations because we don't want to jeopardize our momentum in certain markets that we're having."
1002291,367328591,1016263,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Operator","Your next question comes from Robert Moskow, Crdit Suisse.",9,"Your next question comes from Robert Moskow, Crdit Suisse."
1002291,367328591,1016263,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","I was wondering, when you talked about the inspections on the borders, are you talking about all borders? It's not just the Hong Kong border? But it's just any product kind of coming into the country? And also, I mean, is there anything that you can do to",105,"I was wondering, when you talked about the inspections on the borders, are you talking about all borders? It's not just the Hong Kong border? But it's just any product kind of coming into the country? And also, I mean, is there anything that you can do to expedite it, expedite those inspections and why can't we think of it more as just kind of like a onetime hit to those debt incoming product that kind of slows you down temporarily but then is kind of solved maybe a month or 2 later? It's like a pig going to a snake or something like that."
1002291,367328591,1016263,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Rob, I think it's a good question. And actually, you can think about it sort of like that. There isn't anything we can really do to expedite it because, as I've said, it applies to the formal importation process into China. And the testing is handled by t",404,"Rob, I think it's a good question. And actually, you can think about it sort of like that. There isn't anything we can really do to expedite it because, as I've said, it applies to the formal importation process into China. And the testing is handled by the Chinese -- by Chinese government agencies outside of the control and involvement of the importing party. So you simply have to wait for your turn, so to speak, and for your individual import batch to be tested and then released through the importation process. It's clear that this created a very -- this was a very large undertaking by these responsible agencies in China. And there was some short-term backup. I'm absolutely confident that they are working day and night to resolve that. And sort of, as usual, I have great confidence in the fact that the Chinese government will resolve that and get back to more of a normal importation flow as they refine these processes. So I do think that, that part of it is sort of temporary. I think the part that will impact us is that, of course, our financial year inevitably cuts off on the 31st of December. And there are 2 impacts in the near term from this. Firstly, there are the sales that we lost through supply shortages in the second quarter already. That -- an element of that, we will probably be able to recapture because we'll be able to replenish inventory in our distributors. But as I referenced, in response to David's question at the outset of this Q&A session, there were out of stocks that occurred at the retail level, which means that we did lose sales to consumers. And those are, if you wanted, permanently lost, so to speak. They're not going to be recovered. The second impact of it is that if you think about this, it effectively puts our kind of growth plans behind these products 2 months back because we've been in this constrained supply situation for the last couple of months, which means that the -- given the rather steep growth curve that we had anticipated for these products, we'll be exiting the year, we'll be cutting off the year on the 31st of December at a point of lower sales than we would otherwise have done, given the 2 months that we have sort of inadvertently lost or partially lost."
1002291,367328591,1016263,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","And does this put at all the Enfinitas concept at risk in any way, shape or form? Like are customers who have been notified of the product launching, are they upset that it's not available? Or have they noticed it's not available? Do you -- if you have an",52,"And does this put at all the Enfinitas concept at risk in any way, shape or form? Like are customers who have been notified of the product launching, are they upset that it's not available? Or have they noticed it's not available? Do you -- if you have any feedback on that?"
1002291,367328591,1016263,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","I've never had a customer who was entirely happy when you can't supply their orders. But I think we have a great relationship with the vast majority of our customers in China. And they understand the situation. As I said, it's not completely unique to our",72,"I've never had a customer who was entirely happy when you can't supply their orders. But I think we have a great relationship with the vast majority of our customers in China. And they understand the situation. As I said, it's not completely unique to our company and I think we've managed to explain it to them. And I feel confident that we still have the support of our customer base."
1002291,367328591,1016263,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Operator","Your next question comes from Jon Andersen with William Blair.",10,"Your next question comes from Jon Andersen with William Blair."
1002291,367328591,1016263,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","I just want to put the discrete import testing issue aside for a minute and just, Kasper, if you could comment maybe on some of the broader regulatory changes that are happening in China. I'm thinking here about things that may ultimately result in volume",88,"I just want to put the discrete import testing issue aside for a minute and just, Kasper, if you could comment maybe on some of the broader regulatory changes that are happening in China. I'm thinking here about things that may ultimately result in volume migration away from some of the gray market into more responsible producers or registered product hands. Can you talk a little about what's happening there, the timing of some of those events and where do you think there's a benefit here to meet?"
1002291,367328591,1016263,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Well, I mean, we've been talking about this topic, I guess, it's a broad topic now, for at least a couple of years. I remain very, very optimistic about the way the Chinese government is going about this. It's natural that we would always wish that things",258,"Well, I mean, we've been talking about this topic, I guess, it's a broad topic now, for at least a couple of years. I remain very, very optimistic about the way the Chinese government is going about this. It's natural that we would always wish that things could happen faster than they do. But what I see is a very clear determination by the Chinese government to ensure that products that are sold to China -- for consumption by Chinese children are all safe and in compliance with their standards. And that's a very reasonable goal. There are various initiatives that intersect as they pursue this latest one to try and get a handle on imported products, at least through the formal channels and making sure that those products comply with Chinese standards. I think it's a very positive one. I think there's still a significant amount of product going through sort of informal channels imported into China in small parcels, mainly through what we have previously called consumer-to-consumer e-commerce or what we can perhaps call unofficial exports out of say, Europe or Australia. I would expect the Chinese government just looking at that. And over time,  they will determine a way to ensure that you can't have different quality standards applying to that sales channel than you have to the official sales channels. So overall, I'm very -- I'm very encouraged by what I'm seeing, recognizing that it is challenging us in the short-term but it's a good thing for the long-term development of the China market."
1002291,367328591,1016263,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Thank you.",2,"Thank you."
1002291,367328591,1016263,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Operator","Your next question comes from Mario Contreras from Deutsche Bank.",10,"Your next question comes from Mario Contreras from Deutsche Bank."
1002291,367328591,1016263,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","So I wanted to ask on North America. Earlier in your remarks, you mentioned that share recovery there has been a bit slower than expected. And then later, you also mentioned that A&P was down in that region. So I guess my first question is, is there any c",67,"So I wanted to ask on North America. Earlier in your remarks, you mentioned that share recovery there has been a bit slower than expected. And then later, you also mentioned that A&P was down in that region. So I guess my first question is, is there any correlation there? And second, and more broadly, what does it take to get share to a more acceptable level?"
1002291,367328591,1016263,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Well, Mario, I think first of all, let me just start by saying that the market share comments are all relative and they are relative to where we were 12 months ago. And there's no doubt that we've lost some market share, probably about 100 basis points or",210,"Well, Mario, I think first of all, let me just start by saying that the market share comments are all relative and they are relative to where we were 12 months ago. And there's no doubt that we've lost some market share, probably about 100 basis points or so in market share versus where we were a year ago, at least the way that we look at the profitable part of the U.S. market. We -- I'm not sure I'm prepared to comment on what our plans are exactly for recovering that market share. But you can imagine that it's receiving a fair amount of attention. And I did talk about the particular product segments where we've seen the -- our share develop unfavorably. So it's still -- we are spending at very healthy levels against it. And I'm confident that if we felt that, it was a question of simply investing more money in order to sell more and therefore, gain more share, we would do so. However, I'm not convinced that this is a question of absolute investment levels. I think there have been some execution of issues that we are working through and I'm confident my team in the U.S. are addressing those issues as we speak."
1002291,367328591,1016263,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Operator","Your last question comes from Pablo Zuanic with SIG.",9,"Your last question comes from Pablo Zuanic with SIG."
1002291,367328591,1016263,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","Look, just one question on the import and local mix. In previous presentations, you've given the mix. Can you just give us as an update on where you are in China in terms of imports and local? And related to that, this trade promotion question, it would b",111,"Look, just one question on the import and local mix. In previous presentations, you've given the mix. Can you just give us as an update on where you are in China in terms of imports and local? And related to that, this trade promotion question, it would be nice if you can break it by the 3 product categories, right? And what I mean by that, the local products, the Enfamil imported range and then Enfinitas launch. Because the way I understand it, you're having to promote your old inventory on the shelves, the local product. So if you can just give some color in that regard it would be helpful."
1002291,367328591,1016263,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","I'm going to try and strike a balance here and make sure that I don't give way more information to my competitors than I would like, Pablo. So please be understanding of that. So I don't know that I will go further to identify how we're spending our trade",152,"I'm going to try and strike a balance here and make sure that I don't give way more information to my competitors than I would like, Pablo. So please be understanding of that. So I don't know that I will go further to identify how we're spending our trade support. On the import versus local business, I think we've been very clear that the imported part of our portfolio is still the fastest-growing part of our portfolio. And we see us being in the kind of transition phase where over the long -- over the mid-term, at least we will see our Hong Kong products and our locally produced products probably in decline and you will see us making up for that decline with growth through our imported product portfolio. That assumes that there are no unforeseen changes to the regulatory environment in China that would somehow cause that to change."
1002291,367328591,1016263,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","Right. And if I may, just a very quick follow-up. On the margin question, whether people project 26%, 27%, 28% by 2018, my question is, you had guided for a 300 net gain. But today, you increased your cost savings from $120 million to $180 million, that's",117,"Right. And if I may, just a very quick follow-up. On the margin question, whether people project 26%, 27%, 28% by 2018, my question is, you had guided for a 300 net gain. But today, you increased your cost savings from $120 million to $180 million, that's about 100 bps on sales, and your A&P efficiency went from $50 million to $100 million to $100 million now. So that amounts to almost another $175 million of margin expansion. But you're still sticking to 27%. So that my read of that is great, you have more cost savings. But you have recognize that the reinvestment is greater than you had expected. Is that the right, the correct read?"
1002291,367328591,1016263,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Pablo, before Michel answers, could you put your phone on mute when he answers, we're getting an echo from you.",20,"Pablo, before Michel answers, could you put your phone on mute when he answers, we're getting an echo from you."
1002291,367328591,1016263,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","I'm sorry, okay.",4,"I'm sorry, okay."
1002291,367328591,1016263,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Yes, Pablo, the major part of that incremental $60 million will be reinvested in the business, especially gross to net, especially also for the A&P, 100 basis points decrease. So is it gross to net reinvestments? And like we said, we also potentially, exp",77,"Yes, Pablo, the major part of that incremental $60 million will be reinvested in the business, especially gross to net, especially also for the A&P, 100 basis points decrease. So is it gross to net reinvestments? And like we said, we also potentially, expect over time some further headwinds in gross to margin in-line with what I indicated at Investor's Day in October. That's the reason why you don't see that pulled through -- fall through benefit."
1002291,367328591,1016263,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Thank you for participating in Mead Johnson's earnings conference call. I will now turn it back to the operator.",20,"Thank you for participating in Mead Johnson's earnings conference call. I will now turn it back to the operator."
1002291,367328591,1016263,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Operator","This concludes the presentation. You may now disconnect. Good day.",10,"This concludes the presentation. You may now disconnect. Good day."
1002291,367328591,1016756,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Operator","Good day, ladies and gentlemen, and welcome to the Mead Johnson Nutrition Second Quarter and First Half 2016 Earnings Conference Call. My name is Liz, and I will be your coordinator for today. [Operator Instructions] As a reminder, this conference is bein",66,"Good day, ladies and gentlemen, and welcome to the Mead Johnson Nutrition Second Quarter and First Half 2016 Earnings Conference Call. My name is Liz, and I will be your coordinator for today. [Operator Instructions] As a reminder, this conference is being recorded for replay purposes. 
I would now like to turn the conference call over to Kathy MacDonald, Vice President, Investor Relations. Please proceed, Kathy."
1002291,367328591,1016756,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Thank you, Liz. Good morning, and thank you for joining Mead Johnson's Second Quarter and First Half 2016 Conference Call. With me today are Kasper Jakobsen, our Chief Executive Officer; and Michel Cup, our Chief Financial Officer. Earlier today, we iss",304,"Thank you, Liz. Good morning, and thank you for joining Mead Johnson's Second Quarter and First Half 2016 Conference Call. With me today are Kasper Jakobsen, our Chief Executive Officer; and Michel Cup, our Chief Financial Officer. 
Earlier today, we issued our 10-Q, earnings release and financial reference slides. If you have the slides in front of you, please turn to Slide #2. A detailed explanation of our forward-looking statements appears in the materials posted on our website in connection with today's conference call. 
As we start, let me remind everyone that our comments will include forward-looking statements about our future results, including statements about our financial prospects and projection, commodity costs, currency fluctuations, pricing, taxes, capital spending, new product launches, other growth initiatives and market conditions that constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Keep in mind that our actual results may differ materially from expectations as of today due to various factors, including those listed in our annual report on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K, and each case is filed with or furnished to the Securities and Exchange Commission and our earnings release issued this morning. 
Today's comments will include discussion of non-GAAP financial measures. A reconciliation of these measures to comparable GAAP measures appears in this morning's earnings release and financial reference slides, which are available at meadjohnson.com. In addition, any forward-looking statements represent our estimates only as of today and should not be relied upon as representing our estimates as of any subsequent date. While we may elect to update forward-looking statements at some point in the future, we specifically disclaim any obligation to do so, even if our estimates change. 
I will now turn the call over to Kasper."
1002291,367328591,1016756,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Thank you, Kathy, and good morning to all of you. Thank you for joining us on our earnings call. My comments will focus on our strategy and top line performance. And then Michel will follow up with some additional financial information and elaborate on",2459,"Thank you, Kathy, and good morning to all of you. Thank you for joining us on our earnings call. 
My comments will focus on our strategy and top line performance. And then Michel will follow up with some additional financial information and elaborate on segment profitability and our company's cash flow. 
Let me begin by summarizing the company's second quarter performance before I provide additional details on each of our reporting segments. Except where I note otherwise, I'll be referring to non-GAAP results. At the end of last year, we laid out a 3-year plan for value creation, with this year being a year of transition. I also identified 3 key milestones we'd use to monitor our profits against this value-creation plan. I referenced these plans in our last earnings call, so let me reference them again today. 
Of the 3 milestones we laid out, the first was to return the business to constant-dollar sales-growth. Today, you'll hear us reiterate expectations for 2016 sales that anticipates that we'll return to growth in the coming quarters. Within the most recently completed quarter, demand in China for new products continued to grow. Actual shipments this quarter, however, were constrained by supply shortage caused by newly introduced, additional import processes at Chinese border points. More about this later. 
Despite these constraints, gross sales before trade support and discounts were in line with prior quarter. Net sales were lower than the quarter before, as trade support for new product introductions increased. Michel will elaborate on this a little bit later. 
Our second milestone is centered around our commitment to reduce our operating expense base. Year-to-date, we've delivered $47 million in expense reductions. We've already achieved nearly 80% of our annual target of $60 million. We are ahead of schedule. And in this call, we're announcing a revised, more ambitious target. 
We are both accelerating and expanding our cost initiatives by increasing our 2016 target to $75 million to $80 million in savings from the previously announced $60 million. We're also raising our 3-year cumulative savings goals from $120 million to $180 million. 
Our third and final milestone we said would be to invest a portion of our expense savings to fund key growth initiatives. To date, we've invested substantially behind the introduction of a fully imported Enfamil into China and the building of a toddler franchise in North America. This latest quarter, we made strong investments in support of our Enfinitas launch in China and the expansion of distribution reach. Over time, we'll demonstrate to you that these investments are essential to us delivering on our commitment to shareholder value creation. 
Turning now to our second quarter 2016 results. We continue to manage through a challenging global operating environment. Economic growth in many emerging and developing economies of Asia and Latin America has slowed over the past 18 to 24 months. Simultaneously, political uncertainty affects many markets in both Asia and South America. These effects present near-term headwinds for us. That said, we continue to find opportunity amidst the uncertainty. We continue to invest to put ourselves in the best possible position for when a turnaround and economic growth eventually materializes, and come, it will. 
For the second quarter, sales for the company was $942 million. Reported net sales were $9 million lower than the prior year quarter. Currency adversely impacted our results by 500 basis points. Consequently, constant-dollar sales were below -- excuse me, consequently, constant-dollar sales were 4% below those of the second quarter of 2015. Price was favorable by 1% despite added trade support in China, while volume was 5% unfavorable. 
Second quarter sales were impacted by significant investments to secure trade support and distribution of Enfinitas in China. Though costly in the near term, these investments will help establish the brand and drive long-term revenue growth. I'll return to the topics of Enfinitas a little later. 
In China, a requirement for additional product testing prior to importation took effect towards the end of the second quarter, causing delays to the importation process. I want to commend the Chinese government for its actions to enhance food safety standards and importation guidelines to ensure imported products can be safely used by Chinese parents and children. 
During the quarter, the government implemented new testing standards for imported products within our category. The effect of this change was a temporary delay in the importation of some of our fastest-growing products from our Netherlands facility. This drove some near-term volatility in our sales results. In the mid to long term, we, however, believe these additional processes will benefit both Chinese children and responsible operators within the industry. 
Outside of China, the deteriorating circumstances in Venezuela, that so tragically impact the people and our colleagues there, have resulted in significantly reduced shipments to the country. When comparing to the second quarter of last year, this adversely impacted the company's sales by 130 basis points in the latest quarter. 
Despite the challenging operating environment, I'm pleased with the company's earnings power. Gross margin remained strong. Our strategy to drive growth of higher-value products and product forms is working and helps offset the impact of increased investments above the net sales line. Investments in advertising and promotion represented 17.6% of net sales in the quarter. 
Our Fuel for Growth cost-reduction initiative drove significant reduction in SG&A. Overall, these costs were down 9% in constant dollars in the second quarter compared to the same quarter of prior year. 
While we made significant investments in key growth initiatives, our EBIT margin was 24.4% in the quarter, and non-GAAP earnings per share for the quarter were $0.88. Michel will expand on our earnings delivery a little later. 
I'll now discuss the performance of each of our reporting segments, beginning with the North America/Europe segment. 
Net sales in the North America/Europe segment were in-line with the second quarter of 2015 on a constant-dollar basis and improved sequentially from the first quarter. A 1% benefit from price was offset by lower volumes. Additionally, we experienced additional headwind of 1% from foreign exchange. 
The Center for Disease Control recently issued their report on 2015 U.S. birth and birth rates. Reported annual birth was 0.3% below the 2014 level. Breastfeeding rates, however, appeared to have stabilized. Our market share in the U.S. business stabilized in the second quarter but remained at a level lower than the prior year. In our outlook, we are recognizing it will likely take longer than hoped for to recover market share. Much of our share loss was within the specialty and solution segment of the infant formula market. But we are confident we understand our challenges and we're addressing them. 
There are bright spots within this reporting segment also. Last October, we introduced a new 32-ounce liquids packaging. This product line is now growing double digits, and we are gaining share in the high-value liquids category. 
It's still the early days for our premium-priced Enspire products but reception from retailers has been favorable, and we expect to see distribution increase in the coming quarters as we build consumer demand. 
Our North American toddler business, defined as products targeting children more than 1 year of age, continues to grow at an annual rate in double digits. 
And turning to Canada. I continue to be pleased with our progress. Second quarter sales grew double digits based on strong market share gains in both the infant and children segments. We've executed extremely well over the past year or 2, and our Canadian team is deservedly receiving much internal recognition. 
Our European business remains strong based on a leading position in the growing allergy segment there. We are well-positioned to benefit from future increases in diagnosis and have a strong innovation pipeline to support our growth in Europe. 
Let me now turn to Latin America. Constant-dollar sales for the total region was 3% lower than the prior year same quarter. Pricing benefits of 9% was insufficient to fully offset foreign exchange impacts of 13%. Excluding the impact of our sharply reduced business in Venezuela, Latin America sales grew 4% in constant dollars over the same quarter of 2015. 
Mexico and Colombia were the biggest contributors to growth. In Mexico, we are seeing improved momentum in both our premium pediatric nutrition business and our milk modifier business. We enjoy strong market shares in our milk modifier business and retain our #1 position in this category. In infant formulas, we recently rolled out a product containing Milk Fat Globular Membranes (sic) [ Milk Fat Globule Membranes ], the same key ingredient contained in Enfinitas and Enspire products launched in China and the U.S. 
Trends in other parts of Latin America remain broadly unchanged from the prior quarter. In Brazil, economic challenges continue to hurt demand for discretionary items like our mid-priced children's products. The premium infant formula products are less discretionary, and they continue to grow. We continue to benefit from strong sales in our Colombian unit, which maintains strong market shares, and in addition, is benefiting from cross-border demand from Venezuela. 
We are rolling out our new plastics packaging and refill systems across Latin America. And in some markets, we are testing ready-to-drink versions of our children's products. These initiatives will allow us to take advantage of segment growth opportunities and support selective increases in price. 
I'll turn now to the Asia segment. Constant-dollar-growth sales in Asia were in-line with the second quarter of 2015. In support of the Enfinitas launch in China, trade investments, however, were significantly higher when compared to the prior year. Partly as a result of this, price was unfavorable by 2%, as the increased trade investments in China more than offset the impact of price increases in Southeast Asia. 
Across the region, product mix continued to improve with sales of our premium-priced products going faster than those of our lower-priced variants. Volume was unfavorable by 5%, as we experienced delays to importation in China and dealt with some market share weakness in the Philippines. Despite improving momentum in China, the Asia region has not yet recovered to sales levels seen in the early part of 2015. 
In the Philippines, we've seen softer market share in sales of Lactum, our mid-priced children's brand. We feel we've identified the root causes behind our share loss and have a remedial plan that will allow us to get back on track. 
Our Malaysia business is growing both volume and price. We recently introduced a new formulation and improved packaging that will allow us to recover market share over time. 
Across Southeast Asia, we are rolling out new product formulations and promoting the benefits of our new plastics packaging. Supported by an improved value equation, we are raising prices behind this innovation. 
I will finish my discussion of the Asia segment with China. In my introductory headlines, I described the import delays caused by increased processes at all border points. In Mainland China, the government implemented a new requirement that every batch be extensively tested prior to release to Chinese consumers. Previously, a sampling approach has been applied. The increase in the number of tests required caused temporary delays as testing and verification capacity was stretched. The effect of this was a temporary delay in the importation and shortage of supply of many of our fastest-growing imported line items, as I mentioned earlier. We, nevertheless, are pleased to see these measures implemented. 
Similarly, increased customs monitoring and reduced visitor numbers have adversely impacted our Hong Kong business. It's become more challenging for our Hong Kong business to compete for visiting Chinese tourists that now connects these imported products more easily from within the Mainland. These challenges confirm our China strategy pursuing increased flexibilities through a broader product portfolio sold through a more diverse set of sales channels. 
Turning now to Mainland China, where our fully imported products continues to gather momentum, and we're seeing strong demand from consumers. Through the second quarter, we continued to grow market share of the imported segment. In the baby store channel, we've increased our distribution, supported by our most recent, new product introductions. We are seeing both our ability to make progress and the substantial runway we have ahead of us. 
As of the second quarter, we are no longer under indexing versus the market in the fast-growing baby store channel. Our new Enfinitas product line is off to a solid start. Three months after introductions, we are still building distribution and demand, but we are encouraged by the early signs. 
In totality, I'm satisfied with the progress we've made with our portfolio and channel transformation in China. I also recognize we've got a long way to go and a lot of opportunities ahead of us. It's hard not to be excited about the immense potential of not only our China business but our global business. 
Before I hand over to Michel, I want to provide an updated outlook for full year 2016, our year of transition, a year in which we are addressing several structural opportunities within both our brand portfolio, our product lineup and our cost structure. 
At the beginning of the year, we knew comparisons in the first half 2016 would be challenging. I'm satisfied that many of our critical initiatives have gone as planned, and we are expecting growth over prior year in the second half of the year. However, we've seen 3 developments causing us to revisit our estimate for full year 2016 constant-dollar-sales growth. It's taking us longer than expected to recover the market share we lost in the U.S. towards the end of 2015. 
Secondly, the import-related challenges in China, Hong Kong in the second quarter cost of sales we won't fully recapture until next year. 
Thirdly, we are supporting our imported portfolio in China with additional trade support. In light of these factors, we now expect constant-dollar sales in-line with or not more than 2% below the 2015 level. 
Through the first half of the year, we've identified several opportunities within our cost structure. In doing so, we found additional opportunities to both reduce cost and increase efficiencies. In a moment, Michel will outline an expanded ambition and scope for our operating expense initiative, the project we refer to as Fuel for Growth. Despite lower sales, a slightly improved outlook for gross margin, expense optimization and the benefit realized from a lower tax rate in the just completed quarter allow us to reiterate our expectation for non-GAAP earnings per share of $3 -- of between $3.48 and $3.60 for the full year 2016. 
I'll now hand over to Michel, who will provide additional details on our second quarter and first half financial performance. I'll then return with a few summary remarks before we take your questions. Michel, over to you."
1002291,367328591,1016756,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Thank you, Kasper, and good morning, everyone. Today, I will discuss the company's second quarter and first half 2016 financial results. I will then briefly highlight EBIT results for each segment, cash flow and liquidity items and conclude with a summary",2807,"Thank you, Kasper, and good morning, everyone. Today, I will discuss the company's second quarter and first half 2016 financial results. I will then briefly highlight EBIT results for each segment, cash flow and liquidity items and conclude with a summary of full year guidance. 
Unless otherwise noted, my comments will be on the non-GAAP financial results. References to currency impacts or the effects of currency fluctuations generally refer to the impact on the translation of local currency financial statement into U.S. dollars. In addition, my comments about sales will refer to net sales, unless I explicitly call out gross sales. 
Let me start with sales as shown on Slide 3. Kasper addressed the constant-dollar change. I will focus on the reported sales and the foreign currency impact. For both the second quarter and first half year, adverse foreign exchange rates contributed to a 500 basis points decline compared to the same period of the prior year. Second quarter net sales on a reported dollar basis grew 9% below prior year quarter. Reduced shipments to Venezuela impacted net sales negatively by 1% in the second quarter versus the prior year quarter. 
Slide 4 summarizes the impact of foreign exchange on sales. U.S. dollar continued to be strong and effects of translation of local currencies negatively impacted all reporting segments. However, the impact was slightly less significant in the second quarter of 2016 when compared to the trend from the last 3 quarters. Nearly 2/3 of the second quarter negative currency impact on sales were from the Chinese renminbi, the Mexican peso and the Argentine peso. The balance of the adverse foreign exchange impact was widespread across regions. 
As a result of the year-to-date foreign exchange impact, our outstanding currency hedges for the remaining of the year and the current forward rate, we are revising our currency expectations from minus 6% to minus 5% adverse foreign exchange impact on sales for the full year 2016. I will address foreign exchange impact in the EPS guidance section as well. 
I'm introducing Slide 5 for better transparency of gross sales, which reflects sales to customers before trade investment and other items, which are recorded as gross to net sales adjustments. We reallocated some investments in the second quarter from advertising and promotion to trade investments, in support of the rollout of Enfinitas and build on our momentum of the fully imported premium products which were introduced in the second quarter of last year. Gross sales on a constant-dollar basis were flat compared to the prior year quarter and down 2% for the first half year of 2016 versus the same period last year. The significant gross sales improvement in the second quarter has been realized. 
Slide 6. The second quarter EBIT of $230 million was 10% above the prior year quarter on a constant-dollar basis. Foreign exchange adversely impacted EBIT by 6%, including currency impacts. EBIT increased 4% on a reported basis in the second quarter. 
If you would exclude Venezuela, our EBIT on constant-dollar basis improved by 14% versus prior year quarter. The second quarter EBIT margin of 24.4% of sales was 290 basis points better than the prior year quarter. Despite macroeconomic and country-specific challenges which impacted our sales, we made excellent progress to reduce operating expenses as part of our Fuel for Growth program which allowed continued investments and, at the same time, improve the underlying profitability. Year-to-date EBIT was $474 million, a decline of 1% versus previous year on a constant-dollar basis. Foreign exchange, an adverse impact of 8%. 
Excluding Venezuela, EBIT in the first half year improved by 3% versus previous year period on a constant-dollar basis, mainly driven by a higher gross margin and our cost savings realized in the first half year, partly offset by demand-generating investments. 
I will now move to the factors that impact gross margin on Slide 7. Gross margin was 65.1% in the second quarter of 2016, or 66% on a constant-dollar non-GAAP basis. Adverse foreign exchange impacted the gross margin by 150 basis points in the second quarter. We were able to deliver a nearly flat gross margin on a reported basis in both the second quarter and the first half year compared to the previous-year periods despite the significant currency headwind. 
Sales had a slightly negative impact on gross margin from higher-trade investment, especially in China. Low dairy cost continued to be the large benefit to gross margin in the second quarter and first half of 2016. Our key dairy components have been secured through supply contracts for the remainder of the year, and we expect some further benefits, although the dairy benefits for the remainder of the year will be smaller compared to the first half year. 
We continue to deliver productivity savings within cost of goods sold. Year-to-date, the supply chain team delivered productivity savings of around 3.5% of cost of goods sold, in-line with our expectation. With dairy secured for the full year, we expect full year gross margin to be slightly better than our prior year guidance of 64%. 
Moving to operating expenses. I will start with advertising and promotion investments on Slide 8. Advertising and promotion was 17.6% of sales in the second quarter compared to 18.4% in the prior year quarter. As previously mentioned, in the second quarter, we reallocated a portion of investments from A&P to trade investments, which are recognized in gross to net sales. Despite the year-over-year savings, the second quarter of both years marked noticeably higher investments. The incremental investments were mainly to support key China initiatives, last year for the launch of our fully imported products and in April of this year, the launch of the Enfinitas product line and the continued support of our greater China strategy. 
In the second quarter, we purposefully delayed some A&P investments due to delays in the importation of some of our China product impacting our sales. As such, we expect the third quarter may continue to be in elevated level before it normalizes in the fourth quarter. 
Slide 9 provides the combined spending of the mine-generating investments, both as trade investments classified in gross to net sales and advertising and promotion. Some of the key trade investment activities include trade support, customer programs and promotional pricing. For the second quarter, the combined investment increased above the prior year quarter and was also higher for the last few quarters. 
Trade spending is focused close to our consumer and to ensure our products are present with strong distribution in the key growing channels. In the past few quarters, we've increased these investments, especially in China, to be more competitive in the baby store and e-commerce channels. While we increased trade investments, we plan to reduce the A&P as a percentage of sales over the next few years. 
Last quarter, we committed to provide an update on our review of advertising and promotion expenditures. At Investor's Day last year, when I spoke about advertising and promotion, I stated that we should be able to optimize a lower A&P by 50 to 100 basis points over 3 years. We can now confirm that we expect to be at the top of that range and reduce our A&P by 100 basis points by 2018. We will realize this by prioritizing investment choices that maximize our return on investments of key influence drivers. 
We will continue to optimize our non-media expenses and leverage our decision-supporting tools better. In addition, we will strengthen our focus on digital marketing versus the traditional media. 
Slide 10. We reduced our SG&A cost by 9% on a constant-dollar basis in the second quarter of 2016 versus the previous-year quarter and by 10% year-to-date compared to the prior year period. Like we indicated before, our Fuel for Growth program is focused on cost reduction within our support functions and marketing. 
Areas of focus were the reduction of key vendor contracts, eliminates discretionary spend and optimize organization layers. As you can see from Slide 11, we are significantly ahead of schedule on the original 2016 Fuel for Growth target. Our Fuel for Growth target for this year was $60 million. By mid-year, we've delivered 79% of this year's target savings, or $47 million already. Especially in the corporate overhead functions, we were able to reduce our cost by $30 million in the first half year of 2016 versus the first half year of 2015. Significant progress has been made by systematically renegotiating contracts with our largest vendors. 
Slide 12. Over the last few months, we performed a more extended, deep-dive review of our expenses as well as our organizational structure. We concluded, based also on the success of our results to-date, to accelerate certain cost-savings programs identified earlier and to expand the scope to all operating expenses functions, including sales force and distribution. We now expect to deliver $75 million to $80 million of savings in 2016. This is an increase of $15 million to $20 million versus our original 2016 target. Taking into account the savings realized in 2015 of $20 million, cumulative savings by the end of 2016 are expected to be around $95 million to $100 million. 
In addition to the original program of $120 million, we expect an incremental $60 million of cost-savings opportunities by 2018. The combined Fuel for Growth program will now deliver $180 million savings by 2018. 
The incremental Fuel for Growth savings will provide additional flexibility to invest in the company's future growth. 
Turning to Slide 13 for a discussion of EBIT by segment. Let me start with Asia. In the second quarter, Asia delivered an EBIT of $137 million, a decrease of 4% on a constant-dollar basis compared to prior year quarter. Foreign exchange adversely impacted EBIT by additional 8%. Lastly, from the Chinese renminbi, the Thai baht and the Malaysian ringgit. The Asia EBIT margin at 30% declined 50 basis points compared to the second quarter of 2015. The main drivers were lower sales and an increase in trade investment in gross to net sales. The lower net sales impact was somewhat offset by a favorable dairy cost and some lower A&P expenses. 
For the first half year of 2016, the Asian EBIT margin of 32% were 350 basis points lower than the prior year, as lower sales and higher-demand-generation investments were not fully offset by the dairy benefit. A&P as a percentage of sales increased in the first half year versus the previous period. 
Turning to Slide 14. Latin America delivered EBIT of $36 million in the second quarter, a decrease of 7% on a constant-dollar basis compared to the prior year quarter. For this segment, foreign exchange adversely impacted EBIT by 12%, largely from the Mexican peso. Excluding our Venezuela business, EBIT on a constant dollar increased by 9% in the second quarter -- for the previous year quarter. And EBIT on a constant dollar increased 16% in the first half year of 2016 versus the previous-year period. 
For the balance of the business, lower sales were somewhat offset by lower-demand-generating expenses. The year-to-date Latin America EBIT margin was 23.6% compared to 25.3% for the same period last year. Lower EBIT margin is mainly a result of lower gross margin from the deteriorating situation in Brazil and Venezuela, somewhat offset by cost-reduction programs. 
Slide 15 shows the North America/Europe segment results. For the second quarter, North America/Europe EBIT was $99 million, an increase of 21% on a constant-dollar basis. The EBIT margin of 31.1% was 450 basis points better than previous year quarter. Gross margin remained strong from the benefit of low dairy costs. Within operating expenses, reduction in A&P and SG&A cost savings helped fund selective investments and drove high EBIT margins. Year-to-date, EBIT margin was 29.2%, an improvement of 300 basis points versus previous-year period. Fuel for Growth savings programs and the dairy benefit contributed to the improved EBIT margin. 
I will now address the financial results from EBIT to EPS on Slide 16. The interest expense of $26 million in the second quarter was similar to the first quarter of 2016 expense. When compared to the prior year quarter, the interest expense increase reflects the impact of the November 2015 $1.5 billion notes issuance. A significant portion of the proceeds from the notes were used to finance the accelerated share repurchase program, or ASR. 
Since the ASR concluded on June 30, let me briefly provide you a summary of the transaction. During our Investor Day, we announced the new $1.5 billion share repurchase program, of which $1 billion would be in the form of an ASR. 10.7 million shares of stock were received in the fourth quarter of 2015, an additional 2.1 million of shares of stock were received on June 30, 2016. In total, 12.8 million shares of stock were repurchased through the ASR program at an average price of $78.05 per share. Since the IPO, the company bought back 23.4 million of shares, with a total value of $1.8 billion. There are 184.7 million shares outstanding as of June 30. And in the last 12 months, this is a reduction of 18.5 million shares. 
The benefit from all share repurchase in 2015 and the full ASR program, net of interest expense, delivered almost $0.05 year-to-date and is in-line with our full year guidance of $0.11 benefit per share in 2016. 
As part of the $1.5 billion share buyback program announced in 2015, we still have $500 million available for an additional repurchase program. We continue to focus on shareholder value creation. This includes EBIT margin accretion, sales and EPS growth, along with the return of cash to shareholders through both dividends and share repurchases. 
Next, non-GAAP effective tax rate, or ETR, was 18.3% for the second quarter of 2016 compared to 25.6% in the prior year quarter. In the second quarter of 2016, there was about $0.05 per share benefit as a result of utilizing foreign tax credits on dividends from our foreign operations. We expect the ETR for the balance of the year to normalize. 
Non-GAAP EPS for the second quarter was $0.88, an increase of 16% on a reported basis and 24% on a constant-dollar basis. Year-to-date non-GAAP EPS was $1.75, a decrease of 5% on a reported basis and an increase of 3% on a constant-dollar basis. 
Let me summarize our financial results by addressing the change to EPS on Slide 17. In the second quarter, non-GAAP EPS increased $0.18 to $0.94 per share on a constant-dollar basis versus the prior year quarter. Sales and related gross profit negatively impacted EPS by $0.07. Our Fuel for Growth savings delivered $0.11 benefit. Advertising and promotions were $0.06 lower in the quarter, and that share repurchase program delivered a $0.02 benefit, net of higher interest expense. Tax and other contributed a $0.06 benefit. Despite the negative impact of foreign currency of $0.06 per share, EPS increased by $0.12 versus second quarter last year on a non-GAAP basis. 
Turning to a high-level overview of cash movements. On Slide 18, the cash balance of $1.7 billion as of June 30 was similar to the beginning-of-the-year balance. Cash flow from operations was negatively impacted by $94 million as a result of timing of tax payments and other working capital movements. Our CapEx investments were $81 million, mainly in our U.S. and Europe manufacturing facilities. For the full year ago, our capital spending goal remains about 4% of sales. Dividend payments were $155 million in the first half year. The negative impact of foreign exchange impact of $32 million was related to the currency devaluation in Venezuela. 
To summarize our forward-looking annual guidance on Slide 19, our sales outlook for 2016 on a constant-dollar basis is expected to be 0 to 2% below the prior year. With foreign currency reducing sales growth by about 5%, reported sales are estimated to be 5% to 7% below 2015. 
We reaffirm our 2016 GAAP EPS guidance of $2.91 to $3.03 and our non-GAAP guidance of $3.48 to $3.60 per share for the following reasons: First, we expect a gross margin improvement from our previous guidance of 64%; second, our Fuel for Growth savings are well ahead of plan and will only partly be reinvested in our business; thirdly, we have an ETR benefit around $0.05 in the second quarter; and fourth, the foreign exchange impact is expected to be approximately $0.35 per share from our previous guidance of $0.40 per share. 
GAAP EPS guidance is likely to be impacted by potentially significant future market-to-market pension adjustments, which cannot be estimated and are classified as specified items. Specified items include charges related to Fuel for Growth and our Venezuela business. 
This concludes my discussion on the second quarter and first half year 2016 financial results. Thanks again for your time this morning. I will now hand over the call back to Kasper."
1002291,367328591,1016756,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Thank you, Michel. Before we open the lines for questions, let me briefly reiterate our expectations that our relative performance will improve as we move into the second half of 2016. We expect to see the company return to positive growth in the coming q",150,"Thank you, Michel. Before we open the lines for questions, let me briefly reiterate our expectations that our relative performance will improve as we move into the second half of 2016. We expect to see the company return to positive growth in the coming quarters and our guidance reflects that. Our efforts to reshape our product and brand portfolio in China are progressing well, so is our initiative to strengthen our presence in the fast-growing channels there. We're gaining momentum in Mexico, Canada and Malaysia while we are addressing our performance shortfalls in the U.S. and the Philippines. We are partaking our ability to invest to maximize our opportunities by improving our gross margins to improve product mix and by lowering our expense base. And finally, we remain as committed as ever to shareholder value creation. 
With that, Liz, could I ask you to open the lines for questions, please?"
1002291,367328591,1016756,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Operator","[Operator Instructions] Your first question comes from David Driscoll with Citi.",11,"[Operator Instructions] Your first question comes from David Driscoll with Citi."
1002291,367328591,1016756,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","Kasper, can you comment on your retail performance in China? And distinguish it from all the various shipment issues that I think you were talking about? Can you give us some color on market share? And maybe a little bit more on the imported product gains",86,"Kasper, can you comment on your retail performance in China? And distinguish it from all the various shipment issues that I think you were talking about? Can you give us some color on market share? And maybe a little bit more on the imported product gains? And then to kind of round all this question out, will the third quarter see China shipments pick up because of the problems of shipments within the second quarter because of the customs issues that you talked about? Thank you."
1002291,367328591,1016756,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Thanks, David. It's an excellent question. So what I was implying in my prepared remarks, but I'm quite prepared to be more specific, is that we are very satisfied with the consumer demand trends that we are observing in China. So we feel that we are gain",190,"Thanks, David. It's an excellent question. So what I was implying in my prepared remarks, but I'm quite prepared to be more specific, is that we are very satisfied with the consumer demand trends that we are observing in China. So we feel that we are gaining share in the -- with our new products, both in our -- in the super high-premium segment where we obviously came from a standing start and in the imported product segment where we've now been at it for a little while. However, the difficulty of getting product into China in this latest quarter did result -- with some selective out-of-stocks situations at retail as well as lower inventories in many of our distributors. So to the extent of the latter, we expect that we will gradually recover that over the second half of the year. A little bit hard to say whether we will recover it all in the third quarter because that involves speculating on how the importation process evolves. But we are quite encouraged and we are confident that some of these issues are sort of relatively short term in nature."
1002291,367328591,1016756,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","Then just to follow up, would you say then that the retail performance and the market share gains are more indicative of the success of the strategy rather than the shipment number you're reporting today?",35,"Then just to follow up, would you say then that the retail performance and the market share gains are more indicative of the success of the strategy rather than the shipment number you're reporting today?"
1002291,367328591,1016756,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","That's certainly the way we look at it. So I hope I brought that across in my prepared remarks.",20,"That's certainly the way we look at it. So I hope I brought that across in my prepared remarks."
1002291,367328591,1016756,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Operator","Your next question comes from Michael Lavery from CLSA.",9,"Your next question comes from Michael Lavery from CLSA."
1002291,367328591,1016756,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","I just have 2 quick ones. One on Enfinitas, I was wondering if you could give some sense of -- I know it's early there still, but for the distribution, is that skewed more towards tier 1 cities or is it broad geographically and just how is that progressin",86,"I just have 2 quick ones. One on Enfinitas, I was wondering if you could give some sense of -- I know it's early there still, but for the distribution, is that skewed more towards tier 1 cities or is it broad geographically and just how is that progressing? And then just second in Indonesia, we saw a premium competitor cut prices by about 10%. What are the market dynamics there for you? Are you seeing pricing pressure or share pressure or opportunities in that market?"
1002291,367328591,1016756,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Let me start with Enfinitas. It really is early to say how that brand is performing. And particularly, as these last months or so was affected by these temporary delays in importation that I've referenced now repeatedly in China. We are aiming for a prett",128,"Let me start with Enfinitas. It really is early to say how that brand is performing. And particularly, as these last months or so was affected by these temporary delays in importation that I've referenced now repeatedly in China. We are aiming for a pretty broad distribution but obviously with an emphasis on the baby store channel which is the primary outlet for these high-quality, premium-priced products in China. In Indonesia, we typically don't mention it very often in our earnings call, that's not because it's not a great market, it's simply because we have a very small business there and our market participation is relatively low. So I suspect there are other people that are far more qualified than I to discuss the market trends in Indonesia."
1002291,367328591,1016756,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Thank you, Michael.",3,"Thank you, Michael."
1002291,367328591,1016756,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Operator","Your next question comes from Bryan Spillane with Bank of America.",11,"Your next question comes from Bryan Spillane with Bank of America."
1002291,367328591,1016756,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","Just one question related to the increased investment in trade spend. I guess, Kasper, the question is just, was that in reaction to some of your competitors promoting more? Was it a reaction? Is it really a mix, channel mix issue, that you're increasing",120,"Just one question related to the increased investment in trade spend. I guess, Kasper, the question is just, was that in reaction to some of your competitors promoting more? Was it a reaction? Is it really a mix, channel mix issue, that you're increasing your sales in the baby store and that just tends to need more trade promotion? I guess the reason why I ask is just -- it seems sort of inconsistent that you've got a bottleneck at the border, so you're not getting product across, yet you're promoting more, which would seem to increase the incidence of out of stock. So if you can just kind of tie those things together, I think that would be helpful."
1002291,367328591,1016756,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Bryan, thanks for the question. I mean, the trade support is not always, in every case, tied directly to volume. There are certain amount of sort of fixed expenses that are incurred in order to support the trade and particularly create sufficient presence",97,"Bryan, thanks for the question. I mean, the trade support is not always, in every case, tied directly to volume. There are certain amount of sort of fixed expenses that are incurred in order to support the trade and particularly create sufficient presence and awareness in the early stage of a brand launch. So it really reflects that. It is very directly connected to the launch of Enfinitas, and it is directly connected to the fact that trade support in the baby store channel tends to be higher than it is, for instance, in the food channel."
1002291,367328591,1016756,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","Okay. So it seems like you've got -- you've made more progress maybe than you would've original -- or it's progressing faster than you thought and so the need for the trade spend is kind of increased sooner than you thought as well. Is that a fair way to",51,"Okay. So it seems like you've got -- you've made more progress maybe than you would've original -- or it's progressing faster than you thought and so the need for the trade spend is kind of increased sooner than you thought as well. Is that a fair way to put it?"
1002291,367328591,1016756,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Well, I think it's -- a better way to look at it is that we have chosen to rebalance our investment between A&P and trade support to some degree in this latest quarter. We expect that, that balance would change from quarter-to-quarter depending on what ou",69,"Well, I think it's -- a better way to look at it is that we have chosen to rebalance our investment between A&P and trade support to some degree in this latest quarter. We expect that, that balance would change from quarter-to-quarter depending on what our activities are and whether they are booked in one line of the sort of brand investments or booked above the net sales line."
1002291,367328591,1016756,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Operator","Your next question comes from Amit Sharma with BMO Capital.",10,"Your next question comes from Amit Sharma with BMO Capital."
1002291,367328591,1016756,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","Kasper, just to continue what you just said, so if we -- if you are going to shift funding between above the line and below the line, how should we reconcile that with what Michel said earlier in his comments about 100 basis points decline in R&D spending",61,"Kasper, just to continue what you just said, so if we -- if you are going to shift funding between above the line and below the line, how should we reconcile that with what Michel said earlier in his comments about 100 basis points decline in R&D spending over the next few years? Is that net of higher based funding? Potentially?"
1002291,367328591,1016756,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Michel, do you want to take it [indiscernible]?",8,"Michel, do you want to take it [indiscernible]?"
1002291,367328591,1016756,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Yes, when I was referring to A&P, clearly, we were referring to the A&P line as a percentage of sales. Yes, we have -- stepped up the gross to net investments in the second half year, and like Kasper said, it was really to support trade and reiterated the",98,"Yes, when I was referring to A&P, clearly, we were referring to the A&P line as a percentage of sales. Yes, we have -- stepped up the gross to net investments in the second half year, and like Kasper said, it was really to support trade and reiterated the rollout of certain new product launch like Enfinitas and to get the distribution rights. So that gave us, I would say, especially in the second quarter, a temporary step-up, and we will continue this from higher trade investment. But I don't expect a further strong increase in that line."
1002291,367328591,1016756,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","So just so I understand it well. So trade spending slightly up this quarter without looking for a sustained increase in that. And then A&P spend savings should accrue or should be available for you to reinvest or drop to the bottom line?",43,"So just so I understand it well. So trade spending slightly up this quarter without looking for a sustained increase in that. And then A&P spend savings should accrue or should be available for you to reinvest or drop to the bottom line?"
1002291,367328591,1016756,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","A&P savings should be reinvested into gross net or should be dropped to the bottom line.",17,"A&P savings should be reinvested into gross net or should be dropped to the bottom line."
1002291,367328591,1016756,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Thank you, Amit.",3,"Thank you, Amit."
1002291,367328591,1016756,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Operator","Your next question comes from Ken Goldman, JPMorgan.",8,"Your next question comes from Ken Goldman, JPMorgan."
1002291,367328591,1016756,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Analysts",".Forgive my -- the length of my question here. But from my perspective, the guidance on Fuel for Growth is a bit confusing. And maybe I'm wrong. But I'm just hoping you can clear it up for me. So you explicitly said in your slides from the Investor Day",209,".
Forgive my -- the length of my question here. But from my perspective, the guidance on Fuel for Growth is a bit confusing. And maybe I'm wrong. But I'm just hoping you can clear it up for me. So you explicitly said in your slides from the Investor Day that you're looking for 300 basis points of margin improvement, not savings but margin improvement. And that implies that your EBIT margin will get to around 27% by 2018, all else equal. And that's an outlook that I think I've confirmed with the company in recent weeks. But you've also talked, including today, about how you're going to reinvest some of your savings back into the business, which suggests that maybe model all of that $120 million, now $180 million, is going to flow to the bottom line. So I'm clearly just trying to figure out, Michel, how do I reconcile what seems to be some conflicting information out there? And I know it's not guidance, but from a rough outlook, is it wrong for us on the outside to think that margins are expected to go up by 300 basis points or more net of reinvestments over the next few years? I think that's a key question for people."
1002291,367328591,1016756,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Yes, so let me clarify to avoid any confusion, because I want to be consistent with the messages that I gave at Investor's Day. So at Investor's Day, we said we will deliver $120 million of Fuel for Growth savings. And we also indicated that we will partl",141,"Yes, so let me clarify to avoid any confusion, because I want to be consistent with the messages that I gave at Investor's Day. So at Investor's Day, we said we will deliver $120 million of Fuel for Growth savings. And we also indicated that we will partly reinvest that and partly will be rolled through profitability. And in combination with a couple of other initiatives that we announced at Investor Day, we indicated that, that will deliver a 300 basis points margin improvement from 24% to 27% indeed. So what we announced today is an incremental program of $60 million, which should give us $180 million by 2018. From the $60 million, we indicate that we will use that to reinvest in our business to strengthen our future growth. So that will be not part of the growth through profitability."
1002291,367328591,1016756,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","Okay, so...",2,"Okay, so..."
1002291,367328591,1016756,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Did that clarify your question?",5,"Did that clarify your question?"
1002291,367328591,1016756,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","I think so. I'm on myself, so I apologize, but I just want to make sure. Those of us who are modeling, I'm not asking for guidance. But modeling 27% roughly in 2018, I know it's so far out. But are we absolutely insane to do that? Or is that kind of what",67,"I think so. I'm on myself, so I apologize, but I just want to make sure. Those of us who are modeling, I'm not asking for guidance. But modeling 27% roughly in 2018, I know it's so far out. But are we absolutely insane to do that? Or is that kind of what the company is thinking as well, all else equal, if it goes as planned?"
1002291,367328591,1016756,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","I think that the line what we laid out in Investor's Day that we increased our EBIT margin by 300 basis points to 27%.",25,"I think that the line what we laid out in Investor's Day that we increased our EBIT margin by 300 basis points to 27%."
1002291,367328591,1016756,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","I think you're right, Ken, with the way you're thinking about it, with all the normal caveats about being 2.5 years into the future. But the majority of the margin increase will come from a combination of the impact for the Fuel for Growth initiatives tha",86,"I think you're right, Ken, with the way you're thinking about it, with all the normal caveats about being 2.5 years into the future. But the majority of the margin increase will come from a combination of the impact for the Fuel for Growth initiatives that we are discussing now and, of course, we would expect over that time horizon also, aligned with what we communicated at the Investor Day, to see a return to sales growth which will also help the margin accretion exercise."
1002291,367328591,1016756,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Thank you, Ken.",3,"Thank you, Ken."
1002291,367328591,1016756,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Operator","Your next question comes from Matthew Grainger of Morgan Stanley.",10,"Your next question comes from Matthew Grainger of Morgan Stanley."
1002291,367328591,1016756,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","So Kasper, I wanted to just better understand the issue with the testing standards that you mentioned and the anticipated impact, if there is any, that these could have going forward? And I guess, do you think that this had a similar impact across your pe",98,"So Kasper, I wanted to just better understand the issue with the testing standards that you mentioned and the anticipated impact, if there is any, that these could have going forward? And I guess, do you think that this had a similar impact across your peer set during the quarter? Was it idiosyncratic to you? And I ask only because we haven't heard any mention of it from 2 of your larger competitors that have already reported. And related just -- are there any kind of carryforward costs associated with that, that would be meaningful in any way?"
1002291,367328591,1016756,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","I -- so let me -- I normally don't comment on what my competitors say. But I think it depends on how you read the statements they made. I guess we read them a little bit differently from how you may have read them. I do think that it has impacted everybod",205,"I -- so let me -- I normally don't comment on what my competitors say. But I think it depends on how you read the statements they made. I guess we read them a little bit differently from how you may have read them. I do think that it has impacted everybody in pretty much the same manner. So I think other people have referenced the fact that informal exports or imports into China have slowed, et cetera, et cetera. And I think that we probably all have seen the same impact. I do want to reiterate just that we see this as an incredibly favorable development over the mid-term and a clear sort of sign of the Chinese government's commitment to ensure the safety of products that are being sold in China and ensure that these products, in every case, conform with Chinese-quality standards. So you've heard me mention this a number of times before. So I'm frankly -- though I will openly admit that we had hoped that we would report slightly better sales results in the second quarter due to this issue, I'm actually very happy with it from the potential for it to impact our business favorably as we move forward."
1002291,367328591,1016756,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","Thanks, Kasper. And just -- I'm sure you're well placed to me whatever requirements there are. But just the costs associated with that, with the requirements, is it material in any way?",32,"Thanks, Kasper. And just -- I'm sure you're well placed to me whatever requirements there are. But just the costs associated with that, with the requirements, is it material in any way?"
1002291,367328591,1016756,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","No. I mean, the -- I should perhaps have been more explicit. But actually, the additional testing that is happening is actually done by the Chinese government. And of course, we have invested substantially in ensuring that we can, in every case, meet the",57,"No. I mean, the -- I should perhaps have been more explicit. But actually, the additional testing that is happening is actually done by the Chinese government. And of course, we have invested substantially in ensuring that we can, in every case, meet the Chinese-quality standards on products that we sell in China, whether directly or indirectly."
1002291,367328591,1016756,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Operator","Your next question comes from John Baumgartner with Wells Fargo.",10,"Your next question comes from John Baumgartner with Wells Fargo."
1002291,367328591,1016756,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","Michel, I wanted to touch on the incremental sales force and distribution savings you mentioned. Can you speak more to the specifics of that? In terms of what it entails? And maybe what types of risks, if any, that may present to your top line going forwa",54,"Michel, I wanted to touch on the incremental sales force and distribution savings you mentioned. Can you speak more to the specifics of that? In terms of what it entails? And maybe what types of risks, if any, that may present to your top line going forward in terms of balancing your end-market resources."
1002291,367328591,1016756,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Maybe I'll give one comment and then I'll let Michel expand on it. John, I think as fast it comes to the sales force, the organizations and reductions in spend, firstly, you should not necessarily infer that greater efficiency in our sales force expenses",149,"Maybe I'll give one comment and then I'll let Michel expand on it. John, I think as fast it comes to the sales force, the organizations and reductions in spend, firstly, you should not necessarily infer that greater efficiency in our sales force expenses means a reduction in force. Indeed, in many cases, it's an optimization of discretionary spends that we have in the sales force that sit in the same line of the P&L. But it's also true to say that outside of the sort of frontline sales force, there are probably opportunities selectively across our global organizations to organize ourselves a bit differently. So I would say that. I think maybe the -- on the A&P side, I think we're simply recognizing that there are efficiencies available to us as the world is changing that we ought to put more energy into taking advantage of. Michel?"
1002291,367328591,1016756,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Yes, 2 comments to add. The $60 million additional Fuel for Growth savings that we announced, it is not only related to sales force and distribution, just to make that clear, right? It's a further optimization also of the supporting functions. And I would",87,"Yes, 2 comments to add. The $60 million additional Fuel for Growth savings that we announced, it is not only related to sales force and distribution, just to make that clear, right? It's a further optimization also of the supporting functions. And I would say, even the majority will come from the supporting roles. And your point -- let's be clear. We always said we will be very careful with sales force optimizations because we don't want to jeopardize our momentum in certain markets that we're having."
1002291,367328591,1016756,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Operator","Your next question comes from Robert Moskow, Crdit Suisse.",9,"Your next question comes from Robert Moskow, Crdit Suisse."
1002291,367328591,1016756,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","I was wondering, when you talked about the inspections on the borders, are you talking about all borders? It's not just the Hong Kong border? But it's just any product kind of coming into the country? And also, I mean, is there anything that you can do to",105,"I was wondering, when you talked about the inspections on the borders, are you talking about all borders? It's not just the Hong Kong border? But it's just any product kind of coming into the country? And also, I mean, is there anything that you can do to expedite it, expedite those inspections and why can't we think of it more as just kind of like a onetime hit to those debt incoming product that kind of slows you down temporarily but then is kind of solved maybe a month or 2 later? It's like a pig going to a snake or something like that."
1002291,367328591,1016756,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Rob, I think it's a good question. And actually, you can think about it sort of like that. There isn't anything we can really do to expedite it because, as I've said, it applies to the formal importation process into China. And the testing is handled by t",404,"Rob, I think it's a good question. And actually, you can think about it sort of like that. There isn't anything we can really do to expedite it because, as I've said, it applies to the formal importation process into China. And the testing is handled by the Chinese -- by Chinese government agencies outside of the control and involvement of the importing party. So you simply have to wait for your turn, so to speak, and for your individual import batch to be tested and then released through the importation process. It's clear that this created a very -- this was a very large undertaking by these responsible agencies in China. And there was some short-term backup. I'm absolutely confident that they are working day and night to resolve that. And sort of, as usual, I have great confidence in the fact that the Chinese government will resolve that and get back to more of a normal importation flow as they refine these processes. So I do think that, that part of it is sort of temporary. I think the part that will impact us is that, of course, our financial year inevitably cuts off on the 31st of December. And there are 2 impacts in the near term from this. Firstly, there are the sales that we lost through supply shortages in the second quarter already. That -- an element of that, we will probably be able to recapture because we'll be able to replenish inventory in our distributors. But as I referenced, in response to David's question at the outset of this Q&A session, there were out of stocks that occurred at the retail level, which means that we did lose sales to consumers. And those are, if you wanted, permanently lost, so to speak. They're not going to be recovered. The second impact of it is that if you think about this, it effectively puts our kind of growth plans behind these products 2 months back because we've been in this constrained supply situation for the last couple of months, which means that the -- given the rather steep growth curve that we had anticipated for these products, we'll be exiting the year, we'll be cutting off the year on the 31st of December at a point of lower sales than we would otherwise have done, given the 2 months that we have sort of inadvertently lost or partially lost."
1002291,367328591,1016756,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","And does this put at all the Enfinitas concept at risk in any way, shape or form? Like are customers who have been notified of the product launching, are they upset that it's not available? Or have they noticed it's not available? Do you -- if you have an",52,"And does this put at all the Enfinitas concept at risk in any way, shape or form? Like are customers who have been notified of the product launching, are they upset that it's not available? Or have they noticed it's not available? Do you -- if you have any feedback on that?"
1002291,367328591,1016756,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","I've never had a customer who was entirely happy when you can't supply their orders. But I think we have a great relationship with the vast majority of our customers in China. And they understand the situation. As I said, it's not completely unique to our",72,"I've never had a customer who was entirely happy when you can't supply their orders. But I think we have a great relationship with the vast majority of our customers in China. And they understand the situation. As I said, it's not completely unique to our company and I think we've managed to explain it to them. And I feel confident that we still have the support of our customer base."
1002291,367328591,1016756,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Operator","Your next question comes from Jon Andersen with William Blair.",10,"Your next question comes from Jon Andersen with William Blair."
1002291,367328591,1016756,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","I just want to put the discrete import testing issue aside for a minute and just, Kasper, if you could comment maybe on some of the broader regulatory changes that are happening in China. I'm thinking here about things that may ultimately result in volume",88,"I just want to put the discrete import testing issue aside for a minute and just, Kasper, if you could comment maybe on some of the broader regulatory changes that are happening in China. I'm thinking here about things that may ultimately result in volume migration away from some of the gray market into more responsible producers or registered product hands. Can you talk a little about what's happening there, the timing of some of those events and where do you think there's a benefit here to meet?"
1002291,367328591,1016756,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Well, I mean, we've been talking about this topic, I guess, it's a broad topic now, for at least a couple of years. I remain very, very optimistic about the way the Chinese government is going about this. It's natural that we would always wish that things",258,"Well, I mean, we've been talking about this topic, I guess, it's a broad topic now, for at least a couple of years. I remain very, very optimistic about the way the Chinese government is going about this. It's natural that we would always wish that things could happen faster than they do. But what I see is a very clear determination by the Chinese government to ensure that products that are sold to China -- for consumption by Chinese children are all safe and in compliance with their standards. And that's a very reasonable goal. There are various initiatives that intersect as they pursue this latest one to try and get a handle on imported products, at least through the formal channels and making sure that those products comply with Chinese standards. I think it's a very positive one. I think there's still a significant amount of product going through sort of informal channels imported into China in small parcels, mainly through what we have previously called consumer-to-consumer e-commerce or what we can perhaps call unofficial exports out of say, Europe or Australia. I would expect the Chinese government just looking at that. And over time, they will determine a way to ensure that you can't have different quality standards applying to that sales channel than you have to the official sales channels. So overall, I'm very -- I'm very encouraged by what I'm seeing, recognizing that it is challenging us in the short-term but it's a good thing for the long-term development of the China market."
1002291,367328591,1016756,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Thank you.",2,"Thank you."
1002291,367328591,1016756,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Operator","Your next question comes from Mario Contreras from Deutsche Bank.",10,"Your next question comes from Mario Contreras from Deutsche Bank."
1002291,367328591,1016756,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","So I wanted to ask on North America. Earlier in your remarks, you mentioned that share recovery there has been a bit slower than expected. And then later, you also mentioned that A&P was down in that region. So I guess my first question is, is there any c",67,"So I wanted to ask on North America. Earlier in your remarks, you mentioned that share recovery there has been a bit slower than expected. And then later, you also mentioned that A&P was down in that region. So I guess my first question is, is there any correlation there? And second, and more broadly, what does it take to get share to a more acceptable level?"
1002291,367328591,1016756,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Well, Mario, I think first of all, let me just start by saying that the market share comments are all relative and they are relative to where we were 12 months ago. And there's no doubt that we've lost some market share, probably about 100 basis points or",210,"Well, Mario, I think first of all, let me just start by saying that the market share comments are all relative and they are relative to where we were 12 months ago. And there's no doubt that we've lost some market share, probably about 100 basis points or so in market share versus where we were a year ago, at least the way that we look at the profitable part of the U.S. market. We -- I'm not sure I'm prepared to comment on what our plans are exactly for recovering that market share. But you can imagine that it's receiving a fair amount of attention. And I did talk about the particular product segments where we've seen the -- our share develop unfavorably. So it's still -- we are spending at very healthy levels against it. And I'm confident that if we felt that, it was a question of simply investing more money in order to sell more and therefore, gain more share, we would do so. However, I'm not convinced that this is a question of absolute investment levels. I think there have been some execution of issues that we are working through and I'm confident my team in the U.S. are addressing those issues as we speak."
1002291,367328591,1016756,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Operator","Your last question comes from Pablo Zuanic with SIG.",9,"Your last question comes from Pablo Zuanic with SIG."
1002291,367328591,1016756,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","Look, just one question on the import and local mix. In previous presentations, you've given the mix. Can you just give us as an update on where you are in China in terms of imports and local? And related to that, this trade promotion question, it would b",111,"Look, just one question on the import and local mix. In previous presentations, you've given the mix. Can you just give us as an update on where you are in China in terms of imports and local? And related to that, this trade promotion question, it would be nice if you can break it by the 3 product categories, right? And what I mean by that, the local products, the Enfamil imported range and then Enfinitas launch. Because the way I understand it, you're having to promote your old inventory on the shelves, the local product. So if you can just give some color in that regard it would be helpful."
1002291,367328591,1016756,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","I'm going to try and strike a balance here and make sure that I don't give way more information to my competitors than I would like, Pablo. So please be understanding of that. So I don't know that I will go further to identify how we're spending our trade",152,"I'm going to try and strike a balance here and make sure that I don't give way more information to my competitors than I would like, Pablo. So please be understanding of that. So I don't know that I will go further to identify how we're spending our trade support. On the import versus local business, I think we've been very clear that the imported part of our portfolio is still the fastest-growing part of our portfolio. And we see us being in the kind of transition phase where over the long -- over the mid-term, at least we will see our Hong Kong products and our locally produced products probably in decline and you will see us making up for that decline with growth through our imported product portfolio. That assumes that there are no unforeseen changes to the regulatory environment in China that would somehow cause that to change."
1002291,367328591,1016756,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","Right. And if I may, just a very quick follow-up. On the margin question, whether people project 26%, 27%, 28% by 2018, my question is, you had guided for a 300 net gain. But today, you increased your cost savings from $120 million to $180 million, that's",117,"Right. And if I may, just a very quick follow-up. On the margin question, whether people project 26%, 27%, 28% by 2018, my question is, you had guided for a 300 net gain. But today, you increased your cost savings from $120 million to $180 million, that's about 100 bps on sales, and your A&P efficiency went from $50 million to $100 million to $100 million now. So that amounts to almost another $175 million of margin expansion. But you're still sticking to 27%. So that my read of that is great, you have more cost savings. But you have recognize that the reinvestment is greater than you had expected. Is that the right, the correct read?"
1002291,367328591,1016756,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Pablo, before Michel answers, could you put your phone on mute when he answers, we're getting an echo from you.",20,"Pablo, before Michel answers, could you put your phone on mute when he answers, we're getting an echo from you."
1002291,367328591,1016756,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","I'm sorry, okay.",4,"I'm sorry, okay."
1002291,367328591,1016756,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Yes, Pablo, the major part of that incremental $60 million will be reinvested in the business, especially gross to net, especially also for the A&P, 100 basis points decrease. So is it gross to net reinvestments? And like we said, we also potentially, exp",77,"Yes, Pablo, the major part of that incremental $60 million will be reinvested in the business, especially gross to net, especially also for the A&P, 100 basis points decrease. So is it gross to net reinvestments? And like we said, we also potentially, expect over time some further headwinds in gross to margin in-line with what I indicated at Investor's Day in October. That's the reason why you don't see that pulled through -- fall through benefit."
1002291,367328591,1016756,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Thank you for participating in Mead Johnson's earnings conference call. I will now turn it back to the operator.",20,"Thank you for participating in Mead Johnson's earnings conference call. I will now turn it back to the operator."
1002291,367328591,1016756,"Mead Johnson Nutrition Company, Q2 2016 Earnings Call, Jul 28, 2016",2016-07-28,"Earnings Calls","Mead Johnson Nutrition Company","Operator","This concludes the presentation. You may now disconnect. Good day.",10,"This concludes the presentation. You may now disconnect. Good day."
1002291,367328587,1063038,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Operator","Good day, ladies and gentlemen, and welcome to the Mead Johnson Nutrition Third Quarter 2016 Earnings Conference Call. My name is Liz, and I will be your coordinator for today. [Operator Instructions] As a reminder, this conference is being recorded for r",63,"Good day, ladies and gentlemen, and welcome to the Mead Johnson Nutrition Third Quarter 2016 Earnings Conference Call. My name is Liz, and I will be your coordinator for today. [Operator Instructions] As a reminder, this conference is being recorded for replay purposes.
I would now like to turn the conference call over to Kathy MacDonald, Vice President, Investor Relations. Please proceed, Kathy."
1002291,367328587,1063038,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Thank you, Liz. Good morning, and thank you for joining Mead Johnson's Third Quarter and 9 Months 2016 Conference Call. With me today are Kasper Jakobsen, our Chief Executive Officer; and Michel Cup, our Chief Financial Officer.Earlier today, we issued",345,"Thank you, Liz. Good morning, and thank you for joining Mead Johnson's Third Quarter and 9 Months 2016 Conference Call. With me today are Kasper Jakobsen, our Chief Executive Officer; and Michel Cup, our Chief Financial Officer.
Earlier today, we issued our 10-Q, earnings release and financial reference slides. If you have the slides in front of you, please turn to Slide #2.
A detailed explanation of our forward-looking statements appears in the slides, which are also posted on our website in connection with today's conference call. As we start, let me remind everyone that our comments will include forward-looking statements about our future results, including statements about our financial prospects and projection, commodity costs, currency fluctuations, pricing, taxes, capital spending, new product launches, other growth initiatives and market conditions that constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Keep in mind that our actual results may differ materially from expectations as of today due to various factors, including those listed in our annual report on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K, and each case is filed with or furnished to the Securities and Exchange Commission and our earnings release issued this morning.
Today's comments will include discussion of non-GAAP financial measures. Unless otherwise noted, comments relate to the income statement will be on a non-GAAP basis with the exception of advertising, promotion and interest expense. In addition, comments related to the balance sheet will be on a GAAP basis. A reconciliation of these measures to comparable GAAP measures appears in the morning's earnings release and financial reference slides, which are available at meadjohnson.com. In addition, any forward-looking statements represent our estimates only as of today and should not be relied upon as representing our estimates as of any subsequent date. While we may elect to update forward-looking statements at some point in the future, we specifically disclaim any obligation to do so, even if our estimates change.
I will now turn the call over to Kasper."
1002291,367328587,1063038,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Thank you, Kathy, and good morning to you all. Thank you for joining our earnings call. My comments will stand [ph] on the general business climate, our strategy, our latest quarter top line performance and our outlook. Michel will then follow me by provi",2043,"Thank you, Kathy, and good morning to you all. Thank you for joining our earnings call. My comments will stand [ph] on the general business climate, our strategy, our latest quarter top line performance and our outlook. Michel will then follow me by providing some additional and financial information, including comments on our cash flow related items.
I want to start today's discussion by revisiting our 3-year value creation plan. We laid out this plan at our Investor Day in October of 2015. And at that time, we explained how 2016 would be a year of transition.
We committed to 3 key metrics: a return to growth; a set of expense reductions; and a partial reinvestment of savings in growth initiatives and margin accretion. We said we'd measure our progress against these through the period. I've [ph] since revisited these metrics in every earnings call. So let me now briefly summarize our third quarter results in that context.
Firstly, in the third quarter, we delivered growth at the gross sales level of 1%. On a net sales basis, all 3 geographic segments delivered sales in line with prior year's quarter. This is an improvement over the previous 2 quarters. Excluding the effect of suspended shipments to Venezuela, net sales grew 1% in the third quarter over the prior year quarter.
Our second milestone relates to our targeted operating expense reductions. In our second quarter call, we revised our 2016 estimate from $60 million in reductions to $75 million to $80 million. Year-to-date, we've delivered $67 million in savings, and we've achieved approximately 85% of our annual target. SG&A expenses in the latest quarter were almost $20 million lower than a year earlier.
Our third milestone was to invest a portion of the expense savings to fund key growth initiatives while increasing our EBIT margin. Our investments have largely been supportive of our portfolio reshape and strategic channel shift in China. These initiatives are helping us report strong growth in China this quarter while simultaneously raising our EBIT margin.
Before I go into detail on our third quarter results, let me put these in context. The macroeconomic climate in North America and Europe appear stable. But in many emerging markets, we see consumers pressured by slowing economic growth. This applies broadly across Latin America and Asia and is consistent with what you have heard from other companies this earnings season.
So my view of China, backed by recent economic downturn, is a little more positive than that of some others. There's little doubt that a pickup in economic activity in emerging markets will be linked to a recovery in demand for the exports in North America and Europe.
We also believe that the long-term category fundamentals are intact and remain supportive of our growth ambition. We believe that making the necessary and strategic investments now is critical to delivering on our 3-year road map of value creation.
Let me now expand on our third quarter results. For the third year running, we're experiencing foreign exchange headwinds. And for the second year in a row, economic challenges have combined with low dairy costs to produce a challenging pricing environment. Competitively, our results in the latest quarter were frankly [ph] mixed. We are facing a stiff challenge from competition in the United States. Conversely, we have good evidence that our China strategy is working. And there, [ph] we are strengthening our competitive position in growing channels. In aggregate, third quarter sales for the company were $938 million.
Currency adversely impacted our results by 4%. Constant dollar sales were in line with the third quarter of 2015, while reported sales were 4% lower than the prior year's quarter.
As I mentioned earlier, excluding the impact of our intentionally reduced business in Venezuela, the company's [ph] net sales grew 1% in constant dollars over prior year.
While volume was 5% unfavorable, we saw a fully offsetting benefit from price and product mix of 5%. This, despite continued competitive pressure on low dairy costs.
Gross margin was strong and remains above our historical average, and we continued to invest against our priority initiatives, including the establishment of Enfinitas in China.
Total [ph] investment in advertising and promotion represented 17.3% of net sales in the quarter.
Our Fuel for Growth cost reductions initiative drove significant savings in SG&A costs. Overall, these costs, on a reported basis, were down 12% in the third quarter compared to the same quarter of the prior year.
Our EBIT margin rose to 26.1% in the quarter as EBIT grew 9% in constant dollars.
Non-GAAP earnings per share for the quarter were $0.87 and similar to results in the proceeding 2 quarters.
I'll now discuss the performance of each of our reporting segments, beginning with our North America and Europe segment. Overall, results in this segment were mixed in the quarter. Market share gains in Canada and Europe resulting in strong sales growth there [ph] offset a disappointing quarter for our U.S. business. Net sales in the segment were in line with the third quarter of 2015 on a constant dollar basis. In aggregate, the segment benefited from a 5% pricing benefit, but this was fully offset by lower volumes in the United States. And foreign exchange adversely impacted sales for this segment by 1%.
Competitive pressure -- competitive activity put pressure on market share and resulted in a disappointing sales performance in our U.S. business. While we are actively addressing these challenges, we recognize that [ph] category dynamics of such that it'll take time to stabilize and recover lost market share.
Unconscious [ph] that we've been referencing weakness in U.S. market share for a few quarters now. Unfortunately, we know the category is quite sticky, and to gain new consumers take time. We have a concrete action plan in place, but we must expect share to remain relatively weak through the next couple of quarters.
In the rest of the segment, I'm pleased with our progress. And we reported our highest market share in many years in Canada, as both Canada and Europe grew strongly in the quarter.
The Canadian business experienced strong growth in both its core infant formula business and the chocolate [ph] category. And European sales of our energy products continued to grow on the back of a strengthened competitive position in a growing segment.
Let me now turn to Latin America. Segment performance continues to be heavily impacted by the suspension of sales to Venezuela. These shipments all but ceased at the end of 2015. Excluding this impact, sales in Latin America grew 5% in constant dollars over the same quarter of 2015. However, including the impact of Venezuela, constant dollar sales for the region were in line with the prior year's quarter. Pricing benefits of 10% did not fully offset foreign exchange impacts of negative 13%. And given the weakness in so many of the region's economies, we saw a [ph] volume lower by 10%. Excluding Venezuela, volume was unfavorable by 5%.
With regard to Venezuela, there's been no significant change in circumstances. This situation will again negatively impact results in the coming quarter. But after that, the distorting effect should be neglectable [ph].
In Mexico, our infant and children's businesses delivered growth, and trends in other parts of Latin America remained broadly unchanged from the prior quarter. In much of South America, economic fundamentals remained weak, and we are seeing this reflected in consumer demand. Colombia and Peru provide isolated spots of relative economic stability.
I turn now to the Asia segment. Constant dollar sales in Asia were in line with the third quarter of 2015. Despite increased trade investments, price was favorable compared to the prior year quarter. Price increases in Southeast Asia, along with positive product mix in China, resulted in a 4% improvement in price within the segment. Volume was unfavorable by 4% driven by market share weakness and adjustment to channel inventories in the Philippines. Again, we have implemented a solid remediation plan there, and it's beginning to work. That said, it will take time to rebuild market share. And in the meantime, we'd have [ph] to reduce channel inventory.
In Asia, price inflation remains low in a historical context.
I'll complete my discussion of our Asia segment with a few comments on China. In a sentence, [ph] our strategy to reshape our portfolio and strength and performance in high-growth channels is working. Despite the decline in Hong Kong, sales within our greater China business grew strongly in the latest quarter. We saw improvements in both volume and product mix. Higher-priced new products are replacing sales on legacy lines. Consumers continue to adopt our fully imported product lines of Enfamil and Enfinitas at rapid rates, more than offsetting slowing demand for our locally manufactured products and shrinking exports from Hong Kong. Like many of our competitors, we are seeing the rapid shift in sales channels continue. But with the reshaped product portfolio, we've been able to adapt to this.
A few facts may help illustrate my point and put our results in context. The mainland supermarket channel declined double digits in the quarter. Our sales to our Hong Kong channel continued to decline and was down double digits within the quarter, but our sales into baby stores in and Mainland China were up more than 20% on a year earlier. And our e-commerce sales were up more than 60%.
Our market share of company-controlled e-commerce channels increased by 3 [ph] percentage point over prior year. And our recently launched imported product lines continue to grow market share each month. Imported products now account for 60% of total sales in Mainland China, up from 45% in March.
I think you can understand from this exactly how dynamic the trade environment is and how critical agility and flexibility are as core elements of our China strategy.
In conclusion, let me mention that our third quarter sales did benefit from replenishment of orders we were able -- we were unable to fulfill in the prior quarter due to tightened import processes. You'll remember that I mentioned this in our last call. However, underlying growth, excluding this benefit, was nevertheless healthy in China. China's results this quarter reflect the strategy we put in place 2 to 3 years ago to increase flexibilities through a broader product portfolio, sold to a more diverse set of channels.
This quarter, you can see that our strong organization and infrastructure in China has the ability to flex and adapt than challenged. Much work remains to be done, but I feel good about the latest quarter. I deliberately not devoted any time to a description of our year-to-date sales. Though we've clearly hoped for a faster rebound in sales, we've seen a gradual, progressive improvement in our growth rate from quarter-to-quarter.
I now want to transition to talk about our global outlook for the balance of the year and beyond. While we saw strong growth in China, it's become clear that any sustained recovery in the broader emerging markets will take longer to occur than expected earlier. Additionally, market share losses in the Philippines and the United States are weighing on our current performance, and we do not expect to see these losses reversed until well into 2017.
In recognition of these challenges, we are revising our expectations for both sales and earnings per share. We now expect constant dollar sales for the full year 2016 to come in 2% to 3% below prior year, and we expect non-GAAP earnings per share in between $3.43 and $3.50. These numbers imply we continue to make progress in China in the fourth quarter and gradually improve sales in other geographies. We expect that the recent volatility and changing market dynamics will continue to impact our business in the midterm.
As we look beyond the next quarter to 2017, we expect to see continued but only modest improvement in constant dollar sales and to EPS. Our Fuel for Growth program will continue to help fund growth initiatives and mitigate known headwinds.
I'll now hand the call over to Michel who'll provide additional details on our third quarter financial performance. After that, I'll return with a few summary remarks before we take your questions. Michel, over to you."
1002291,367328587,1063038,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Thank you, Kasper, and good morning, everyone. Today, I will discuss the company's third quarter and 9 months 2016 financial results. I will then briefly highlight cash flow and liquidity items and conclude with a summary of the full year guidance. My com",1775,"Thank you, Kasper, and good morning, everyone. Today, I will discuss the company's third quarter and 9 months 2016 financial results. I will then briefly highlight cash flow and liquidity items and conclude with a summary of the full year guidance. My comments about sales will refer to net sales, unless I explicitly state gross sales. References to currency impacts or the effects of currency fluctuations generally refer to the impact on the translation of local currency financial statement into U.S. dollars.
Kathy already covered Slide 2, so let me start with sales on Slide 3. Slide 3 shows the improving trend of net sales on a constant dollar basis when compared to prior year periods. As Kasper already indicated, excluding the impact of reduced shipments to Venezuela, the company's net sales were 1% above the prior year quarter. The adverse impact of Venezuela will be less in the fourth quarter of 2016 as we significantly slowed shipments in the fourth quarter of 2015. The negative impact of Venezuela on our net sales is over 1% on a constant dollar basis.
Turning to Slide 4. Gross sales reflects sales to customers before trade investment on our [ph] items, which are recorded as gross to net sales adjustments. For the third quarter, gross sales were 1% above the prior year quarter on a constant dollar basis. A significant portion of this quarter gross [ph] came from China. This is the first time our gross sales returned to positive growth since the first quarter of 2015.
Net sales on a reported basis were 4% below the prior year quarter and 8% below on a year-to-date basis. The adverse impact of foreign exchange on sales was 4%. The U.S. dollar continued to be strong, and the effect on the translation of local currencies negatively impacted all reporting segments.
On Slide 5, the third quarter EBIT of $244 million was 9% above the prior year quarter on a constant dollar basis. Foreign exchange adversely impacted EBIT by 7%. Including currency impacts, EBIT increased 2% on a reported basis in the third quarter. The third quarter EBIT margin of 26.1% of sales was 160 basis points better than the prior year quarter. This sales [ph] nearly in line with the prior year, the benefit of lower dairy cost rolled through for a positive gross profit.
We continue to make strong progress to reduce operating expenses as part of our Fuel for Growth program, which allows continued investments while improving the underlying profitability. Year-to-date EBIT was $719 million, and we delivered positive growth of 2% above the previous year period on a constant dollar basis. The EBIT margin of 25.3% of sales was 80 basis points better than the prior year period. Foreign exchange had an adverse impact of 8%. Despite macroeconomic and country-specific challenges, which negatively impacted our sales, we benefited from low dairy cost and made excellent progress on realizing Fuel for Growth savings.
I will now move to factors that impacted gross margin on Slide 6. Gross margin was 64.6% in the third quarter of 2016. Adverse foreign currency impacted gross margin by 150 basis points in the quarter. We continued to deliver nearly flat gross margin on a reported basis despite the significantly currency headwinds we had. On a constant dollar basis, the gross margin percentage improved 120 basis points. Price/mix and gross to net adjustment had a slightly negative impact on gross margin, mainly from higher trade investments. Low dairy was the large benefit to gross margin in the third quarter of 2016.
Within cost of goods sold, productivity savings continued to be strong. Projects for the full year have been identified, and we expect savings to be above our earlier estimate of 3.5% of cost of goods sold. When you compare the 3 months and the 9 months charts, you can see the key drivers are the same. As this year progressed, the dairy benefit is lower as we lap towards the lowest 2015 dairy cost comparison. The adverse foreign currency impact on gross margin in the third quarter is higher, mainly due to hedges. If dairy is secured for the full year and larger productivity savings, we expect full year gross margin to be up to 64.5%, better than our previous guidance of 64%.
Moving to operating expenses on Slide 7. The chart [ph] provides the combined spending of demand-generating investments, both as trade investment classified in gross to net sales adjustments and as advertising and promotion in operating expense category. The combined investments in the third quarter were above the prior year quarter. As a percentage of gross sales, the third quarter was similar to the second quarter as a result of increased investments to support our China strategy to become more competitive in the baby store and e-commerce channels with our Enfa imported and Enfinitas product lines.
Slide 8. We reduced our SG&A cost by 9% on a constant dollar basis in the third quarter of 2016 versus the previous year quarter and by 10% year-to-date compared to the prior year period. As a reminder, we delivered $20 million savings in the fourth quarter of 2015. So in the fourth quarter of 2016, the year-over-year percentage reduction is likely to be smaller.
As you can see on Slide 9, year-to-date, we have achieved nearly 85% of this year's target. We now expect to realize savings toward the higher end of the $75 million to $80 million target range. In the corporate and other functions, we reduced our cost by $50 million year-to-date compared to prior year period. This is 3/4 of the year-to-date savings.
Turning to Slide 10 for a discussion of EBIT. Positive price/mix was offset by volume decline in all segments. The positive price/mix was mainly driven by a mix benefit as a result of the rollout of imported premium products in China, new innovations in several [ph] markets as well as price increases in markets to partly compensate of currency devaluations. All segments benefited from lower dairy and cost -- and crops [ph] productivity.
EBIT at Asia was lower due to higher trade investments. Promotional activities and advertising, which resulted in lower EBITDA loss and margin percentage in the third quarter. Our EBIT in both Latin America and North America improved. For Latin America, this was due to lower advertising and promotion expenses when compared to the prior year where we had higher expenses related to product launches.
On [ph] North America and Europe, SG&A cost savings helped fund investments and drove higher EBIT margins. Lower corporate and other expenses were most notably attributable to Fuel for Growth savings.
I will now address the financial results from EBIT to EPS on Slide 11. The interest expense of $26 million in the third quarter was in line with 2016 run rate. When compared to the prior year quarter, interest expense increase reflects the impact of the November 2015 $1.5 billion notes issuance. A significant portion of the proceeds from the notes were used to finance the accelerated repurchase program, or the ASR. The benefit of the ASR is reflected in the third quarter 2016 share count. There was no significant share repurchase in the third quarter.
Non-GAAP effective tax rate, or ETR, was 26% for the third quarter of 2016 compared to 28.1% in the prior year quarter. In the third quarter of 2016, the ETR decrease was driven by tax credits from repatriation of foreign earnings, somewhat offset by change in allowances against tax assets. The prior year quarter was adversely impacted by an unfavorable geographic mix.
Non-GAAP EPS for the third quarter was $0.87, an increase of 9% on a reported basis and 16% on a constant dollar basis. Year-to-date, non-GAAP EPS was $2.63, a 1% decrease from the prior year on a reported basis and an increase of 7% on a constant dollar basis.
Let me summarize our financial results by addressing the change to EPS on Slide 12. In the third quarter, non-GAAP EPS increased $0.13 to $0.93 per share on a constant dollar basis versus the prior year quarter. Sales and related gross profit delivered a $0.03 benefit to EPS. The adverse impact of higher advertising and promotion was $0.04. Fuel for Growth savings delivered $0.07 benefit. The share repurchase programs delivered a $0.03 benefit, net of higher interest expense. And tax and other contributed a $0.03 benefit. Despite the negative impact of foreign exchange of $0.06 per share, EPS increased $0.07 versus third quarter last year on a non-GAAP basis.
Turning to a high-level overview of cash movements on Slide 13. The cash balance of $1.8 billion as of September 30 was $142 million higher than in the beginning of the year. Cash flow from operations was negatively impacted by operating working capital. Our year-to-date CapEx investments were [ph] $110 million, mainly in our U.S. and operating in Europe manufacturing facilities, along with ongoing quality and planned enhancements globally. For the full year, our capital spending goal remains at 4% of sales. Dividend payments were $232 million in the 9 months of 2016. The negative impact of foreign currency exchange of $33 million was mainly related to the currency devaluation in Venezuela.
To summarize our forward-looking annual guidance on Slide 14, our sales outlook for 2016 on a constant dollar basis is expected to be 2% to 3% below the prior year. With foreign currency reducing sales growth by about 4%, reported sales are estimated to be 6% to 7% below 2015. The 2016 GAAP EPS guidance is expected to be in the range of $2.80 to $2.87. And our non-GAAP guidance is $3.43 to $3.50 per share.
The guidance changed for the following reasons: sales on a constant currency basis may be lower due to the market share weakness in several markets, especially in the U.S., along with continued macroeconomic challenges in several emerging markets. Partially offsetting the sales impact, we expect gross margin to be up 64.5%, while Fuel for Growth savings is expected to be at the high end of the $75 million to $80 million range. And finally, the foreign exchange impact is expected to be approximately $0.30 per share from our previous guidance of $0.35 per share.
GAAP EPS guidance is likely to be impacted by potentially significant future market-to-market pension adjustments, which cannot be estimated and are classified as specified items. Specified items include charges related to our Venezuela business, Fuel for Growth and year-to-date pension adjustments.
This concludes my discussion on the third quarter and 9 months 2016 financial results. Thank you again for your time this morning. I will now turn the call back to Kasper."
1002291,367328587,1063038,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Thank you, Michel. In today's prepared remarks, we've discussed both the positive news from China as well the number of headwinds we will continue to tackle as we move into next year.I want to acknowledge the difficulty we've had in accurately projectin",310,"Thank you, Michel. In today's prepared remarks, we've discussed both the positive news from China as well the number of headwinds we will continue to tackle as we move into next year.
I want to acknowledge the difficulty we've had in accurately projecting our top line trajectory over the past 18 months in what is perhaps the most uncertain environment I've seen in nearly 20 years in the industry. The global economy has been weaker than we'd expect, and we are facing a strong challenge in the United States.
But before we open the lines to your questions, I want to take you back 3 years. 3 years ago, when it first became obvious that our trajectory in China was changing, many of you, I'm sure, had doubts we could successfully navigate our way through the adaptations we needed to make. Today, I feel very proud of the way our people embraced the challenge and worked hard on implementation. We certainly have much work left in China and elsewhere, but we also have many more opportunities from which we can benefit. We've taken the first important steps, and we're on our way forward.
As was the case when we discussed our challenges in China, I feel confident that we can overcome the current challenges in Southeast Asia and the United States. Our organizations have proven that they can adjust and reverse trajectories and focus on identified issues.
Overall, the shape of our recovery remains broadly as outlined at our Investor Day in October 2015. Yes, the rate of improvement has been slower than we'd hoped for, but we are doing the right thing in [ph] focusing on innovation and execution, and we're on a positive path.
I'll now hand the call back to the operator, Liz, and ask her to open the lines to your questions. Liz, back to you."
1002291,367328587,1063038,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Operator","[Operator Instructions] Your first question comes from Bryan Spillane with Bank of America.",13,"[Operator Instructions] Your first question comes from Bryan Spillane with Bank of America."
1002291,367328587,1063038,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","Just a question about -- you've made a reference about the -- Kasper, about the adaptations you had to make in China, which have been significant. Can you give us a sense, now that you've made that adaptation, has the rest of the market made that adaptati",123,"Just a question about -- you've made a reference about the -- Kasper, about the adaptations you had to make in China, which have been significant. Can you give us a sense, now that you've made that adaptation, has the rest of the market made that adaptation? Meaning, you now have fully imported product coming in -- multiple products that are fully imported coming into the market that's giving you more range in terms of the channels that you can now access with those products? And it's hard from, I guess, where we sit to see whether or not your competitors have done something similar or whether you're just ahead of kind of where the competition is in terms of making that change."
1002291,367328587,1063038,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Well, Bryan, firstly, I think -- let me be clear, I think we have made that change, and I feel good about the current product line that we've now got in China. It allows us to play much more effectively in the faster-growing channels, particularly the bab",275,"Well, Bryan, firstly, I think -- let me be clear, I think we have made that change, and I feel good about the current product line that we've now got in China. It allows us to play much more effectively in the faster-growing channels, particularly the baby stores and the e-commerce channel. I think, in some cases, as I have acknowledged over the last couple of years, in some cases, we were slower than competitors to enter the super-high premium segment. So I mean, I'm very encouraged with the progress we are making in that business and how we are building share from month to month with quite substantial opportunities ahead of us to continue to grow, both through increased distribution and share gains. In other areas, I think we have probably been somewhat ahead of our competitors in focusing on the former or company-organized e-commerce trade where some other competitors have relied quite heavily on kind of informal trade out of either Australia or Europe which clearly is now being quite challenged by the changes to the regulatory environment, which I think we anticipated would happen. So our focus has always been on kind of the trade, the amount of the e-commerce trade that we feel we can control ourselves. And I referenced in my comments, prepared remarks, that in that part of the e-commerce channel, our sales are up 60% on a year ago, which outstrips the growth of the channel in general. And I think I said that we have increased our share of that channel by just over 100 basis points. So I think that answers your question. If not, [indiscernible]"
1002291,367328587,1063038,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","Yes, it does. Just I think in summary, just, you're in a much better competitive position now than you were before because you've moved further into really having a fully imported product supply chain.",34,"Yes, it does. Just I think in summary, just, you're in a much better competitive position now than you were before because you've moved further into really having a fully imported product supply chain."
1002291,367328587,1063038,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Yes, no doubt. I mean, in the third quarter, 60% of our sales in Mainland China were in our imported product lines.",22,"Yes, no doubt. I mean, in the third quarter, 60% of our sales in Mainland China were in our imported product lines."
1002291,367328587,1063038,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Operator","Your next question comes from Amit Sharma with BMO Capital Markets.",11,"Your next question comes from Amit Sharma with BMO Capital Markets."
1002291,367328587,1063038,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","Kasper, I want to talk about U.S. a little bit. So clearly disappointed with the market share performance there and you talked about that some of this going to be just a timing issue. Can you go a little deeper into it? And like what's causing -- is it yo",91,"Kasper, I want to talk about U.S. a little bit. So clearly disappointed with the market share performance there and you talked about that some of this going to be just a timing issue. Can you go a little deeper into it? And like what's causing -- is it you may have taken more pricing than the competitor? Or are you deliberately not exiting but may be more strategic with some of the big contracts that you may have lost recently? Can you talk a little bit more about that, please?"
1002291,367328587,1063038,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Executives","No, I mean, I think look, I take my hats off to, at least, one of our very strong competitors in the U.S. business. They've done it, they've simply done a better job than we've done in the last 12 months or so. So we had to acknowledge. When we are on the",264,"No, I mean, I think look, I take my hats off to, at least, one of our very strong competitors in the U.S. business. They've done it, they've simply done a better job than we've done in the last 12 months or so. So we had to acknowledge. When we are on the receiving end of that, we believe that is important to acknowledge that and not try to kind of sugarcoat it with you guys. There will continue to be, going forward, changes in rate contracts. That's a natural part of the business cycle. So that's had some impact. But -- and I would say the rest of it has been mostly about execution both in a trade environment and on programs that are generally responsible for driving consumer starts to our brands. I think some of it, in all honesty, some of it have been self-inflicted. Which in a way, I take some comfort from because that means we can fix it unilaterally. And I fear, and I have really very little doubt that we can do that. But I understand that the category is ultimately a very sticky category as a mentioned in my prepared remarks. We have to regain our share of stocks in the category and we have to do that kind of 1 child at a time as they enter the category. So it's going to take time. It would be wrong and nave for me to say that we would expect some kind of V-shaped turn around and market share. But I think we know what's wrong."
1002291,367328587,1063038,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Operator to the next question.",5,"Operator to the next question."
1002291,367328587,1063038,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Operator","Our next question comes from John Baumgartner, Wells Fargo.",9,"Our next question comes from John Baumgartner, Wells Fargo."
1002291,367328587,1063038,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","Kasper, I like to stay with the U.S. market. Because on the phase, it seemed like after a number of years during which Mead really dominated the innovation discussion for the category, that pendulum is kind of swinging back now towards your largest compet",96,"Kasper, I like to stay with the U.S. market. Because on the phase, it seemed like after a number of years during which Mead really dominated the innovation discussion for the category, that pendulum is kind of swinging back now towards your largest competitor. So is that the right way to think about it? And if it is, can you provide any context you these near-term innovation pipeline? And maybe just lastly, price/mix being up so strong in North America this quarter, how sustainable is that going forward given just the competitive pressures in share loss?"
1002291,367328587,1063038,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Executives","I think it's hard for me to speculate on price going forward. I mean, there's obviously -- there's a fair amount of promotional activity, as there always is, in the U.S. market. And we fundamentally don't believe that at the margins, this category is driv",265,"I think it's hard for me to speculate on price going forward. I mean, there's obviously -- there's a fair amount of promotional activity, as there always is, in the U.S. market. And we fundamentally don't believe that at the margins, this category is driven significantly by price. That said, there is a certain, which I will say, range within which we can play. We typically play at a premium to our competitors in the U.S. I expect we'll continue to do that. But we'll stay relatively close to them. And we'll see how the dynamics evolve. You're asking about, John, the innovation cycle. I think we have a strong innovation program laid out going forward. It's clear that over the last 12, 18 months, we perhaps had not a strong a program that, at least, the evidence would suggest that. But I think it's more about kind of operational excellence on some of our more basic initiatives. We just let our standards slip a little bit. I suppose I don't want to go to too much detail on it, if you forgive me for that. But I think we have 2 or 3 things that we have clearly identified that we could and should have done better in the United States in the last 12 months or so. And we are clearly facing them quickly. But it will take some time for that to show up in market share, given that the heavy consumption period that we see from children really is only about 4 to 5 months after they enter the category."
1002291,367328587,1063038,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Operator","Your next question comes from Jason English with Goldman Sachs.",10,"Your next question comes from Jason English with Goldman Sachs."
1002291,367328587,1063038,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","First, real quick, semantics. The comment about 2017, modest improvement for both underlying sales and earnings per share. Is it wrong to interpret that improvement means growth? Or is there -- is the risk, where we sit today, that we don't have top and b",50,"First, real quick, semantics. The comment about 2017, modest improvement for both underlying sales and earnings per share. Is it wrong to interpret that improvement means growth? Or is there -- is the risk, where we sit today, that we don't have top and bottom line growth into next year?"
1002291,367328587,1063038,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Executives","I mean, we -- I think the words I used to describe our outlook for '17 was that we expected only modest improvement to both [ph] constant dollar sales and to EPS. That would clearly imply improvement would mean improvement. And therefore, it would imply a",53,"I mean, we -- I think the words I used to describe our outlook for '17 was that we expected only modest improvement to both [ph] constant dollar sales and to EPS. That would clearly imply improvement would mean improvement. And therefore, it would imply a number that was better than this year."
1002291,367328587,1063038,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","Thank you. Yes, I wanted to make sure that was clear. It could be spun a couple of different ways. So I appreciate the clarification on that. A [indiscernible] question on the U.S., but surprisingly, we're getting quite a few on those today. So I'm going",151,"Thank you. Yes, I wanted to make sure that was clear. It could be spun a couple of different ways. So I appreciate the clarification on that. A [indiscernible] question on the U.S., but surprisingly, we're getting quite a few on those today. So I'm going to pivot back to what I thought would be more crowded and that's China. As you think about the forward on China, some of your competitors out there have flagged a risk of the markets would be flooded with more product ahead of the January 2018 regulatory change. It's created some consternation that we have, that the pricing intensity, the competitive intensity, gets worse before it gets better. And that gets worse at a time that we've got rising dairy cost inflation. Can you weigh in with your view on how you see that unfolding and what you think the implications are for your business?"
1002291,367328587,1063038,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Yes. I mean, I -- I don't think our view has significantly changed in the sense that at the consumer level, this is not a brand choice, it's not significantly influenced by price. Certainly, not in the infant formula business. A little bit more price sens",261,"Yes. I mean, I -- I don't think our view has significantly changed in the sense that at the consumer level, this is not a brand choice, it's not significantly influenced by price. Certainly, not in the infant formula business. A little bit more price sensitivity in the children segments. So I think the key dynamic that will be influenced by all of this price discounting that we are seeing right now and that I suspect people are saying will continue to see through '17, it's mainly influencing retail dynamics. In other words, the amount of inventory that people are pushing into the retail channel. And I suspect that we are going to see a lot of people being caught with very big fluctuations in sales as they need to adjust for inventory swings at some point in the economic cycle. Single influence, different companies at different times, I think to some degree, already within this quarter, you've seen relatively big fluctuations in the financial results announced by many of the companies in the industry. We've sort of prided ourselves on trying to keep our inventory relatively tight at the retail level. And we feel we've got very good visibility on what it is and we are happy with the level of inventory we have in the channels. Some -- there are some quarters when that hurts our relative competitive performance as you look at it versus others. And there are some quarters where it perhaps helps us. And I think this was a quarter where that approach clearly helped us."
1002291,367328587,1063038,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Operator","Your next question comes from the line of Ken Goldman with JPMorgan.",12,"Your next question comes from the line of Ken Goldman with JPMorgan."
1002291,367328587,1063038,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","Do you still see a 27% EBIT margin in to 2018? Because if you're not getting much EBIT growth next year, you're going to need a huge 2018 to get there.",31,"Do you still see a 27% EBIT margin in to 2018? Because if you're not getting much EBIT growth next year, you're going to need a huge 2018 to get there."
1002291,367328587,1063038,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Kasper, let me address that question. For 2017, we indeed expect more flat EBIT margin on a constant dollar basis. We always said in the three-year roadmap that we laid out that ultimately, we would like to deliver the 300 [ph] basis point improvement. Bu",123,"Kasper, let me address that question. For 2017, we indeed expect more flat EBIT margin on a constant dollar basis. We always said in the three-year roadmap that we laid out that ultimately, we would like to deliver the 300 [ph] basis point improvement. But like we said, for us, it's very important to position us very strongly for the future, make the right deliberate choices on the investments that we need to make. Also in 2017, also in China, to position us very strongly, specifically in China to take the opportunity on the developments that are happening there. So it might take some longer time before we will reach the 200 -- 300 basis points EBIT margin that we estimate out earlier."
1002291,367328587,1063038,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","Can I ask a quick follow up, Kathy?",8,"Can I ask a quick follow up, Kathy?"
1002291,367328587,1063038,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Go ahead.",2,"Go ahead."
1002291,367328587,1063038,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","Along these lines, there are a lot of things in this call that I think are disappointing to some people, including me. And I really, there's a lot of exogenous macroeconomic headwinds you can't control. But you've lost market share in the Philippines. You",148,"Along these lines, there are a lot of things in this call that I think are disappointing to some people, including me. And I really, there's a lot of exogenous macroeconomic headwinds you can't control. But you've lost market share in the Philippines. You've lost market share in China. Although obviously it's coming back a little bit now. You've lost market share in the U.S. Kasper, do you need to make a larger adjustment to the company's strategic mindset in terms of marketing? We've seen some successful tactical adjustments, right? Obviously, things have changed in China this past quarter. But it just feels like it can't continue forever to experience market share losses. And I'm just curious if there is anything, in your mind, that needs to change in a more dramatic way in terms of how you go to market or how you think about your strategy?"
1002291,367328587,1063038,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Executives","I think, Ken, the comment is well taken. As you might imagine, nobody is, what shall we say, more sensitive around us referencing market share losses than I am. And certainly, it's not what we want to see. Having said that, we have a portfolio that is hea",274,"I think, Ken, the comment is well taken. As you might imagine, nobody is, what shall we say, more sensitive around us referencing market share losses than I am. And certainly, it's not what we want to see. Having said that, we have a portfolio that is heavily exposed to, let's call it, 10 global businesses or 10 businesses around the world. It's inevitable that amongst those 10, you're going to have ups and downs. We've gained a lot of market share in Canada, we've gained a lot of market share in Europe. And I would argue at the moment, we are gaining market share in China. Now unfortunately, if you have problems market share wise and you have them in a couple of your really big markets, we both know that the U.S. and China, between the 2 of them, account for more than half of our sales, our global sales. So it's very hard for us to offset any significant loss of market share in one of those 2 markets with performance in other markets. I'm certainly disappointed that we have not been able to proactively address some of these challenges as opposed to finding ourselves in the mode where we are, so to speak, reacting in [indiscernible] and adapting. I would obviously much rather be driving change proactively. So your implied criticism is well taken. I don't think it's structural. I don't think it's related to, what shall we say, the way we do marketing or our marketing capabilities in general. But you might rightly imagine that a fair amount of social chain is going on as a consequence of this."
1002291,367328587,1063038,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Thank you. Operator, to the next call.",7,"Thank you. Operator, to the next call."
1002291,367328587,1063038,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Operator","Next question comes from Matthew Grainger with Morgan Stanley.",9,"Next question comes from Matthew Grainger with Morgan Stanley."
1002291,367328587,1063038,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","I wanted to squeeze in 2 questions but I'll ask them quickly. First, on North America, the Northeast State's [indiscernible] contracts, I was hoping could contextualize the size of that relative to some others that had a material impact on your results su",104,"I wanted to squeeze in 2 questions but I'll ask them quickly. First, on North America, the Northeast State's [indiscernible] contracts, I was hoping could contextualize the size of that relative to some others that had a material impact on your results such as Florida a few years ago and how material that is for 2017? And then in China, just on the market generally, curious for your latest thoughts on birth rates and whether you're seeing any uptick in trend in recent months. Some of the feedback that we've gotten have suggested that there's been a bit more acceleration birth rate trend."
1002291,367328587,1063038,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Let me address at a high-level the contracts that are coming up and we always are very transparent that there a couple of significant contracts that were coming off a bit. One of them is California and the other one that's coming up of Texas. We don't dis",125,"Let me address at a high-level the contracts that are coming up and we always are very transparent that there a couple of significant contracts that were coming off a bit. One of them is California and the other one that's coming up of Texas. We don't disclose, obviously, the details, what is the magnitude of impact potentially could be. But we are very well aware about the importance of these contracts and the potential impact. We're always trying to have a strategy behind it that we always can find the right balance between other new goals and initiatives in the U.S. markets as well. So that has been taken into account as well when Kasper was talking about the outlook for next year."
1002291,367328587,1063038,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Executives","I want to -- let me try to put it in sort of a strategic context. I think the participation in weight [ph] contracts is one of a number of important demand drivers that we have in the U.S. business. As such, we view it, to a certain extent, the same way w",160,"I want to -- let me try to put it in sort of a strategic context. I think the participation in weight [ph] contracts is one of a number of important demand drivers that we have in the U.S. business. As such, we view it, to a certain extent, the same way we view A&P. We look for an appropriate level of return on investment. And it's likely that as we look forward to 2017, there are a couple of important countries, in both of our 2 biggest markets, China and the U.S., we're planning increased investments and demand creation. In both of those markets. In China, it will be important to support our growth momentum. And in the U.S., it will obviously be important in order to turn around the market share performance that we've just discussed. And that's what we've tried to do is sort of capture that all under this heading of increased investment and demand creation."
1002291,367328587,1063038,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Right. Operator, I think onto the next.",7,"Right. Operator, I think onto the next."
1002291,367328587,1063038,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Operator","[Operator Instructions]",2,"[Operator Instructions]"
1002291,367328587,1063038,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Operator, I heard there's about 6 other people, they're coming back now on the list.",15,"Operator, I heard there's about 6 other people, they're coming back now on the list."
1002291,367328587,1063038,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Operator","Your next question comes from the line of David Driscoll with Citibank.",12,"Your next question comes from the line of David Driscoll with Citibank."
1002291,367328587,1063038,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","Yes, I've been here the whole time. So thanks, Kathy. Like to just, my neurologic line of questioning is about cost savings. And a couple of ways I want to say it if you could just give me a second. On EPS, kind of why can't you protect EPS growth more gi",185,"Yes, I've been here the whole time. So thanks, Kathy. Like to just, my neurologic line of questioning is about cost savings. And a couple of ways I want to say it if you could just give me a second. On EPS, kind of why can't you protect EPS growth more given the size and scope of the cost savings? What -- I'm just surprised, if not helping it more in the 2017 comments, Kasper, obviously, kind of disappointed because it doesn't really fit the 3 year trend and I think you guys already pulled back on the 27% margin [indiscernible] question. And then just [indiscernible] specifically, are you going to step up this cost-saving program again? And are you confident that all of this reinvestment is being well spent? Because it just feels like we're getting a very different answer from Mead Johnson versus the rest of the companies in the sector that are generating fairly massive cost savings that are showing up in earnings. But it's not really happening here. I'm just hoping to hear your thoughts on what to make of it."
1002291,367328587,1063038,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Thanks, David. It's a great question. And obviously, one we had anticipated. And I think let's start by going back to Ken's -- Ken Goldman's question about what should we expect in terms of EBIT accretion in 2017. And Michel's response was that while we d",341,"Thanks, David. It's a great question. And obviously, one we had anticipated. And I think let's start by going back to Ken's -- Ken Goldman's question about what should we expect in terms of EBIT accretion in 2017. And Michel's response was that while we don't see EBIT accretion as we do get, as we look at 2017 and that, of course, is really reflective of the comments I made about our expectations for both sales and EPS growth. And implicitly in that is the fact that there won't -- there's very unlikely to be EBIT margin accretion. So the question is in the face of some fairly significant progress against cost-saving initiatives, why is that? And it really relates to -- it relates simply to the fact that we believe that it is in the long-term interest of our shareholders to continue to drive strong growth in China and that requires continued investment. You will understand implicitly that some of the important initiatives that we have implemented in China were launched only approximately halfway through the year, 2016. So we'll have a full year impact of that higher level of spend in 2017. And then we believe we need to make additional investments in turning around market share in the U.S. which we also believe is in the long-term interest of the business. I do want to say that on the topic of margin accretion, it is -- it's an objective that is subservient to our primary objective which is to turn around the growth trajectory of the business. So that's important to understand. It's also important to understand that where you will see that significant margin accretion occur is at the point in time that our growth rate picks up from the sort of very modest level that we are currently discussing. We clearly, at that point in time, have put our cost structure in place that will allow the company to get a great amount of EBIT leverage on any kind of growth in sales. Does that help?"
1002291,367328587,1063038,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","It does. Any comments about further improvements to the cost savings program given the stresses?",15,"It does. Any comments about further improvements to the cost savings program given the stresses?"
1002291,367328587,1063038,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Yes, I mean, we will -- we have initiatives in place for '17. It will remain a focus for the company going forward. I think we, in the last call, I think we took our target up for this year. We indicated that we would move the needle from the previously a",206,"Yes, I mean, we will -- we have initiatives in place for '17. It will remain a focus for the company going forward. I think we, in the last call, I think we took our target up for this year. We indicated that we would move the needle from the previously announced $60 million to now somewhere between $75 million and $80 million in cost savings this year. I think we also -- I forgot exactly when we expanded our three-year target from $120 million to $180 million. So we are clearly very focused on this particular objective. And I have to say that it's helping us greatly continue to fund a high level of investment. Your question about whereas all of this investment was spent this a great question. It's a question I ask our operators almost on a daily basis. And I'm quite sure that we can -- we will continue to identify small pockets of suboptimal expenditure. But we also have opportunities to spend more on things that we know will work for us. So it will be a balancing act. Obviously, we will continue to look for efficiencies. Great question, David. We can talk more about it when we get together next."
1002291,367328587,1063038,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Thank you, operator. Next question.",5,"Thank you, operator. Next question."
1002291,367328587,1063038,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","Thank you.",2,"Thank you."
1002291,367328587,1063038,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Operator","Your next question comes from the line of Robert Moskow with Crdit Suisse.",13,"Your next question comes from the line of Robert Moskow with Crdit Suisse."
1002291,367328587,1063038,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","I had a question about North American profits. Your profits are still looking like they're going to be up this year. And they're up substantially since 2014 in North America and Europe. But the market share is weak and you're talking about having to reinv",105,"I had a question about North American profits. Your profits are still looking like they're going to be up this year. And they're up substantially since 2014 in North America and Europe. But the market share is weak and you're talking about having to reinvest. So is -- did you feel like North America, did not get enough resources in terms of dollars this year? Or is it just the money was spent on the wrong things? And so what do you think is a more normalized margin for North America? We've gone from 23% to 30%. Where do you think it really should land?"
1002291,367328587,1063038,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Let me address that question in terms of EBIT margin. The increase of the EBIT margin in the U.S., we had a significant benefit from there, which is a significant pressure on uplifting gross margin. So that's one area where we had an improved margin. In g",190,"Let me address that question in terms of EBIT margin. The increase of the EBIT margin in the U.S., we had a significant benefit from there, which is a significant pressure on uplifting gross margin. So that's one area where we had an improved margin. In general, we'll see, as a total company, more gross margin pressure also on '17 as a result of dairy prices where we see some slightly increases that are coming in. So that also will have an effect on our U.S. business as such. In addition, like Kasper just said, we made a deliberate choice to step up additional investment in the U.S. from a demand generating investment point of view. Whether that's through A&P or the level that's gross to net initiatives and we could be one of them as one of demand generating investment. So we will see some pressure on EBIT margin. I think we won't see a level that we have currently. But I also don't expect it will go to the levels that we have seen historically. I would say that we would see a midpoint between those EBIT margins."
1002291,367328587,1063038,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","Michel, just a follow-up then for Kasper, what's your confidence that you have the pricing power for 2017 to offset higher input costs?",23,"Michel, just a follow-up then for Kasper, what's your confidence that you have the pricing power for 2017 to offset higher input costs?"
1002291,367328587,1063038,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Executives","I don't think we will fully offset input -- higher input costs. So I think it's implied in the words that I used in my prepared remarks, which I'm quite sure will be scrutinized by all of you. Implied in that is some contraction to gross margin. I should",209,"I don't think we will fully offset input -- higher input costs. So I think it's implied in the words that I used in my prepared remarks, which I'm quite sure will be scrutinized by all of you. Implied in that is some contraction to gross margin. I should put that in the context of the fact that our gross margin, supported by historically low dairy costs, had been well above historic norms over the last, I want to say, the last 18 to 24 months. So I think over time, we would expect to see gross margin come down to sort of normal levels. That's not all going to happen in one year. It's not all going to happen in '17. But we -- as we look at it now, we would expect some reduction in gross margin next year. We are -- I'm sure we'll say more about it when we give a bit more detail and more formal guidance next time around in our next call. But we thought it was important to kind of help you develop your thinking for '17 that's why we're spending a little bit more time than we usually do talking about next year at this point of the cycle."
1002291,367328587,1063038,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Operator","Our next question comes from the line of Pablo Zuanic with SAG.",12,"Our next question comes from the line of Pablo Zuanic with SAG."
1002291,367328587,1063038,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","Just 2 quick questions. First, I mean, when I look at Abbott, and their [indiscernible] product, I had to think that for an IMF business, it's almost a legal company, that they must have advantages over you in terms of their communication with doctors and",205,"Just 2 quick questions. First, I mean, when I look at Abbott, and their [indiscernible] product, I had to think that for an IMF business, it's almost a legal company, that they must have advantages over you in terms of their communication with doctors and people recommending IMF products. And then I look at Nestle which obviously owns Wyeth with Illumina, they are a much larger consumer company with much better distribution. So can you comment. Obviously, you've made significant changes and improvements in China. But then your comment was you're disadvantaged when you look at the Abbott's sort of over Nestle's. And the second one, very quickly, I know you give us a lot of numbers in terms of the pieces of growth in China. But I don't know, maybe I missed it, but what was the growth year-on-year in China in your IMF business there and if you can just compare that with what was the sell-through? I mean, in my visits to baby stores that you have very good displays for Enfinitas, Enfamil, great merchandising, window displays. And I'm just worried about the sell-through, what are we going to see in the fourth quarter? If you can comment on that, please. Thanks."
1002291,367328587,1063038,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Thanks, Pablo. Let me address your question on competitiveness first and then I'll talk about -- then I'll reiterate what I said earlier about inventory. I see absolutely no reason why we should not be able to compete with either of the 2 companies that y",367,"Thanks, Pablo. Let me address your question on competitiveness first and then I'll talk about -- then I'll reiterate what I said earlier about inventory. I see absolutely no reason why we should not be able to compete with either of the 2 companies that you mentioned in China. And indeed, we've done so successfully for many years. The China market is somewhat different from many of the other markets in the world that we compete in in the sense that, frankly speaking, healthcare professional endorsement of your brand is far less influential in China than it is elsewhere in our -- in the world we operate in. So any potential disadvantage, which I'm not sure it exists to begin with, vis--vis our U.S. competitor there, certainly, is never being used as a reason for shortfalls by our local team in China and nor would it be accepted. You referenced our larger and more broad-based consumer products competitor. And I would only say to that, that again, the primary sales channel for these very high-priced products or high-quality products in China is really the baby store channel in China and that's not a channel where your muscle and product range from other parts of the grocery industry can necessarily be leveraged very effectively. So again, I don't think we are at a significant disadvantage. Apart from what you would generally say is that obviously, we are smaller company than either of those two and that means we can't leverage our cost base, our general infrastructure cost over a broader sales base. But despite that, it appears to me that we have got best-in-class EBIT margins. And I think we can maintain that while growing at the same time. On the inventory side, in China, I just want to refer to what I said earlier. We are very comfortable with our inventory levels in the sales channels in China. We pride ourselves on not building up those inventories artificially from quarter-to-quarter. And hence, I don't expect, assuming that offtake develops the way we expect them, anticipate, I don't expect that we're going to be seeing any changes to our sales trajectory that will not reflect underlying consumer demand."
1002291,367328587,1063038,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","Just a quick follow up. I mean, I was surprised that the [indiscernible] for example, the baby stores that I visited, are the displays of Enfinitas, a full share as big of the displays of the Enfa range. I was just wondering, Enfinitas is clearly not half",128,"Just a quick follow up. I mean, I was surprised that the [indiscernible] for example, the baby stores that I visited, are the displays of Enfinitas, a full share as big of the displays of the Enfa range. I was just wondering, Enfinitas is clearly not half of your sales there. And it retails around CNY 445, [ph] compared to [indiscernible] that are in the CNY 300 [ph], CNY 400 [ph] range. So I understand that the question around inventory was answered before. But I'm just wondering it sounds like you doubled your space at the baby stores, at least when I look at Enfinitas versus Enfa unless you lost Enfa space. And then you have a price point that is way above your competitors in [indiscernible] thanks."
1002291,367328587,1063038,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Executives","I think you've visited a small selection of stores and I, some ways, what you saw was the case everywhere, unfortunately, it is. But I think of, joking aside, Pablo, it's a natural dynamic when you launch new brands that you had to build a certain amount",88,"I think you've visited a small selection of stores and I, some ways, what you saw was the case everywhere, unfortunately, it is. But I think of, joking aside, Pablo, it's a natural dynamic when you launch new brands that you had to build a certain amount of exposure for them. We are very comfortable that the sales trajectory that we are seeing grow week, week on week since launch on Enfinitas, is supportive of the amount of inventory that we have sold into the retail channel."
1002291,367328587,1063038,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Good. Thank you, operator, we'll take one more question.",9,"Good. Thank you, operator, we'll take one more question."
1002291,367328587,1063038,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Operator","Our next question comes from the line of Steven Strycula of UBS.",12,"Our next question comes from the line of Steven Strycula of UBS."
1002291,367328587,1063038,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","A quick question for Kasper and then a quick follow-up for Michel. So the question will be related to the China growth. It seems like you had a nice acceleration there in the third quarter. Just any help, Kasper, as you could kind of split apart or like t",110,"A quick question for Kasper and then a quick follow-up for Michel. So the question will be related to the China growth. It seems like you had a nice acceleration there in the third quarter. Just any help, Kasper, as you could kind of split apart or like the baseline sales improvement and what was more of a bump from a little bit of early bottleneck that we're having in terms of shipments? And then conversely, how do you -- how are trends outside of China trending? Were they downsizing single digits and China was up high single digits to got to flat ratio overall? That would be helpful."
1002291,367328587,1063038,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Executives","I mean, you're probably in the right territory with your last remark, Steve. But that's pretty close. And I would say that roughly 1/3 of their growth we saw in China in the third quarter, we are attributing to what shall we would say, carryover of orders",82,"I mean, you're probably in the right territory with your last remark, Steve. But that's pretty close. And I would say that roughly 1/3 of their growth we saw in China in the third quarter, we are attributing to what shall we would say, carryover of orders we could not fulfill in the second quarter. That would still mean that, as I said, it would still mean that our growth was very healthy in the third quarter on an underlying demand basis."
1002291,367328587,1063038,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","Okay, that's very helpful. And then my last question for Michel would be, with respect to the 27% margin target for the out years, is any have caused a more tempered outlook or reflection of the business naturally rotating out of Hong Kong, which was your",87,"Okay, that's very helpful. And then my last question for Michel would be, with respect to the 27% margin target for the out years, is any have caused a more tempered outlook or reflection of the business naturally rotating out of Hong Kong, which was your highest margin region, to now an important model from Europe? Is that any of the thing to do as an explanatory fact or is there something else we should really be focusing on or just a lack of top line levers?"
1002291,367328587,1063038,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Executives","No, it is clearly the last one, the top line and the required investments that we would like to make, also in 2017. That's the main reason.",27,"No, it is clearly the last one, the top line and the required investments that we would like to make, also in 2017. That's the main reason."
1002291,367328587,1063038,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Thank you for everybody participating in Mead Johnson's earnings call today. Operator, I'll turn it over to you to close out the call. Thank you.",26,"Thank you for everybody participating in Mead Johnson's earnings call today. Operator, I'll turn it over to you to close out the call. Thank you."
1002291,367328587,1063038,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Operator","This concludes the presentation. You may now disconnect. Everyone, have a good day.",13,"This concludes the presentation. You may now disconnect. Everyone, have a good day."
1002291,367328587,1063335,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Operator","Good day, ladies and gentlemen, and welcome to the Mead Johnson Nutrition Third Quarter 2016 Earnings Conference Call. My name is Liz, and I will be your coordinator for today. [Operator Instructions] As a reminder, this conference is being recorded for r",63,"Good day, ladies and gentlemen, and welcome to the Mead Johnson Nutrition Third Quarter 2016 Earnings Conference Call. My name is Liz, and I will be your coordinator for today. [Operator Instructions] As a reminder, this conference is being recorded for replay purposes.
I would now like to turn the conference call over to Kathy MacDonald, Vice President, Investor Relations. Please proceed, Kathy."
1002291,367328587,1063335,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Thank you, Liz. Good morning, and thank you for joining Mead Johnson's Third Quarter and 9 Months 2016 Conference Call. With me today are Kasper Jakobsen, our Chief Executive Officer; and Michel Cup, our Chief Financial Officer.Earlier today, we issued",345,"Thank you, Liz. Good morning, and thank you for joining Mead Johnson's Third Quarter and 9 Months 2016 Conference Call. With me today are Kasper Jakobsen, our Chief Executive Officer; and Michel Cup, our Chief Financial Officer.
Earlier today, we issued our 10-Q, earnings release and financial reference slides. If you have the slides in front of you, please turn to Slide #2.
A detailed explanation of our forward-looking statements appears in the slides, which are also posted on our website in connection with today's conference call. As we start, let me remind everyone that our comments will include forward-looking statements about our future results, including statements about our financial prospects and projection, commodity costs, currency fluctuations, pricing, taxes, capital spending, new product launches, other growth initiatives and market conditions that constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Keep in mind that our actual results may differ materially from expectations as of today due to various factors, including those listed in our annual report on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K, and each case is filed with or furnished to the Securities and Exchange Commission and our earnings release issued this morning.
Today's comments will include discussion of non-GAAP financial measures. Unless otherwise noted, comments relate to the income statement will be on a non-GAAP basis with the exception of advertising, promotion and interest expense. In addition, comments related to the balance sheet will be on a GAAP basis. A reconciliation of these measures to comparable GAAP measures appears in the morning's earnings release and financial reference slides, which are available at meadjohnson.com. In addition, any forward-looking statements represent our estimates only as of today and should not be relied upon as representing our estimates as of any subsequent date. While we may elect to update forward-looking statements at some point in the future, we specifically disclaim any obligation to do so, even if our estimates change.
I will now turn the call over to Kasper."
1002291,367328587,1063335,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Thank you, Kathy, and good morning to you all. Thank you for joining our earnings call. My comments will stand on the general business climate, our strategy, our latest quarter top line performance and our outlook. Michel will then follow me by providing",2027,"Thank you, Kathy, and good morning to you all. Thank you for joining our earnings call. My comments will stand on the general business climate, our strategy, our latest quarter top line performance and our outlook. Michel will then follow me by providing some additional and financial information, including comments on our cash flow related items.
I want to start today's discussion by revisiting our 3-year value creation plan. We laid out this plan at our Investor Day in October of 2015. And at that time, we explained how 2016 would be a year of transition.
We committed to 3 key metrics: a return to growth; a set of expense reductions; and a partial reinvestment of savings in growth initiatives and margin accretion. We said we'd measure our progress against these through the period. I've since revisited these metrics in every earnings call. So let me now briefly summarize our third quarter results in that context.
Firstly, in the third quarter, we delivered growth at the gross sales level of 1%. On a net sales basis, all 3 geographic segments delivered sales in line with prior year's quarter. This is an improvement over the previous 2 quarters. Excluding the effect of suspended shipments to Venezuela, net sales grew 1% in the third quarter over the prior year quarter.
Our second milestone relates to our targeted operating expense reductions. In our second quarter call, we revised our 2016 estimate from $60 million in reductions to $75 million to $80 million. Year-to-date, we've delivered $67 million in savings, and we've achieved approximately 85% of our annual target. SG&A expenses in the latest quarter were almost $20 million lower than a year earlier.
Our third milestone was to invest a portion of the expense savings to fund key growth initiatives while increasing our EBIT margin. Our investments have largely been supportive of our portfolio reshape and strategic channel shift in China. These initiatives are helping us report strong growth in China this quarter while simultaneously raising our EBIT margin.
Before I go into detail on our third quarter results, let me put these in context. The macroeconomic climate in North America and Europe appear stable. But in many emerging markets, we see consumers pressured by slowing economic growth. This applies broadly across Latin America and Asia and is consistent with what you have heard from other companies this earnings season.
So my view of China, backed by recent economic downturn, is a little more positive than that of some others. There's little doubt that a pickup in economic activity in emerging markets will be linked to a recovery in demand for the exports in North America and Europe.
We also believe that the long-term category fundamentals are intact and remain supportive of our growth ambition. We believe that making the necessary and strategic investments now is critical to delivering on our 3-year road map of value creation.
Let me now expand on our third quarter results. For the third year running, we're experiencing foreign exchange headwinds. And for the second year in a row, economic challenges have combined with low dairy costs to produce a challenging pricing environment. Competitively, our results in the latest quarter were frankly mixed. We are facing a stiff challenge from competition in the United States. Conversely, we have good evidence that our China strategy is working. And there, we are strengthening our competitive position in growing channels. In aggregate, third quarter sales for the company were $938 million.
Currency adversely impacted our results by 4%. Constant dollar sales were in line with the third quarter of 2015, while reported sales were 4% lower than the prior year's quarter.
As I mentioned earlier, excluding the impact of our intentionally reduced business in Venezuela, the company's net sales grew 1% in constant dollars over prior year.
While volume was 5% unfavorable, we saw a fully offsetting benefit from price and product mix of 5%. This, despite continued competitive pressure on low dairy costs.
Gross margin was strong and remains above our historical average, and we continued to invest against our priority initiatives, including the establishment of Enfinitas in China.
Total investment in advertising and promotion represented 17.3% of net sales in the quarter.
Our Fuel for Growth cost reductions initiative drove significant savings in SG&A costs. Overall, these costs, on a reported basis, were down 12% in the third quarter compared to the same quarter of the prior year.
Our EBIT margin rose to 26.1% in the quarter as EBIT grew 9% in constant dollars.
Non-GAAP earnings per share for the quarter were $0.87 and similar to results in the proceeding 2 quarters.
I'll now discuss the performance of each of our reporting segments, beginning with our North America and Europe segment. Overall, results in this segment were mixed in the quarter. Market share gains in Canada and Europe resulting in strong sales growth there offset a disappointing quarter for our U.S. business. Net sales in the segment were in line with the third quarter of 2015 on a constant dollar basis. In aggregate, the segment benefited from a 5% pricing benefit, but this was fully offset by lower volumes in the United States. And foreign exchange adversely impacted sales for this segment by 1%.
Competitive pressure -- competitive activity put pressure on market share and resulted in a disappointing sales performance in our U.S. business. While we are actively addressing these challenges, we recognize that category dynamics of such that it'll take time to stabilize and recover lost market share.
Unconscious that we've been referencing weakness in U.S. market share for a few quarters now. Unfortunately, we know the category is quite sticky, and to gain new consumers take time. We have a concrete action plan in place, but we must expect share to remain relatively weak through the next couple of quarters.
In the rest of the segment, I'm pleased with our progress. And we reported our highest market share in many years in Canada, as both Canada and Europe grew strongly in the quarter.
The Canadian business experienced strong growth in both its core infant formula business and the toddler category. And European sales of our energy products continued to grow on the back of a strengthened competitive position in a growing segment.
Let me now turn to Latin America. Segment performance continues to be heavily impacted by the suspension of sales to Venezuela. These shipments all but ceased at the end of 2015. Excluding this impact, sales in Latin America grew 5% in constant dollars over the same quarter of 2015. However, including the impact of Venezuela, constant dollar sales for the region were in line with the prior year's quarter. Pricing benefits of 10% did not fully offset foreign exchange impacts of negative 13%. And given the weakness in so many of the region's economies, we saw a volume lower by 10%. Excluding Venezuela, volume was unfavorable by 5%.
With regard to Venezuela, there's been no significant change in circumstances. This situation will again negatively impact results in the coming quarter. But after that, the distorting effect should be negligible.
In Mexico, our infant and children's businesses delivered growth, and trends in other parts of Latin America remained broadly unchanged from the prior quarter. In much of South America, economic fundamentals remained weak, and we are seeing this reflected in consumer demand. Colombia and Peru provide isolated spots of relative economic stability.
I turn now to the Asia segment. Constant dollar sales in Asia were in line with the third quarter of 2015. Despite increased trade investments, price was favorable compared to the prior year quarter. Price increases in Southeast Asia, along with positive product mix in China, resulted in a 4% improvement in price within the segment. Volume was unfavorable by 4% driven by market share weakness and adjustment to channel inventories in the Philippines. Again, we have implemented a solid remediation plan there, and it's beginning to work. That said, it will take time to rebuild market share. And in the meantime, we'd have to reduce channel inventory.
In Asia, price inflation remains low in a historical context.
I'll complete my discussion of our Asia segment with a few comments on China. In a sentence, our strategy to reshape our portfolio and strengthen performance in high-growth channels is working. Despite the decline in Hong Kong, sales within our greater China business grew strongly in the latest quarter. We saw improvements in both volume and product mix. Higher-priced new products are replacing sales on legacy lines. Consumers continue to adopt our fully imported product lines of Enfamil and Enfinitas at rapid rates, more than offsetting slowing demand for our locally manufactured products and shrinking exports from Hong Kong. Like many of our competitors, we are seeing the rapid shift in sales channels continue. But with the reshaped product portfolio, we've been able to adapt to this.
A few facts may help illustrate my point and put our results in context. The mainland supermarket channel declined double digits in the quarter. Our sales to our Hong Kong channel continued to decline and was down double digits within the quarter, but our sales into baby stores in and Mainland China were up more than 20% on a year earlier. And our e-commerce sales were up more than 60%.
Our market share of company-controlled e-commerce channels increased by 3 percentage point over prior year. And our recently launched imported product lines continue to grow market share each month. Imported products now account for 60% of total sales in Mainland China, up from 45% in March.
I think you can understand from this exactly how dynamic the trade environment is and how critical agility and flexibility are as core elements of our China strategy.
In conclusion, let me mention that our third quarter sales did benefit from replenishment of orders we were able -- we were unable to fulfill in the prior quarter due to tightened import processes. You'll remember that I mentioned this in our last call. However, underlying growth, excluding this benefit, was nevertheless healthy in China. China's results this quarter reflect the strategy we put in place 2 to 3 years ago to increase flexibilities through a broader product portfolio, sold to a more diverse set of channels.
This quarter, you can see that our strong organization and infrastructure in China has the ability to flex and adapt than challenged. Much work remains to be done, but I feel good about the latest quarter. I deliberately not devoted any time to a description of our year-to-date sales. Though we've clearly hoped for a faster rebound in sales, we've seen a gradual, progressive improvement in our growth rate from quarter-to-quarter.
I now want to transition to talk about our global outlook for the balance of the year and beyond. While we saw strong growth in China, it's become clear that any sustained recovery in the broader emerging markets will take longer to occur than expected earlier. Additionally, market share losses in the Philippines and the United States are weighing on our current performance, and we do not expect to see these losses reversed until well into 2017.
In recognition of these challenges, we are revising our expectations for both sales and earnings per share. We now expect constant dollar sales for the full year 2016 to come in 2% to 3% below prior year, and we expect non-GAAP earnings per share in between $3.43 and $3.50. These numbers imply we continue to make progress in China in the fourth quarter and gradually improve sales in other geographies. We expect that the recent volatility and changing market dynamics will continue to impact our business in the midterm.
As we look beyond the next quarter to 2017, we expect to see continued but only modest improvement in constant dollar sales and to EPS. Our Fuel for Growth program will continue to help fund growth initiatives and mitigate known headwinds.
I'll now hand the call over to Michel who'll provide additional details on our third quarter financial performance. After that, I'll return with a few summary remarks before we take your questions. Michel, over to you."
1002291,367328587,1063335,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Thank you, Kasper, and good morning, everyone. Today, I will discuss the company's third quarter and 9 months 2016 financial results. I will then briefly highlight cash flow and liquidity items and conclude with a summary of the full year guidance. My com",1766,"Thank you, Kasper, and good morning, everyone. Today, I will discuss the company's third quarter and 9 months 2016 financial results. I will then briefly highlight cash flow and liquidity items and conclude with a summary of the full year guidance. My comments about sales will refer to net sales, unless I explicitly state gross sales. References to currency impacts or the effects of currency fluctuations generally refer to the impact on the translation of local currency financial statement into U.S. dollars.
Kathy already covered Slide 2, so let me start with sales on Slide 3. Slide 3 shows the improving trend of net sales on a constant dollar basis when compared to prior year periods. As Kasper already indicated, excluding the impact of reduced shipments to Venezuela, the company's net sales were 1% above the prior year quarter. The adverse impact of Venezuela will be less in the fourth quarter of 2016 as we significantly slowed shipments in the fourth quarter of 2015. The negative impact of Venezuela on our net sales is over 1% on a constant dollar basis.
Turning to Slide 4. Gross sales reflects sales to customers before trade investment and other items, which are recorded as gross to net sales adjustments. For the third quarter, gross sales were 1% above the prior year quarter on a constant dollar basis. A significant portion of this quarter growth came from China. This is the first time our gross sales returned to positive growth since the first quarter of 2015.
Net sales on a reported basis were 4% below the prior year quarter and 8% below on a year-to-date basis. The adverse impact of foreign exchange on sales was 4%. The U.S. dollar continued to be strong, and the effect on the translation of local currencies negatively impacted all reporting segments.
On Slide 5, the third quarter EBIT of $244 million was 9% above the prior year quarter on a constant dollar basis. Foreign exchange adversely impacted EBIT by 7%. Including currency impacts, EBIT increased 2% on a reported basis in the third quarter. The third quarter EBIT margin of 26.1% of sales was 160 basis points better than the prior year quarter. With sales nearly in line with the prior year, the benefit of lower dairy cost rolled through for a positive gross profit.
We continue to make strong progress to reduce operating expenses as part of our Fuel for Growth program, which allows continued investments while improving the underlying profitability. Year-to-date EBIT was $719 million, and we delivered positive growth of 2% above the previous year period on a constant dollar basis. The EBIT margin of 25.3% of sales was 80 basis points better than the prior year period. Foreign exchange had an adverse impact of 8%. Despite macroeconomic and country-specific challenges, which negatively impacted our sales, we benefited from low dairy cost and made excellent progress on realizing Fuel for Growth savings.
I will now move to factors that impacted gross margin on Slide 6. Gross margin was 64.6% in the third quarter of 2016. Adverse foreign currency impacted gross margin by 150 basis points in the quarter. We continued to deliver nearly flat gross margin on a reported basis despite the significantly currency headwinds we had. On a constant dollar basis, the gross margin percentage improved 120 basis points. Price/mix and gross to net adjustment had a slightly negative impact on gross margin, mainly from higher trade investments. Low dairy was the large benefit to gross margin in the third quarter of 2016.
Within cost of goods sold, productivity savings continued to be strong. Projects for the full year have been identified, and we expect savings to be above our earlier estimate of 3.5% of cost of goods sold. When you compare the 3 months and the 9 months charts, you can see the key drivers are the same. As this year progressed, the dairy benefit is lower as we lap towards the lowest 2015 dairy cost comparison. The adverse foreign currency impact on gross margin in the third quarter is higher, mainly due to hedges. If dairy is secured for the full year and larger productivity savings, we expect full year gross margin to be up to 64.5%, better than our previous guidance of 64%.
Moving to operating expenses on Slide 7. The chart provides the combined spending of demand-generating investments, both as trade investment classified in gross to net sales adjustments and as advertising and promotion in operating expense category. The combined investments in the third quarter were above the prior year quarter. As a percentage of gross sales, the third quarter was similar to the second quarter as a result of increased investments to support our China strategy to become more competitive in the baby store and e-commerce channels with our Enfa imported and Enfinitas product lines.
Slide 8. We reduced our SG&A cost by 9% on a constant dollar basis in the third quarter of 2016 versus the previous year quarter and by 10% year-to-date compared to the prior year period. As a reminder, we delivered $20 million savings in the fourth quarter of 2015. So in the fourth quarter of 2016, the year-over-year percentage reduction is likely to be smaller.
As you can see on Slide 9, year-to-date, we have achieved nearly 85% of this year's target. We now expect to realize savings toward the higher end of the $75 million to $80 million target range. In the corporate and other functions, we reduced our cost by $50 million year-to-date compared to prior year period. This is 3/4 of the year-to-date savings.
Turning to Slide 10 for a discussion of EBIT. Positive price/mix was offset by volume decline in all segments. The positive price/mix was mainly driven by a mix benefit as a result of the rollout of imported premium products in China, new innovations in several markets as well as price increases in markets to partly compensate currency devaluations. All segments benefited from lower dairy and cost -- and crops productivity.
EBIT at Asia was lower due to higher trade investments. Promotional activities and advertising, which resulted in lower EBITDA loss and margin percentage in the third quarter. Our EBIT in both Latin America and North America improved. For Latin America, this was due to lower advertising and promotion expenses when compared to the prior year where we had higher expenses related to product launches.
For North America and Europe, SG&A cost savings helped fund investments and drove higher EBIT margins. Lower corporate and other expenses were most notably attributable to Fuel for Growth savings.
I will now address the financial results from EBIT to EPS on Slide 11. The interest expense of $26 million in the third quarter was in line with 2016 run rate. When compared to the prior year quarter, interest expense increase reflects the impact of the November 2015 $1.5 billion notes issuance. A significant portion of the proceeds from the notes were used to finance the accelerated repurchase program, or the ASR. The benefit of the ASR is reflected in the third quarter 2016 share count. There was no significant share repurchase in the third quarter.
Non-GAAP effective tax rate, or ETR, was 26% for the third quarter of 2016 compared to 28.1% in the prior year quarter. In the third quarter of 2016, the ETR decrease was driven by tax credits from repatriation of foreign earnings, somewhat offset by change in allowances against tax assets. The prior year quarter was adversely impacted by an unfavorable geographic mix.
Non-GAAP EPS for the third quarter was $0.87, an increase of 9% on a reported basis and 16% on a constant dollar basis. Year-to-date, non-GAAP EPS was $2.63, a 1% decrease from the prior year on a reported basis and an increase of 7% on a constant dollar basis.
Let me summarize our financial results by addressing the change to EPS on Slide 12. In the third quarter, non-GAAP EPS increased $0.13 to $0.93 per share on a constant dollar basis versus the prior year quarter. Sales and related gross profit delivered a $0.03 benefit to EPS. The adverse impact of higher advertising and promotion was $0.04. Fuel for Growth savings delivered $0.07 benefit. The share repurchase programs delivered a $0.03 benefit, net of higher interest expense. And tax and other contributed a $0.03 benefit. Despite the negative impact of foreign exchange of $0.06 per share, EPS increased $0.07 versus third quarter last year on a non-GAAP basis.
Turning to a high-level overview of cash movements on Slide 13. The cash balance of $1.8 billion as of September 30 was $142 million higher than in the beginning of the year. Cash flow from operations was negatively impacted by operating working capital. Our year-to-date CapEx investments were $110 million, mainly in our U.S. and operating in Europe manufacturing facilities, along with ongoing quality and planned enhancements globally. For the full year, our capital spending goal remains at 4% of sales. Dividend payments were $232 million in the 9 months of 2016. The negative impact of foreign currency exchange of $33 million was mainly related to the currency devaluation in Venezuela.
To summarize our forward-looking annual guidance on Slide 14, our sales outlook for 2016 on a constant dollar basis is expected to be 2% to 3% below the prior year. With foreign currency reducing sales growth by about 4%, reported sales are estimated to be 6% to 7% below 2015. The 2016 GAAP EPS guidance is expected to be in the range of $2.80 to $2.87. And our non-GAAP guidance is $3.43 to $3.50 per share.
The guidance changed for the following reasons: sales on a constant currency basis may be lower due to the market share weakness in several markets, especially in the U.S., along with continued macroeconomic challenges in several emerging markets. Partially offsetting the sales impact, we expect gross margin to be up 64.5%, while Fuel for Growth savings is expected to be at the high end of the $75 million to $80 million range. And finally, the foreign exchange impact is expected to be approximately $0.30 per share from our previous guidance of $0.35 per share.
GAAP EPS guidance is likely to be impacted by potentially significant future market-to-market pension adjustments, which cannot be estimated and are classified as specified items. Specified items include charges related to our Venezuela business, Fuel for Growth and year-to-date pension adjustments.
This concludes my discussion on the third quarter and 9 months 2016 financial results. Thank you again for your time this morning. I will now turn the call back to Kasper."
1002291,367328587,1063335,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Thank you, Michel. In today's prepared remarks, we've discussed both the positive news from China as well the number of headwinds we will continue to tackle as we move into next year.I want to acknowledge the difficulty we've had in accurately projectin",309,"Thank you, Michel. In today's prepared remarks, we've discussed both the positive news from China as well the number of headwinds we will continue to tackle as we move into next year.
I want to acknowledge the difficulty we've had in accurately projecting our top line trajectory over the past 18 months in what is perhaps the most uncertain environment I've seen in nearly 20 years in the industry. The global economy has been weaker than we'd expect, and we are facing a strong challenge in the United States.
But before we open the lines to your questions, I want to take you back 3 years. 3 years ago, when it first became obvious that our trajectory in China was changing, many of you, I'm sure, had doubts we could successfully navigate our way through the adaptations we needed to make. Today, I feel very proud of the way our people embraced the challenge and worked hard on implementation. We certainly have much work left in China and elsewhere, but we also have many more opportunities from which we can benefit. We've taken the first important steps, and we're on our way forward.
As was the case when we discussed our challenges in China, I feel confident that we can overcome the current challenges in Southeast Asia and the United States. Our organizations have proven that they can adjust and reverse trajectories and focus on identified issues.
Overall, the shape of our recovery remains broadly as outlined at our Investor Day in October 2015. Yes, the rate of improvement has been slower than we'd hoped for, but we are doing the right thing in focusing on innovation and execution, and we're on a positive path.
I'll now hand the call back to the operator, Liz, and ask her to open the lines to your questions. Liz, back to you."
1002291,367328587,1063335,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Operator","[Operator Instructions] Your first question comes from Bryan Spillane with Bank of America.",13,"[Operator Instructions] Your first question comes from Bryan Spillane with Bank of America."
1002291,367328587,1063335,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","Just a question about -- you've made a reference about the -- Kasper, about the adaptations you had to make in China, which have been significant. Can you give us a sense, now that you've made that adaptation, has the rest of the market made that adaptati",123,"Just a question about -- you've made a reference about the -- Kasper, about the adaptations you had to make in China, which have been significant. Can you give us a sense, now that you've made that adaptation, has the rest of the market made that adaptation? Meaning, you now have fully imported product coming in -- multiple products that are fully imported coming into the market that's giving you more range in terms of the channels that you can now access with those products? And it's hard from, I guess, where we sit to see whether or not your competitors have done something similar or whether you're just ahead of kind of where the competition is in terms of making that change."
1002291,367328587,1063335,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Well, Bryan, firstly, I think -- let me be clear, I think we have made that change, and I feel good about the current product line that we've now got in China. It allows us to play much more effectively in the faster-growing channels, particularly the bab",276,"Well, Bryan, firstly, I think -- let me be clear, I think we have made that change, and I feel good about the current product line that we've now got in China. It allows us to play much more effectively in the faster-growing channels, particularly the baby stores and the e-commerce channel. I think, in some cases, as I have acknowledged over the last couple of years, in some cases, we were slower than competitors to enter the super-high premium segment. So I mean, I'm very encouraged with the progress we are making in that business and how we are building share from month to month with quite substantial opportunities ahead of us to continue to grow, both through increased distribution and share gains. In other areas, I think we have probably been somewhat ahead of our competitors in focusing on the former or company-organized e-commerce trade where some other competitors have relied quite heavily on kind of informal trade out of either Australia or Europe, which clearly is now being quite challenged by the changes to the regulatory environment, which I think we anticipated would happen. So our focus has always been on kind of the trade that -- the amount of the e-commerce trade that we feel we can control ourselves. And I referenced in my comments, prepared remarks that in that part of the e-commerce channel, our sales are up 60% on a year ago, which outstrips the growth of the channel in general. And I think I said that we had increased our share of that channel by just over 100 basis points.
So I think that answers your question. If not..."
1002291,367328587,1063335,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","Yes, it does. I think, just -- in summary, it's just you're in a much better competitive position now than you were before because you've moved further into really having a fully imported product supply chain.",36,"Yes, it does. I think, just -- in summary, it's just you're in a much better competitive position now than you were before because you've moved further into really having a fully imported product supply chain."
1002291,367328587,1063335,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Yes, no doubt. I mean, in the third quarter, 60% of our sales in Mainland China were in our imported product lines.",22,"Yes, no doubt. I mean, in the third quarter, 60% of our sales in Mainland China were in our imported product lines."
1002291,367328587,1063335,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Operator","Your next question comes from Amit Sharma with BMO Capital Markets.",11,"Your next question comes from Amit Sharma with BMO Capital Markets."
1002291,367328587,1063335,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","Kasper, I just want to talk about U.S. a little bit. So clearly, disappointed with the market share performance there, and you talked about some of this is going to be just a timing issue. Can you go a little bit deeper into it? And like what's -- is it y",91,"Kasper, I just want to talk about U.S. a little bit. So clearly, disappointed with the market share performance there, and you talked about some of this is going to be just a timing issue. Can you go a little bit deeper into it? And like what's -- is it you may have taken more pricing than the competitor? Or are you deliberately not exiting but maybe more strategic with some of the big contracts that you may have lost recently? Can you talk a little bit more about that, please?"
1002291,367328587,1063335,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Executives","No. I mean, I think, look, I take my hats off to at least one of our very strong competitors in the U.S. business. They've done a -- they've simply done a better job than we've done in the last 12 months or so. So we have to acknowledge -- when we're on t",268,"No. I mean, I think, look, I take my hats off to at least one of our very strong competitors in the U.S. business. They've done a -- they've simply done a better job than we've done in the last 12 months or so. So we have to acknowledge -- when we're on the receiving end of that, we believe that it's important we acknowledge that and not try to kind of sugarcoat it with you guys. There's -- there will continue to be, going forward, changes in rate contracts. That's a natural part of the business cycle. So that's had some impact. But -- and I would say the rest of it has been mostly about execution both in a trade environment and on programs that are generally responsible for driving consumer starts to our brands. I think some of it -- in all honesty, some of it has been self-inflicted, which, in a way, I take some comfort from because that means we can fix it unilaterally. And I feel -- and I have really very little doubt that we can do that, but I understand that the category is ultimately a very sticky category as I mentioned in my prepared remarks. We have to regain our share of stocks in the category, and we have to do that kind of one child at a time as they enter the category. So it's going to take time. It would be wrong and nave for me to say that we would expect some kind of v-shaped turnaround in market share. But I think we know what's wrong."
1002291,367328587,1063335,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Operator","Our next question comes from John Baumgartner, Wells Fargo.",9,"Our next question comes from John Baumgartner, Wells Fargo."
1002291,367328587,1063335,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","Kasper, I like to stay with the U.S. market because on the phase of it seemed like after a number of years during which Mead really dominated the innovation discussion for the category, that pendulum is kind of swinging back now towards your largest compe",97,"Kasper, I like to stay with the U.S. market because on the phase of it seemed like after a number of years during which Mead really dominated the innovation discussion for the category, that pendulum is kind of swinging back now towards your largest competitor. So is that the right way to think about it? And if it is, can you provide any context to Mead's near-term innovation pipeline? And maybe just lastly, price/mix being up so strong in North America this quarter, how sustainable is that going forward given just the competitive pressures and share loss?"
1002291,367328587,1063335,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Executives","I think it's hard for me to speculate on price going forward. I mean, there's -- obviously, there's a fair amount of promotional activity, as there always is, in the U.S. market. And we fundamentally don't believe that at the margins, this category is dri",263,"I think it's hard for me to speculate on price going forward. I mean, there's -- obviously, there's a fair amount of promotional activity, as there always is, in the U.S. market. And we fundamentally don't believe that at the margins, this category is driven significantly by price. That said, there is a certain, what I will say, range within which we can play. We typically play at a premium to our competitors in the U.S. I expect we'll continue to do that, but we'll stay relatively close to them. And we'll see how the dynamics evolve. You're asking about, John, innovation cycle. I think we have a strong innovation program laid out going forward. It's clear that over the last 12, 18 months, we perhaps had not a strong a program that, at least, the evidence would suggest that. But I think it's more about kind of operational excellence on some of our more basic initiatives. We just let our standards slip a little bit. I suppose I don't want to go into too much detail on it, if you'll forgive me for that. But I think we have 2 or 3 things that we have clearly identified that we could and should have done better in the United States in the last 12 months or so, and we are clearly facing them quickly. But it'll take some time for that to show up in market share given that the heavy consumption period that we see from children really is only about 4 to 5 months after they enter the category."
1002291,367328587,1063335,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Operator","Your next question comes from Jason English with Goldman Sachs.",10,"Your next question comes from Jason English with Goldman Sachs."
1002291,367328587,1063335,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","First, real quick, semantics. The comment about 2017, modest improvement to both underlying sales and earnings per share, is it wrong to interpret that improvement means growth? Or is there -- is the risk where we sit today that we don't have top and bott",50,"First, real quick, semantics. The comment about 2017, modest improvement to both underlying sales and earnings per share, is it wrong to interpret that improvement means growth? Or is there -- is the risk where we sit today that we don't have top and bottom line growth into next year?"
1002291,367328587,1063335,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Executives","I mean, we -- I think the words I use to describe our outlook for '17 was that we expected only modest improvement to both constant dollar sales and to EPS. That would clearly imply improvement would mean improvement. And therefore, it would imply a numbe",52,"I mean, we -- I think the words I use to describe our outlook for '17 was that we expected only modest improvement to both constant dollar sales and to EPS. That would clearly imply improvement would mean improvement. And therefore, it would imply a number that was better than this year."
1002291,367328587,1063335,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","Yes, I wanted to make sure that was clear. It can be spun a couple of different ways. So I appreciate the clarification on that. And I'm going to ask questions on the U.S., but surprisingly, we're getting quite a few on those today, so I'm going to pivot",155,"Yes, I wanted to make sure that was clear. It can be spun a couple of different ways. So I appreciate the clarification on that. And I'm going to ask questions on the U.S., but surprisingly, we're getting quite a few on those today, so I'm going to pivot back to what I thought would be more crowded, and that's China. As we think about the forward on China, some of your competitors out there have flagged a risk of the markets are going to be flooded with more product ahead of the January 2018 regulatory change. It's created some consternation that we have, that the pricing intensity, the competitive intensity gets worse before it gets better. And that gets worse at a time that we've got rising dairy cost inflation. Can you weigh in with your view on how you see that unfolding and what do you think the implications are for your business?"
1002291,367328587,1063335,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Yes. I mean, I don't think our view has significantly changed in the sense that at the consumer level, this is not a brand choice. It's not significantly influenced by price, and certainly not in the infant formula business; a little bit more price sensit",262,"Yes. I mean, I don't think our view has significantly changed in the sense that at the consumer level, this is not a brand choice. It's not significantly influenced by price, and certainly not in the infant formula business; a little bit more price sensitivity in the children segment. So I think the key dynamic that will be influenced by all of this price discounting that we are seeing right now, and that I suspect people are right in saying we'll continue to see through '17, it's mainly influencing retail dynamics; in other words, the amount of inventory that people are pushing into the retail channel. And I suspect that we are going to see a lot of people being caught with very big fluctuations in sales as they need to adjust for inventory swings at some point in the economic cycle. Single influence, different companies at different times, I think, to some degree, already within this quarter, you've seen relatively big fluctuations in the financial results announced by many of the companies in the industry. We've sort of prided ourselves on trying to keep our inventory relatively tight at the retail level. And we feel we've got very good visibility on what it is, and we are happy with the level of inventory we have in the channels. Some -- there are some quarters when that hurts our relative competitive performance as you look at it versus others, and there are some quarters where it perhaps helps us. And I think this was a quarter where that approach clearly helped us."
1002291,367328587,1063335,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Operator","Your next question comes from the line of Ken Goldman with JPMorgan.",12,"Your next question comes from the line of Ken Goldman with JPMorgan."
1002291,367328587,1063335,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","Do you still see a 27% EBIT margin in 2018? Because if you're not getting much EBIT growth next year, you're going to need a huge 2018 to get there.",30,"Do you still see a 27% EBIT margin in 2018? Because if you're not getting much EBIT growth next year, you're going to need a huge 2018 to get there."
1002291,367328587,1063335,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Ken, let me address that question. Indeed, for 2017, we, indeed, expect a more flat EBIT margin on a constant dollar basis. We always said in the 3-year road map that we laid out that ultimately, we would like to deliver the 300 basis point improvement. B",126,"Ken, let me address that question. Indeed, for 2017, we, indeed, expect a more flat EBIT margin on a constant dollar basis. We always said in the 3-year road map that we laid out that ultimately, we would like to deliver the 300 basis point improvement. But like we said, for us, it's very important to position us very strongly for the future, make the right deliberate choices on investments that we need to make. Also in 2017, also in China, to position us very strongly, specifically in China, to take opportunity on the developments that are happening there. So it might take some longer time before we will reach the 200 -- the 300 basis points EBIT margin that -- as we laid out earlier."
1002291,367328587,1063335,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","All right. Can I ask a quick follow-up, Kathy?",9,"All right. Can I ask a quick follow-up, Kathy?"
1002291,367328587,1063335,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Go ahead.",2,"Go ahead."
1002291,367328587,1063335,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","Along these lines, in a lot of the things in this call that I think are disappointing to some people, including me, and I really -- there's a lot of exogenous macroeconomic headwinds you can't control. But you've lost market share in the Philippines. You'",151,"Along these lines, in a lot of the things in this call that I think are disappointing to some people, including me, and I really -- there's a lot of exogenous macroeconomic headwinds you can't control. But you've lost market share in the Philippines. You've lost market share in China, although, obviously, it's coming back a little bit now. You've lost market share in the U.S. Kasper, do you need to make a larger adjustment to the company's strategic mindset in terms of marketing? I mean, we've seen some successful tactical adjustments, right? Obviously, things have changed in China this past quarter. But it just feels like it can't continue forever to experience market share losses. And I'm just curious if there is anything in your mind that needs to change in a more dramatic way in terms of how you go to market or how you think about your strategy."
1002291,367328587,1063335,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Executives","I think, Ken, the comment is well taken. As you might imagine, nobody is, what shall we say, more sensitive around us referencing market share losses than I am. And certainly, it's not what we want to see. Having said that, we have a portfolio that is hea",274,"I think, Ken, the comment is well taken. As you might imagine, nobody is, what shall we say, more sensitive around us referencing market share losses than I am. And certainly, it's not what we want to see. Having said that, we have a portfolio that is heavily exposed to, let's call it, 10 global businesses or 10 businesses around the world. It's inevitable that amongst those 10, you're going to have ups and downs. We've gained a lot of market share in Canada. We've gained a lot of market share in Europe. And I would argue, at the moment, we are gaining market share in China. Now unfortunately, if you have problems, market share-wise, and you have them in a couple of your really big markets, we both know that the U.S. and China, between the 2 of them, account for more than half our sales, our global sales. So it's very hard for us to offset any significant loss of market share in 1 of those 2 markets with performance in other markets. I'm certainly disappointed that we have not been able to proactively address some of these challenges as opposed to finding ourselves in the mode where we are, so to speak, reacting in state and adapting. I would obviously much rather be driving the change proactively. So your implied criticism is well taken. I don't think it's structural. I don't think it's related to, what shall we say, the way we do marketing or our marketing capabilities in general. But you might rightly imagine that a fair amount of social chain [ph] is going on as a consequence of this."
1002291,367328587,1063335,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Operator","Your next question comes from Matthew Grainger with Morgan Stanley.",10,"Your next question comes from Matthew Grainger with Morgan Stanley."
1002291,367328587,1063335,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","I wanted to squeeze in 2 questions, but I'll ask them quickly. First, on North America, the northeast states WIC contracts, just hoping you could contextualize the size of that relative to some others that have had a material impact on your results such a",105,"I wanted to squeeze in 2 questions, but I'll ask them quickly. First, on North America, the northeast states WIC contracts, just hoping you could contextualize the size of that relative to some others that have had a material impact on your results such as Florida a few years ago and how material that is for 2017. And then in China, just on the market generally, curious for your latest thoughts on birth rates and whether you've seen any uptick in trend in recent months. Some of the feedback that we've gotten have suggested that there's been a bit more acceleration in birth rate trend."
1002291,367328587,1063335,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Let me address high level the contracts that are coming up, and we always were very transparent that there are a couple of significant contracts that were coming off a bit. One of them is California, and the other one that's coming up is  Texas. We don't",121,"Let me address high level the contracts that are coming up, and we always were very transparent that there are a couple of significant contracts that were coming off a bit. One of them is California, and the other one that's coming up is  Texas. We don't disclose, obviously, the details, what the magnitude of impact potentially could be. But we are very well aware about the importance of these contracts and the potential impact. We're always trying to have a strategy behind it that we always can find the right balance between other growth initiatives in the U.S. markets as well. So that has been taken into account as well when Kasper was talking about the outlook for next year."
1002291,367328587,1063335,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Executives","I want to maybe just -- Matt, let me try and put it in sort of a strategic context. I think the participation in WIC contracts is one of a number of important demand drivers that we have in the U.S. business. As such, we view it, to a certain extent, the",164,"I want to maybe just -- Matt, let me try and put it in sort of a strategic context. I think the participation in WIC contracts is one of a number of important demand drivers that we have in the U.S. business. As such, we view it, to a certain extent, the same way we view A&P. We look for an appropriate level of return on investment. And it's likely that as we look forward to 2017, there are a couple of important countries, in both of our 2 biggest markets, China and the U.S., we are planning increased investments and demand creation in both of those markets. In China, it will be important to support our growth momentum. And in the U.S., it will obviously be important in order to turn around the market share performance that we've just discussed. And that's -- what we've tried to do is sort of capture that all onto this heading of increased investment and demand creation."
1002291,367328587,1063335,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Operator","[Operator Instructions]",2,"[Operator Instructions]"
1002291,367328587,1063335,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Operator, I had about 6 other people -- oh, they're coming back, I think, now on the list.",18,"Operator, I had about 6 other people -- oh, they're coming back, I think, now on the list."
1002291,367328587,1063335,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Operator","Your next question comes from the line of David Driscoll with Citibank.",12,"Your next question comes from the line of David Driscoll with Citibank."
1002291,367328587,1063335,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","And yes, I've been here the whole time, so thanks, Kathy. So like to just kind of line a logic here, the line of questioning is about cost savings. And there are a couple of ways that I want to say it, so give me -- just give me a second. On EPS, kind of",197,"And yes, I've been here the whole time, so thanks, Kathy. So like to just kind of line a logic here, the line of questioning is about cost savings. And there are a couple of ways that I want to say it, so give me -- just give me a second. On EPS, kind of why can't you protect EPS growth more given the size and scope of the cost savings? Just I'm just surprised, it's not helping it more in the 2017 comments, Kasper, or obviously, kind of disappointing because it doesn't really fit the 3-year trend, and I think you guys already pulled back on the 27% margin to Ken's question. And then just super specifically, are you going to step up this cost savings program again? And are you confident that all of this reinvestment is being well spent? Because it just feels like we're getting a very different answer from Mead Johnson versus the rest of the companies in the sector that are generating fairly massive cost savings that are showing up in earnings, but it's not really happening here. We're just hoping to hear your thoughts on what to make of it."
1002291,367328587,1063335,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Thanks, David. It's a great question, and obviously, one we had anticipated. And I think let's start by going back to Ken's -- to Ken Goldman's question about so what should we expect in terms of EBIT accretion in 2017. And Michel's response that while we",339,"Thanks, David. It's a great question, and obviously, one we had anticipated. And I think let's start by going back to Ken's -- to Ken Goldman's question about so what should we expect in terms of EBIT accretion in 2017. And Michel's response that while we don't see EBIT accretion as we look at 2017 and that, of course, is really reflective of the comments I made about our expectations for both sales and EPS growth. And implicitly in that is the fact that there won't -- there's very unlikely to be EBIT margin accretion. So the question is in the face of some fairly significant progress against cost saving initiatives, why is that? And it really relates into -- it relates simply to the fact that we believe that it is in the long-term interest of our shareholders to continue to drive strong growth in China, and that requires continued investment. You will understand implicitly that some of the important initiatives that we have implemented in China were launched only approximately halfway through the year, 2016. So we'll have a full year impact of that higher level of spend in 2017. And then we believe we need to make additional investments in turning around market share in the U.S., which we also believe is in the long-term interest of the business. I do want to say that on the topic of margin accretion, it is -- it's an objective that is subservient to our primary objective, which is to turn around the growth trajectory of the business. So that's important to understand. It's also important to understand that where you will see that significant margin accretion occur is at the point in time that our growth rate picks up from the sort of very modest level that we are currently discussing. We clearly, at that point in time, have put our cost structure in place that will allow the company to get a great amount of EBIT leverage on any kind of growth in sales.
Does that help?"
1002291,367328587,1063335,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","It does. Any comments about further improvements to the cost savings program given the stresses?",15,"It does. Any comments about further improvements to the cost savings program given the stresses?"
1002291,367328587,1063335,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Yes. I mean, we'll -- we have initiatives in place for '17. It'll remain a focus for the company going forward. I think we -- in the last call, I think we took our target up for this year. We indicated that we would move the needle from the previously ann",207,"Yes. I mean, we'll -- we have initiatives in place for '17. It'll remain a focus for the company going forward. I think we -- in the last call, I think we took our target up for this year. We indicated that we would move the needle from the previously announced $60 million to now somewhere between $75 million and $80 million in cost savings this year. I think we also -- I forgot exactly when we expanded our 3-year target from $120 million to $180 million. So we are clearly very focused on this particular objective. And I have to say that it's helping us greatly continue to fund a high level of investment. Your question about where does all of this investment will spend is a great question. It's a question I ask our operators almost on a daily basis. And I'm quite sure that we can -- we would continue to identify small pockets of suboptimal expenditure, but we also have opportunities to spend more on things that we know will work for us. So it'll be a balancing act. Obviously, we will continue to look for efficiencies.
Great question, David. I -- we can talk more about it when we get together next."
1002291,367328587,1063335,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Operator","Your next question comes from the line of Robert Moskow with Crdit Suisse.",13,"Your next question comes from the line of Robert Moskow with Crdit Suisse."
1002291,367328587,1063335,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","I had a question about North American profits. Your profits are still looking like they're going to be up this year, and they're up substantially since 2014 in North America and Europe. But the market share is weak, and you're talking about having to rein",105,"I had a question about North American profits. Your profits are still looking like they're going to be up this year, and they're up substantially since 2014 in North America and Europe. But the market share is weak, and you're talking about having to reinvest. So is -- did you feel like North America did not get enough resources in terms of dollars this year? Or is it just the money was spent on the wrong things? And so what do you think is a more normalized margin for North America? We've gone from 23% to 30%. Where do you think it really should land?"
1002291,367328587,1063335,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Yes. Let me address that question in terms of EBIT margin. The increase of the EBIT margin in the U.S., we had a significant benefit from there, which gives a significant pressure on uplifting gross margin. So that's one area why we had an improved margin",190,"Yes. Let me address that question in terms of EBIT margin. The increase of the EBIT margin in the U.S., we had a significant benefit from there, which gives a significant pressure on uplifting gross margin. So that's one area why we had an improved margin. In general, we'll see, as a total company, more gross margin pressure also on '17 as a result of dairy prices where we see some slightly increases that are coming in. So that also will have an effect on our U.S. business as such. In addition, like Kasper just said, we made a deliberate choice to step up additional investment in the U.S. from a demand-generating investment point of view, whether that's through A&P or whether that's from gross to net initiatives, and we could be one of them as one of demand-generating investments. So we will see some pressure on EBIT margin. I think we won't see a level that we have currently. But I also don't expect that it will go to the levels that we have seen historically. I would say that we would see a midpoint between those EBIT margins."
1002291,367328587,1063335,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","Michel, just a follow-up, then, for Kasper, what's your confidence that you have the pricing power in 2017 to offset higher input costs?",23,"Michel, just a follow-up, then, for Kasper, what's your confidence that you have the pricing power in 2017 to offset higher input costs?"
1002291,367328587,1063335,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Executives","I don't think we will fully offset input -- higher input costs. So I think it's implied in the words that I used in my prepared remarks, which I'm quite sure will be scrutinized by all of you. Implied in that is some contraction to gross margin. I should",209,"I don't think we will fully offset input -- higher input costs. So I think it's implied in the words that I used in my prepared remarks, which I'm quite sure will be scrutinized by all of you. Implied in that is some contraction to gross margin. I should put that in the context of the fact that our gross margin, supported by historically low dairy costs, had been well above historic norms over the last, I want to say, the last 18 to 24 months. So I think over time, we would expect to see gross margin come down to sort of normal levels. That's not all going to happen in 1 year. It's not all going to happen in '17. But we -- as we look at it now, we would expect some reduction in gross margin next year. We'll -- I'm sure we'll say more about it when we give a bit more detail and more formal guidance next time around in our next call. But we feel it was important to kind of help you develop your thinking for '17, that's why we are spending a little bit more time than we usually do talking about next year at this point of the cycle."
1002291,367328587,1063335,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Operator","Our next question comes from the line of Pablo Zuanic with SIG.",12,"Our next question comes from the line of Pablo Zuanic with SIG."
1002291,367328587,1063335,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","Just 2 quick questions. First, I mean, when I look at Abbott, and their Eleva product, I have to think that for an IMF business, in sizes [ph] almost legal company, that they must have advantages over you in terms of their communication with doctors, and",211,"Just 2 quick questions. First, I mean, when I look at Abbott, and their Eleva product, I have to think that for an IMF business, in sizes [ph] almost legal company, that they must have advantages over you in terms of their communication with doctors, and then people recommending IMF products. And then I look at Nestle, which obviously owns Wyeth with Illuma doing well, they are a much larger consumer company with much better distribution. So can you comment? Obviously, you've made significant changes and improvements in China, but then you comment whether you're at a disadvantage when you look at the Abbott's over where on the Nestle's. And the second one, very quickly, I know you gave us a lot of numbers in terms of the pieces of growth in China. But I don't know, maybe I missed it, but what was the growth year-on-year in China in your IMF business there, and if you can just compare that with what was the sell-through? I mean, my visits to baby stores show that you have very good displays for Enfinitas, Enfamil, great merchandising, window displays, and I'm just worried about the sell-through. What are we going to see in the fourth quarter? If you can comment on that, please."
1002291,367328587,1063335,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Thanks, Pablo. Let me address your question on competitiveness first, and then I'll talk about -- then I'll reiterate what I said earlier about inventory. I see absolutely no reason why we should not be able to compete with either of the 2 companies that",367,"Thanks, Pablo. Let me address your question on competitiveness first, and then I'll talk about -- then I'll reiterate what I said earlier about inventory. I see absolutely no reason why we should not be able to compete with either of the 2 companies that you mentioned in China. And indeed, we've done so successfully for many years. The China market is somewhat different from many of the other markets in the world that we compete in, in the sense that, frankly speaking, health care professional endorsement of your brand is far less influential in China than it is elsewhere in our -- in the world we operate in. So any potential disadvantage, which I'm not sure exists to begin with, vis--vis our U.S. competitor there, certainly is never being used as a reason for shortfalls by our local team in China and nor would it be accepted. You referenced our larger and more broad-based consumer products competitor, and I would only say to that, that again, the primary sales channel for these very high-priced products, high-quality products in China is really the baby store channel in China, and that's not a channel where your muscle and product range from other parts of the grocery industry can necessarily be leveraged very effectively. So again, I don't think we are at a significant disadvantage. Apart from what you would generally say is that obviously, we are a smaller company than either of those 2, and that means we can't leverage our cost base, our general infrastructure cost over a broader sales base. But despite that, it appears to me that we have got best-in-class EBIT margins. And I think we can maintain that while growing at the same time. On the inventory side in China, I just want to refer to what I said earlier. We are very comfortable with our inventory levels in the sales channels in China. We pride ourselves on not building up those inventories artificially from quarter-to-quarter. And hence, I don't expect, assuming that offtake develops the way we expect and anticipate, I don't expect that we're going to be seeing any changes to our sales trajectory that will not reflect underlying consumer demand."
1002291,367328587,1063335,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","But just a quick follow-up, I mean, I was surprised [indiscernible], for example, baby stores that I visited, are the displays of Enfinitas, a full share of -- are as big as the displays of the Enfa range. And I was just wondering, Enfinitas is clearly no",128,"But just a quick follow-up, I mean, I was surprised [indiscernible], for example, baby stores that I visited, are the displays of Enfinitas, a full share of -- are as big as the displays of the Enfa range. And I was just wondering, Enfinitas is clearly not half of your sales there. And it retails around CNY 445 compared to Eleva and Illuma that are in the CNY 380, CNY 400 range. So I understand that the question about inventories was answered before. But I'm just wondering it sounds like you doubled your space at the baby stores, at least when I look at Enfinitas versus Enfa, unless you lost Enfa space, and then you have a price point that's way above your competitors, Eleva and Illuma."
1002291,367328587,1063335,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Yes. I think you've visited a small selection of stores, and I -- in some ways, I wish it was -- what you saw was the case everywhere. Unfortunately, it isn't. But I think it's, joking aside, Pablo, it's a natural dynamic when you launch new brands that y",95,"Yes. I think you've visited a small selection of stores, and I -- in some ways, I wish it was -- what you saw was the case everywhere. Unfortunately, it isn't. But I think it's, joking aside, Pablo, it's a natural dynamic when you launch new brands that you have to build a certain amount of exposure for them. We are very comfortable that the sales trajectory that we are seeing grow week, week on week since launch on Enfinitas is supportive of the amount of inventory that we have sold into the retail channel."
1002291,367328587,1063335,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Operator","Our next question comes from the line of Steven Strycula of UBS.",12,"Our next question comes from the line of Steven Strycula of UBS."
1002291,367328587,1063335,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","Quick question for Kasper, and then a quick follow-up for Michel. So the question would be related to the China growth. It seems like you had a nice acceleration there in the third quarter. Just any help, Kasper, as you could kind of split apart more like",112,"Quick question for Kasper, and then a quick follow-up for Michel. So the question would be related to the China growth. It seems like you had a nice acceleration there in the third quarter. Just any help, Kasper, as you could kind of split apart more like the baseline sales improvement and what was more of a bump from now a little bit of a relief in the bottleneck that we're having in terms of shipments. And then conversely, how do -- how are trends outside of China trending? Were they down high single digits, and China was up high single digits, so we got to flat ratio overall? That'd be helpful."
1002291,367328587,1063335,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Executives","I mean, you broke in the right territory with your last remark, Steve, but that's pretty close. And I would say that roughly 1/3 of the growth we saw in China in the third quarter we are attributing to, what shall we say, carryover of orders we could not",81,"I mean, you broke in the right territory with your last remark, Steve, but that's pretty close. And I would say that roughly 1/3 of the growth we saw in China in the third quarter we are attributing to, what shall we say, carryover of orders we could not fulfill in the second quarter. That would still mean that, as I said, it would still mean that our growth was very healthy in the third quarter on an underlying demand basis."
1002291,367328587,1063335,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","Okay, that's very helpful. And then my last question for Michel would be, with respect to the 27% margin target for the out-years, is any of, call it, the more tempered outlook or reflection of the business naturally rotating out of Hong Kong, which was y",87,"Okay, that's very helpful. And then my last question for Michel would be, with respect to the 27% margin target for the out-years, is any of, call it, the more tempered outlook or reflection of the business naturally rotating out of Hong Kong, which was your highest margin region, to now an imported model from Europe? Is that any of the things you do as an explanatory fact? Or is there something else we should really be focusing on? Or just a lack of top line levers?"
1002291,367328587,1063335,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Executives","No, it is clearly the last one, the top line and the required investments that we would like to make also in 2017. That's the main reason.",27,"No, it is clearly the last one, the top line and the required investments that we would like to make also in 2017. That's the main reason."
1002291,367328587,1063335,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Thank you for everybody participating in Mead Johnson's earnings call today.Operator, I'll turn it over to you to close out the call. Thank you.",26,"Thank you for everybody participating in Mead Johnson's earnings call today.
Operator, I'll turn it over to you to close out the call. Thank you."
1002291,367328587,1063335,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Operator","This concludes the presentation. You may now disconnect. Everyone, have a good day.",13,"This concludes the presentation. You may now disconnect. Everyone, have a good day."
1002291,367328587,1064076,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Operator","Good day, ladies and gentlemen, and welcome to the Mead Johnson Nutrition Third Quarter 2016 Earnings Conference Call. My name is Liz, and I will be your coordinator for today. [Operator Instructions] As a reminder, this conference is being recorded for r",63,"Good day, ladies and gentlemen, and welcome to the Mead Johnson Nutrition Third Quarter 2016 Earnings Conference Call. My name is Liz, and I will be your coordinator for today. [Operator Instructions] As a reminder, this conference is being recorded for replay purposes.
I would now like to turn the conference call over to Kathy MacDonald, Vice President, Investor Relations. Please proceed, Kathy."
1002291,367328587,1064076,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Thank you, Liz. Good morning, and thank you for joining Mead Johnson's Third Quarter and 9 Months 2016 Conference Call. With me today are Kasper Jakobsen, our Chief Executive Officer; and Michel Cup, our Chief Financial Officer.Earlier today, we issued",345,"Thank you, Liz. Good morning, and thank you for joining Mead Johnson's Third Quarter and 9 Months 2016 Conference Call. With me today are Kasper Jakobsen, our Chief Executive Officer; and Michel Cup, our Chief Financial Officer.
Earlier today, we issued our 10-Q, earnings release and financial reference slides. If you have the slides in front of you, please turn to Slide #2.
A detailed explanation of our forward-looking statements appears in the slides, which are also posted on our website in connection with today's conference call. As we start, let me remind everyone that our comments will include forward-looking statements about our future results, including statements about our financial prospects and projections, commodity costs, currency fluctuations, pricing, taxes, capital spending, new product launches, other growth initiatives and market conditions that constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Keep in mind that our actual results may differ materially from expectations as of today due to various factors, including those listed in our annual report on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K. In each case, that's filed with or furnished to the Securities and Exchange Commission, and our earnings release issued this morning.
Today's comments will include discussion of non-GAAP financial measures. Unless otherwise noted, comments related to the income statement will be on a non-GAAP basis with the exception of advertising, promotion and interest expense. In addition, comments related to the balance sheet will be on a GAAP basis. A reconciliation of these measures to comparable GAAP measures appears in the morning's earnings release and financial reference slides, which are available at meadjohnson.com. In addition, any forward-looking statements represent our estimates only as of today and should not be relied upon as representing our estimates as of any subsequent date. While we may elect to update forward-looking statements at some point in the future, we specifically disclaim any obligation to do so, even if our estimates change.
I will now turn the call over to Kasper."
1002291,367328587,1064076,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Thank you, Kathy, and good morning to you all. Thank you for joining our earnings call. My comments will center on the general business climate, our strategy, our latest quarter top line performance and our outlook. Michel will then follow me by providing",2027,"Thank you, Kathy, and good morning to you all. Thank you for joining our earnings call. My comments will center on the general business climate, our strategy, our latest quarter top line performance and our outlook. Michel will then follow me by providing some additional and financial information, including comments on our cash flow related items.
I want to start today's discussion by revisiting our 3-year value creation plan. We laid out this plan at our Investor Day in October of 2015. And at that time, we explained how 2016 would be a year of transition.
We committed to 3 key metrics: a return to growth; a set of expense reductions; and a partial reinvestment of savings in growth initiatives and margin accretion. We said we'd measure our progress against these through the period. I've since revisited these metrics in every earnings call. So let me now briefly summarize our third quarter results in that context.
Firstly, in the third quarter, we delivered growth at the gross sales level of 1%. On a net sales basis, all 3 geographic segments delivered sales in line with prior year's quarter. This is an improvement over the previous 2 quarters. Excluding the effect of suspended shipments to Venezuela, net sales grew 1% in the third quarter over the prior year quarter.
Our second milestone relates to our targeted operating expense reductions. In our second quarter call, we revised our 2016 estimate from $60 million in reductions to $75 million to $80 million. Year-to-date, we've delivered $67 million in savings, and we've achieved approximately 85% of our annual target. SG&A expenses in the latest quarter were almost $20 million lower than a year earlier.
Our third milestone was to invest a portion of the expense savings to fund key growth initiatives while increasing our EBIT margin. Our investments have largely been supportive of our portfolio reshape and strategic channel shift in China. These initiatives are helping us report strong growth in China this quarter while simultaneously raising our EBIT margin.
Before I go into detail on our third quarter results, let me put these in context. The macroeconomic climate in North America and Europe appears stable. But in many emerging markets, we see consumers pressured by slowing economic growth. This applies broadly across Latin America and Asia and is consistent with what you have heard from other companies this earnings season.
Though my view of China, backed by recent economic data, is a little more positive than that of some others, there's little doubt that a pickup in economic activity in emerging markets will be linked to a recovery in demand for the exports in North America and Europe.
We also believe that the long-term category fundamentals are intact and remain supportive of our growth ambition. We believe that making the necessary and strategic investments now is critical to delivering on our 3-year road map of value creation.
Let me now expand on our third quarter results. For the third year running, we're experiencing foreign exchange headwinds. And for the second year in a row, economic challenges have combined with low dairy costs to produce a challenging pricing environment. Competitively, our results in the latest quarter were frankly mixed. We are facing a stiff challenge from competition in the United States. Conversely, we have good evidence that our China strategy is working. And there, we are strengthening our competitive position in growing channels. In aggregate, third quarter sales for the company were $938 million.
Currency adversely impacted our results by 4%. Constant dollar sales were in line with the third quarter of 2015, while reported sales were 4% lower than the prior year's quarter.
As I mentioned earlier, excluding the impact of our intentionally reduced business in Venezuela, the company's net sales grew 1% in constant dollars over prior year.
While volume was 5% unfavorable, we saw a fully offsetting benefit from price and product mix of 5%. This, despite continued competitive pressure and low dairy costs.
Gross margin was strong and remains above our historical average, and we continued to invest against our priority initiatives, including the establishment of Enfinitas in China.
Total investment in advertising and promotion represented 17.3% of net sales in the quarter.
Our Fuel for Growth cost reductions initiative drove significant savings in SG&A costs. Overall, these costs, on a reported basis, were down 12% in the third quarter compared to the same quarter of the prior year.
Our EBIT margin rose to 26.1% in the quarter as EBIT grew 9% in constant dollars.
Non-GAAP earnings per share for the quarter were $0.87 and similar to results in the proceeding 2 quarters.
I'll now discuss the performance of each of our reporting segments, beginning with our North America and Europe segment. Overall, results in this segment were mixed in the quarter. Market share gains in Canada and Europe resulting in strong sales growth there offset a disappointing quarter for our U.S. business. Net sales in the segment were in line with the third quarter of 2015 on a constant dollar basis. In aggregate, the segment benefited from a 5% pricing benefit, but this was fully offset by lower volumes in the United States. And foreign exchange adversely impacted sales for this segment by 1%.
Competitive pressure -- competitive activity put pressure on market share and resulted in a disappointing sales performance in our U.S. business. While we are actively addressing these challenges, we recognize that category dynamics are such that it'll take time to stabilize and recover lost market share.
I'm conscious that we've been referencing weakness in U.S. market share for a few quarters now. Unfortunately, we know the category is quite sticky, and to gain new consumers take time. We have a concrete action plan in place, but we must expect share to remain relatively weak through the next couple of quarters.
In the rest of the segment, I'm pleased with our progress. And we reported our highest market share in many years in Canada, as both Canada and Europe grew strongly in the quarter.
The Canadian business experienced strong growth in both its core infant formula business and the toddler category. And European sales of our energy products continued to grow on the back of a strengthened competitive position in a growing segment.
Let me now turn to Latin America. Segment performance continues to be heavily impacted by the suspension of sales to Venezuela. These shipments all but ceased at the end of 2015. Excluding this impact, sales in Latin America grew 5% in constant dollars over the same quarter of 2015. However, including the impact of Venezuela, constant dollar sales for the region were in line with the prior year's quarter. Pricing benefits of 10% did not fully offset foreign exchange impacts of negative 13%. And given the weakness in so many of the region's economies, we saw volume lower by 10%. Excluding Venezuela, volume was unfavorable by 5%.
With regard to Venezuela, there's been no significant change in circumstances. This situation will again negatively impact results in the coming quarter. But after that, the distorting effect should be negligible.
In Mexico, our infant and children's businesses delivered growth, and trends in other parts of Latin America remained broadly unchanged from the prior quarter. In much of South America, economic fundamentals remained weak, and we are seeing this reflected in consumer demand. Colombia and Peru provide isolated spots of relative economic stability.
I turn now to the Asia segment. Constant dollar sales in Asia were in line with the third quarter of 2015. Despite increased trade investments, price was favorable compared to the prior year quarter. Price increases in Southeast Asia, along with positive product mix in China, resulted in a 4% improvement in price within the segment. Volume was unfavorable by 4% driven by market share weakness and adjustment to channel inventories in the Philippines. Again, we have implemented a solid remediation plan there, and it's beginning to work. That said, it will take time to rebuild market share. And in the meantime, we've had to reduce channel inventory.
In Asia, price inflation remains low in a historical context.
I'll complete my discussion of our Asia segment with a few comments on China. In a sentence, our strategy to reshape our portfolio and strengthen performance in high-growth channels is working. Despite the decline in Hong Kong, sales within our greater China business grew strongly in the latest quarter. We saw improvements in both volume and product mix. Higher-priced new products are replacing sales of legacy lines. Consumers continue to adopt our fully imported product lines of Enfamil and Enfinitas at rapid rates, more than offsetting slowing demand for our locally manufactured products and shrinking exports from Hong Kong. Like many of our competitors, we are seeing the rapid shift in sales channels continue. But with the reshaped product portfolio, we've been able to adapt to this.
A few facts may help illustrate my point and put our results in context. The mainland supermarket channel declined double digits in the quarter. Our sales through our Hong Kong channel continued to decline and was down double digits within the quarter, but our sales into baby stores in Mainland China were up more than 20% on a year earlier. And our e-commerce sales were up more than 60%.
Our market share of company-controlled e-commerce channels increased by a full percentage point over prior year. And our recently launched imported product lines continue to grow market share each month. Imported products now account for 60% of total sales in Mainland China, up from 45% in March.
I think you can understand from this exactly how dynamic the trade environment is and how critical agility and flexibility are as core elements of our China strategy.
In conclusion, let me mention that our third quarter sales did benefit from replenishment of orders we were able -- we were unable to fulfill in the prior quarter due to tightened import processes. You'll remember that I mentioned this in our last call. However, underlying growth, excluding this benefit, was nevertheless healthy in China. China's results this quarter reflect the strategy we put in place 2 to 3 years ago to increase flexibilities through a broader product portfolio, sold through a more diverse set of channels.
This quarter, you can see that our strong organization and infrastructure in China has the ability to flex and adapt when challenged. Much work remains to be done, but I feel good about the latest quarter. I've deliberately not devoted any time to a description of our year-to-date sales. Though we've clearly hoped for a faster rebound in sales, we've seen a gradual, progressive improvement in our growth rate from quarter-to-quarter.
I now want to transition to talk about our global outlook for the balance of the year and beyond. While we saw strong growth in China, it's become clear that any sustained recovery in the broader emerging markets will take longer to occur than expected earlier. Additionally, market share losses in the Philippines and the United States are weighing on our current performance, and we do not expect to see these losses reversed until well into 2017.
In recognition of these challenges, we are revising our expectations for both sales and earnings per share. We now expect constant dollar sales for the full year 2016 to come in 2% to 3% below prior year, and we expect non-GAAP earnings per share in between $3.43 and $3.50. These numbers imply we continue to make progress in China in the fourth quarter and gradually improve sales in other geographies. We expect that the recent volatility and changing market dynamics will continue to impact our business in the midterm.
As we look beyond the next quarter to 2017, we expect to see continued but only modest improvement in constant dollar sales and to EPS. Our Fuel for Growth program will continue to help fund growth initiatives and mitigate known headwinds.
I'll now hand the call over to Michel who'll provide additional details on our third quarter financial performance. After that, I'll return with a few summary remarks before we take your questions. Michel, over to you."
1002291,367328587,1064076,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Thank you, Kasper, and good morning, everyone. Today, I will discuss the company's third quarter and 9 months 2016 financial results. I will then briefly highlight cash flow and liquidity items and conclude with a summary of the full year guidance. My com",1764,"Thank you, Kasper, and good morning, everyone. Today, I will discuss the company's third quarter and 9 months 2016 financial results. I will then briefly highlight cash flow and liquidity items and conclude with a summary of the full year guidance. My comments about sales will refer to net sales, unless I explicitly state gross sales. References to currency impacts or the effects of currency fluctuations generally refer to the impact on the translation of local currency financial statement into U.S. dollars.
Kathy already covered Slide 2, so let me start with sales on Slide 3. Slide 3 shows the improving trend of net sales on a constant dollar basis when compared to prior year periods. As Kasper already indicated, excluding the impact of reduced shipments to Venezuela, the company's net sales were 1% above the prior year quarter. The adverse impact of Venezuela will be less in the fourth quarter of 2016 as we significantly slowed shipments in the fourth quarter of 2015. The negative impact of Venezuela on our net sales is over 1% on a constant dollar basis.
Turning to Slide 4. Gross sales reflects sales to customers before trade investment and other items, which are recorded as gross to net sales adjustments. For the third quarter, gross sales were 1% above the prior year quarter on a constant dollar basis. A significant portion of this quarter growth came from China. This is the first time our gross sales returned to positive growth since the first quarter of 2015.
Net sales on a reported basis were 4% below the prior year quarter and 8% below on a year-to-date basis. The adverse impact of foreign exchange on sales was 4%. The U.S. dollar continued to be strong, and the effect on the translation of local currencies negatively impacted all reporting segments.
On Slide 5, the third quarter EBIT of $244 million was 9% above the prior year quarter on a constant dollar basis. Foreign exchange adversely impacted EBIT by 7%. Including currency impacts, EBIT increased 2% on a reported basis in the third quarter. The third quarter EBIT margin of 26.1% of sales was 160 basis points better than the prior year quarter. With sales nearly in line with the prior year, the benefit of lower dairy cost rolled through for a positive gross profit.
We continue to make strong progress to reduce operating expenses as part of our Fuel for Growth program, which allows continued investments while improving the underlying profitability. Year-to-date EBIT was $719 million, and we delivered positive growth of 2% above the previous year period on a constant dollar basis. The EBIT margin of 25.3% of sales was 80 basis points better than the prior year period. Foreign exchange had an adverse impact of 8%. Despite macroeconomic and country-specific challenges, which negatively impacted our sales, we benefited from low dairy cost and made excellent progress on realizing Fuel for Growth savings.
I will now move to factors that impacted gross margin on Slide 6. Gross margin was 64.6% in the third quarter of 2016. Adverse foreign currency impacted gross margin by 150 basis points in the quarter. We continued to deliver nearly flat gross margin on a reported basis despite the significantly currency headwinds we had. On a constant dollar basis, the gross margin percentage improved 120 basis points. Price/mix and gross to net adjustment had a slightly negative impact on gross margin, mainly from higher trade investments. Low dairy was the largest benefit to gross margin in the third quarter of 2016.
Within cost of goods sold, productivity savings continued to be strong. Projects for the full year have been identified, and we expect savings to be above our earlier estimate of 3.5% of cost of goods sold. When you compare the 3 months and the 9 months charts, you can see the key drivers are the same. As this year progressed, the dairy benefit is lower as we lap towards the lowest 2015 dairy cost comparison. The adverse foreign currency impact on gross margin in the third quarter is higher, mainly due to hedges. With dairy secured for the full year and larger productivity savings, we expect full year gross margin to be up to 64.5%, better than our previous guidance of 64%.
Moving to operating expenses on Slide 7. The chart provides the combined spending of demand-generating investments, both as trade investment classified in gross to net sales adjustments and as advertising and promotion in operating expense category. The combined investments in the third quarter were above the prior year quarter. As a percentage of gross sales, the third quarter was similar to the second quarter as a result of increased investments to support our China strategy to become more competitive in the baby store and e-commerce channels with our Enfa imported and Enfinitas product lines.
Slide 8. We reduced our SG&A cost by 9% on a constant dollar basis in the third quarter of 2016 versus the previous year quarter and by 10% year-to-date compared to the prior year period. As a reminder, we delivered $20 million savings in the fourth quarter of 2015. So in the fourth quarter of 2016, the year-over-year percentage reduction is likely to be smaller.
As you can see on Slide 9, year-to-date, we have achieved nearly 85% of this year's target. We now expect to realize savings toward the higher end of the $75 million to $80 million target range. In the corporate and other functions, we reduced our cost by $50 million year-to-date compared to prior year period. This is 3/4 of the year-to-date savings.
Turning to Slide 10 for a discussion of EBIT. Positive price/mix was offset by volume decline in all segments. The positive price/mix was mainly driven by a mix benefit as a result of the rollout of imported premium products in China, new innovations in several markets as well as price increases in markets to partly compensate for currency devaluations. All segments benefited from lower dairy and cost -- and cost productivity.
EBIT in Asia was lower due to higher trade investments. Promotional activities and advertising, which resulted in lower EBITDA loss and margin percentage in the third quarter. Our EBIT in both Latin America and North America improved. For Latin America, this was due to lower advertising and promotion expenses when compared to the prior year when we had higher expenses related to product launches.
For North America/Europe, SG&A cost savings helped fund investments and drove higher EBIT margins. Lower corporate and other expenses were most notably attributable to Fuel for Growth savings.
I will now address the financial results from EBIT to EPS on Slide 11. The interest expense of $26 million in the third quarter was in line with 2016 run rate. When compared to the prior year quarter, interest expense increase reflects the impact of the November 2015 $1.5 billion notes issuance. A significant portion of the proceeds from the notes were used to finance the accelerated repurchase program, or the ASR. The benefit of the ASR is reflected in the third quarter 2016 share count. There was no significant share repurchase in the third quarter.
Non-GAAP effective tax rate, or ETR, was 26% for the third quarter of 2016 compared to 28.1% in the prior year quarter. In the third quarter of 2016, the ETR decrease was driven by tax credits from repatriation of foreign earnings, somewhat offset by change in allowances against tax assets. The prior year quarter was adversely impacted by an unfavorable geographic mix.
Non-GAAP EPS for the third quarter was $0.87, an increase of 9% on a reported basis and 16% on a constant dollar basis. Year-to-date, non-GAAP EPS was $2.63, a 1% decrease from the prior year on a reported basis and an increase of 7% on a constant dollar basis.
Let me summarize our financial results by addressing the change to EPS on Slide 12. In the third quarter, non-GAAP EPS increased $0.13 to $0.93 per share on a constant dollar basis versus the prior year quarter. Sales and related gross profit delivered a $0.03 benefit to EPS. The adverse impact of higher advertising and promotion was $0.04. Fuel for Growth savings delivered $0.07 benefit. The share repurchase programs delivered a $0.03 benefit, net of higher interest expense. And tax and other contributed a $0.03 benefit. Despite the negative impact of foreign exchange of $0.06 per share, EPS increased $0.07 versus third quarter last year on a non-GAAP basis.
Turning to a high-level overview of cash movements on Slide 13. The cash balance of $1.8 billion as of September 30 was $142 million higher than in the beginning of the year. Cash flow from operations was negatively impacted by operating working capital. Our year-to-date CapEx investments were $110 million, mainly in our U.S. and operating in Europe manufacturing facilities, along with ongoing quality and planned enhancements globally. For the full year, our capital spending goal remains at 4% of sales. Dividend payments were $232 million in the 9 months of 2016. The negative impact of foreign currency exchange of $33 million was mainly related to the currency devaluation in Venezuela.
To summarize our forward-looking annual guidance on Slide 14, our sales outlook for 2016 on a constant dollar basis is expected to be 2% to 3% below the prior year. With foreign currency reducing sales growth by about 4%, reported sales are estimated to be 6% to 7% below 2015. The 2016 GAAP EPS guidance is expected to be in the range of $2.80 to $2.87. And our non-GAAP guidance is $3.43 to $3.50 per share.
The guidance changed for the following reasons: sales on a constant currency basis may be lower due to the market share weakness in several markets, especially in the U.S., along with continued macroeconomic challenges in several emerging markets. Partially offsetting the sales impact, we expect gross margin to be up 64.5%, while Fuel for Growth savings is expected to be at the high end of the $75 million to $80 million range. And finally, the foreign exchange impact is expected to be approximately $0.30 per share from our previous guidance of $0.35 per share.
GAAP EPS guidance is likely to be impacted by potentially significant future mark-to-market pension adjustments, which cannot be estimated and are classified as specified items. Specified items include charges related to our Venezuela business, Fuel for Growth and year-to-date pension adjustments.
This concludes my discussion on the third quarter and 9 months 2016 financial results. Thank you again for your time this morning. I will now turn the call back to Kasper."
1002291,367328587,1064076,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Thank you, Michel. In today's prepared remarks, we've discussed both the positive news from China as well a number of headwinds we will continue to tackle as we move into next year.I want to acknowledge the difficulty we've had in accurately projecting",309,"Thank you, Michel. In today's prepared remarks, we've discussed both the positive news from China as well a number of headwinds we will continue to tackle as we move into next year.
I want to acknowledge the difficulty we've had in accurately projecting our top line trajectory over the past 18 months in what is perhaps the most uncertain environment I've seen in nearly 20 years in the industry. The global economy has been weaker than we'd expected, and we are facing a strong challenge in the United States.
But before we open the lines to your questions, I want to take you back 3 years. Three years ago, when it first became obvious that our trajectory in China was changing, many of you, I'm sure, had doubts we could successfully navigate our way through the adaptations we needed to make. Today, I feel very proud of the way our people embraced the challenge and worked hard on implementation. We certainly have much work left in China and elsewhere, but we also have many more opportunities from which we can benefit. We've taken the first important steps, and we're on our way forward.
As was the case when we discussed our challenges in China, I feel confident that we can overcome the current challenges in Southeast Asia and the United States. Our organizations have proven that they can adjust and reverse trajectories and focus on identified issues.
Overall, the shape of our recovery remains broadly as outlined at our Investor Day in October 2015. Yes, the rate of improvement has been slower than we'd hoped for, but we are doing the right thing in focusing on innovation and execution, and we're on a positive path.
I'll now hand the call back to the operator, Liz, and ask her to open the lines to your questions. Liz, back to you."
1002291,367328587,1064076,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Operator","[Operator Instructions] Your first question comes from Bryan Spillane with Bank of America.",13,"[Operator Instructions] Your first question comes from Bryan Spillane with Bank of America."
1002291,367328587,1064076,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","Just a question about -- you made a reference about the -- Kasper, about the adaptations you've had to make in China, which have been significant. Can you give us a sense, now that you've made that adaptation, has the rest of the market made that adaptati",123,"Just a question about -- you made a reference about the -- Kasper, about the adaptations you've had to make in China, which have been significant. Can you give us a sense, now that you've made that adaptation, has the rest of the market made that adaptation? Meaning, you now have fully imported product coming in -- multiple products that are fully imported coming into the market. It's given you more range in terms of the channels that you can now access with those products. And it's hard from, I guess, where we sit to see whether or not your competitors have done something similar or whether you're just ahead of kind of where the competition is in terms of making that change."
1002291,367328587,1064076,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Well, Bryan, firstly, I think -- let me be clear, I think we have made that change, and I feel good about the current product lineup that we've now got in China. It allows us to play much more effectively in the faster-growing channels, particularly the b",276,"Well, Bryan, firstly, I think -- let me be clear, I think we have made that change, and I feel good about the current product lineup that we've now got in China. It allows us to play much more effectively in the faster-growing channels, particularly the baby stores and the e-commerce channel. I think, in some cases, as I have acknowledged over the last couple of years, in some cases, we were slower than competitors to enter the super-high premium segment. So I mean, I'm very encouraged with the progress we are making in that business and how we are building share from month to month with quite substantial opportunities ahead of us to continue to grow, both through increased distribution and share gains. In other areas, I think we have probably been somewhat ahead of our competitors in focusing on the formal or company-organized e-commerce trade where some other competitors have relied quite heavily on kind of informal trade out of either Australia or Europe, which clearly is now being quite challenged by the changes to the regulatory environment, which I think we anticipated would happen. So our focus has always been on kind of the trade that -- the amount of the e-commerce trade that we feel we can control ourselves. And I referenced in my comments, prepared remarks that in that part of the e-commerce channel, our sales are up 60% on a year ago, which outstrips the growth of the channel in general. And I think I said that we had increased our share of that channel by just over 100 basis points.
So I think that answers your question. If not..."
1002291,367328587,1064076,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","Yes, it does. I think, just -- in summary, it's just you're in a much better competitive position now than you were before because you've moved further into really having a fully imported product supply chain than your competition [ph].",40,"Yes, it does. I think, just -- in summary, it's just you're in a much better competitive position now than you were before because you've moved further into really having a fully imported product supply chain than your competition [ph]."
1002291,367328587,1064076,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Yes, no doubt. I mean, in the third quarter, 60% of our sales in Mainland China were in our imported product lines.",22,"Yes, no doubt. I mean, in the third quarter, 60% of our sales in Mainland China were in our imported product lines."
1002291,367328587,1064076,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Operator","Your next question comes from Amit Sharma with BMO Capital Markets.",11,"Your next question comes from Amit Sharma with BMO Capital Markets."
1002291,367328587,1064076,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","Kasper, I just want to talk about U.S. a little bit. So clearly, disappointed with the market share performance there, and you talked about some of this is going to be just a timing issue. Can you go a little bit deeper into it? And like what's -- is it t",92,"Kasper, I just want to talk about U.S. a little bit. So clearly, disappointed with the market share performance there, and you talked about some of this is going to be just a timing issue. Can you go a little bit deeper into it? And like what's -- is it that you may have taken more pricing than the competitor? Or are you deliberately not exiting but maybe more strategic with some of the WIC contracts that you may have lost recently? Can you talk a little bit more about that, please?"
1002291,367328587,1064076,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Executives","No. I mean, I think, look, I take my hats off to at least one of our very strong competitors in the U.S. business. They've done a -- they've simply done a better job than we've done in the last 12 months or so. So we have to acknowledge -- when we're on t",268,"No. I mean, I think, look, I take my hats off to at least one of our very strong competitors in the U.S. business. They've done a -- they've simply done a better job than we've done in the last 12 months or so. So we have to acknowledge -- when we're on the receiving end of that, we believe that it's important we acknowledge that and not try to kind of sugarcoat it with you guys. There's -- there will continue to be, going forward, changes in WIC contracts. That's a natural part of the business cycle. So that's had some impact. But -- and I would say the rest of it has been mostly about execution both in a trade environment and on programs that are generally responsible for driving consumer starts to our brands. I think some of it -- in all honesty, some of it has been self-inflicted, which, in a way, I take some comfort from because that means we can fix it unilaterally. And I feel -- and I have really very little doubt that we can do that, but I understand that the category is ultimately a very sticky category as I mentioned in my prepared remarks. We have to regain our share of starts in the category, and we have to do that kind of one child at a time as they enter the category. So it's going to take time. It would be wrong and nave for me to say that we would expect some kind of v-shaped turnaround in market share. But I think we know what's wrong."
1002291,367328587,1064076,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Operator","Our next question comes from John Baumgartner, Wells Fargo.",9,"Our next question comes from John Baumgartner, Wells Fargo."
1002291,367328587,1064076,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","Kasper, I'd like to stay with the U.S. market because on the face of it, it seems like after a number of years during which Mead really dominated the innovation discussion for the category, that pendulum is kind of swinging back now towards your largest c",98,"Kasper, I'd like to stay with the U.S. market because on the face of it, it seems like after a number of years during which Mead really dominated the innovation discussion for the category, that pendulum is kind of swinging back now towards your largest competitor. So is that the right way to think about it? And if it is, can you provide any context to Mead's near-term innovation pipeline? And maybe just lastly, price/mix being up so strong in North America this quarter, how sustainable is that going forward given just the competitive pressures and share loss?"
1002291,367328587,1064076,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Executives","I think it's hard for me to speculate on price going forward. I mean, there's -- obviously, there's a fair amount of promotional activity, as there always is, in the U.S. market. And we fundamentally don't believe that at the margins, this category is dri",264,"I think it's hard for me to speculate on price going forward. I mean, there's -- obviously, there's a fair amount of promotional activity, as there always is, in the U.S. market. And we fundamentally don't believe that at the margins, this category is driven significantly by price. That said, there is a certain, what shall we say, range within which we can play. We typically play at a premium to our competitors in the U.S. I expect we'll continue to do that, but we'll stay relatively close to them. And we'll see how the dynamics evolve. You're asking about, John, our innovation cycle. I think we have a strong innovation program laid out going forward. It's clear that over the last 12, 18 months, we perhaps had not as strong a program that, at least, the evidence would suggest that. But I think it's more about kind of operational excellence on some of our more basic initiatives. We just let our standards slip a little bit. I suppose I don't want to go into too much detail on it, if you'll forgive me for that. But I think we have 2 or 3 things that we have clearly identified that we could and should have done better in the United States in the last 12 months or so, and we are clearly fixing them quickly. But it'll take some time for that to show up in market share given that the heavy consumption period that we see from children really is only about 4 to 5 months after they enter the category."
1002291,367328587,1064076,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Operator","Your next question comes from Jason English with Goldman Sachs.",10,"Your next question comes from Jason English with Goldman Sachs."
1002291,367328587,1064076,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","First, real quick, semantics. The comment about 2017, modest improvement to both underlying sales and earnings per share, is it wrong to interpret that improvement means growth? Or is there -- is the risk where we sit today that we don't have top and bott",50,"First, real quick, semantics. The comment about 2017, modest improvement to both underlying sales and earnings per share, is it wrong to interpret that improvement means growth? Or is there -- is the risk where we sit today that we don't have top and bottom line growth into next year?"
1002291,367328587,1064076,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Executives","I mean, we -- I think the words I used to describe our outlook for '17 was that we expected only modest improvement to both constant dollar sales and to EPS. That would clearly imply improvement would mean improvement. And therefore, it would imply a numb",52,"I mean, we -- I think the words I used to describe our outlook for '17 was that we expected only modest improvement to both constant dollar sales and to EPS. That would clearly imply improvement would mean improvement. And therefore, it would imply a number that was better than this year."
1002291,367328587,1064076,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","Yes, I wanted to make sure that was clear. It can be spun a couple of different ways. So I appreciate the clarification on that. And I was going to ask questions on the U.S., but surprisingly, we're getting quite a few on those today, so I'm going to pivo",155,"Yes, I wanted to make sure that was clear. It can be spun a couple of different ways. So I appreciate the clarification on that. And I was going to ask questions on the U.S., but surprisingly, we're getting quite a few on those today, so I'm going to pivot back to what I thought would be more crowded, and that's China. As we think about the forward on China, some of your competitors out there have flagged a risk of the market sort of being flooded with more product ahead of the January 2018 regulatory change. It's created some consternation that we have, that the pricing intensity, the competitive intensity gets worse before it gets better. And that gets worse at a time that we've got rising dairy cost inflation. Can you weigh in with your view on how you see that unfolding and what do you think the implications are for your business?"
1002291,367328587,1064076,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Yes. I mean, I don't think our view has significantly changed in the sense that at the consumer level, this is not a -- brand choice is not significantly influenced by price, and certainly not in the infant formula business; a little bit more price sensit",266,"Yes. I mean, I don't think our view has significantly changed in the sense that at the consumer level, this is not a -- brand choice is not significantly influenced by price, and certainly not in the infant formula business; a little bit more price sensitivity in the children segment. So I think the key dynamic that will be influenced by all of this price discounting that we are seeing right now, and that I suspect people are right in saying we'll continue to see through '17, it's mainly influencing retail dynamics; in other words, the amount of inventory that people are pushing into the retail channel. And I suspect that we are going to see a lot of people being caught with very big fluctuations in sales as they need to adjust for inventory swings at some point in the economic cycle. I think it will influence different companies at different times. I think, to some degree, already within this quarter, you've seen relatively big fluctuations in the financial results announced by many of the companies in the industry. We've sort of prided ourselves on trying to keep our inventory relatively tight at the retail level. And we feel we've got very good visibility on what it is, and we are happy with the level of inventory we have in the channels. Some -- there are some quarters when that hurts our relative competitive performance as you look at it versus others, and there are some quarters where it perhaps helps us. And I think this was a quarter where that approach clearly helped us."
1002291,367328587,1064076,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Operator","Your next question comes from the line of Ken Goldman with JPMorgan.",12,"Your next question comes from the line of Ken Goldman with JPMorgan."
1002291,367328587,1064076,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","Do you still see a 27% EBIT margin in 2018? Because if you're not getting much EBIT growth next year, you're going to need a huge 2018 to get there.",30,"Do you still see a 27% EBIT margin in 2018? Because if you're not getting much EBIT growth next year, you're going to need a huge 2018 to get there."
1002291,367328587,1064076,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Ken, let me address that question. Indeed, for 2017, we, indeed, expect a more flat EBIT margin on a constant dollar basis. We always said in the 3-year road map that we laid out that ultimately, we would like to deliver the 300 basis point improvement. B",127,"Ken, let me address that question. Indeed, for 2017, we, indeed, expect a more flat EBIT margin on a constant dollar basis. We always said in the 3-year road map that we laid out that ultimately, we would like to deliver the 300 basis point improvement. But like we said, for us, it's very important to position us very strongly for the future, make the right deliberate choices on investments that we need to make. Also in 2017, also in China, to position us very strongly, specifically in China, to take the opportunity on the developments that are happening there. So it might take some longer time before we will reach the 200 -- the 300 basis points EBIT margin that -- as we laid out earlier."
1002291,367328587,1064076,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","All right. Can I ask a quick follow-up, Kathy?",9,"All right. Can I ask a quick follow-up, Kathy?"
1002291,367328587,1064076,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Go right ahead.",3,"Go right ahead."
1002291,367328587,1064076,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","Along these lines, there are a lot of things in this call that I think are disappointing to some people, including me, and I realize there's a lot of exogenous macroeconomic headwinds you can't control. But you've lost market share in the Philippines. You",148,"Along these lines, there are a lot of things in this call that I think are disappointing to some people, including me, and I realize there's a lot of exogenous macroeconomic headwinds you can't control. But you've lost market share in the Philippines. You've lost market share in China, although, obviously, it's coming back a little bit now. You've lost market share in the U.S. Kasper, do you need to make a larger adjustment to the company's strategic mindset in terms of marketing? I mean, we've seen some successful tactical adjustments, right? Obviously, things have changed in China this past quarter. But it just feels like it can't continue forever to experience market share losses. And I'm just curious if there is anything in your mind that needs to change in a more dramatic way in terms of how you go to market or think about your strategy?"
1002291,367328587,1064076,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Executives","I think, Ken, the comment is well taken. As you might imagine, nobody is, what shall we say, more sensitive around us referencing market share losses than I am. And certainly, it's not what we want to see. Having said that, we have a portfolio that is hea",272,"I think, Ken, the comment is well taken. As you might imagine, nobody is, what shall we say, more sensitive around us referencing market share losses than I am. And certainly, it's not what we want to see. Having said that, we have a portfolio that is heavily exposed to, let's call it, 10 global businesses or 10 businesses around the world. It's inevitable that amongst those 10, you're going to have ups and downs. We've gained a lot of market share in Canada. We've gained a lot of market share in Europe. And I would argue, at the moment, we are gaining market share in China. Now unfortunately, if you have problems, market share-wise, and you have them in a couple of your really big markets, we both know that the U.S. and China, between the 2 of them, account for more than half our sales, our global sales. So it's very hard for us to offset any significant loss of market share in 1 of those 2 markets with performance in other markets. I'm certainly disappointed that we have not been able to proactively address some of these challenges as opposed to finding ourselves in the mode where we are, so to speak, reacting instead and adapting. I would obviously much rather be driving the change proactively. So your implied criticism is well taken. I don't think it's structural. I don't think it's related to, what shall we say, the way we do marketing or our marketing capabilities in general. But you might rightly imagine that a fair amount of soul searching is going on as a consequence of this."
1002291,367328587,1064076,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Operator","Your next question comes from Matthew Grainger with Morgan Stanley.",10,"Your next question comes from Matthew Grainger with Morgan Stanley."
1002291,367328587,1064076,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","I wanted to squeeze in 2 questions, but I'll ask them quickly. First, on North America, the northeast states WIC contracts, just hoping you could contextualize the size of that relative to some others that have had a material impact on your results such a",105,"I wanted to squeeze in 2 questions, but I'll ask them quickly. First, on North America, the northeast states WIC contracts, just hoping you could contextualize the size of that relative to some others that have had a material impact on your results such as Florida a few years ago and how material that is for 2017. And then in China, just on the market generally, curious for your latest thoughts on birth rates and whether you've seen any uptick in trend in recent months. Some of the feedback that we've gotten has suggested that there's been a bit more acceleration in birth rate trend."
1002291,367328587,1064076,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Let me address high level the contracts that are coming up, and we always were very transparent that there are a couple of significant contracts that were coming up for bid. One of them is California, and the other one that's coming up is Texas. We don't",121,"Let me address high level the contracts that are coming up, and we always were very transparent that there are a couple of significant contracts that were coming up for bid. One of them is California, and the other one that's coming up is Texas. We don't disclose, obviously, the details, what the magnitude of impact potentially could be. But we are very well aware about the importance of these contracts and the potential impact. We always try to have a strategy behind it that we always can find the right balance between other growth initiatives in the U.S. markets as well. So that has been taken into account as well when Kasper was talking about the outlook for next year."
1002291,367328587,1064076,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Executives","I want to maybe just -- Matt, let me try and put it in sort of a strategic context. I think the participation in WIC contracts is one of a number of important demand drivers that we have in the U.S. business. As such, we view it, to a certain extent, the",164,"I want to maybe just -- Matt, let me try and put it in sort of a strategic context. I think the participation in WIC contracts is one of a number of important demand drivers that we have in the U.S. business. As such, we view it, to a certain extent, the same way we view A&P. We look for an appropriate level of return on investment. And it's likely that as we look forward to 2017, there are a couple of important countries, in both of our 2 biggest markets, China and the U.S., we are planning increased investments in demand creation in both of those markets. In China, it will be important to support our growth momentum. And in the U.S., it will obviously be important in order to turn around the market share performance that we've just discussed. And that's -- what we've tried to do is sort of capture that all under this heading of increased investment in demand creation."
1002291,367328587,1064076,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Operator","[Operator Instructions]",2,"[Operator Instructions]"
1002291,367328587,1064076,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Operator, I had about 6 other people -- oh, they're coming back, I think, now on the list.",18,"Operator, I had about 6 other people -- oh, they're coming back, I think, now on the list."
1002291,367328587,1064076,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Operator","Your next question comes from the line of David Driscoll with Citibank.",12,"Your next question comes from the line of David Driscoll with Citibank."
1002291,367328587,1064076,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","And yes, I've been here the whole time, so thanks, Kathy. So like to just kind of line of logic here, the line of questioning is about cost savings. And there are a couple of ways that I want to say it, so give me -- just give me a second. On EPS, kind of",197,"And yes, I've been here the whole time, so thanks, Kathy. So like to just kind of line of logic here, the line of questioning is about cost savings. And there are a couple of ways that I want to say it, so give me -- just give me a second. On EPS, kind of why can't you protect EPS growth more given the size and scope of the cost savings? Just I'm just surprised, it's not helping it more and the 2017 comments, Kasper, are obviously, kind of disappointing because it doesn't really fit the 3-year trend, and I think you guys already pulled back on the 27% margin to Ken's question. And then just super specifically, are you going to step up this cost savings program again? And are you confident that all of this reinvestment is being well spent? Because it just feels like we're getting a very different answer from Mead Johnson versus the rest of the companies in the sector that are generating fairly massive cost savings that are showing up in earnings, but it's not really happening here. Would just love to hear your thoughts on what to make of it."
1002291,367328587,1064076,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Thanks, David. It's a great question, and obviously, one we had anticipated. And I think let's start by going back to Ken's -- to Ken Goldman's question about, so what should we expect in terms of EBIT accretion in 2017? And Michel's response that while w",339,"Thanks, David. It's a great question, and obviously, one we had anticipated. And I think let's start by going back to Ken's -- to Ken Goldman's question about, so what should we expect in terms of EBIT accretion in 2017? And Michel's response that while we don't see EBIT accretion as we look at 2017 and that, of course, is really reflective of the comments I made about our expectations for both sales and EPS growth. And implicitly in that is the fact that there won't -- there's very unlikely to be EBIT margin accretion. So the question is in the face of some fairly significant progress against cost saving initiatives, why is that? And it really relates into -- it relates simply to the fact that we believe that it is in the long-term interest of our shareholders to continue to drive strong growth in China, and that requires continued investment. You will understand implicitly that some of the important initiatives that we have implemented in China were launched only approximately halfway through the year, 2016. So we'll have a full year impact of that higher level of spend in 2017. And then we believe we need to make additional investments in turning around market share in the U.S., which we also believe is in the long-term interest of the business. I do want to say that on the topic of margin accretion, it is -- it's an objective that is subservient to our primary objective, which is to turn around the growth trajectory of the business. So that's important to understand. It's also important to understand that where you will see that significant margin accretion occur is at the point in time that our growth rate picks up from the sort of very modest level that we are currently discussing. We clearly, at that point in time, have put a cost structure in place that will allow the company to get a great amount of EBIT leverage on any kind of growth in sales.
Does that help?"
1002291,367328587,1064076,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","It does. Any comments about further improvements to the cost savings program given the stresses?",15,"It does. Any comments about further improvements to the cost savings program given the stresses?"
1002291,367328587,1064076,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Yes. I mean, we'll -- we have initiatives in place for '17. It'll remain a focus for the company going forward. I think we -- in the last call, I think we took our target up for this year. We indicated that we would move the needle from the previously ann",208,"Yes. I mean, we'll -- we have initiatives in place for '17. It'll remain a focus for the company going forward. I think we -- in the last call, I think we took our target up for this year. We indicated that we would move the needle from the previously announced $60 million to now somewhere between $75 million and $80 million in cost savings this year. I think we also -- I forget now exactly when we expanded our 3-year target from $120 million to $180 million. So we are clearly very focused on this particular objective. And I have to say that it's helping us greatly continue to fund a high level of investment. Your question about, well, is all of this investment well spent, is a great question. It's a question I ask our operators almost on a daily basis. And I'm quite sure that we can -- we will continue to identify small pockets of suboptimal expenditure, but we also have opportunities to spend more on things that we know will work for us. So it'll be a balancing act. Obviously, we will continue to look for efficiencies.
Great question, David. I -- we can talk more about it when we get together next."
1002291,367328587,1064076,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Operator","Your next question comes from the line of Robert Moskow with Crdit Suisse.",13,"Your next question comes from the line of Robert Moskow with Crdit Suisse."
1002291,367328587,1064076,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","I had a question about North American profits. Your profits are still looking like they're going to be up this year, and they're up substantially since 2014 in North America/Europe. But market share is weak, and you're talking about having to reinvest. So",102,"I had a question about North American profits. Your profits are still looking like they're going to be up this year, and they're up substantially since 2014 in North America/Europe. But market share is weak, and you're talking about having to reinvest. So is -- did you feel like North America did not get enough resources in terms of dollars this year? Or is it just the money was spent on the wrong things? And so what do you think is a more normalized margin for North America? We've gone from 23% to 30%. Where do you think it really should land?"
1002291,367328587,1064076,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Yes. Let me address that question in terms of EBIT margin. The increase of the EBIT margin in the U.S., we had a significant benefit from dairy, which gives a significant pressure on uplifting gross margin. So that's one area why we had an improved margin",191,"Yes. Let me address that question in terms of EBIT margin. The increase of the EBIT margin in the U.S., we had a significant benefit from dairy, which gives a significant pressure on uplifting gross margin. So that's one area why we had an improved margin. In general, we'll see, as a total company, more gross margin pressure also in '17 as a result of dairy prices where we see some slightly increases that are coming in. So that also will have an effect on our U.S. business as such. In addition, like Kasper just said, we made a deliberate choice to step up additional investment in the U.S. from a demand-generating investment point of view, whether that's through A&P or whether that's from gross to net initiatives, and WIC could be one of them as one of the demand-generating investments. So we will see some pressure on EBIT margin. I think we won't see a level that we have currently. But I also don't expect that it will go to the levels that we have seen historically. I would say that we would see a midpoint between those EBIT margins."
1002291,367328587,1064076,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","Michel, just a follow-up, then, for Kasper, what's your confidence that you have the pricing power in 2017 to offset higher input costs?",23,"Michel, just a follow-up, then, for Kasper, what's your confidence that you have the pricing power in 2017 to offset higher input costs?"
1002291,367328587,1064076,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Executives","I don't think we will fully offset input -- higher input costs. So I think it's implied in the words that I used in my prepared remarks, which I'm quite sure will be scrutinized by all of you. Implied in that is some contraction to gross margin. I should",209,"I don't think we will fully offset input -- higher input costs. So I think it's implied in the words that I used in my prepared remarks, which I'm quite sure will be scrutinized by all of you. Implied in that is some contraction to gross margin. I should put that in the context of the fact that our gross margin, supported by historically low dairy costs, have been well above historic norms over the last, I want to say, the last 18 to 24 months. So I think over time, we would expect to see gross margin come down to sort of normal levels. That's not all going to happen in 1 year. It's not all going to happen in '17. But we -- as we look at it now, we would expect some reduction in gross margin next year. We'll -- I'm sure we'll say more about it when we give a bit more detail and more formal guidance next time around in our next call. But we felt it was important to kind of help you develop your thinking for '17, that's why we are spending a little bit more time than we usually do talking about next year at this point of the cycle."
1002291,367328587,1064076,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Operator","Our next question comes from the line of Pablo Zuanic with SIG.",12,"Our next question comes from the line of Pablo Zuanic with SIG."
1002291,367328587,1064076,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","Just 2 quick questions. First, I mean, when I look at Abbott, and their Eleva product, I have to think that for an IMF business, inside of a pharmaceutical company, that they must have advantages over you in terms of their communication with doctors, and",211,"Just 2 quick questions. First, I mean, when I look at Abbott, and their Eleva product, I have to think that for an IMF business, inside of a pharmaceutical company, that they must have advantages over you in terms of their communication with doctors, and then people recommending IMF products. And then I look at Nestle, which obviously owns Wyeth with Illuma doing well, they are a much larger consumer company with much better distribution. So can you comment? Obviously, you've made significant changes and improvements in China, but can you comment whether you're at a disadvantage when you look at the Abbotts of the world and the Nestles. And the second one, very quickly, I know you gave us a lot of numbers in terms of the pieces of growth in China. But I don't know, maybe I missed it, but what was the growth year-on-year in China in your IMF business there, and if you can just compare that with what was the sell-through? I mean, my visits to baby stores show that you have very good displays for Enfinitas, Enfamil, great merchandising, window displays, and I'm just worried about the sell-through. What are we going to see in the fourth quarter? If you can comment on that, please."
1002291,367328587,1064076,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Thanks, Pablo. Let me address your question on competitiveness first, and then I'll talk about -- then I'll reiterate what I said earlier about inventory. I see absolutely no reason why we should not be able to compete with either of the 2 companies that",367,"Thanks, Pablo. Let me address your question on competitiveness first, and then I'll talk about -- then I'll reiterate what I said earlier about inventory. I see absolutely no reason why we should not be able to compete with either of the 2 companies that you mentioned in China. And indeed, we've done so successfully for many years. The China market is somewhat different from many of the other markets in the world that we compete in, in the sense that, frankly speaking, health care professional endorsement of your brand is far less influential in China than it is elsewhere in our -- in the world we operate in. So any potential disadvantage, which I'm not sure exists to begin with, vis--vis our U.S. competitor there, certainly is never being used as a reason for shortfalls by our local team in China and nor would it be accepted. You referenced our larger and more broad-based consumer products competitor, and I would only say to that, that again, the primary sales channel for these very high-priced products, high-quality products in China is really the baby store channel in China, and that's not a channel where your muscle and product range from other parts of the grocery industry can necessarily be leveraged very effectively. So again, I don't think we are at a significant disadvantage. Apart from what you would generally say is that obviously, we are a smaller company than either of those 2, and that means we can't leverage our cost base, our general infrastructure cost over a broader sales base. But despite that, it appears to me that we have got best-in-class EBIT margins. And I think we can maintain that while growing at the same time. On the inventory side in China, I just want to refer to what I said earlier. We are very comfortable with our inventory levels in the sales channels in China. We pride ourselves on not building up those inventories artificially from quarter-to-quarter. And hence, I don't expect, assuming that offtake develops the way we expect and anticipate, I don't expect that we're going to be seeing any changes to our sales trajectory that do not reflect underlying consumer demand."
1002291,367328587,1064076,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","But just a quick follow-up, I mean, I was surprised in Beijing at one show [ph], for example, at baby stores that I visited, are the displays of Enfinitas, a full shelf, are as big as the displays of the Enfa range. And I was just wondering, Enfinitas is",132,"But just a quick follow-up, I mean, I was surprised in Beijing at one show [ph], for example, at baby stores that I visited, are the displays of Enfinitas, a full shelf, are as big as the displays of the Enfa range. And I was just wondering, Enfinitas is clearly not half of your sales there. And it retails for around CNY 445 compared to Eleva and Illuma that are in the CNY 380, CNY 400 range. So I understand that the question about inventories was answered before. But I'm just wondering it sounds like you doubled your space at baby stores, at least when I look at Enfinitas versus Enfa, unless you lost Enfa space, and then you have a price point that's way above your competitors, Eleva and Illuma."
1002291,367328587,1064076,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Yes. I think you've visited a small selection of stores, and I -- in some ways, I wish it was -- what you saw was the case everywhere. Unfortunately, it isn't. But I think it's, joking aside, Pablo, it's a natural dynamic when you launch new brands that y",95,"Yes. I think you've visited a small selection of stores, and I -- in some ways, I wish it was -- what you saw was the case everywhere. Unfortunately, it isn't. But I think it's, joking aside, Pablo, it's a natural dynamic when you launch new brands that you have to build a certain amount of exposure for them. We are very comfortable that the sales trajectory that we are seeing grow week, week on week since launch on Enfinitas is supportive of the amount of inventory that we have sold into the retail channel."
1002291,367328587,1064076,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Operator","Our last question comes from the line of Steven Strycula with UBS.",12,"Our last question comes from the line of Steven Strycula with UBS."
1002291,367328587,1064076,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","Quick question for Kasper, and then a quick follow-up for Michel. So the question would be related to the China growth. It seems like you had a nice acceleration there in the third quarter. Just any help, Kasper, as you could kind of split apart what were",114,"Quick question for Kasper, and then a quick follow-up for Michel. So the question would be related to the China growth. It seems like you had a nice acceleration there in the third quarter. Just any help, Kasper, as you could kind of split apart what were like the baseline sales improvement and what was more of a bump from a little bit of a relief in the bottleneck that we were having in terms of shipments. And then conversely, how do -- how are trends outside of China trending? Were they down high single digits, and China was up high single digits, and we got to flat for Asia overall? That'd be helpful."
1002291,367328587,1064076,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Executives","I mean, you're broadly in the right territory with your last remark, Steve, but that's pretty close. And I would say that roughly 1/3 of the growth we saw in China in the third quarter we are attributing to, what shall we say, carryover of orders we could",81,"I mean, you're broadly in the right territory with your last remark, Steve, but that's pretty close. And I would say that roughly 1/3 of the growth we saw in China in the third quarter we are attributing to, what shall we say, carryover of orders we could not fulfill in the second quarter. That would still mean that, as I said, it would still mean that our growth was very healthy in the third quarter on an underlying demand basis."
1002291,367328587,1064076,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","Okay, that's very helpful. And then my last question for Michel would be, with respect to the 27% margin target for the out years, is any of, call it, the more tempered outlook a reflection of the business naturally rotating out of Hong Kong, which was yo",85,"Okay, that's very helpful. And then my last question for Michel would be, with respect to the 27% margin target for the out years, is any of, call it, the more tempered outlook a reflection of the business naturally rotating out of Hong Kong, which was your highest margin region, to an imported model from Europe? Is that -- anything to do as an explanatory fact? Or is there something else we should really be focusing on? Or just a lack of top line levers?"
1002291,367328587,1064076,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Executives","No, it is clearly the last one, the top line and the required investments that we would like to make also in 2017. That's the main reason.",27,"No, it is clearly the last one, the top line and the required investments that we would like to make also in 2017. That's the main reason."
1002291,367328587,1064076,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Thank you for everybody participating in Mead Johnson's earnings call today.Operator, I'll turn it over to you to close out the call. Thank you.",26,"Thank you for everybody participating in Mead Johnson's earnings call today.
Operator, I'll turn it over to you to close out the call. Thank you."
1002291,367328587,1064076,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Operator","This concludes the presentation. You may now disconnect. Everyone, have a good day.",13,"This concludes the presentation. You may now disconnect. Everyone, have a good day."
1002291,367328587,1064769,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Operator","Good day, ladies and gentlemen, and welcome to the Mead Johnson Nutrition Third Quarter 2016 Earnings Conference Call. My name is Liz, and I will be your coordinator for today. [Operator Instructions] As a reminder, this conference is being recorded for r",63,"Good day, ladies and gentlemen, and welcome to the Mead Johnson Nutrition Third Quarter 2016 Earnings Conference Call. My name is Liz, and I will be your coordinator for today. [Operator Instructions] As a reminder, this conference is being recorded for replay purposes.
I would now like to turn the conference call over to Kathy MacDonald, Vice President, Investor Relations. Please proceed, Kathy."
1002291,367328587,1064769,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Thank you, Liz. Good morning, and thank you for joining Mead Johnson's Third Quarter and 9 Months 2016 Conference Call. With me today are Kasper Jakobsen, our Chief Executive Officer; and Michel Cup, our Chief Financial Officer.Earlier today, we issued",345,"Thank you, Liz. Good morning, and thank you for joining Mead Johnson's Third Quarter and 9 Months 2016 Conference Call. With me today are Kasper Jakobsen, our Chief Executive Officer; and Michel Cup, our Chief Financial Officer.
Earlier today, we issued our 10-Q, earnings release and financial reference slides. If you have the slides in front of you, please turn to Slide #2.
A detailed explanation of our forward-looking statements appears in the slides, which are also posted on our website in connection with today's conference call. As we start, let me remind everyone that our comments will include forward-looking statements about our future results, including statements about our financial prospects and projections, commodity costs, currency fluctuations, pricing, taxes, capital spending, new product launches, other growth initiatives and market conditions that constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Keep in mind that our actual results may differ materially from expectations as of today due to various factors, including those listed in our annual report on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K. In each case, that's filed with or furnished to the Securities and Exchange Commission, and our earnings release issued this morning.
Today's comments will include discussion of non-GAAP financial measures. Unless otherwise noted, comments related to the income statement will be on a non-GAAP basis with the exception of advertising, promotion and interest expense. In addition, comments related to the balance sheet will be on a GAAP basis. A reconciliation of these measures to comparable GAAP measures appears in the morning's earnings release and financial reference slides, which are available at meadjohnson.com. In addition, any forward-looking statements represent our estimates only as of today and should not be relied upon as representing our estimates as of any subsequent date. While we may elect to update forward-looking statements at some point in the future, we specifically disclaim any obligation to do so, even if our estimates change.
I will now turn the call over to Kasper."
1002291,367328587,1064769,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Thank you, Kathy, and good morning to you all. Thank you for joining our earnings call. My comments will center on the general business climate, our strategy, our latest quarter top line performance and our outlook. Michel will then follow me by providing",2027,"Thank you, Kathy, and good morning to you all. Thank you for joining our earnings call. My comments will center on the general business climate, our strategy, our latest quarter top line performance and our outlook. Michel will then follow me by providing some additional and financial information, including comments on our cash flow related items.
I want to start today's discussion by revisiting our 3-year value creation plan. We laid out this plan at our Investor Day in October of 2015. And at that time, we explained how 2016 would be a year of transition.
We committed to 3 key metrics: a return to growth; a set of expense reductions; and a partial reinvestment of savings in growth initiatives and margin accretion. We said we'd measure our progress against these through the period. I've since revisited these metrics in every earnings call. So let me now briefly summarize our third quarter results in that context.
Firstly, in the third quarter, we delivered growth at the gross sales level of 1%. On a net sales basis, all 3 geographic segments delivered sales in line with prior year's quarter. This is an improvement over the previous 2 quarters. Excluding the effect of suspended shipments to Venezuela, net sales grew 1% in the third quarter over the prior year quarter.
Our second milestone relates to our targeted operating expense reductions. In our second quarter call, we revised our 2016 estimate from $60 million in reductions to $75 million to $80 million. Year-to-date, we've delivered $67 million in savings, and we've achieved approximately 85% of our annual target. SG&A expenses in the latest quarter were almost $20 million lower than a year earlier.
Our third milestone was to invest a portion of the expense savings to fund key growth initiatives while increasing our EBIT margin. Our investments have largely been supportive of our portfolio reshape and strategic channel shift in China. These initiatives are helping us report strong growth in China this quarter while simultaneously raising our EBIT margin.
Before I go into detail on our third quarter results, let me put these in context. The macroeconomic climate in North America and Europe appears stable. But in many emerging markets, we see consumers pressured by slowing economic growth. This applies broadly across Latin America and Asia and is consistent with what you have heard from other companies this earnings season.
Though my view of China, backed by recent economic data, is a little more positive than that of some others, there's little doubt that a pickup in economic activity in emerging markets will be linked to a recovery in demand for the exports in North America and Europe.
We also believe that the long-term category fundamentals are intact and remain supportive of our growth ambition. We believe that making the necessary and strategic investments now is critical to delivering on our 3-year road map of value creation.
Let me now expand on our third quarter results. For the third year running, we're experiencing foreign exchange headwinds. And for the second year in a row, economic challenges have combined with low dairy costs to produce a challenging pricing environment. Competitively, our results in the latest quarter were frankly mixed. We are facing a stiff challenge from competition in the United States. Conversely, we have good evidence that our China strategy is working. And there, we are strengthening our competitive position in growing channels. In aggregate, third quarter sales for the company were $938 million.
Currency adversely impacted our results by 4%. Constant dollar sales were in line with the third quarter of 2015, while reported sales were 4% lower than the prior year's quarter.
As I mentioned earlier, excluding the impact of our intentionally reduced business in Venezuela, the company's net sales grew 1% in constant dollars over prior year.
While volume was 5% unfavorable, we saw a fully offsetting benefit from price and product mix of 5%. This, despite continued competitive pressure and low dairy costs.
Gross margin was strong and remains above our historical average, and we continued to invest against our priority initiatives, including the establishment of Enfinitas in China.
Total investment in advertising and promotion represented 17.3% of net sales in the quarter.
Our Fuel for Growth cost reductions initiative drove significant savings in SG&A costs. Overall, these costs, on a reported basis, were down 12% in the third quarter compared to the same quarter of the prior year.
Our EBIT margin rose to 26.1% in the quarter as EBIT grew 9% in constant dollars.
Non-GAAP earnings per share for the quarter were $0.87 and similar to results in the proceeding 2 quarters.
I'll now discuss the performance of each of our reporting segments, beginning with our North America and Europe segment. Overall, results in this segment were mixed in the quarter. Market share gains in Canada and Europe resulting in strong sales growth there offset a disappointing quarter for our U.S. business. Net sales in the segment were in line with the third quarter of 2015 on a constant dollar basis. In aggregate, the segment benefited from a 5% pricing benefit, but this was fully offset by lower volumes in the United States. And foreign exchange adversely impacted sales for this segment by 1%.
Competitive pressure -- competitive activity put pressure on market share and resulted in a disappointing sales performance in our U.S. business. While we are actively addressing these challenges, we recognize that category dynamics are such that it'll take time to stabilize and recover lost market share.
I'm conscious that we've been referencing weakness in U.S. market share for a few quarters now. Unfortunately, we know the category is quite sticky, and to gain new consumers take time. We have a concrete action plan in place, but we must expect share to remain relatively weak through the next couple of quarters.
In the rest of the segment, I'm pleased with our progress. And we reported our highest market share in many years in Canada, as both Canada and Europe grew strongly in the quarter.
The Canadian business experienced strong growth in both its core infant formula business and the toddler category. And European sales of our energy products continued to grow on the back of a strengthened competitive position in a growing segment.
Let me now turn to Latin America. Segment performance continues to be heavily impacted by the suspension of sales to Venezuela. These shipments all but ceased at the end of 2015. Excluding this impact, sales in Latin America grew 5% in constant dollars over the same quarter of 2015. However, including the impact of Venezuela, constant dollar sales for the region were in line with the prior year's quarter. Pricing benefits of 10% did not fully offset foreign exchange impacts of negative 13%. And given the weakness in so many of the region's economies, we saw volume lower by 10%. Excluding Venezuela, volume was unfavorable by 5%.
With regard to Venezuela, there's been no significant change in circumstances. This situation will again negatively impact results in the coming quarter. But after that, the distorting effect should be negligible.
In Mexico, our infant and children's businesses delivered growth, and trends in other parts of Latin America remained broadly unchanged from the prior quarter. In much of South America, economic fundamentals remained weak, and we are seeing this reflected in consumer demand. Colombia and Peru provide isolated spots of relative economic stability.
I turn now to the Asia segment. Constant dollar sales in Asia were in line with the third quarter of 2015. Despite increased trade investments, price was favorable compared to the prior year quarter. Price increases in Southeast Asia, along with positive product mix in China, resulted in a 4% improvement in price within the segment. Volume was unfavorable by 4% driven by market share weakness and adjustment to channel inventories in the Philippines. Again, we have implemented a solid remediation plan there, and it's beginning to work. That said, it will take time to rebuild market share. And in the meantime, we've had to reduce channel inventory.
In Asia, price inflation remains low in a historical context.
I'll complete my discussion of our Asia segment with a few comments on China. In a sentence, our strategy to reshape our portfolio and strengthen performance in high-growth channels is working. Despite the decline in Hong Kong, sales within our greater China business grew strongly in the latest quarter. We saw improvements in both volume and product mix. Higher-priced new products are replacing sales of legacy lines. Consumers continue to adopt our fully imported product lines of Enfamil and Enfinitas at rapid rates, more than offsetting slowing demand for our locally manufactured products and shrinking exports from Hong Kong. Like many of our competitors, we are seeing the rapid shift in sales channels continue. But with the reshaped product portfolio, we've been able to adapt to this.
A few facts may help illustrate my point and put our results in context. The mainland supermarket channel declined double digits in the quarter. Our sales through our Hong Kong channel continued to decline and was down double digits within the quarter, but our sales into baby stores in Mainland China were up more than 20% on a year earlier. And our e-commerce sales were up more than 60%.
Our market share of company-controlled e-commerce channels increased by a full percentage point over prior year. And our recently launched imported product lines continue to grow market share each month. Imported products now account for 60% of total sales in Mainland China, up from 45% in March.
I think you can understand from this exactly how dynamic the trade environment is and how critical agility and flexibility are as core elements of our China strategy.
In conclusion, let me mention that our third quarter sales did benefit from replenishment of orders we were able -- we were unable to fulfill in the prior quarter due to tightened import processes. You'll remember that I mentioned this in our last call. However, underlying growth, excluding this benefit, was nevertheless healthy in China. China's results this quarter reflect the strategy we put in place 2 to 3 years ago to increase flexibilities through a broader product portfolio, sold through a more diverse set of channels.
This quarter, you can see that our strong organization and infrastructure in China has the ability to flex and adapt when challenged. Much work remains to be done, but I feel good about the latest quarter. I've deliberately not devoted any time to a description of our year-to-date sales. Though we've clearly hoped for a faster rebound in sales, we've seen a gradual, progressive improvement in our growth rate from quarter-to-quarter.
I now want to transition to talk about our global outlook for the balance of the year and beyond. While we saw strong growth in China, it's become clear that any sustained recovery in the broader emerging markets will take longer to occur than expected earlier. Additionally, market share losses in the Philippines and the United States are weighing on our current performance, and we do not expect to see these losses reversed until well into 2017.
In recognition of these challenges, we are revising our expectations for both sales and earnings per share. We now expect constant dollar sales for the full year 2016 to come in 2% to 3% below prior year, and we expect non-GAAP earnings per share in between $3.43 and $3.50. These numbers imply we continue to make progress in China in the fourth quarter and gradually improve sales in other geographies. We expect that the recent volatility and changing market dynamics will continue to impact our business in the midterm.
As we look beyond the next quarter to 2017, we expect to see continued but only modest improvement in constant dollar sales and to EPS. Our Fuel for Growth program will continue to help fund growth initiatives and mitigate known headwinds.
I'll now hand the call over to Michel who'll provide additional details on our third quarter financial performance. After that, I'll return with a few summary remarks before we take your questions. Michel, over to you."
1002291,367328587,1064769,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Thank you, Kasper, and good morning, everyone. Today, I will discuss the company's third quarter and 9 months 2016 financial results. I will then briefly highlight cash flow and liquidity items and conclude with a summary of the full year guidance. My com",1764,"Thank you, Kasper, and good morning, everyone. Today, I will discuss the company's third quarter and 9 months 2016 financial results. I will then briefly highlight cash flow and liquidity items and conclude with a summary of the full year guidance. My comments about sales will refer to net sales, unless I explicitly state gross sales. References to currency impacts or the effects of currency fluctuations generally refer to the impact on the translation of local currency financial statement into U.S. dollars.
Kathy already covered Slide 2, so let me start with sales on Slide 3. Slide 3 shows the improving trend of net sales on a constant dollar basis when compared to prior year periods. As Kasper already indicated, excluding the impact of reduced shipments to Venezuela, the company's net sales were 1% above the prior year quarter. The adverse impact of Venezuela will be less in the fourth quarter of 2016 as we significantly slowed shipments in the fourth quarter of 2015. The negative impact of Venezuela on our net sales is over 1% on a constant dollar basis.
Turning to Slide 4. Gross sales reflects sales to customers before trade investment and other items, which are recorded as gross to net sales adjustments. For the third quarter, gross sales were 1% above the prior year quarter on a constant dollar basis. A significant portion of this quarter growth came from China. This is the first time our gross sales returned to positive growth since the first quarter of 2015.
Net sales on a reported basis were 4% below the prior year quarter and 8% below on a year-to-date basis. The adverse impact of foreign exchange on sales was 4%. The U.S. dollar continued to be strong, and the effect on the translation of local currencies negatively impacted all reporting segments.
On Slide 5, the third quarter EBIT of $244 million was 9% above the prior year quarter on a constant dollar basis. Foreign exchange adversely impacted EBIT by 7%. Including currency impacts, EBIT increased 2% on a reported basis in the third quarter. The third quarter EBIT margin of 26.1% of sales was 160 basis points better than the prior year quarter. With sales nearly in line with the prior year, the benefit of lower dairy cost rolled through for a positive gross profit.
We continue to make strong progress to reduce operating expenses as part of our Fuel for Growth program, which allows continued investments while improving the underlying profitability. Year-to-date EBIT was $719 million, and we delivered positive growth of 2% above the previous year period on a constant dollar basis. The EBIT margin of 25.3% of sales was 80 basis points better than the prior year period. Foreign exchange had an adverse impact of 8%. Despite macroeconomic and country-specific challenges, which negatively impacted our sales, we benefited from low dairy cost and made excellent progress on realizing Fuel for Growth savings.
I will now move to factors that impacted gross margin on Slide 6. Gross margin was 64.6% in the third quarter of 2016. Adverse foreign currency impacted gross margin by 150 basis points in the quarter. We continued to deliver nearly flat gross margin on a reported basis despite the significantly currency headwinds we had. On a constant dollar basis, the gross margin percentage improved 120 basis points. Price/mix and gross to net adjustment had a slightly negative impact on gross margin, mainly from higher trade investments. Low dairy was the largest benefit to gross margin in the third quarter of 2016.
Within cost of goods sold, productivity savings continued to be strong. Projects for the full year have been identified, and we expect savings to be above our earlier estimate of 3.5% of cost of goods sold. When you compare the 3 months and the 9 months charts, you can see the key drivers are the same. As this year progressed, the dairy benefit is lower as we lap towards the lowest 2015 dairy cost comparison. The adverse foreign currency impact on gross margin in the third quarter is higher, mainly due to hedges. With dairy secured for the full year and larger productivity savings, we expect full year gross margin to be up to 64.5%, better than our previous guidance of 64%.
Moving to operating expenses on Slide 7. The chart provides the combined spending of demand-generating investments, both as trade investment classified in gross to net sales adjustments and as advertising and promotion in operating expense category. The combined investments in the third quarter were above the prior year quarter. As a percentage of gross sales, the third quarter was similar to the second quarter as a result of increased investments to support our China strategy to become more competitive in the baby store and e-commerce channels with our Enfa imported and Enfinitas product lines.
Slide 8. We reduced our SG&A cost by 9% on a constant dollar basis in the third quarter of 2016 versus the previous year quarter and by 10% year-to-date compared to the prior year period. As a reminder, we delivered $20 million savings in the fourth quarter of 2015. So in the fourth quarter of 2016, the year-over-year percentage reduction is likely to be smaller.
As you can see on Slide 9, year-to-date, we have achieved nearly 85% of this year's target. We now expect to realize savings toward the higher end of the $75 million to $80 million target range. In the corporate and other functions, we reduced our cost by $50 million year-to-date compared to prior year period. This is 3/4 of the year-to-date savings.
Turning to Slide 10 for a discussion of EBIT. Positive price/mix was offset by volume decline in all segments. The positive price/mix was mainly driven by a mix benefit as a result of the rollout of imported premium products in China, new innovations in several markets as well as price increases in markets to partly compensate for currency devaluations. All segments benefited from lower dairy and cost -- and cost productivity.
EBIT in Asia was lower due to higher trade investments. Promotional activities and advertising, which resulted in lower EBITDA loss and margin percentage in the third quarter. Our EBIT in both Latin America and North America improved. For Latin America, this was due to lower advertising and promotion expenses when compared to the prior year when we had higher expenses related to product launches.
For North America/Europe, SG&A cost savings helped fund investments and drove higher EBIT margins. Lower corporate and other expenses were most notably attributable to Fuel for Growth savings.
I will now address the financial results from EBIT to EPS on Slide 11. The interest expense of $26 million in the third quarter was in line with 2016 run rate. When compared to the prior year quarter, interest expense increase reflects the impact of the November 2015 $1.5 billion notes issuance. A significant portion of the proceeds from the notes were used to finance the accelerated repurchase program, or the ASR. The benefit of the ASR is reflected in the third quarter 2016 share count. There was no significant share repurchase in the third quarter.
Non-GAAP effective tax rate, or ETR, was 26% for the third quarter of 2016 compared to 28.1% in the prior year quarter. In the third quarter of 2016, the ETR decrease was driven by tax credits from repatriation of foreign earnings, somewhat offset by change in allowances against tax assets. The prior year quarter was adversely impacted by an unfavorable geographic mix.
Non-GAAP EPS for the third quarter was $0.87, an increase of 9% on a reported basis and 16% on a constant dollar basis. Year-to-date, non-GAAP EPS was $2.63, a 1% decrease from the prior year on a reported basis and an increase of 7% on a constant dollar basis.
Let me summarize our financial results by addressing the change to EPS on Slide 12. In the third quarter, non-GAAP EPS increased $0.13 to $0.93 per share on a constant dollar basis versus the prior year quarter. Sales and related gross profit delivered a $0.03 benefit to EPS. The adverse impact of higher advertising and promotion was $0.04. Fuel for Growth savings delivered $0.07 benefit. The share repurchase programs delivered a $0.03 benefit, net of higher interest expense. And tax and other contributed a $0.03 benefit. Despite the negative impact of foreign exchange of $0.06 per share, EPS increased $0.07 versus third quarter last year on a non-GAAP basis.
Turning to a high-level overview of cash movements on Slide 13. The cash balance of $1.8 billion as of September 30 was $142 million higher than in the beginning of the year. Cash flow from operations was negatively impacted by operating working capital. Our year-to-date CapEx investments were $110 million, mainly in our U.S. and operating in Europe manufacturing facilities, along with ongoing quality and planned enhancements globally. For the full year, our capital spending goal remains at 4% of sales. Dividend payments were $232 million in the 9 months of 2016. The negative impact of foreign currency exchange of $33 million was mainly related to the currency devaluation in Venezuela.
To summarize our forward-looking annual guidance on Slide 14, our sales outlook for 2016 on a constant dollar basis is expected to be 2% to 3% below the prior year. With foreign currency reducing sales growth by about 4%, reported sales are estimated to be 6% to 7% below 2015. The 2016 GAAP EPS guidance is expected to be in the range of $2.80 to $2.87. And our non-GAAP guidance is $3.43 to $3.50 per share.
The guidance changed for the following reasons: sales on a constant currency basis may be lower due to the market share weakness in several markets, especially in the U.S., along with continued macroeconomic challenges in several emerging markets. Partially offsetting the sales impact, we expect gross margin to be up 64.5%, while Fuel for Growth savings is expected to be at the high end of the $75 million to $80 million range. And finally, the foreign exchange impact is expected to be approximately $0.30 per share from our previous guidance of $0.35 per share.
GAAP EPS guidance is likely to be impacted by potentially significant future mark-to-market pension adjustments, which cannot be estimated and are classified as specified items. Specified items include charges related to our Venezuela business, Fuel for Growth and year-to-date pension adjustments.
This concludes my discussion on the third quarter and 9 months 2016 financial results. Thank you again for your time this morning. I will now turn the call back to Kasper."
1002291,367328587,1064769,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Thank you, Michel. In today's prepared remarks, we've discussed both the positive news from China as well a number of headwinds we will continue to tackle as we move into next year.I want to acknowledge the difficulty we've had in accurately projecting",309,"Thank you, Michel. In today's prepared remarks, we've discussed both the positive news from China as well a number of headwinds we will continue to tackle as we move into next year.
I want to acknowledge the difficulty we've had in accurately projecting our top line trajectory over the past 18 months in what is perhaps the most uncertain environment I've seen in nearly 20 years in the industry. The global economy has been weaker than we'd expected, and we are facing a strong challenge in the United States.
But before we open the lines to your questions, I want to take you back 3 years. Three years ago, when it first became obvious that our trajectory in China was changing, many of you, I'm sure, had doubts we could successfully navigate our way through the adaptations we needed to make. Today, I feel very proud of the way our people embraced the challenge and worked hard on implementation. We certainly have much work left in China and elsewhere, but we also have many more opportunities from which we can benefit. We've taken the first important steps, and we're on our way forward.
As was the case when we discussed our challenges in China, I feel confident that we can overcome the current challenges in Southeast Asia and the United States. Our organizations have proven that they can adjust and reverse trajectories and focus on identified issues.
Overall, the shape of our recovery remains broadly as outlined at our Investor Day in October 2015. Yes, the rate of improvement has been slower than we'd hoped for, but we are doing the right thing in focusing on innovation and execution, and we're on a positive path.
I'll now hand the call back to the operator, Liz, and ask her to open the lines to your questions. Liz, back to you."
1002291,367328587,1064769,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Operator","[Operator Instructions] Your first question comes from Bryan Spillane with Bank of America.",13,"[Operator Instructions] Your first question comes from Bryan Spillane with Bank of America."
1002291,367328587,1064769,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","Just a question about -- you made a reference about the -- Kasper, about the adaptations you've had to make in China, which have been significant. Can you give us a sense, now that you've made that adaptation, has the rest of the market made that adaptati",123,"Just a question about -- you made a reference about the -- Kasper, about the adaptations you've had to make in China, which have been significant. Can you give us a sense, now that you've made that adaptation, has the rest of the market made that adaptation? Meaning, you now have fully imported product coming in -- multiple products that are fully imported coming into the market. It's given you more range in terms of the channels that you can now access with those products. And it's hard from, I guess, where we sit to see whether or not your competitors have done something similar or whether you're just ahead of kind of where the competition is in terms of making that change."
1002291,367328587,1064769,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Well, Bryan, firstly, I think -- let me be clear, I think we have made that change, and I feel good about the current product lineup that we've now got in China. It allows us to play much more effectively in the faster-growing channels, particularly the b",276,"Well, Bryan, firstly, I think -- let me be clear, I think we have made that change, and I feel good about the current product lineup that we've now got in China. It allows us to play much more effectively in the faster-growing channels, particularly the baby stores and the e-commerce channel. I think, in some cases, as I have acknowledged over the last couple of years, in some cases, we were slower than competitors to enter the super-high premium segment. So I mean, I'm very encouraged with the progress we are making in that business and how we are building share from month to month with quite substantial opportunities ahead of us to continue to grow, both through increased distribution and share gains. In other areas, I think we have probably been somewhat ahead of our competitors in focusing on the formal or company-organized e-commerce trade where some other competitors have relied quite heavily on kind of informal trade out of either Australia or Europe, which clearly is now being quite challenged by the changes to the regulatory environment, which I think we anticipated would happen. So our focus has always been on kind of the trade that -- the amount of the e-commerce trade that we feel we can control ourselves. And I referenced in my comments, prepared remarks that in that part of the e-commerce channel, our sales are up 60% on a year ago, which outstrips the growth of the channel in general. And I think I said that we had increased our share of that channel by just over 100 basis points.
So I think that answers your question. If not..."
1002291,367328587,1064769,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","Yes, it does. I think, just -- in summary, it's just you're in a much better competitive position now than you were before because you've moved further into really having a fully imported product supply chain than your competition [ph].",40,"Yes, it does. I think, just -- in summary, it's just you're in a much better competitive position now than you were before because you've moved further into really having a fully imported product supply chain than your competition [ph]."
1002291,367328587,1064769,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Yes, no doubt. I mean, in the third quarter, 60% of our sales in Mainland China were in our imported product lines.",22,"Yes, no doubt. I mean, in the third quarter, 60% of our sales in Mainland China were in our imported product lines."
1002291,367328587,1064769,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Operator","Your next question comes from Amit Sharma with BMO Capital Markets.",11,"Your next question comes from Amit Sharma with BMO Capital Markets."
1002291,367328587,1064769,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","Kasper, I just want to talk about U.S. a little bit. So clearly, disappointed with the market share performance there, and you talked about some of this is going to be just a timing issue. Can you go a little bit deeper into it? And like what's -- is it t",92,"Kasper, I just want to talk about U.S. a little bit. So clearly, disappointed with the market share performance there, and you talked about some of this is going to be just a timing issue. Can you go a little bit deeper into it? And like what's -- is it that you may have taken more pricing than the competitor? Or are you deliberately not exiting but maybe more strategic with some of the WIC contracts that you may have lost recently? Can you talk a little bit more about that, please?"
1002291,367328587,1064769,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Executives","No. I mean, I think, look, I take my hats off to at least one of our very strong competitors in the U.S. business. They've done a -- they've simply done a better job than we've done in the last 12 months or so. So we have to acknowledge -- when we're on t",268,"No. I mean, I think, look, I take my hats off to at least one of our very strong competitors in the U.S. business. They've done a -- they've simply done a better job than we've done in the last 12 months or so. So we have to acknowledge -- when we're on the receiving end of that, we believe that it's important we acknowledge that and not try to kind of sugarcoat it with you guys. There's -- there will continue to be, going forward, changes in WIC contracts. That's a natural part of the business cycle. So that's had some impact. But -- and I would say the rest of it has been mostly about execution both in a trade environment and on programs that are generally responsible for driving consumer starts to our brands. I think some of it -- in all honesty, some of it has been self-inflicted, which, in a way, I take some comfort from because that means we can fix it unilaterally. And I feel -- and I have really very little doubt that we can do that, but I understand that the category is ultimately a very sticky category as I mentioned in my prepared remarks. We have to regain our share of starts in the category, and we have to do that kind of one child at a time as they enter the category. So it's going to take time. It would be wrong and nave for me to say that we would expect some kind of v-shaped turnaround in market share. But I think we know what's wrong."
1002291,367328587,1064769,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Operator","Our next question comes from John Baumgartner, Wells Fargo.",9,"Our next question comes from John Baumgartner, Wells Fargo."
1002291,367328587,1064769,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","Kasper, I'd like to stay with the U.S. market because on the face of it, it seems like after a number of years during which Mead really dominated the innovation discussion for the category, that pendulum is kind of swinging back now towards your largest c",98,"Kasper, I'd like to stay with the U.S. market because on the face of it, it seems like after a number of years during which Mead really dominated the innovation discussion for the category, that pendulum is kind of swinging back now towards your largest competitor. So is that the right way to think about it? And if it is, can you provide any context to Mead's near-term innovation pipeline? And maybe just lastly, price/mix being up so strong in North America this quarter, how sustainable is that going forward given just the competitive pressures and share loss?"
1002291,367328587,1064769,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Executives","I think it's hard for me to speculate on price going forward. I mean, there's -- obviously, there's a fair amount of promotional activity, as there always is, in the U.S. market. And we fundamentally don't believe that at the margins, this category is dri",264,"I think it's hard for me to speculate on price going forward. I mean, there's -- obviously, there's a fair amount of promotional activity, as there always is, in the U.S. market. And we fundamentally don't believe that at the margins, this category is driven significantly by price. That said, there is a certain, what shall we say, range within which we can play. We typically play at a premium to our competitors in the U.S. I expect we'll continue to do that, but we'll stay relatively close to them. And we'll see how the dynamics evolve. You're asking about, John, our innovation cycle. I think we have a strong innovation program laid out going forward. It's clear that over the last 12, 18 months, we perhaps had not as strong a program that, at least, the evidence would suggest that. But I think it's more about kind of operational excellence on some of our more basic initiatives. We just let our standards slip a little bit. I suppose I don't want to go into too much detail on it, if you'll forgive me for that. But I think we have 2 or 3 things that we have clearly identified that we could and should have done better in the United States in the last 12 months or so, and we are clearly fixing them quickly. But it'll take some time for that to show up in market share given that the heavy consumption period that we see from children really is only about 4 to 5 months after they enter the category."
1002291,367328587,1064769,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Operator","Your next question comes from Jason English with Goldman Sachs.",10,"Your next question comes from Jason English with Goldman Sachs."
1002291,367328587,1064769,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","First, real quick, semantics. The comment about 2017, modest improvement to both underlying sales and earnings per share, is it wrong to interpret that improvement means growth? Or is there -- is the risk where we sit today that we don't have top and bott",50,"First, real quick, semantics. The comment about 2017, modest improvement to both underlying sales and earnings per share, is it wrong to interpret that improvement means growth? Or is there -- is the risk where we sit today that we don't have top and bottom line growth into next year?"
1002291,367328587,1064769,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Executives","I mean, we -- I think the words I used to describe our outlook for '17 was that we expected only modest improvement to both constant dollar sales and to EPS. That would clearly imply improvement would mean improvement. And therefore, it would imply a numb",52,"I mean, we -- I think the words I used to describe our outlook for '17 was that we expected only modest improvement to both constant dollar sales and to EPS. That would clearly imply improvement would mean improvement. And therefore, it would imply a number that was better than this year."
1002291,367328587,1064769,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","Yes, I wanted to make sure that was clear. It can be spun a couple of different ways. So I appreciate the clarification on that. And I was going to ask questions on the U.S., but surprisingly, we're getting quite a few on those today, so I'm going to pivo",155,"Yes, I wanted to make sure that was clear. It can be spun a couple of different ways. So I appreciate the clarification on that. And I was going to ask questions on the U.S., but surprisingly, we're getting quite a few on those today, so I'm going to pivot back to what I thought would be more crowded, and that's China. As we think about the forward on China, some of your competitors out there have flagged a risk of the market sort of being flooded with more product ahead of the January 2018 regulatory change. It's created some consternation that we have, that the pricing intensity, the competitive intensity gets worse before it gets better. And that gets worse at a time that we've got rising dairy cost inflation. Can you weigh in with your view on how you see that unfolding and what do you think the implications are for your business?"
1002291,367328587,1064769,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Yes. I mean, I don't think our view has significantly changed in the sense that at the consumer level, this is not a -- brand choice is not significantly influenced by price, and certainly not in the infant formula business; a little bit more price sensit",266,"Yes. I mean, I don't think our view has significantly changed in the sense that at the consumer level, this is not a -- brand choice is not significantly influenced by price, and certainly not in the infant formula business; a little bit more price sensitivity in the children segment. So I think the key dynamic that will be influenced by all of this price discounting that we are seeing right now, and that I suspect people are right in saying we'll continue to see through '17, it's mainly influencing retail dynamics; in other words, the amount of inventory that people are pushing into the retail channel. And I suspect that we are going to see a lot of people being caught with very big fluctuations in sales as they need to adjust for inventory swings at some point in the economic cycle. I think it will influence different companies at different times. I think, to some degree, already within this quarter, you've seen relatively big fluctuations in the financial results announced by many of the companies in the industry. We've sort of prided ourselves on trying to keep our inventory relatively tight at the retail level. And we feel we've got very good visibility on what it is, and we are happy with the level of inventory we have in the channels. Some -- there are some quarters when that hurts our relative competitive performance as you look at it versus others, and there are some quarters where it perhaps helps us. And I think this was a quarter where that approach clearly helped us."
1002291,367328587,1064769,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Operator","Your next question comes from the line of Ken Goldman with JPMorgan.",12,"Your next question comes from the line of Ken Goldman with JPMorgan."
1002291,367328587,1064769,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","Do you still see a 27% EBIT margin in 2018? Because if you're not getting much EBIT growth next year, you're going to need a huge 2018 to get there.",30,"Do you still see a 27% EBIT margin in 2018? Because if you're not getting much EBIT growth next year, you're going to need a huge 2018 to get there."
1002291,367328587,1064769,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Ken, let me address that question. Indeed, for 2017, we, indeed, expect a more flat EBIT margin on a constant dollar basis. We always said in the 3-year road map that we laid out that ultimately, we would like to deliver the 300 basis point improvement. B",127,"Ken, let me address that question. Indeed, for 2017, we, indeed, expect a more flat EBIT margin on a constant dollar basis. We always said in the 3-year road map that we laid out that ultimately, we would like to deliver the 300 basis point improvement. But like we said, for us, it's very important to position us very strongly for the future, make the right deliberate choices on investments that we need to make. Also in 2017, also in China, to position us very strongly, specifically in China, to take the opportunity on the developments that are happening there. So it might take some longer time before we will reach the 200 -- the 300 basis points EBIT margin that -- as we laid out earlier."
1002291,367328587,1064769,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","All right. Can I ask a quick follow-up, Kathy?",9,"All right. Can I ask a quick follow-up, Kathy?"
1002291,367328587,1064769,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Go right ahead.",3,"Go right ahead."
1002291,367328587,1064769,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","Along these lines, there are a lot of things in this call that I think are disappointing to some people, including me, and I realize there's a lot of exogenous macroeconomic headwinds you can't control. But you've lost market share in the Philippines. You",148,"Along these lines, there are a lot of things in this call that I think are disappointing to some people, including me, and I realize there's a lot of exogenous macroeconomic headwinds you can't control. But you've lost market share in the Philippines. You've lost market share in China, although, obviously, it's coming back a little bit now. You've lost market share in the U.S. Kasper, do you need to make a larger adjustment to the company's strategic mindset in terms of marketing? I mean, we've seen some successful tactical adjustments, right? Obviously, things have changed in China this past quarter. But it just feels like it can't continue forever to experience market share losses. And I'm just curious if there is anything in your mind that needs to change in a more dramatic way in terms of how you go to market or think about your strategy?"
1002291,367328587,1064769,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Executives","I think, Ken, the comment is well taken. As you might imagine, nobody is, what shall we say, more sensitive around us referencing market share losses than I am. And certainly, it's not what we want to see. Having said that, we have a portfolio that is hea",272,"I think, Ken, the comment is well taken. As you might imagine, nobody is, what shall we say, more sensitive around us referencing market share losses than I am. And certainly, it's not what we want to see. Having said that, we have a portfolio that is heavily exposed to, let's call it, 10 global businesses or 10 businesses around the world. It's inevitable that amongst those 10, you're going to have ups and downs. We've gained a lot of market share in Canada. We've gained a lot of market share in Europe. And I would argue, at the moment, we are gaining market share in China. Now unfortunately, if you have problems, market share-wise, and you have them in a couple of your really big markets, we both know that the U.S. and China, between the 2 of them, account for more than half our sales, our global sales. So it's very hard for us to offset any significant loss of market share in 1 of those 2 markets with performance in other markets. I'm certainly disappointed that we have not been able to proactively address some of these challenges as opposed to finding ourselves in the mode where we are, so to speak, reacting instead and adapting. I would obviously much rather be driving the change proactively. So your implied criticism is well taken. I don't think it's structural. I don't think it's related to, what shall we say, the way we do marketing or our marketing capabilities in general. But you might rightly imagine that a fair amount of soul searching is going on as a consequence of this."
1002291,367328587,1064769,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Operator","Your next question comes from Matthew Grainger with Morgan Stanley.",10,"Your next question comes from Matthew Grainger with Morgan Stanley."
1002291,367328587,1064769,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","I wanted to squeeze in 2 questions, but I'll ask them quickly. First, on North America, the northeast states WIC contracts, just hoping you could contextualize the size of that relative to some others that have had a material impact on your results such a",105,"I wanted to squeeze in 2 questions, but I'll ask them quickly. First, on North America, the northeast states WIC contracts, just hoping you could contextualize the size of that relative to some others that have had a material impact on your results such as Florida a few years ago and how material that is for 2017. And then in China, just on the market generally, curious for your latest thoughts on birth rates and whether you've seen any uptick in trend in recent months. Some of the feedback that we've gotten has suggested that there's been a bit more acceleration in birth rate trend."
1002291,367328587,1064769,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Let me address high level the contracts that are coming up, and we always were very transparent that there are a couple of significant contracts that were coming up for bid. One of them is California, and the other one that's coming up is Texas. We don't",121,"Let me address high level the contracts that are coming up, and we always were very transparent that there are a couple of significant contracts that were coming up for bid. One of them is California, and the other one that's coming up is Texas. We don't disclose, obviously, the details, what the magnitude of impact potentially could be. But we are very well aware about the importance of these contracts and the potential impact. We always try to have a strategy behind it that we always can find the right balance between other growth initiatives in the U.S. markets as well. So that has been taken into account as well when Kasper was talking about the outlook for next year."
1002291,367328587,1064769,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Executives","I want to maybe just -- Matt, let me try and put it in sort of a strategic context. I think the participation in WIC contracts is one of a number of important demand drivers that we have in the U.S. business. As such, we view it, to a certain extent, the",164,"I want to maybe just -- Matt, let me try and put it in sort of a strategic context. I think the participation in WIC contracts is one of a number of important demand drivers that we have in the U.S. business. As such, we view it, to a certain extent, the same way we view A&P. We look for an appropriate level of return on investment. And it's likely that as we look forward to 2017, there are a couple of important countries, in both of our 2 biggest markets, China and the U.S., we are planning increased investments in demand creation in both of those markets. In China, it will be important to support our growth momentum. And in the U.S., it will obviously be important in order to turn around the market share performance that we've just discussed. And that's -- what we've tried to do is sort of capture that all under this heading of increased investment in demand creation."
1002291,367328587,1064769,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Operator","[Operator Instructions]",2,"[Operator Instructions]"
1002291,367328587,1064769,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Operator, I had about 6 other people -- oh, they're coming back, I think, now on the list.",18,"Operator, I had about 6 other people -- oh, they're coming back, I think, now on the list."
1002291,367328587,1064769,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Operator","Your next question comes from the line of David Driscoll with Citibank.",12,"Your next question comes from the line of David Driscoll with Citibank."
1002291,367328587,1064769,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","And yes, I've been here the whole time, so thanks, Kathy. So like to just kind of line of logic here, the line of questioning is about cost savings. And there are a couple of ways that I want to say it, so give me -- just give me a second. On EPS, kind of",197,"And yes, I've been here the whole time, so thanks, Kathy. So like to just kind of line of logic here, the line of questioning is about cost savings. And there are a couple of ways that I want to say it, so give me -- just give me a second. On EPS, kind of why can't you protect EPS growth more given the size and scope of the cost savings? Just I'm just surprised, it's not helping it more and the 2017 comments, Kasper, are obviously, kind of disappointing because it doesn't really fit the 3-year trend, and I think you guys already pulled back on the 27% margin to Ken's question. And then just super specifically, are you going to step up this cost savings program again? And are you confident that all of this reinvestment is being well spent? Because it just feels like we're getting a very different answer from Mead Johnson versus the rest of the companies in the sector that are generating fairly massive cost savings that are showing up in earnings, but it's not really happening here. Would just love to hear your thoughts on what to make of it."
1002291,367328587,1064769,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Thanks, David. It's a great question, and obviously, one we had anticipated. And I think let's start by going back to Ken's -- to Ken Goldman's question about, so what should we expect in terms of EBIT accretion in 2017? And Michel's response that while w",339,"Thanks, David. It's a great question, and obviously, one we had anticipated. And I think let's start by going back to Ken's -- to Ken Goldman's question about, so what should we expect in terms of EBIT accretion in 2017? And Michel's response that while we don't see EBIT accretion as we look at 2017 and that, of course, is really reflective of the comments I made about our expectations for both sales and EPS growth. And implicitly in that is the fact that there won't -- there's very unlikely to be EBIT margin accretion. So the question is in the face of some fairly significant progress against cost saving initiatives, why is that? And it really relates into -- it relates simply to the fact that we believe that it is in the long-term interest of our shareholders to continue to drive strong growth in China, and that requires continued investment. You will understand implicitly that some of the important initiatives that we have implemented in China were launched only approximately halfway through the year, 2016. So we'll have a full year impact of that higher level of spend in 2017. And then we believe we need to make additional investments in turning around market share in the U.S., which we also believe is in the long-term interest of the business. I do want to say that on the topic of margin accretion, it is -- it's an objective that is subservient to our primary objective, which is to turn around the growth trajectory of the business. So that's important to understand. It's also important to understand that where you will see that significant margin accretion occur is at the point in time that our growth rate picks up from the sort of very modest level that we are currently discussing. We clearly, at that point in time, have put a cost structure in place that will allow the company to get a great amount of EBIT leverage on any kind of growth in sales.
Does that help?"
1002291,367328587,1064769,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","It does. Any comments about further improvements to the cost savings program given the stresses?",15,"It does. Any comments about further improvements to the cost savings program given the stresses?"
1002291,367328587,1064769,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Yes. I mean, we'll -- we have initiatives in place for '17. It'll remain a focus for the company going forward. I think we -- in the last call, I think we took our target up for this year. We indicated that we would move the needle from the previously ann",208,"Yes. I mean, we'll -- we have initiatives in place for '17. It'll remain a focus for the company going forward. I think we -- in the last call, I think we took our target up for this year. We indicated that we would move the needle from the previously announced $60 million to now somewhere between $75 million and $80 million in cost savings this year. I think we also -- I forget now exactly when we expanded our 3-year target from $120 million to $180 million. So we are clearly very focused on this particular objective. And I have to say that it's helping us greatly continue to fund a high level of investment. Your question about, well, is all of this investment well spent, is a great question. It's a question I ask our operators almost on a daily basis. And I'm quite sure that we can -- we will continue to identify small pockets of suboptimal expenditure, but we also have opportunities to spend more on things that we know will work for us. So it'll be a balancing act. Obviously, we will continue to look for efficiencies.
Great question, David. I -- we can talk more about it when we get together next."
1002291,367328587,1064769,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Operator","Your next question comes from the line of Robert Moskow with Crdit Suisse.",13,"Your next question comes from the line of Robert Moskow with Crdit Suisse."
1002291,367328587,1064769,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","I had a question about North American profits. Your profits are still looking like they're going to be up this year, and they're up substantially since 2014 in North America/Europe. But market share is weak, and you're talking about having to reinvest. So",102,"I had a question about North American profits. Your profits are still looking like they're going to be up this year, and they're up substantially since 2014 in North America/Europe. But market share is weak, and you're talking about having to reinvest. So is -- did you feel like North America did not get enough resources in terms of dollars this year? Or is it just the money was spent on the wrong things? And so what do you think is a more normalized margin for North America? We've gone from 23% to 30%. Where do you think it really should land?"
1002291,367328587,1064769,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Yes. Let me address that question in terms of EBIT margin. The increase of the EBIT margin in the U.S., we had a significant benefit from dairy, which gives a significant pressure on uplifting gross margin. So that's one area why we had an improved margin",191,"Yes. Let me address that question in terms of EBIT margin. The increase of the EBIT margin in the U.S., we had a significant benefit from dairy, which gives a significant pressure on uplifting gross margin. So that's one area why we had an improved margin. In general, we'll see, as a total company, more gross margin pressure also in '17 as a result of dairy prices where we see some slightly increases that are coming in. So that also will have an effect on our U.S. business as such. In addition, like Kasper just said, we made a deliberate choice to step up additional investment in the U.S. from a demand-generating investment point of view, whether that's through A&P or whether that's from gross to net initiatives, and WIC could be one of them as one of the demand-generating investments. So we will see some pressure on EBIT margin. I think we won't see a level that we have currently. But I also don't expect that it will go to the levels that we have seen historically. I would say that we would see a midpoint between those EBIT margins."
1002291,367328587,1064769,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","Michel, just a follow-up, then, for Kasper, what's your confidence that you have the pricing power in 2017 to offset higher input costs?",23,"Michel, just a follow-up, then, for Kasper, what's your confidence that you have the pricing power in 2017 to offset higher input costs?"
1002291,367328587,1064769,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Executives","I don't think we will fully offset input -- higher input costs. So I think it's implied in the words that I used in my prepared remarks, which I'm quite sure will be scrutinized by all of you. Implied in that is some contraction to gross margin. I should",209,"I don't think we will fully offset input -- higher input costs. So I think it's implied in the words that I used in my prepared remarks, which I'm quite sure will be scrutinized by all of you. Implied in that is some contraction to gross margin. I should put that in the context of the fact that our gross margin, supported by historically low dairy costs, have been well above historic norms over the last, I want to say, the last 18 to 24 months. So I think over time, we would expect to see gross margin come down to sort of normal levels. That's not all going to happen in 1 year. It's not all going to happen in '17. But we -- as we look at it now, we would expect some reduction in gross margin next year. We'll -- I'm sure we'll say more about it when we give a bit more detail and more formal guidance next time around in our next call. But we felt it was important to kind of help you develop your thinking for '17, that's why we are spending a little bit more time than we usually do talking about next year at this point of the cycle."
1002291,367328587,1064769,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Operator","Our next question comes from the line of Pablo Zuanic with SIG.",12,"Our next question comes from the line of Pablo Zuanic with SIG."
1002291,367328587,1064769,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","Just 2 quick questions. First, I mean, when I look at Abbott, and their Eleva product, I have to think that for an IMF business, inside of a pharmaceutical company, that they must have advantages over you in terms of their communication with doctors, and",211,"Just 2 quick questions. First, I mean, when I look at Abbott, and their Eleva product, I have to think that for an IMF business, inside of a pharmaceutical company, that they must have advantages over you in terms of their communication with doctors, and then people recommending IMF products. And then I look at Nestle, which obviously owns Wyeth with Illuma doing well, they are a much larger consumer company with much better distribution. So can you comment? Obviously, you've made significant changes and improvements in China, but can you comment whether you're at a disadvantage when you look at the Abbotts of the world and the Nestles. And the second one, very quickly, I know you gave us a lot of numbers in terms of the pieces of growth in China. But I don't know, maybe I missed it, but what was the growth year-on-year in China in your IMF business there, and if you can just compare that with what was the sell-through? I mean, my visits to baby stores show that you have very good displays for Enfinitas, Enfamil, great merchandising, window displays, and I'm just worried about the sell-through. What are we going to see in the fourth quarter? If you can comment on that, please."
1002291,367328587,1064769,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Thanks, Pablo. Let me address your question on competitiveness first, and then I'll talk about -- then I'll reiterate what I said earlier about inventory. I see absolutely no reason why we should not be able to compete with either of the 2 companies that",367,"Thanks, Pablo. Let me address your question on competitiveness first, and then I'll talk about -- then I'll reiterate what I said earlier about inventory. I see absolutely no reason why we should not be able to compete with either of the 2 companies that you mentioned in China. And indeed, we've done so successfully for many years. The China market is somewhat different from many of the other markets in the world that we compete in, in the sense that, frankly speaking, health care professional endorsement of your brand is far less influential in China than it is elsewhere in our -- in the world we operate in. So any potential disadvantage, which I'm not sure exists to begin with, vis--vis our U.S. competitor there, certainly is never being used as a reason for shortfalls by our local team in China and nor would it be accepted. You referenced our larger and more broad-based consumer products competitor, and I would only say to that, that again, the primary sales channel for these very high-priced products, high-quality products in China is really the baby store channel in China, and that's not a channel where your muscle and product range from other parts of the grocery industry can necessarily be leveraged very effectively. So again, I don't think we are at a significant disadvantage. Apart from what you would generally say is that obviously, we are a smaller company than either of those 2, and that means we can't leverage our cost base, our general infrastructure cost over a broader sales base. But despite that, it appears to me that we have got best-in-class EBIT margins. And I think we can maintain that while growing at the same time. On the inventory side in China, I just want to refer to what I said earlier. We are very comfortable with our inventory levels in the sales channels in China. We pride ourselves on not building up those inventories artificially from quarter-to-quarter. And hence, I don't expect, assuming that offtake develops the way we expect and anticipate, I don't expect that we're going to be seeing any changes to our sales trajectory that do not reflect underlying consumer demand."
1002291,367328587,1064769,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","But just a quick follow-up, I mean, I was surprised in Beijing at one show [ph], for example, at baby stores that I visited, are the displays of Enfinitas, a full shelf, are as big as the displays of the Enfa range. And I was just wondering, Enfinitas is",132,"But just a quick follow-up, I mean, I was surprised in Beijing at one show [ph], for example, at baby stores that I visited, are the displays of Enfinitas, a full shelf, are as big as the displays of the Enfa range. And I was just wondering, Enfinitas is clearly not half of your sales there. And it retails for around CNY 445 compared to Eleva and Illuma that are in the CNY 380, CNY 400 range. So I understand that the question about inventories was answered before. But I'm just wondering it sounds like you doubled your space at baby stores, at least when I look at Enfinitas versus Enfa, unless you lost Enfa space, and then you have a price point that's way above your competitors, Eleva and Illuma."
1002291,367328587,1064769,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Yes. I think you've visited a small selection of stores, and I -- in some ways, I wish it was -- what you saw was the case everywhere. Unfortunately, it isn't. But I think it's, joking aside, Pablo, it's a natural dynamic when you launch new brands that y",95,"Yes. I think you've visited a small selection of stores, and I -- in some ways, I wish it was -- what you saw was the case everywhere. Unfortunately, it isn't. But I think it's, joking aside, Pablo, it's a natural dynamic when you launch new brands that you have to build a certain amount of exposure for them. We are very comfortable that the sales trajectory that we are seeing grow week, week on week since launch on Enfinitas is supportive of the amount of inventory that we have sold into the retail channel."
1002291,367328587,1064769,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Operator","Our last question comes from the line of Steven Strycula with UBS.",12,"Our last question comes from the line of Steven Strycula with UBS."
1002291,367328587,1064769,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","Quick question for Kasper, and then a quick follow-up for Michel. So the question would be related to the China growth. It seems like you had a nice acceleration there in the third quarter. Just any help, Kasper, as you could kind of split apart what were",114,"Quick question for Kasper, and then a quick follow-up for Michel. So the question would be related to the China growth. It seems like you had a nice acceleration there in the third quarter. Just any help, Kasper, as you could kind of split apart what were like the baseline sales improvement and what was more of a bump from a little bit of a relief in the bottleneck that we were having in terms of shipments. And then conversely, how do -- how are trends outside of China trending? Were they down high single digits, and China was up high single digits, and we got to flat for Asia overall? That'd be helpful."
1002291,367328587,1064769,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Executives","I mean, you're broadly in the right territory with your last remark, Steve, but that's pretty close. And I would say that roughly 1/3 of the growth we saw in China in the third quarter we are attributing to, what shall we say, carryover of orders we could",81,"I mean, you're broadly in the right territory with your last remark, Steve, but that's pretty close. And I would say that roughly 1/3 of the growth we saw in China in the third quarter we are attributing to, what shall we say, carryover of orders we could not fulfill in the second quarter. That would still mean that, as I said, it would still mean that our growth was very healthy in the third quarter on an underlying demand basis."
1002291,367328587,1064769,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Analysts","Okay, that's very helpful. And then my last question for Michel would be, with respect to the 27% margin target for the out years, is any of, call it, the more tempered outlook a reflection of the business naturally rotating out of Hong Kong, which was yo",85,"Okay, that's very helpful. And then my last question for Michel would be, with respect to the 27% margin target for the out years, is any of, call it, the more tempered outlook a reflection of the business naturally rotating out of Hong Kong, which was your highest margin region, to an imported model from Europe? Is that -- anything to do as an explanatory fact? Or is there something else we should really be focusing on? Or just a lack of top line levers?"
1002291,367328587,1064769,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Executives","No, it is clearly the last one, the top line and the required investments that we would like to make also in 2017. That's the main reason.",27,"No, it is clearly the last one, the top line and the required investments that we would like to make also in 2017. That's the main reason."
1002291,367328587,1064769,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Executives","Thank you for everybody participating in Mead Johnson's earnings call today.Operator, I'll turn it over to you to close out the call. Thank you.",26,"Thank you for everybody participating in Mead Johnson's earnings call today.
Operator, I'll turn it over to you to close out the call. Thank you."
1002291,367328587,1064769,"Mead Johnson Nutrition Company, Q3 2016 Earnings Call, Oct 27, 2016",2016-10-27,"Earnings Calls","Mead Johnson Nutrition Company","Operator","This concludes the presentation. You may now disconnect. Everyone, have a good day.",13,"This concludes the presentation. You may now disconnect. Everyone, have a good day."
